US20040259247A1 - Rna interference mediating small rna molecules - Google Patents
Rna interference mediating small rna molecules Download PDFInfo
- Publication number
- US20040259247A1 US20040259247A1 US10/433,050 US43305004A US2004259247A1 US 20040259247 A1 US20040259247 A1 US 20040259247A1 US 43305004 A US43305004 A US 43305004A US 2004259247 A1 US2004259247 A1 US 2004259247A1
- Authority
- US
- United States
- Prior art keywords
- target
- rna
- gene
- cell
- sirna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000009368 gene silencing by RNA Effects 0.000 title claims abstract description 92
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 title claims abstract description 23
- 108091032955 Bacterial small RNA Proteins 0.000 title 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 498
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims abstract description 284
- 238000000034 method Methods 0.000 claims abstract description 37
- 108090000623 proteins and genes Proteins 0.000 claims description 123
- 210000004027 cell Anatomy 0.000 claims description 84
- 125000003729 nucleotide group Chemical group 0.000 claims description 82
- 239000002773 nucleotide Substances 0.000 claims description 73
- 108020004414 DNA Proteins 0.000 claims description 67
- 102000004169 proteins and genes Human genes 0.000 claims description 48
- 150000007523 nucleic acids Chemical class 0.000 claims description 46
- 102000039446 nucleic acids Human genes 0.000 claims description 44
- 108020004707 nucleic acids Proteins 0.000 claims description 44
- 230000014509 gene expression Effects 0.000 claims description 43
- 108020004999 messenger RNA Proteins 0.000 claims description 30
- 238000004458 analytical method Methods 0.000 claims description 19
- 238000012986 modification Methods 0.000 claims description 19
- 241000282414 Homo sapiens Species 0.000 claims description 18
- 210000004962 mammalian cell Anatomy 0.000 claims description 18
- 230000004048 modification Effects 0.000 claims description 18
- 230000015556 catabolic process Effects 0.000 claims description 16
- 238000006731 degradation reaction Methods 0.000 claims description 16
- 230000007067 DNA methylation Effects 0.000 claims description 11
- 230000005764 inhibitory process Effects 0.000 claims description 11
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 238000012360 testing method Methods 0.000 claims description 9
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 8
- 230000001404 mediated effect Effects 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 210000005260 human cell Anatomy 0.000 claims description 6
- 239000002831 pharmacologic agent Substances 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 108010085220 Multiprotein Complexes Proteins 0.000 claims description 5
- 102000007474 Multiprotein Complexes Human genes 0.000 claims description 5
- 108010026552 Proteome Proteins 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 125000001475 halogen functional group Chemical group 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 230000002194 synthesizing effect Effects 0.000 claims description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 108700005077 Viral Genes Proteins 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims description 2
- 244000052769 pathogen Species 0.000 claims description 2
- 230000001717 pathogenic effect Effects 0.000 claims description 2
- 230000001575 pathological effect Effects 0.000 claims description 2
- 230000000144 pharmacologic effect Effects 0.000 claims description 2
- 125000005642 phosphothioate group Chemical group 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 abstract description 302
- 230000000692 anti-sense effect Effects 0.000 abstract description 102
- 238000003776 cleavage reaction Methods 0.000 abstract description 76
- 230000007017 scission Effects 0.000 abstract description 74
- 230000007022 RNA scission Effects 0.000 abstract description 45
- 238000012545 processing Methods 0.000 abstract description 36
- 239000012634 fragment Substances 0.000 abstract description 31
- 239000006166 lysate Substances 0.000 abstract description 26
- 238000006243 chemical reaction Methods 0.000 abstract description 25
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 abstract description 22
- 238000000338 in vitro Methods 0.000 abstract description 13
- 230000032361 posttranscriptional gene silencing Effects 0.000 abstract description 7
- 102000006382 Ribonucleases Human genes 0.000 abstract description 5
- 108010083644 Ribonucleases Proteins 0.000 abstract description 5
- 230000008569 process Effects 0.000 abstract description 5
- 230000000694 effects Effects 0.000 description 37
- 108060001084 Luciferase Proteins 0.000 description 30
- 239000000047 product Substances 0.000 description 29
- 235000018102 proteins Nutrition 0.000 description 28
- 239000005089 Luciferase Substances 0.000 description 27
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 19
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 18
- 239000000499 gel Substances 0.000 description 18
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 16
- 241001599018 Melanogaster Species 0.000 description 15
- 108010057163 Ribonuclease III Proteins 0.000 description 14
- 102000003661 Ribonuclease III Human genes 0.000 description 14
- 239000013612 plasmid Substances 0.000 description 14
- 238000011534 incubation Methods 0.000 description 13
- 108091081021 Sense strand Proteins 0.000 description 12
- 230000000295 complement effect Effects 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 230000030279 gene silencing Effects 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- 238000006467 substitution reaction Methods 0.000 description 11
- 101710163270 Nuclease Proteins 0.000 description 10
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 10
- 239000002777 nucleoside Substances 0.000 description 10
- 230000008685 targeting Effects 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 108700008625 Reporter Genes Proteins 0.000 description 9
- 238000013518 transcription Methods 0.000 description 9
- 230000035897 transcription Effects 0.000 description 9
- 241000196324 Embryophyta Species 0.000 description 8
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 108091081024 Start codon Proteins 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 230000029087 digestion Effects 0.000 description 7
- 238000013507 mapping Methods 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 150000003833 nucleoside derivatives Chemical class 0.000 description 7
- 230000036961 partial effect Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- IQFYYKKMVGJFEH-BIIVOSGPSA-N 2'-deoxythymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-BIIVOSGPSA-N 0.000 description 6
- 102100031780 Endonuclease Human genes 0.000 description 6
- 108090000331 Firefly luciferases Proteins 0.000 description 6
- 241000242743 Renilla reniformis Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000000137 annealing Methods 0.000 description 6
- -1 cationic lipid Chemical class 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 238000004020 luminiscence type Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000001743 silencing effect Effects 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- 108010042407 Endonucleases Proteins 0.000 description 5
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 230000009977 dual effect Effects 0.000 description 5
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 5
- 235000021317 phosphate Nutrition 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 4
- 108010067770 Endopeptidase K Proteins 0.000 description 4
- 230000006819 RNA synthesis Effects 0.000 description 4
- 108091028664 Ribonucleotide Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000001177 diphosphate Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000001161 mammalian embryo Anatomy 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 239000002336 ribonucleotide Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 229940104230 thymidine Drugs 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 101100297345 Caenorhabditis elegans pgl-2 gene Proteins 0.000 description 3
- 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 3
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108020005004 Guide RNA Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000254064 Photinus pyralis Species 0.000 description 3
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 3
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 3
- 101710086015 RNA ligase Proteins 0.000 description 3
- 108010046983 Ribonuclease T1 Proteins 0.000 description 3
- 101710137500 T7 RNA polymerase Proteins 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000012761 co-transfection Methods 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 230000010468 interferon response Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 101150066555 lacZ gene Proteins 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 235000004252 protein component Nutrition 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 108090000446 ribonuclease T(2) Proteins 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000003104 tissue culture media Substances 0.000 description 3
- 239000001226 triphosphate Substances 0.000 description 3
- 235000011178 triphosphate Nutrition 0.000 description 3
- 229940045145 uridine Drugs 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 229930010555 Inosine Natural products 0.000 description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 2
- 241000254158 Lampyridae Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 101710149004 Nuclease P1 Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108010039259 RNA Splicing Factors Proteins 0.000 description 2
- 102000015097 RNA Splicing Factors Human genes 0.000 description 2
- 102100029683 Ribonuclease T2 Human genes 0.000 description 2
- 102000004389 Ribonucleoproteins Human genes 0.000 description 2
- 108010081734 Ribonucleoproteins Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 102000018686 U4-U6 Small Nuclear Ribonucleoprotein Human genes 0.000 description 2
- 108010091808 U4-U6 Small Nuclear Ribonucleoprotein Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000012226 gene silencing method Methods 0.000 description 2
- 238000010363 gene targeting Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 229960003786 inosine Drugs 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 150000008300 phosphoramidites Chemical class 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- GUUBJKMBDULZTE-UHFFFAOYSA-M potassium;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid;hydroxide Chemical compound [OH-].[K+].OCCN1CCN(CCS(O)(=O)=O)CC1 GUUBJKMBDULZTE-UHFFFAOYSA-M 0.000 description 2
- 108020001580 protein domains Proteins 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 102000033955 single-stranded RNA binding proteins Human genes 0.000 description 2
- 108091000371 single-stranded RNA binding proteins Proteins 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 2
- GZEFTKHSACGIBG-UGKPPGOTSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-propyloxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1=CC(=O)NC(=O)N1[C@]1(CCC)O[C@H](CO)[C@@H](O)[C@H]1O GZEFTKHSACGIBG-UGKPPGOTSA-N 0.000 description 1
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
- YKBGVTZYEHREMT-UHFFFAOYSA-N 2'-deoxyguanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1CC(O)C(CO)O1 YKBGVTZYEHREMT-UHFFFAOYSA-N 0.000 description 1
- AGFIRQJZCNVMCW-UAKXSSHOSA-N 5-bromouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 AGFIRQJZCNVMCW-UAKXSSHOSA-N 0.000 description 1
- ASUCSHXLTWZYBA-UMMCILCDSA-N 8-Bromoguanosine Chemical compound C1=2NC(N)=NC(=O)C=2N=C(Br)N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ASUCSHXLTWZYBA-UMMCILCDSA-N 0.000 description 1
- HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 241000269350 Anura Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000854388 Homo sapiens Ribonuclease 3 Proteins 0.000 description 1
- 101000587430 Homo sapiens Serine/arginine-rich splicing factor 2 Proteins 0.000 description 1
- 101000587434 Homo sapiens Serine/arginine-rich splicing factor 3 Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101000663223 Mus musculus Serine/arginine-rich splicing factor 1 Proteins 0.000 description 1
- VQAYFKKCNSOZKM-IOSLPCCCSA-N N(6)-methyladenosine Chemical compound C1=NC=2C(NC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VQAYFKKCNSOZKM-IOSLPCCCSA-N 0.000 description 1
- VQAYFKKCNSOZKM-UHFFFAOYSA-N NSC 29409 Natural products C1=NC=2C(NC)=NC=NC=2N1C1OC(CO)C(O)C1O VQAYFKKCNSOZKM-UHFFFAOYSA-N 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108091036407 Polyadenylation Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108090000944 RNA Helicases Proteins 0.000 description 1
- 102000004409 RNA Helicases Human genes 0.000 description 1
- 108010065868 RNA polymerase SP6 Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 102100036007 Ribonuclease 3 Human genes 0.000 description 1
- 101710192197 Ribonuclease 3 Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102100029666 Serine/arginine-rich splicing factor 2 Human genes 0.000 description 1
- 102100029665 Serine/arginine-rich splicing factor 3 Human genes 0.000 description 1
- 108020004688 Small Nuclear RNA Proteins 0.000 description 1
- 102000039471 Small Nuclear RNA Human genes 0.000 description 1
- 108020003224 Small Nucleolar RNA Proteins 0.000 description 1
- 102000042773 Small Nucleolar RNA Human genes 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000008049 TAE buffer Substances 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102000006986 U2 Small Nuclear Ribonucleoprotein Human genes 0.000 description 1
- 108010072724 U2 Small Nuclear Ribonucleoprotein Proteins 0.000 description 1
- 108091026831 U4 spliceosomal RNA Proteins 0.000 description 1
- 108091026837 U5 spliceosomal RNA Proteins 0.000 description 1
- 108091026822 U6 spliceosomal RNA Proteins 0.000 description 1
- HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000003838 adenosines Chemical class 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000007068 beta-elimination reaction Methods 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 108020001778 catalytic domains Proteins 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000019113 chromatin silencing Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000003169 complementation method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- VGONTNSXDCQUGY-UHFFFAOYSA-N desoxyinosine Natural products C1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 VGONTNSXDCQUGY-UHFFFAOYSA-N 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 238000003197 gene knockdown Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 108010064833 guanylyltransferase Proteins 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000007422 luminescence assay Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000004879 molecular function Effects 0.000 description 1
- 150000004712 monophosphates Chemical group 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000005257 nucleotidylation Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 238000003322 phosphorimaging Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 239000002213 purine nucleotide Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 239000002719 pyrimidine nucleotide Substances 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010583 slow cooling Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012033 transcriptional gene silencing Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- HDZZVAMISRMYHH-KCGFPETGSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HDZZVAMISRMYHH-KCGFPETGSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1079—Screening libraries by altering the phenotype or phenotypic trait of the host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised
Definitions
- RNA interference was coined after the discovery that injection of dsRNA into the nematode C. elegans leads to specific silencing of genes highly homologous in sequence to the delivered dsRNA (Fire et al., 1998). RNAi was subsequently also observed in insects, frogs (Oelgeschlager et al., 2000), and other animals including mice (Svoboda et al., 2000; Wianny and Zernicka-Goetz, 2000) and is likely to also exist in human.
- RNAi is closely linked to the post-transcriptional gene-silencing (PTGS) mechanism of co-suppression in plants and quelling in fungi (Catalanotto et al., 2000; Cogoni and Macino, 1999; Dalmay et al., 2000; Ketting and Plasterk, 2000; Mourrain et al., 2000; Smardon et al., 2000) and some components of the RNAi machinery are also necessary for post-transcriptional silencing by co-suppression (Catalanotto et al., 2000; Dernburg et al., 2000; Ketting and Plasterk, 2000).
- PTGS post-transcriptional gene-silencing
- transgenes can also lead to transcriptional gene silencing via RNA-directed DNA methylation of cytosines (see references in Wassenegger, 2000). Genomic targets as short as 30 bp are methylated in plants in an RNA-directed manner (Pelissier, 2000). DNA methylation is also present in mammals.
- RNAi and co-suppression appear to be protection of the genome against invasion by mobile genetic elements such as retro-transposons and viruses which produce aberrant RNA or dsRNA in the host cell when they become active (Jensen et al, 1999; Ketting et al., 1999; Ratcliff et al., 1999; Tabara et al., 1999).
- Specific mRNA degradation prevents transposon and virus replication although some viruses are able to overcome or prevent this process by expressing proteins that suppress PTGS (Lucy et al., 2000; Voinnet et al., 2000).
- RNA molecules of similar size also accumulate in plant tissue that exhibits PTGS (Hamilton and Baulcombe, 1999).
- siRNAs short interfering RNAs
- the siRNAs may also be important tools for transcriptional modulating, e.g. silencing of mammalian genes by guiding DNA methylation.
- the object underlying the present invention is to provide novel agents capable of mediating target-specific RNA interference or other target-specific nucleic acid modifications such as DNA methylation, said agents having an improved efficacy and safety compared to prior art agents.
- each RNA strand has a length from 19-25, particularly from 19-23 nucleotides, wherein said RNA molecule is capable of mediating target-specific nucleic acid modifications, particularly RNA interference and/or DNA methylation.
- at least one strand has a 3′-overhang from 1-5 nucleotides, more preferably from 1-3 nucleotides and most preferably 2 nucleotides.
- the other strand may be blunt-ended or has up to 6 nucleotides 3′ overhang.
- the RNA molecule is preferably a synthetic RNA molecule which is substantially free from contaminants occurring in cell extracts, e.g. from Drosophila embryos. Further, the RNA molecule is preferably substantially free from any non-target-specific contaminants, particularly non-target-specific RNA molecules e.g. from contaminants occuring in cell extracts.
- the invention relates to the use of isolated double-stranded RNA molecules, wherein each RNA strand has a length from 19-25 nucleotides, for mediating, target-specific nucleic acid modifications, particularly RNAi, in mammalian cells, particularly in human cells.
- each strand of the RNA molecule has a length from 20-22 nucleotides (or 20-25 nucleotides in mammalian cells), wherein the length of each strand may be the same or different.
- the length of the 3′-overhang reaches from 1-3 nucleotides, wherein the length of the overhang may be the same or different for each strand.
- the RNA-strands preferably have 3′-hydroxyl groups.
- the 5′-terminus preferably comprises a phosphate, diphosphate, triphosphate or hydroxyl group.
- the most effective dsRNAs are composed of two 21 nt strands which are paired such that 1-3, particularly 2 nt 3′ overhangs are present on both ends of the dsRNA.
- the target RNA cleavage reaction guided by siRNAs is highly sequence-specific. However, not all positions of a siRNA contribute equally to target recognition. Mismatches in the center of the siRNA duplex are most critical and essentially abolish target RNA cleavage. In contrast, the 3′ nucleotide of the siRNA strand (e.g. position 21) that is complementary to the single-stranded target RNA, does not contribute to specificity of the target recognition. Further, the sequence of the unpaired 2-nt 3′ overhang of the siRNA strand with the same polarity as the target RNA is not critical for target RNA cleavage as only the antisense siRNA strand guides target recognition. Thus, from the single-stranded overhanging nucleotides only the penultimate position of the antisense siRNA (e.g. position 20) needs to match the targeted sense mRNA.
- the double-stranded RNA molecules of the present invention exhibit a high in vivo stability in serum or in growth medium for cell cultures.
- the 3′-overhangs may be stablized against degradation, e.g. they may be selected such that they consist of purine nucleotides, particularly adenosine or guanosine nucleotides.
- substitution of pyrimidine nucleotides by modified analogues e.g. substitution of uridine 2 nt 3′ overhangs by 2′-deoxythymidine is tolerated and does not affect the efficiency of RNA interference.
- the absence of a 2′ hydroxyl significantly enhances the nuclease resistance of the overhang in tissue culture medium.
- the RNA molecule may contain at least one modified nucleotide analogue.
- the nucleotide analogues may be located at positions where the target-specific activity, e.g. the RNAi mediating activity is not substantially effected, e.g. in a region at the 5′-end and/or the 3′-end of the double-stranded RNA molecule.
- the overhangs may be stabilized by incorporating modified nucleotide analogues.
- O- and N-alkylated nucleotides e.g. N6-methyl adenosine are suitable.
- the 2′OH-group is replaced by a group selected from H, OR, R, halo, SH, SR, NH 2 , NHR, NR 2 or CN, wherein R is C 1 -C 6 alkyl, alkenyl or alkynyl and halo is F, Cl, Br or I.
- R is C 1 -C 6 alkyl, alkenyl or alkynyl and halo is F, Cl, Br or I.
- the phosphoester group connecting to adjacent ribonucleotides is replaced by a modified group, e.g. of phosphothioate group. It should be noted that the above modifications may be combined.
- the sequence of the double-stranded RNA molecule of the present invention has to have a sufficient identity to a nucleic acid target molecule in order to mediate target-specific RNAi and/or DNA methylation.
- the sequence has an identity of at least 50%, particularly of at least 70% to the desired target molecule in the double-stranded portion of the RNA molecule. More preferably, the identity is at least 85% and most preferably 100% in the double-stranded portion of the RNA molecule.
- I is the identity in percent
- n is the number of identical nucleotides in the double-stranded portion of the ds RNA and the target
- L is the length of the sequence overlap of the double-stranded portion of the dsRNA and the target.
- the identity of the double-stranded RNA molecule to the target sequence may also be defined including the 3′ overhang, particularly an overhang having a length from 1-3 nucleotides.
- the sequence identity is preferably at least 50%, more preferably at least 70% and most preferably at least 85% to the target sequence.
- the nucleotides from the 3′ overhang and up to 2 nucleotides from the 5′ and/or 3′ terminus of the double strand may be modified without significant loss of activity.
- the double-stranded RNA molecule of the invention may be prepared by a method comprising the steps:
- RNA molecules Methods of synthesizing RNA molecules are known in the art. In this context, it is particularly referred to chemical synthesis methods as described in Verma and Eckstein (1998).
- the single-stranded RNAs can also be prepared by enzymatic transcription from synthetic DNA templates or from DNA plasmids isolated from recombinant bacteria.
- phage RNA polymerases are used such as T7, T3 or SP6 RNA polymerase (Milligan and Uhlenbeck (1989)).
- a further aspect of the present invention relates to a method of mediating target-specific nucleic acid modifications, particularly RNA interference and/or DNA methylation in a cell or an organism comprising the steps:
- the contacting step (a) comprises introducing the double-stranded RNA molecule into a target cell, e.g. an isolated target cell, e.g. in cell culture, a unicellular microorganism or a target cell or a plurality of target cells within a multicellular organism.
- a target cell e.g. an isolated target cell, e.g. in cell culture, a unicellular microorganism or a target cell or a plurality of target cells within a multicellular organism.
- the introducing step comprises a carrier-mediated delivery, e.g. by liposomal carriers or by injection.
- the method of the invention may be used for determining the function of a gene in a cell or an organism or even for modulating the function of a gene in a cell or an organism, being capable of mediating RNA interference.
- the cell is preferably a eukaryotic cell or a cell line, e.g. a plant cell or an animal cell, such as a mammalian cell, e.g. an embryonic cell, a pluripotent stem cell, a tumor cell, e.g. a teratocarcinoma cell or a virus-infected cell.
- the organism is preferably a eukaryotic organism, e.g. a plant or an animal, such as a mammal, particularly a human.
- the target gene to which the RNA molecule of the invention is directed may be associated with a pathological condition.
- the gene may be a pathogen-associated gene, e.g. a viral gene, a tumor-associated gene or an autoimmune disease-associated gene.
- the target gene may also be a heterologous gene expressed in a recombinant cell or a genetically altered organism. By determinating or modulating, particularly, inhibiting the function of such a gene valuable information and therapeutic benefits in the agricultural field or in the medicine or veterinary medicine field may be obtained.
- the dsRNA is usually administered as a pharmaceutical composition.
- the administration may be carried out by known methods, wherein a nucleic acid is introduced into a desired target cell in vitro or in vivo.
- Commonly used gene transfer techniques include calcium phosphate, DEAE-dextran, electroporation and microinjection and viral methods (Graham, F. L. and van der Eb, A. J. (1973) Virol. 52, 456; McCutchan, J. H. and Pagano, J. S. (1968), J. Natl. Cancer Inst. 41, 351; Chu, G. et al (1987), Nucl. Acids Res. 15, 1311; Fraley, R. et al. (1980), J. Biol. Chem.
- the invention also relates to a pharmaceutical composition containing as an active agent at least one double-stranded RNA molecule as described above and a pharmaceutical carrier.
- the composition may be used for diagnostic and for therapeutic applications in human medicine or in veterinary medicine.
- the composition may be in form of a solution, e.g. an injectable solution, a cream, ointment, tablet, suspension or the like.
- the composition may be administered in any suitable way, e.g. by injection, by oral, topical, nasal, rectal application etc.
- the carrier may be any suitable pharmaceutical carrier.
- a carrier is used, which is capable of increasing the efficacy of the RNA molecules to enter the target-cells. Suitable examples of such carriers are liposomes, particularly cationic liposomes.
- a further preferred administration method is injection.
- a further subject matter of the invention is a eukaryotic cell or a eukaryotic non-human organism exhibiting a target gene-specific knockout phenotype comprising an at least partially deficient expression of at least one endogeneous target gene wherein said cell or organism is transfected with at least one double-stranded RNA molecule capable of inhibiting the expression of at least one endogeneous target gene or with a DNA encoding at least one double stranded RNA molecule capable of inhibiting the expression of at least one endogeneous target gene.
- the present invention allows a target-specific knockout of several different endogeneous genes due to the specificity of RNAi.
- RNAi based knockout technologies the expression of an endogeneous target gene may be inhibited in a target cell or a target organism.
- the endogeneous gene may be complemented by an exogeneous target nucleic acid coding for the target protein or a variant or mutated form of the target protein, e.g. a gene or a cDNA, which may optionally be fused to a further nucleic acid sequence encoding a detectable peptide or polypeptide, e.g. an affinity tag, particularly a multiple affinity tag.
- Variants or mutated forms of the target gene differ from the endogeneous target gene in that they encode a gene product which differs from the endogeneous gene product on the amino acid level by substitutions, insertions and/or deletions of single or multiple amino acids.
- the variants or mutated forms may have the same biological activity as the endogeneous target gene.
- the variant or mutated target gene may also have a biological activity, which differs from the biological activity of the endogeneous target gene, e.g. a partially deleted activity, a completely deleted activity, an enhanced activity etc.
- the complementation may be accomplished by coexpressing the polypeptide encoded by the exogeneous nucleic acid, e.g. a fusion protein comprising the target protein and the affinity tag and the double stranded RNA molecule for knocking out the endogeneous gene in the target cell.
- This coexpression may be accomplished by using a suitable expression vector expressing both the polypeptide encoded by the exogeneous nucleic acid, e.g. the tag-modified target protein and the double stranded RNA molecule or alternatively by using a combination of expression vectors. Proteins and protein complexes which are synthesized de novo in the target cell will contain the exogeneous gene product, e.g. the modified fusion protein.
- the nucleotide sequence encoding the exogeneous nucleic acid may be altered on the DNA level (with or without causing mutations on the amino acid level) in the part of the sequence which is homologous to the double stranded RNA molecule.
- the endogeneous target gene may be complemented by corresponding nucleotide sequences from other species, e.g. from mouse.
- the method and cell of the invention are also suitable in a procedure for identifying and/or characterizing pharmacological agents, e.g. identifying new pharmacological agents from a collection of test substances and/or characterizing mechanisms of action and/or side effects of known pharmacological agents.
- test substance or a collection of test substances wherein pharmacological properties of said test substance or said collection are to be identified and/or characterized.
- the preparative method may be employed for the purification of high molecular weight protein complexes which preferably have a mass of ⁇ 150 kD and more preferably of ⁇ 500 kD and which optionally may contain nucleic acids such as RNA.
- heterotrimeric protein complex consisting of the 20 kD, 60 kD and 90 kD proteins of the U4/U6 snRNP particle, the splicing factor SF3b from the 17S U2 snRNP consisting of 5 proteins having molecular weights of 14, 49, 1 20, 145 and 155 kD and the 25S U41U6/U5 tri-snRNP particle containing the U4, U5 and U6 snRNA molecules and about 30 proteins, which has a molecular weight of about 1.7 MD.
- FIG. 2 A 29 bp dsRNA is no longer processed to 21-23 nt fragments.
- FIG. 4 21 and 22 nt RNA fragments are generated by an RNase III-like mechanism.
- RNAs were generated by incubation of internally radiolabeled 504 bp Pp-luc dsRNA in Drosophila lysate, gel-purified, and then digested to mononucleotides with nuclease P1 (top row) or ribonuclease T2 (bottom row).
- the dsRNA was internally radiolabeled by transcription in the presence of one of the indicated ⁇ - 32 P nucleoside triphosphates. Radioactivity was detected by phosphorimaging.
- Nucleoside 5′-monophosphates, nucleoside 3′-mono-phosphates, nucleoside 5′,3′-diphosphates, and inorganic phosphate are indicated as pN, Np, pNp, and p i , respectively.
- Black circles indicate UV-absorbing spots from non-radioactive carrier nucleotides.
- the 3′,5′-bis-phosphates (red circles) were identified by co-migration with radiolabeled standards prepared by 5′-phosphorylation of nucleoside 3′-mono-phosphates with T4 polynucleotide kinase and ⁇ - 32 P-ATP.
- the sense strand of 21 and 22 nt short interfering RNAs (siRNAs) is shown blue, the antisense strand in red.
- the sequences of the siRNAs were derived from the cloned fragments of 52 and 111 bp dsRNAs (FIG. 4A), except for the 22 nt antisense strand of duplex 5.
- the siRNAs in duplex 6 and 7 were unique to the 111 bp dsRNA processing reaction.
- the two 3′ overhanging nucleotides indicated in green are present in the sequence of the synthetic antisense strand of duplexes 1 and 3.
- the stable 5′ cleavage products were resolved on the gel.
- the cleavage sites are indicated in FIG. 5A.
- the region targeted by the 52 bp dsRNA or the sense (s) or antisense (as) strands are indicated by the black bars to the side of the gel.
- the cleavage sites are all located within the region of identity of the dsRNAs. For precise determination of the cleavage sites of the antisense strand, a lower percentage gel was used.
- RNAi is predicted to begin with processing of dsRNA (sense strand in black, antisense strand in red) to predominantly 21 and 22 nt short interfering RNAs (siRNAs). Short overhanging 3′ nucleotides, if present on the dsRNA, may be beneficial for processing of short dsRNAs.
- the dsRNA-processing proteins which remain to be characterized, are represented as green and blue ovals, and assembled on the dsRNA in asymmetric fashion. In our model, this is illustrated by binding of a hypothetical blue protein or protein domain with the siRNA strand in 3′ to 5′ direction while the hypothetical green protein or protein domain is always bound to the opposing siRNA strand.
- siRNA duplex proteins remain associated with the siRNA duplex and preserve its orientation as determined by the direction of the dsRNA processing reaction. Only the siRNA sequence associated with the blue protein is able to guide target RNA cleavage.
- the endonuclease complex is referred to as small interfering ribonucleoprotein complex or siRNP. It is presumed here, that the endonuclease that cleaves the dsRNA may also cleave the target RNA, probably by temporarily displacing the passive siRNA strand not used for target recognition. The target RNA is then cleaved in the center of the region recognized by the sequence-complementary guide siRNA.
- FIG. 8 Reporter constructs and siRNA duplexes.
- the region targeted by the siRNA duplexes is indicated as black bar below the coding region of the luciferase genes.
- the sense (top) and antisense (bottom) sequences of the siRNA duplexes targeting GL2, GL3 and RL luciferase are shown.
- the GL2 and GL3 siRNA duplexes differ by only 3 single nucleotide substitutions (boxed in gray).
- a duplex with the inverted GL2 sequence, invGL2 was synthesized.
- the 2 nt 3′ overhang of 2′-deoxythymidine is indicated as TT; uGL2 is similar to GL2 siRNA but contains ribo-uridine 3′ overhangs.
- FIG. 9 RNA interference by siRNA duplexes.
- Ratios of target control luciferase were normalized to a buffer control (bu, black bars); gray bars indicate ratios of Photinus pyralis (Pp-luc) GL2 or GL3 luciferase to Renilla reniformis (Rr-luc) RL luciferase (left axis), white bars indicate RL to GL2 or GL3 ratios (right axis).
- Panels a, c, e, g and i describe experiments performed with the combination of pGL2-Control and pRL-TK reporter plasmids, panels b, d, f, h and j with pGL3-Control and pRL-TK reporter plasmids.
- the cell line used for the interference experiment is indicated at the top of each plot.
- the ratios of Pp-luc/Rr-luc for the buffer control (bu) varied between 0.5 and 10 for pGL2/pRL and between 0.03 and 1 for pGL3/pRL, respectively, before normalization and between the various cell lines tested.
- the plotted data were averaged from three independent experiments ⁇ S.D.
- FIG. 10 Effects of 21 nt siRNA, 50 bp and 500 bp dsRNAs on luciferase expression in HeLa cells.
- the ratios of luciferase activity for siRNA duplexes were normalized to a buffer control (bu, black bars); the luminescence ratios for 50 or 500 bp dsRNAs were normalized to the respective ratios observed for 50 and 500 bp dsRNA from humanized GFP (hG, black bars). It should be noted that the overall differences in sequences between the 49 and 484 bp dsRNAs targeting GL2 and GL3 are not sufficient to confer specificity between GL2 and GL3 targets (43 nt uninterrupted identity in 49 bp segment, 239 nt longest uninterrupted identity in 484 bp segment).
- FIG. 11 Variation of the 3′ overhang of duplexes of 21-nt siRNAs.
- the luminescence ratios determined in the presence of dsRNA were normalized to the ratio obtained for a buffer control (bu, black bar). Normalized ratios less than 1 indicate specific interference.
- C-J Normalized interference ratios for eight series of 21-nt siRNA duplexes. The sequences of siRNA duplexes are depicted above the bar graphs. Each panel shows the interference ratio for a set of duplexes formed with a given antisense guide siRNA and 5 different sense siRNAs. The number of overhanging nucleotides (3′ overhang, positive numbers; 5′ overhangs, negative numbers) is indicated on the x-axis. Data points were averaged from at least 3 independent experiments, error bars represent standard deviations.
- FIG. 12 Variation of the length of the sense strand of siRNA duplexes.
- FIG. 13 Variation of the length of siRNA duplexes with preserved 2-nt 3′ overhangs.
- FIG. 11H or 12 C The siRNA duplexes were extended to the 3′ side of the sense siRNA (B) or the 5′ side of the sense siRNA (C). The siRNA duplex sequences and the respective interference ratios are indicated.
- FIG. 14 Substitution of the 2′-hydroxyl groups of the siRNA ribose residues.
- FIG. 15 Mapping of sense and antisense target RNA cleavage by 21-nt siRNA duplexes with 2-nt 3′ overhangs.
- the antisense siRNA was the same in all siRNA duplexes, but the sense strand was varied between 18 to 25 nt by changing the 3′ end (A) or 18 to 23 nt by changing the 5′ end (B).
- the position of sense and antisense target RNA cleavage is indicated by triangles on top and below the siRNA duplexes, respectively.
- C, D Analysis of target RNA cleavage using cap-labelled sense (top panel) or antisense (bottom panel) target RNAs. Only the cap-labelled 5′ cleavage products are shown. The sequences of the siRNA duplexes are indicated, and the length of the sense siRNA strands is marked on top of the panel.
- the control lane marked with a dash in panel (C) shows target RNA incubated in absence of siRNAs. Markers were as described in FIG. 15.
- the arrows in (D), bottom panel, indicate the target RNA cleavage sites that differ by 1 nt.
- FIG. 17 Sequence variation of the 3′ overhang of siRNA duplexes.
- the 2-nt 3′ overhang (NN, in gray) was changed in sequence and composition as indicated (T, 2′-deoxythymidine, dG, 2′-deoxyguanosine; asterisk, wild-type siRNA duplex). Normalized interference ratios were determined as described in FIG. 11. The wild-type sequence is the same as depicted in FIG. 14.
- FIG. 18 Sequence specificity of target recognition.
- the sequences of the mismatched siRNA duplexes are shown, modified sequence segments or single nucleotides are underlayed in gray.
- the reference duplex (ref) and the siRNA duplexes 1 to 7 contain 2′-deoxythymidine 2-nt overhangs.
- the silencing efficiency of the thymidine-modified reference duplex was comparable to the wild-type sequence (FIG. 17). Normnalized interference ratios were determined as described in FIG. 11.
- FIG. 19 Variation of the length of siRNA duplexes with preserved 2-nt 3′ overhangs.
- siRNA duplexes were extended to the 3′ side of the sense siRNA (A) or the 5′ side of the sense siRNA (B).
- the siRNA duplex sequences and the respective interference ratios are indicated.
- siRNA duplexes (0.84 ⁇ g) targeting GL2 luciferase were transfected together with pGL2-Control and pRL-TK plasmids.
- the in vitro RNAi activities of siRNA duplexes tested in D. melanogaster lysate are indicated.
- RNAi translation assays were performed with dsRNA concentrations of 5 nM and an-extended pre-incubation period of 15 min at 25° C. prior to the addition of in vitro transcribed, capped and polyadenylated Pp-luc and Rr-luc reporter mRNAs. The incubation was continued for 1 h and the relative amount of Pp-luc and Rr-luc protein was analyzed using the dual luciferase assay (Promega) and a Monolight 3010C luminometer (PharMingen).
- RNA was prepared using Expedite RNA phosphoramidites (Proligo).
- the 3′ adapter oligonucleotide was synthesized using dimethoxytrityl-1,4-benzenedimethanol-succinyl-aminopropyl-CPG.
- the oligoribonucleotides were deprotected in 3 ml of 32% ammonia/ethanol (3/1) for 4 h at 55° C. (Expedite RNA) or 16 h at 55° C.
- RNA transcripts for dsRNA preparation including long 3′ overhangs were generated from PCR templates that contained a T7 promoter in sense and an SP6 promoter in antisense direction.
- the transcription template for sense and antisense target RNA was PCR-amplified with GCG TAATACGACTCACTATA GAACAATTGCTTTTACAG (underlined, T7 promoter) as 5′ primer and ATTTAGGTGACACTATA GGCATAAAGAATTGAAGA (underlined, SP6 promoter) as 3′ primer and the linearized Pp-luc plasmid (pGEM-luc sequence) (Tuschl et al., 1999) as template; the T7-transcribed sense RNA was 177 nt long with the Pp-luc sequence between pos. 113-273 relative to the start codon and followed by 17 nt of the complement of the SP6 promoter sequence at the 3′ end. Transcripts for blunt-ended dsRNA formation were prepared by transcription from two different PCR products which only contained a single promoter sequence.
- DsRNA annealing was carried out using a phenol/chloroform extraction.
- Equimolar concentration of sense and antisense RNA 50 nM to 10 ⁇ M, depending on the length and amount available
- 0.3 M NaOAc pH 6
- the resulting dsRNA was precipitated by addition of 2.5-3 volumes of ethanol.
- the pellet was dissolved in lysis buffer (100 mM KCl, 30 mM HEPES-KOH, pH 7.4, 2 mM Mg(OAc) 2 ) and the quality of the dsRNA was verified by standard agarose gel electrophoreses in 1 ⁇ TAE-buffer.
- the 52 bp dsRNAs with the 17 nt and 20 nt 3′ overhangs (FIG. 6) were annealed by incubating for 1 min at 95 ° C., then rapidly cooled to 70° C. and followed by slow cooling to room temperature over a 3 h period (50 ⁇ l annealing reaction, 1 ⁇ M strand concentration, 300 mM NaCl, 10 mM Tris-HCl, pH 7.5).
- the dsRNAs were then phenol/chloroform extracted, ethanol-precipitated and dissolved in lysis buffer.
- RNA used for dsRNA preparation was performed using 1 mM ATP, CTP, GTP, 0.1 or 0.2 mM UTP, and 0.2-0.3 ⁇ M- 32 P-UTP (3000 Ci/mmol), or the respective ratio for radiolabeled nucleoside triphosphates other than UTP. Labeling of the cap of the target RNAs was performed as described previously. The target RNAs were gel-purified after cap-labeling.
- RNAi reactions were performed by pre-incubating 10 nM dsRNA for 15 min followed by addition of 10 nM cap-labeled target RNA. The reaction was stopped after a further 2 h (FIG. 2A) or 2.5 h incubation (FIGS. 5B and 6B) by proteinase K treatment (Tuschl et al., 1999). The samples were then analyzed on 8 or 10% sequencing gels. The 21 and 22 nt synthetic RNA duplexes were used at 100 nM final concentration (FIG. 5B).
- the 21 nt RNAs were produced by incubation of radiolabeled dsRNA in Drosophila lysate in absence of target RNA (200 ⁇ l reaction, 1 h incubation, 50 nM dsP111, or 100 nM dsP52 or dsP39).
- the reaction mixture was subsequently treated with proteinase K (Tuschl et al., 1999) and the dsRNA-processing products were separated on a denaturing 15% polyacrylamide gel.
- A-band including a size range of at least 18 to 24 nt, was excised, eluted into 0.3 M NaCl overnight at 4° C. and in siliconized tubes.
- RNA was recovered by ethanol-precipitation and dephosphorylated (30 ⁇ l reaction, 30 min, 50° C., 10 U alkaline phosphatase, Roche). The reaction was stopped by phenol/chloroform extraction and the RNA was ethanol-precipitated.
- the 3′ adapter oligonucleotide (pUUUaaccgcatccttctcx: uppercase, RNA; lowercase, DNA; p, phosphate; x, 4-hydroxymethylbenzyl) was then ligated to the dephosphorylated ⁇ 21 nt RNA (20 ⁇ l reaction, 30 min, 37° C., 5 ⁇ M 3′ adapter, 50 mM Tris-HCl, pH 7.6, 10 mM MgCl 2 , 0.2 mM ATP, 0.1 mg/ml acetylated BSA, 15% DMSO, 25 U T4 RNA ligase, Amersham-Pharmacia) (Pan and Uhlenbeck, 1992).
- the ligation reaction was stopped by the addition of an equal volume of 8 M urea/50 mM EDTA stopmix and directly loaded on a 15% gel. Ligation yields were greater 50%.
- the ligation product was recovered from the gel and 5′-phosphorylated (20 ⁇ l reaction, 30 min, 37° C., 2 mM ATP, 5 U T4 polynucleotide kinase, NEB).
- the phosphorylation reaction was stopped by phenol/chloroform extraction and RNA was recovered by ethanol-precipitation.
- the 5′ adapter (tactaatacgactcactAAA: uppercase, RNA; lowercase, DNA) was ligated to the phosphorylated ligation product as described above.
- the new ligation product was gel-purified and eluted from the gel slice in the presence of reverse transcription primer (GACTAGCTGGAATTCAAGGATGCGGTTAAA: bold, Eco RI site) used as carrier.
- Reverse transcription (15 ⁇ l reaction, 30 min, 42° C., 150 U Superscript 11 reverse transcriptase, Life Technologies) was followed by PCR using as 5′ primer CAGCCAACGGAATTCATACGACTCACTAAA (bold, Eco RI site) and the 3′ RT primer.
- the PCR product was purified by phenol/chloroform extraction and ethanol-precipitated.
- PCR product was then digested with Eco RI (NEB) and concatamerized using T4 DNA ligase (high conc., NEB). Concatamers of a size range of 200 to 800 bp were separated on a low-melt agarose gel, recovered from the gel by a standard melting and phenol extraction procedure, and ethanol-precipitated. The unpaired ends were filled in by incubation with Taq polymerase under standard conditions for 1 5 min at 72° C. and the DNA product was directly ligated into the pCR2.1-TOPO vector using the TOPO TA cloning kit (Invitrogen). Colonies were screened using PCR and M13-20 and M13 Reverse sequencing primers. PCR products were directly submitted for custom sequencing (Sequence Laboratories Göttingen GmbH, Germany). On average, four to five 21 mer sequences were obtained per clone.
- Nuclease P1 digestion of radiolabeled, gel-purified siRNAs and 2D-TLC was carried out as described (Zamore et al., 2000). Nuclease T2 digestion was performed in 10 ⁇ l reactions for 3 h at 50° C. in 10 mM ammonium acetate (pH 4.5) using 2 ⁇ g/ ⁇ l carrier tRNA and 30 U ribonuclease T2 (Life Technologies). The migration of non-radioactive standards was determined by UV shadowing.
- nucleoside-3′,5′-disphosphates The identity of nucleoside-3′,5′-disphosphates was confirmed by co-migration of the T2 digestion products with standards prepared by 5′- 32 P-phosphorylation of commercial nucleoside 3′-monophosphates using ⁇ -32P-ATP and T4 polynucleotide kinase (data not shown).
- Lysate prepared from D. melanogaster syncytial embryos recapitulates RNAi in vitro providing a novel tool for biochemical analysis of the mechanism of RNAi (Tuschl et al., 1999; Zamore et al., 2000).
- In vitro and in vivo analysis of the length requirements of dsRNA for RNAi has revealed that short dsRNA ( ⁇ 1 50 bp) are less effective than longer dsRNAs in degrading target mRNA (Caplen et al., 2000; Hammond et al., 2000; Ngo et al., 1998); Tuschl et al., 1999). The reasons for reduction in mRNA degrading efficiency are not understood.
- 21-23 nt RNA fragments generated by processing of dsRNAs are the mediators of RNA interference and co-suppression (Hamilton and Baulcombe, 1999; Hammond et al., 2000; Zamore et al., 2000).
- Formation of 21-23 nt fragments in Drosophila lysate (FIG. 2) was readily detectable for 39 to 501 bp long dsRNAs but was significantly delayed for the 29 bp dsRNA.
- the 52 bp dsRNA which shares the same 5′ end with the 39 bp dsRNA, produces the same cleavage site on the sense target, located 10 nt from the 5′ end of the region of identity with the dsRNA, in addition to two weaker cleavage sites 23 and 24 nt downstream of the first site.
- the antisense target was only cleaved once, again 10 nt from the 5′ end of the region covered by its respective dsRNA. Mapping of the cleavage sites for the 38 to 49 bp dsRNAs shown in FIG. 1 showed that the first and predominant cleavage site was always located 7 to 10 nt downstream of the region covered by the dsRNA (data not shown). This suggests that the point of target RNA cleavage is determined by the end of the dsRNA and could imply that processing to 21-23 mers starts from the ends of the duplex.
- Cleavage sites on sense and antisense target for the longer 111 bp dsRNA were much more frequent than anticipated and most of them appear in clusters separated by 20 to 23 nt (FIGS. 3A and 3B).
- the first cleavage site on the sense target is 10 nt from the 5′ end of the region spanned by the dsRNA
- the first cleavage site on the antisense target is located 9 nt from the 5′ end of region covered by the dsRNA.
- RNAi in transposon silencing.
- 3′ nucleotides that are derived from untemplated addition of nucleotides during RNA synthesis using T7 RNA polymerase.
- endogenous Drosophila ⁇ 21 nt RNAs were also cloned, some of them from LTR and non-LTR retrotransposons (data not shown). This is consistent with a possible role for RNAi in transposon silencing.
- the ⁇ 21 nt RNAs appear in clustered groups (FIG. 4A) which cover the entire dsRNA sequences. Apparently, the processing reaction cuts the dsRNA by leaving staggered 3′ ends, another characteristic of RNase III cleavage. For the 39 bp dsRNA, two clusters of ⁇ 21 nt RNAs were found from each dsRNA-constituting strand including overhanging 3′ ends, yet only one cleavage site was detected on the sense and antisense target (FIGS. 3A and 3B).
- ⁇ 21 nt fragments were present as single-stranded guide RNAs in a complex that mediates mRNA degradation, it could be assumed that at least two target cleavage sites exist, but this was not the case. This suggests that the ⁇ 21 nt RNAs may be present in double-stranded form in the endonuclease complex but that only one of the strands can be used for target RNA recognition and cleavage.
- the use of only one of the ⁇ 21 nt strands for target cleavage may simply be determined by the orientation in which the ⁇ 21 nt duplex is bound to the nuclease complex. This orientation is defined by the direction in which the original dsRNA was processed.
- the ⁇ 21 mer clusters for the 52 bp and 111 bp dsRNA are less well defined when compared to the 39 bp dsRNA.
- the clusters are spread over regions of 25 to 30 nt most likely representing several distinct subpopulations of ⁇ 21 nt duplexes and therefore guiding target cleavage at several nearby sites. These cleavage regions are still predominantly separated by 20 to. 23 nt intervals.
- the rules determining how regular dsRNA can be processed to ⁇ 21 nt fragments are not yet understood, but it was previously observed that the approx. 21-23 nt spacing of cleavage sites could be altered by a run of uridines (Zamore et al., 2000).
- dsRNA cleavage by E. coli RNase III appears to be mainly controlled by antideterminants, i.e. excluding some specific base-pairs at given positions relative to the cleavage site (Zhang and Nicholson, 1997).
- nucleoside 3′,5′-diphosphates All four nucleoside 3′,5′-diphosphates were detected and suggest that the internucleotidic linkage was cleaved with little or no sequence-specificity.
- the ⁇ 21 nt fragments are unmodified and were generated from dsRNA such that 5′-monophosphates and 3′-hydroxyls were present at the 5′-end.
- the 21 and 22 nt RNA duplexes were incubated at 100 nM concentrations in the lysate, a 10-fold higher concentrations-than the 52 bp control dsRNA. Under these conditions, target RNA cleavage is readily detectable. Reducing the concentration of 21 and 22 nt duplexes from 100 to 10 nM does still cause target RNA cleavage. Increasing the duplex concentration from 100 nM to 1000 nM however does not further increase target cleavage, probably due to a limiting protein factor within the lysate.
- the 21 and 22 nt dsRNAs with overhanging 3′ ends of 2 to 4 nt mediated efficient degradation of target RNA (duplexes 1, 3, 4, 6, FIGS. 5A and 5B).
- Blunt-ended 21 or 22 nt dsRNAs (duplexes 2, 5, and 7, FIGS. 5A and 5B) were reduced in their ability to degrade the target and indicate that overhanging 3′ ends are critical for reconstitution of the RNA-protein nuclease complex.
- the single-stranded overhangs may be required for high affinity binding of the ⁇ 21 nt duplex to the protein components.
- the target cleavage site is located 11 or 1 2 nt downstream of the first nucleotide that is complementary to the 21 or 22 nt guide sequence, i.e. the cleavage site is near center of the region covered by the 21 or 22 nt RNAs (FIGS. 4A and 4B).
- Displacing the sense strand of a 22 nt duplex by two nucleotides (compare duplexes 1 and 3 in FIG. 5A) displaced the cleavage site of only the antisense target by two nucleotides.
- Displacing both sense and antisense strand by two nucleotides shifted both cleavage sites by two nucleotides (compare duplexes 1 and 4).
- siRNAs short interfering RNAs
- siRNP small interfering ribonucleoprotein particle
- long dsRNAs may also contain internal dsRNA-processing signals or may get processed cooperatively due to the association of multiple cleavage factors.
- Double-stranded RNA is first processed to short RNA duplexes of predominantly 21 and 22 nt in length and with staggered 3′ ends similar to an RNase III-like reaction (Dunn, 1982; Nicholson, 1999; Robertson, 1982). Based on the 21-23 nt length of the processed RNA fragments it has already been speculated that an RNase III-like activity may be involved in RNAi (Bass, 2000).
- RNase III homologs Little is known about the biochemistry of RNase III homologs from plants, animals or human.
- Two families of RNase III enzymes have been identified predominantly by database-guided sequence analysis or cloning of cDNAs.
- the first RNase-III family is represented by the 1327 amino acid long D. melanogaster protein drosha (Acc. AF116572).
- the C-terminus is composed of two RNase III and one dsRNA-binding domain and the N-terminus is of unknown function. Close homologs are also found in C. elegans (Acc. AF160248) and human (Acc. AF18901 1) (Filippov et al., 2000; Wu et al., 2000).
- the drosha-like human RNase III was recently cloned and characterized (Wu et al., 2000).
- the gene is ubiquitously expressed in human tissues and cell lines, and the protein is localized in the nucleus and the nucleolus of the cell. Based on results inferred from antisense inhibition studies, a role of this protein for rRNA processing was suggested.
- the second class is represented by the C. elegans gene K12H4.8 (Acc. S44849) coding for a 1822 amino acid long protein.
- This protein has an N-terminal RNA helicase motif which is followed by 2 RNase III catalytic domains and a dsRNA-binding motif, similar to the drosha RNase III family. There are close homologs in S.
- pombe (Acc. Q09884), A. thaliana (Acc. AF187317), D. melanogaster (Acc. AE003740), and human (Acc. AB028449) (Filippov et al., 2000; Jacobsen et al., 1 999; Matsuda et al., 2000). Possibly the K12H4.8 RNase III/helicase is the likely candidate to be involved in RNAi.
- Processing to the siRNA duplexes appears to start from the ends of both blunt-ended dsRNAs or dsRNAs with short (1-5 nt) 3′ overhangs, and proceeds in approximately 21-23 nt steps.
- Long ( ⁇ 20 nt) 3′ staggered ends on short dsRNAs suppress RNAi, possibly through interaction with single-stranded RNA-binding proteins.
- the suppression of RNAi by single-stranded regions flanking short dsRNA and the lack of siRNA formation from short 30 bp dsRNAs may explain why structured regions frequently encountered in mRNAs do not lead to activation of RNAi.
- siRNA duplexes guide cleavage of sense as well as antisense target RNA as they are able to associate with the protein components in either of the two possible orientation.
- siRNA duplexes represent a new alternative to antisense or ribozyme therapeutics.
- RNAs were chemically synthesized using Expedite RNA phosphoramidites and thymidine phosphoramidite (Proligo, Germany). Synthetic oligonucleotides were deprotected and gel-purified (Example 1), followed by Sep-Pak C18 cartridge (Waters, Milford, Mass., USA) purification (Tuschl, 1993).
- the siRNA sequences targeting GL2 (Acc. X65324) and GL3 luciferase (Acc. U47296) corresponded to the coding regions 153-173 relative to the first nucleotide of the start codon, siRNAs targeting RL (Acc.
- AF025846 corresponded to region 119-129 after the start codon.
- Longer RNAs were transcribed with T7 RNA polymerase from PCR products, followed by gel and Sep-Pak purification.
- the 49 and 484 bp GL2 or GL3 dsRNAs corresponded to position 113-161 and 113-596, respectively, relative to the start of translation; the 50 and 501 bp RL dsRNAs corresponded to position 118-167 and 118-618, respectively.
- PCR templates for dsRNA synthesis targeting humanized GFP were amplified from pAD3 (Kehlenbach, 1998), whereby 50 and 501 bp hG dsRNA corresponded to position 118-167 and 118-618, respectively, to the start codon.
- annealing buffer 100 mM potassium acetate, 30 mM HEPES-KOH at pH 7.4, 2 mM magnesium acetate
- annealing buffer 100 mM potassium acetate, 30 mM HEPES-KOH at pH 7.4, 2 mM magnesium acetate
- the 37° C. incubation step was extended overnight for the 50 and 500 bp dsRNAs and these annealing reactions were performed at 8.4 ⁇ M and 0.84 ⁇ M strand concentrations, respectively.
- S2 cells were propagated in Schneider's Drosophila medium (Life Technologies) supplemented with 10% FBS, 100 units/ml penicillin and 100 ⁇ g/ml streptomycin at 25° C. 293, NIH/3T3, HeLa S3, COS-7 cells were grown at 37° C. in Dulbecco's modified Eagle's medium supplemented with 10% FBS, 100 units/ml penicillin and 100 ⁇ g/ml streptomycin. Cells were regularly passaged to maintain exponential growth. 24 h before transfection at approx.
- mammalian cells were trypsinized and diluted 1:5 with fresh medium without antibiotics (1-3 ⁇ 10 5 cells/ml) and transferred to 24-well plates (500 ⁇ l/well). S2 cells were not trypsinized before splitting. Transfection was carried out with Lipofectamine 2000 reagent (Life Technologies) as described by the manufacturer for adherent cell lines. Per well, 1.0 ⁇ g pGL2-Control (Promega) or pGL3-Control (Promega), 0.1 ⁇ g pRL-TK (Promega) and 0.28 ⁇ g siRNA duplex or dsRNA, formulated into liposomes, were applied; the final volume was 600 ⁇ l per well.
- siRNA duplexes were co-transfected with the reporter plasmid combinations pGL2/pRL or pGL3/pRL into D. melanogaster Schneider S2 cells or mammalian cells using cationic liposomes. Luciferase activities were determined 20 h after transfection.
- FIG. 9 a - j In all cell lines tested, we observed specific reduction of the expression of the reporter genes in the presence of cognate siRNA duplexes (FIG. 9 a - j ). Remarkably, the absolute luciferase expression levels were unaffected by non-cognate siRNAs, indicating the absence of harmful side effects by 21 nt RNA duplexes (e.g. FIG. 10 a - d for HeLa cells). In D. melanogaster S2 cells (FIG. 9 a, b ), the specific inhibition of luciferases was complete. In mammalian cells, where the reporter genes were 50- to 100-fold stronger expressed, the specific suppression was less complete (FIG. 9 c - j ).
- GL2 expression was reduced 3- to 12-fold, GL3 expression 9- to 25-fold and RL expression 1- to 3-fold, in response to the cognate siRNAs.
- targeting of RL luciferase by RL siRNAs was ineffective, although GL2 and GL3 targets responded specifically (FIG. 9 i, j ).
- the lack of reduction of RL expression in 293 cells may be due to its 5- to 20-fold higher expression compared to any other mammalian cell line tested and/or to limited accessibility of the target sequence due to RNA secondary structure or associated proteins. Nevertheless, specific targeting of GL2 and GL3 luciferase by the cognate siRNA duplexes indicated that RNAi is also functioning in 293 cells.
- the thymidine overhang was chosen, because it is supposed to enhance nuclease resistance of siRNAs in the tissue culture medium and within transfected cells. Indeed, the thymidine-modified GL2 siRNA was slightly more potent than the unmodified uGL2 siRNA in all cell lines tested (FIG. 9 a, c, e, g, i ). It is conceivable that further modifications of the 3′ overhanging nucleotides may provide additional benefits to the delivery and stability of siRNA duplexes.
- siRNA duplexes were used (FIG. 9, 10).
- Increasing the siRNA concentration to 100 nM did not enhance the specific silencing effects, but started to affect transfection efficiencies due to competition for liposome encapsulation between plasmid DNA and siRNA (data not shown).
- Decreasing the siRNA concentration to 1.5 nM did not reduce the specific silencing effect (data not shown), even though the siRNAs were now only 2- to 20-fold more concentrated than the DNA plasmids. This indicates that siRNAs are extraordinarily powerful reagents for mediating gene silencing and that siRNAs are effective at concentrations that are several orders of magnitude below the concentrations applied in conventional antisense or ribozyme gene targeting experiments.
- dsRNAs In order to monitor the effect of longer dsRNAs on mammalian cells, 50 and 500 bp dsRNAs cognate to the reporter genes were prepared. As non-specific control, dsRNAs from humanized GFP (hG) (Kehlenbach, 1998) was used. When dsRNAs were co-transfected, in identical amounts (not concentrations) to the siRNA duplexes, the reporter gene expression was strongly and unspecifically reduced. This effect is illustrated for HeLa cells as a representative example (FIG. 10 a - d ).
- the absolute luciferase activities were decreased unspecifically 10- to 20-fold by 50 bp dsRNA and 20- to 200-fold by 500 bp dsRNA co-transfection, respectively. Similar unspecific effects were observed for COS-7 and NIH/3T3 cells. For 293 cells, a 10- to 20-fold unspecific reduction was observed only for 500 bp dsRNAs. Unspecific reduction in reporter gene expression by dsRNA >30 bp was expected as part of the interferon response.
- CHO-K1 cells appear to be deficient in the interferon response.
- 293, NIH/3T3 and BHK-21 cells were tested for RNAi using luciferase/lacZ reporter combinations and 829 bp specific lacZ or 717 bp unspecific GFP dsRNA (Caplen, 2000).
- the failure of detecting RNAi in this case may be due to the less sensitive luciferase/lacZ reporter assay and the length differences of target and control dsRNA.
- our results indicate that RNAi is active in mammalian cells, but that the silencing effect is difficult to detect, if the interferon system is activated by dsRNA >30 bp.
- siRNA-mediated gene silencing in mammalian cells.
- the use of short siRNAs holds great promise for inactivation of gene function in human tissue culture and the development of gene-specific therapeutics.
- RNA synthesis, annealing, and luciferase-based RNAi assays were performed as described in Examples 1 or 2 or in previous publications (Tuschl et al., 1999; Zamore et al., 2000). All siRNA duplexes were directed against firefly luciferase, and the luciferase mRNA sequence was derived from pGEM-luc (GenBank acc. X65316) as described (Tuschl et al., 1999). The siRNA duplexes were incubated in D. melanogaster RNAi/translation reaction for 15 min prior to addition of mRNAs. Translation-based RNAi assays were performed at least in triplicates.
- mapping of sense target RNA cleavage a 177-nt transcript was generated, corresponding to the firefly luciferase sequence between positions 113-273 relative to the start codon, followed by the 17-nt complement of the SP6 promoter sequence.
- mapping of antisense target RNA cleavage a 166-nt transcript was produced from a template, which was amplified from plasmid sequence by PCR using 5′ primer TAATACGACTCACTATAGA GCCCATATCGTTTCATA (T7 promoter underlined) and 3! primer AGAGGATGGAACCGCTGG.
- the target sequence corresponds to the complement of the firefly luciferase sequence between positions 50-215 relative to the start codon.
- Guanylyl transferase labelling was performed as previously described (Zamore et al., 2000).
- 100 nM siRNA duplex was incubated with 5 to 10 nM target RNA in D. melanogaster embryo lysate under standard conditions (Zamore et al., 2000) for 2 h at 25° C.
- the reaction was stopped by the addition of 8 volumes of proteinase K buffer (200 mM Tris-HCl pH 7.5, 25 mM EDTA, 300 mM NaCl, 2% w/v sodium dodecyl sulfate). Proteinase K (E.M.
- siRNA duplexes As described above, 2 or 3 unpaired nucleotides at the 3′ end of siRNA duplexes were more efficient in target RNA degradation than the respective blunt-ended duplexes.
- sense and antisense siRNAs eight series of siRNA duplexes with synthetic overhanging ends were generated covering a range of 7-nt 3′ overhang to 4-nt 5′ overhang.
- siRNA duplexes The interference of siRNA duplexes was measured using the dual luciferase assay system (Tuschl et al., 1999; Zamore et al., 2000). siRNA duplexes were directed against firefly luciferase mRNA, and sea pansy luciferase mRNA was used as internal control. The luminescence ratio of target to control luciferase activity was determined in the presence of siRNA duplex and was normalized to the ratio observed in the absence of dsRNA. For comparison, the interference ratios of long dsRNAs (39 to 504 pb) are shown in FIG. 11B. The interference ratios were determined at concentrations of 5 nM for long dsRNAs (FIG.
- FIG. 13A Two series of siRNA duplexes were prepared including the 21-nt siRNA duplex of FIG. 11H as reference. The length of the duplexes was varied between 20 to 25 bp by extending the base-paired segment at the 3′ end of the sense siRNA (FIG. 13B) or at the 3′ end of the antisense siRNA (FIG. 13C). Duplexes of 20 to 23 bp caused specific repression of target luciferase activity, but the 21-nt siRNA duplex was at least 8-fold more efficient than any of the other duplexes. 24- and 25-nt siRNA duplexes did not result in any detectable interference. Sequence-specific effects were minor as variations on both ends of the duplex produced similar effects.
- siRNA ribose residues were examined (FIG. 14).
- Substitution of the 2-nt 3′ overhangs by 2′-deoxy nucleotides had no effect, and even the replacement of two additional riboncleotides adjacent to the overhangs in the paired region, produced significantly active siRNAs.
- 8 out of 42 nt of a siRNA duplex were replaced by DNA residues without loss of activity.
- Complete substitution of one or both siRNA strands by 2′-deoxy residues abolished RNAi, as did substitution by 2′-O-methyl residues.
- Target RNA cleavage positions were previously determined for 22-nt siRNA duplexes and for a 21-nt/22-nt duplex. It was found that the position of the target RNA cleavage was located in the centre of the region covered by the siRNA duplex, 11 or 12 nt downstream of the first nucleotide that was complementary to the 21- or 22-nt siRNA guide sequence.
- Five distinct 21-nt siRNA duplexes with 2-nt 3′ overhang (FIG. 1 5 A) were incubated with 5′ cap-labelled sense or antisense target RNA in D. melanogaster lysate (Tuschl et al., 1999; Zamore et al., 2000).
- the 5′ cleavage products were resolved on sequencing gels (FIG. 15B).
- the amount of sense target RNA cleaved correlates with the efficiency of siRNA duplexes determined in the translation-based assay, and siRNA duplexes 1, 2 and 4 (FIGS. 15B and 11H, G, E) cleave target RNA faster than duplexes 3 and 5 (FIGS. 15B and 11F, D).
- the sum of radioactivity of the 5′ cleavage product and the input target RNA were not constant over time, and the 5′ cleavage products did not accumulate.
- the cleavage products, once released from the siRNA-endonuclease complex are rapidly degraded due to the lack of either of the poly(A) tail of the 5′-cap.
- the cleavage sites for both, sense and antisense target RNAs were located in the middle of the region spanned by the siRNA duplexes.
- the cleavage sites for each target produced by the 5 different duplexes varied by 1-nt according to the 1-nt displacement of the duplexes along the target sequences.
- the targets were cleaved precisely 11 nt downstream of the target position complementary to the 3′-most nucleotide of the sequence-complementary guide siRNA (FIG. 15A, B).
- a 2-nt 3′ overhang is preferred for siRNA function.
- RISC or siRNP endonuclease complex
- sequence changes were introduced by inverting short segments of 3- or 4-nt length or as point mutations (FIG. 18).
- the sequence changes in one siRNA strand were compensated in the complementary siRNA strand to avoid pertubing the base-paired siRNA duplex structure.
- the sequence of all 2-nt 3′ overhangs was TT (T, 2′-deoxythymidine) to reduce costs of synthesis.
- the TT/TT reference siRNA duplex was comparable in RNAi to the wild-type siRNA duplex AA/UG (FIG. 17).
- Efficiently silencing siRNA duplexes are preferably composed of 21-nt antisense siRNAs, and should be selected to form a 19 bp double helix with 2-nt 3′ overhanging ends.
- 2′-deoxy substitutions of the 2-nt 3′ overhanging ribonucleotides do not affect RNAi, but help to reduce the costs of RNA synthesis and may enhance RNAse resistance of siRNA duplexes. More extensive 2′-deoxy or 2′-O-methyl modifications, however, reduce the ability of siRNAs to mediate RNAi, probably by interfering with protein association for siRNAP assembly.
- Target recognition is a highly sequence-specific process, mediated by the siRNA complementary to the target.
- the 3′-most nucleotide of the guide siRNA does not contribute to specificity of target recognition, while the penultimate nucleotide of the 3′ overhang affects target RNA cleavage, and a mismatch reduces RNAi 2- to 4-fold.
- the 5′ end of a guide siRNA also appears more permissive for mismatched target RNA recognition when compared to the 3′ end.
- Nucleotides in the centre of the siRNA, located opposite the target RNA cleavage site are important specificity determinants and even single nucleotide changes reduce RNAi to undetectable level. This suggests that siRNA duplexes may be able to discriminate mutant or polymorphic alleles in gene targeting experiments, which may become an important feature for future therapeutic developments.
- siRNA sequences with identical 3′ overhanging sequences.
- Asymmetry in reconstitution of sense and antisense-cleaving siRNPs could be (partially) responsible for the variation in RNAi efficiency observed for various 21-nt siRNA duplexes with 2-nt 3′ overhangs used in this study (FIG. 14).
- the nucleotide sequence at the target site and/or the accessibility of the target RNA structure may be responsible for the variation in efficiency for these siRNA duplexes.
- PKR a protein kinase regulated by double-stranded RNA. Int. J. Biochem. Cell Biol. 29, 945-949.
- EGO-1 is related to RNA-directed RNA polymerase and functions in germ-line development and RNA interference in C. elegans. Curr. Biol. 10, 169-178.
- RNAi Double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101, 25-33.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (23)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/433,050 US20040259247A1 (en) | 2000-12-01 | 2001-11-29 | Rna interference mediating small rna molecules |
US10/832,257 US20050026278A1 (en) | 2000-12-01 | 2004-04-27 | RNA interference mediating small RNA molecules |
US11/142,865 US20050234006A1 (en) | 2000-12-01 | 2005-06-02 | RNA interference mediating small RNA molecules |
US11/142,866 US20050234007A1 (en) | 2000-12-01 | 2005-06-02 | RNA interference mediating small RNA molecules |
US11/634,138 US20080269147A1 (en) | 2000-12-01 | 2006-12-06 | RNA interference mediating small RNA molecules |
US11/634,129 US20070093445A1 (en) | 2000-12-01 | 2006-12-06 | RNA interference mediating small RNA molecules |
US12/260,443 US20090155174A1 (en) | 2000-12-01 | 2008-10-29 | RNA Interference Mediating Small RNA Molecules |
US12/537,602 US8372968B2 (en) | 2000-12-01 | 2009-08-07 | RNA interference mediating small RNA molecules |
US12/537,632 US20100010207A1 (en) | 2000-12-01 | 2009-08-07 | Rna interference mediating small rna molecules |
US12/591,829 US8853384B2 (en) | 2000-12-01 | 2009-12-02 | RNA interference mediating small RNA molecules |
US12/683,081 US8362231B2 (en) | 2000-12-01 | 2010-01-06 | RNA interference mediating small RNA molecules |
US12/683,070 US8933044B2 (en) | 2000-12-01 | 2010-01-06 | RNA interference mediating small RNA molecules |
US12/794,071 US8765930B2 (en) | 2000-12-01 | 2010-06-04 | RNA interference mediating small RNA molecules |
US12/819,444 US8796016B2 (en) | 2000-12-01 | 2010-06-21 | RNA interference mediating small RNA molecules |
US12/834,311 US8445237B2 (en) | 2000-12-01 | 2010-07-12 | RNA interference mediating small RNA molecules |
US12/835,086 US8778902B2 (en) | 2000-12-01 | 2010-07-13 | RNA interference mediating small RNA molecules |
US12/838,786 US8329463B2 (en) | 2000-12-01 | 2010-07-19 | RNA interference mediating small RNA molecules |
US12/879,300 US8993745B2 (en) | 2000-12-01 | 2010-09-10 | RNA interference mediating small RNA molecules |
US12/897,374 US8895718B2 (en) | 2000-12-01 | 2010-10-04 | RNA interference mediating small RNA molecules |
US13/725,262 US8895721B2 (en) | 2000-12-01 | 2012-12-21 | RNA interference mediating small RNA molecules |
US14/476,465 US9567582B2 (en) | 2000-12-01 | 2014-09-03 | RNA interference mediating small RNA molecules |
US15/388,681 US10633656B2 (en) | 2000-12-01 | 2016-12-22 | RNA interference mediating small RNA molecules |
US16/805,072 US20200299693A1 (en) | 2000-12-01 | 2020-02-28 | Rna interference mediating small rna molecules |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00126325.0 | 2000-12-01 | ||
EP00126325 | 2000-12-01 | ||
US27966101P | 2001-03-30 | 2001-03-30 | |
WOPCT/US01/10188 | 2001-03-30 | ||
PCT/US2001/010188 WO2001075164A2 (en) | 2000-03-30 | 2001-03-30 | Rna sequence-specific mediators of rna interference |
US10/433,050 US20040259247A1 (en) | 2000-12-01 | 2001-11-29 | Rna interference mediating small rna molecules |
PCT/EP2001/013968 WO2002044321A2 (en) | 2000-12-01 | 2001-11-29 | Rna interference mediating small rna molecules |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2001/013968 A-371-Of-International WO2002044321A2 (en) | 2000-12-01 | 2001-11-29 | Rna interference mediating small rna molecules |
Related Child Applications (13)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/832,432 Division US7056704B2 (en) | 2000-12-01 | 2004-04-27 | RNA interference mediating small RNA molecules |
US10/832,257 Division US20050026278A1 (en) | 2000-12-01 | 2004-04-27 | RNA interference mediating small RNA molecules |
US10/832,248 Division US7078196B2 (en) | 2000-12-01 | 2004-04-27 | RNA interference mediating small RNA molecules |
US11/142,865 Division US20050234006A1 (en) | 2000-12-01 | 2005-06-02 | RNA interference mediating small RNA molecules |
US11/142,866 Division US20050234007A1 (en) | 2000-12-01 | 2005-06-02 | RNA interference mediating small RNA molecules |
US11/634,129 Division US20070093445A1 (en) | 2000-12-01 | 2006-12-06 | RNA interference mediating small RNA molecules |
US11/634,138 Division US20080269147A1 (en) | 2000-12-01 | 2006-12-06 | RNA interference mediating small RNA molecules |
US12/260,443 Division US20090155174A1 (en) | 2000-12-01 | 2008-10-29 | RNA Interference Mediating Small RNA Molecules |
US12/537,602 Division US8372968B2 (en) | 2000-12-01 | 2009-08-07 | RNA interference mediating small RNA molecules |
US12/537,632 Division US20100010207A1 (en) | 2000-12-01 | 2009-08-07 | Rna interference mediating small rna molecules |
US12/683,070 Division US8933044B2 (en) | 2000-12-01 | 2010-01-06 | RNA interference mediating small RNA molecules |
US12/683,081 Division US8362231B2 (en) | 2000-12-01 | 2010-01-06 | RNA interference mediating small RNA molecules |
US12/897,374 Continuation US8895718B2 (en) | 2000-12-01 | 2010-10-04 | RNA interference mediating small RNA molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040259247A1 true US20040259247A1 (en) | 2004-12-23 |
Family
ID=40529293
Family Applications (25)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/433,050 Abandoned US20040259247A1 (en) | 2000-12-01 | 2001-11-29 | Rna interference mediating small rna molecules |
US10/832,248 Expired - Lifetime US7078196B2 (en) | 2000-12-01 | 2004-04-27 | RNA interference mediating small RNA molecules |
US10/832,257 Abandoned US20050026278A1 (en) | 2000-12-01 | 2004-04-27 | RNA interference mediating small RNA molecules |
US10/832,432 Expired - Lifetime US7056704B2 (en) | 2000-12-01 | 2004-04-27 | RNA interference mediating small RNA molecules |
US11/142,865 Abandoned US20050234006A1 (en) | 2000-12-01 | 2005-06-02 | RNA interference mediating small RNA molecules |
US11/142,866 Abandoned US20050234007A1 (en) | 2000-12-01 | 2005-06-02 | RNA interference mediating small RNA molecules |
US11/634,138 Abandoned US20080269147A1 (en) | 2000-12-01 | 2006-12-06 | RNA interference mediating small RNA molecules |
US11/634,129 Abandoned US20070093445A1 (en) | 2000-12-01 | 2006-12-06 | RNA interference mediating small RNA molecules |
US12/260,443 Abandoned US20090155174A1 (en) | 2000-12-01 | 2008-10-29 | RNA Interference Mediating Small RNA Molecules |
US12/537,632 Abandoned US20100010207A1 (en) | 2000-12-01 | 2009-08-07 | Rna interference mediating small rna molecules |
US12/537,602 Expired - Lifetime US8372968B2 (en) | 2000-12-01 | 2009-08-07 | RNA interference mediating small RNA molecules |
US12/591,829 Expired - Fee Related US8853384B2 (en) | 2000-12-01 | 2009-12-02 | RNA interference mediating small RNA molecules |
US12/683,081 Expired - Lifetime US8362231B2 (en) | 2000-12-01 | 2010-01-06 | RNA interference mediating small RNA molecules |
US12/683,070 Expired - Fee Related US8933044B2 (en) | 2000-12-01 | 2010-01-06 | RNA interference mediating small RNA molecules |
US12/794,071 Expired - Fee Related US8765930B2 (en) | 2000-12-01 | 2010-06-04 | RNA interference mediating small RNA molecules |
US12/819,444 Expired - Fee Related US8796016B2 (en) | 2000-12-01 | 2010-06-21 | RNA interference mediating small RNA molecules |
US12/834,311 Expired - Lifetime US8445237B2 (en) | 2000-12-01 | 2010-07-12 | RNA interference mediating small RNA molecules |
US12/835,086 Expired - Fee Related US8778902B2 (en) | 2000-12-01 | 2010-07-13 | RNA interference mediating small RNA molecules |
US12/838,786 Expired - Lifetime US8329463B2 (en) | 2000-12-01 | 2010-07-19 | RNA interference mediating small RNA molecules |
US12/879,300 Expired - Fee Related US8993745B2 (en) | 2000-12-01 | 2010-09-10 | RNA interference mediating small RNA molecules |
US12/897,374 Expired - Fee Related US8895718B2 (en) | 2000-12-01 | 2010-10-04 | RNA interference mediating small RNA molecules |
US13/725,262 Expired - Fee Related US8895721B2 (en) | 2000-12-01 | 2012-12-21 | RNA interference mediating small RNA molecules |
US14/476,465 Expired - Lifetime US9567582B2 (en) | 2000-12-01 | 2014-09-03 | RNA interference mediating small RNA molecules |
US15/388,681 Expired - Lifetime US10633656B2 (en) | 2000-12-01 | 2016-12-22 | RNA interference mediating small RNA molecules |
US16/805,072 Abandoned US20200299693A1 (en) | 2000-12-01 | 2020-02-28 | Rna interference mediating small rna molecules |
Family Applications After (24)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/832,248 Expired - Lifetime US7078196B2 (en) | 2000-12-01 | 2004-04-27 | RNA interference mediating small RNA molecules |
US10/832,257 Abandoned US20050026278A1 (en) | 2000-12-01 | 2004-04-27 | RNA interference mediating small RNA molecules |
US10/832,432 Expired - Lifetime US7056704B2 (en) | 2000-12-01 | 2004-04-27 | RNA interference mediating small RNA molecules |
US11/142,865 Abandoned US20050234006A1 (en) | 2000-12-01 | 2005-06-02 | RNA interference mediating small RNA molecules |
US11/142,866 Abandoned US20050234007A1 (en) | 2000-12-01 | 2005-06-02 | RNA interference mediating small RNA molecules |
US11/634,138 Abandoned US20080269147A1 (en) | 2000-12-01 | 2006-12-06 | RNA interference mediating small RNA molecules |
US11/634,129 Abandoned US20070093445A1 (en) | 2000-12-01 | 2006-12-06 | RNA interference mediating small RNA molecules |
US12/260,443 Abandoned US20090155174A1 (en) | 2000-12-01 | 2008-10-29 | RNA Interference Mediating Small RNA Molecules |
US12/537,632 Abandoned US20100010207A1 (en) | 2000-12-01 | 2009-08-07 | Rna interference mediating small rna molecules |
US12/537,602 Expired - Lifetime US8372968B2 (en) | 2000-12-01 | 2009-08-07 | RNA interference mediating small RNA molecules |
US12/591,829 Expired - Fee Related US8853384B2 (en) | 2000-12-01 | 2009-12-02 | RNA interference mediating small RNA molecules |
US12/683,081 Expired - Lifetime US8362231B2 (en) | 2000-12-01 | 2010-01-06 | RNA interference mediating small RNA molecules |
US12/683,070 Expired - Fee Related US8933044B2 (en) | 2000-12-01 | 2010-01-06 | RNA interference mediating small RNA molecules |
US12/794,071 Expired - Fee Related US8765930B2 (en) | 2000-12-01 | 2010-06-04 | RNA interference mediating small RNA molecules |
US12/819,444 Expired - Fee Related US8796016B2 (en) | 2000-12-01 | 2010-06-21 | RNA interference mediating small RNA molecules |
US12/834,311 Expired - Lifetime US8445237B2 (en) | 2000-12-01 | 2010-07-12 | RNA interference mediating small RNA molecules |
US12/835,086 Expired - Fee Related US8778902B2 (en) | 2000-12-01 | 2010-07-13 | RNA interference mediating small RNA molecules |
US12/838,786 Expired - Lifetime US8329463B2 (en) | 2000-12-01 | 2010-07-19 | RNA interference mediating small RNA molecules |
US12/879,300 Expired - Fee Related US8993745B2 (en) | 2000-12-01 | 2010-09-10 | RNA interference mediating small RNA molecules |
US12/897,374 Expired - Fee Related US8895718B2 (en) | 2000-12-01 | 2010-10-04 | RNA interference mediating small RNA molecules |
US13/725,262 Expired - Fee Related US8895721B2 (en) | 2000-12-01 | 2012-12-21 | RNA interference mediating small RNA molecules |
US14/476,465 Expired - Lifetime US9567582B2 (en) | 2000-12-01 | 2014-09-03 | RNA interference mediating small RNA molecules |
US15/388,681 Expired - Lifetime US10633656B2 (en) | 2000-12-01 | 2016-12-22 | RNA interference mediating small RNA molecules |
US16/805,072 Abandoned US20200299693A1 (en) | 2000-12-01 | 2020-02-28 | Rna interference mediating small rna molecules |
Country Status (28)
Country | Link |
---|---|
US (25) | US20040259247A1 (ja) |
EP (3) | EP1873259B1 (ja) |
JP (5) | JP4095895B2 (ja) |
KR (2) | KR100872437B1 (ja) |
CN (1) | CN100523215C (ja) |
AT (1) | ATE373724T2 (ja) |
AU (3) | AU2002235744B8 (ja) |
BR (1) | BRPI0115814B8 (ja) |
CA (1) | CA2429814C (ja) |
CY (1) | CY1119062T1 (ja) |
CZ (2) | CZ308053B6 (ja) |
DE (1) | DE60130583T3 (ja) |
DK (2) | DK2813582T3 (ja) |
ES (2) | ES2728168T3 (ja) |
HK (4) | HK1110631A1 (ja) |
HU (1) | HU230458B1 (ja) |
IL (3) | IL155991A0 (ja) |
LT (1) | LTPA2021005I1 (ja) |
MX (1) | MXPA03004836A (ja) |
NO (2) | NO333713B1 (ja) |
NZ (1) | NZ525888A (ja) |
PL (1) | PL218876B1 (ja) |
PT (1) | PT1407044E (ja) |
RU (2) | RU2322500C2 (ja) |
SI (1) | SI1407044T2 (ja) |
TR (1) | TR200401292T3 (ja) |
WO (1) | WO2002044321A2 (ja) |
ZA (1) | ZA200303929B (ja) |
Cited By (467)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020086356A1 (en) * | 2000-03-30 | 2002-07-04 | Whitehead Institute For Biomedical Research | RNA sequence-specific mediators of RNA interference |
US20030139363A1 (en) * | 2001-07-23 | 2003-07-24 | Kay Mark A. | Methods and compositions for RNAi mediated inhibition of viral gene expression in mammals |
US20030139585A1 (en) * | 2001-07-12 | 2003-07-24 | Eugen Uhlmann | Synthetic double-stranded oligonucleotides for specific inhibition of gene expression |
US20030153519A1 (en) * | 2001-07-23 | 2003-08-14 | Kay Mark A. | Methods and compositions for RNAi mediated inhibition of gene expression in mammals |
US20030157030A1 (en) * | 2001-11-02 | 2003-08-21 | Insert Therapeutics, Inc. | Methods and compositions for therapeutic use of rna interference |
US20040005593A1 (en) * | 2002-03-06 | 2004-01-08 | Rigel Pharmaceuticals, Inc. | Novel method for delivery and intracellular synthesis of siRNA molecules |
US20040014956A1 (en) * | 2002-02-01 | 2004-01-22 | Sequitur, Inc. | Double-stranded oligonucleotides |
US20040053411A1 (en) * | 2002-05-03 | 2004-03-18 | Duke University | Method of regulating gene expression |
US20040063654A1 (en) * | 2001-11-02 | 2004-04-01 | Davis Mark E. | Methods and compositions for therapeutic use of RNA interference |
US20040086845A1 (en) * | 1999-10-20 | 2004-05-06 | Tzyy-Choou Wu | Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen |
US20040091457A1 (en) * | 2001-10-12 | 2004-05-13 | Ribopharma Ag | Compositions and methods for inhibiting viral replication |
US20040096882A1 (en) * | 2002-08-21 | 2004-05-20 | Martin Gleave | RNAi probes targeting cancer-related proteins |
US20040096843A1 (en) * | 2002-02-14 | 2004-05-20 | Rossi John J. | Methods for producing interfering RNA molecules in mammalian cells and therapeutic uses for such molecules |
US20040147027A1 (en) * | 2003-01-28 | 2004-07-29 | Troy Carol M. | Complex for facilitating delivery of dsRNA into a cell and uses thereof |
US20040180357A1 (en) * | 2002-11-01 | 2004-09-16 | The Trustees Of The University Of Pennsylvania | Compositions and methods for siRNA inhibition of HIF-1 alpha |
US20040191905A1 (en) * | 2002-11-22 | 2004-09-30 | University Of Massachusetts | Modulation of HIV replication by RNA interference |
US20040192626A1 (en) * | 2002-02-20 | 2004-09-30 | Mcswiggen James | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20040203145A1 (en) * | 2002-08-07 | 2004-10-14 | University Of Massachusetts | Compositions for RNA interference and methods of use thereof |
US20040219671A1 (en) * | 2002-02-20 | 2004-11-04 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of parkinson disease using short interfering nucleic acid (siNA) |
US20040221337A1 (en) * | 1999-10-27 | 2004-11-04 | Baulcombe David C. | Gene silencing |
US20040242518A1 (en) * | 2002-09-28 | 2004-12-02 | Massachusetts Institute Of Technology | Influenza therapeutic |
US20040248296A1 (en) * | 2002-03-20 | 2004-12-09 | Beresford Paul J. | HIV therapeutic |
US20040248174A1 (en) * | 2003-04-18 | 2004-12-09 | Thetrustees Of The University Of Pennsylvania | Compositions and methods for siRNA inhibition of angiopoietin 1and 2 and their receptor Tie2 |
US20050004064A1 (en) * | 2001-11-21 | 2005-01-06 | Mitsubishi Chemical Corporation | Method of inhibiting gene expression |
US20050009042A1 (en) * | 2003-02-10 | 2005-01-13 | Aventis Pharma S.A. | Oligonucleotides which inhibit expression of the OB-RGRP protein and method for detecting compounds which modify the interaction between proteins of the OB-RGRP family and the leptin receptor |
US20050019918A1 (en) * | 2003-06-03 | 2005-01-27 | Hidetoshi Sumimoto | Treatment of cancer by inhibiting BRAF expression |
US20050037988A1 (en) * | 2003-06-02 | 2005-02-17 | University Of Massachusetts | Methods and compositions for controlling efficacy of RNA silencing |
US20050043524A1 (en) * | 2003-08-18 | 2005-02-24 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
US20050096289A1 (en) * | 2002-02-07 | 2005-05-05 | Hans Prydz | Methods and compositions for modulating tissue factor |
US20050136437A1 (en) * | 2003-08-25 | 2005-06-23 | Nastech Pharmaceutical Company Inc. | Nanoparticles for delivery of nucleic acids and stable double-stranded RNA |
US20050136430A1 (en) * | 2003-07-15 | 2005-06-23 | California Institute Of Technology | Inhibitor nucleic acids |
US20050142578A1 (en) * | 2002-02-20 | 2005-06-30 | Sirn Therapeutics, Inc. | RNA interference mediated target discovery and target validation using short interfering nucleic acid (siNA) |
US20050148526A1 (en) * | 2002-01-23 | 2005-07-07 | Kisielow Malgorzata A. | Methods of obtaining isoform specific expression in mammalian cells |
US20050159381A1 (en) * | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of chromosome translocation gene expression using short interfering nucleic acid (siNA) |
US20050164212A1 (en) * | 2003-03-06 | 2005-07-28 | Todd Hauser | Modulation of gene expression using DNA-RNA hybrids |
US20050176024A1 (en) * | 2001-05-18 | 2005-08-11 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of epidermal growth factor receptor (EGFR) gene expression using short interfering nucleic acid (siNA) |
US20050176025A1 (en) * | 2001-05-18 | 2005-08-11 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA) |
US20050181382A1 (en) * | 2003-06-02 | 2005-08-18 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of RNAi |
US20050202075A1 (en) * | 2004-03-12 | 2005-09-15 | Pardridge William M. | Delivery of genes encoding short hairpin RNA using receptor-specific nanocontainers |
US20050208658A1 (en) * | 2003-11-21 | 2005-09-22 | The University Of Maryland | RNA interference mediated inhibition of 11beta hydroxysteriod dehydrogenase-1 (11beta HSD-1) gene expression |
US20050227256A1 (en) * | 2003-11-26 | 2005-10-13 | Gyorgy Hutvagner | Sequence-specific inhibition of small RNA function |
US20050234000A1 (en) * | 2003-12-12 | 2005-10-20 | Mitchell Gordon S | SiRNA delivery into mammalian nerve cells |
US20050239731A1 (en) * | 2001-05-18 | 2005-10-27 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of MAP kinase gene expression using short interfering nucleic acid (siNA) |
US20050245475A1 (en) * | 2002-11-14 | 2005-11-03 | Dharmacon, Inc. | Functional and hyperfunctional siRNA directed against Bcl-2 |
US20050256076A1 (en) * | 2004-03-26 | 2005-11-17 | Curis, Inc. | RNA interference modulators of hedgehog signaling and uses thereof |
US20050256071A1 (en) * | 2003-07-15 | 2005-11-17 | California Institute Of Technology | Inhibitor nucleic acids |
US20050260214A1 (en) * | 2004-05-12 | 2005-11-24 | Simon Michael R | Composition and method for introduction of RNA interference sequences into targeted cells and tissues |
US20050272682A1 (en) * | 2004-03-22 | 2005-12-08 | Evers Bernard M | SiRNA targeting PI3K signal transduction pathway and siRNA-based therapy |
US20050273868A1 (en) * | 2004-02-17 | 2005-12-08 | University Of Massachusetts | Methods and compositions for enhancing RISC activity in vitro and in vivo |
US20050277610A1 (en) * | 2004-03-15 | 2005-12-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
US20060003915A1 (en) * | 2002-04-18 | 2006-01-05 | Karina Drumm | Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification |
US20060008910A1 (en) * | 2004-06-07 | 2006-01-12 | Protiva Biotherapeuties, Inc. | Lipid encapsulated interfering RNA |
US20060008907A1 (en) * | 2004-06-09 | 2006-01-12 | The Curators Of The University Of Missouri | Control of gene expression via light activated RNA interference |
US20060009409A1 (en) * | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
US20060014289A1 (en) * | 2004-04-20 | 2006-01-19 | Nastech Pharmaceutical Company Inc. | Methods and compositions for enhancing delivery of double-stranded RNA or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells |
US20060025366A1 (en) * | 2004-07-02 | 2006-02-02 | Protiva Biotherapeutics, Inc. | Immunostimulatory siRNA molecules and uses therefor |
US20060030003A1 (en) * | 2004-05-12 | 2006-02-09 | Simon Michael R | Composition and method for introduction of RNA interference sequences into targeted cells and tissues |
WO2006020557A2 (en) * | 2004-08-10 | 2006-02-23 | Immusol, Inc. | Methods of using or identifying agents that inhibit cancer growth |
US20060040882A1 (en) * | 2004-05-04 | 2006-02-23 | Lishan Chen | Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells |
WO2005044976A3 (en) * | 2003-06-20 | 2006-02-23 | Isis Pharmaceuticals Inc | Oligomeric compounds for use in gene modulation |
US20060051815A1 (en) * | 2004-06-25 | 2006-03-09 | The J. David Gladstone Institutes | Methods of treating smooth muscle cell disorders |
US20060058252A1 (en) * | 2002-06-26 | 2006-03-16 | Clawson Gary A | Methods and materials for treating human papillomavirus infections |
US20060063181A1 (en) * | 2004-08-13 | 2006-03-23 | Green Pamela J | Method for identification and quantification of short or small RNA molecules |
US20060069050A1 (en) * | 2004-02-17 | 2006-03-30 | University Of Massachusetts | Methods and compositions for mediating gene silencing |
WO2006033965A2 (en) * | 2004-09-16 | 2006-03-30 | The Trustees Of The University Of Pennsylvania | Nadph oxidase inhibition pharmacotherapies for obstructive sleep apnea syndrome and its associated morbidities |
US20060078902A1 (en) * | 2004-04-15 | 2006-04-13 | Michaeline Bunting | Method and compositions for RNA interference |
US20060083780A1 (en) * | 2004-06-07 | 2006-04-20 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use |
US20060089324A1 (en) * | 2004-10-22 | 2006-04-27 | Sailen Barik | RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof |
US20060094676A1 (en) * | 2004-10-29 | 2006-05-04 | Ronit Lahav | Compositions and methods for treating cancer using compositions comprising an inhibitor of endothelin receptor activity |
US20060128650A1 (en) * | 2002-11-04 | 2006-06-15 | University Of Massachusetts | Allele-specific RNA interference |
US20060134787A1 (en) * | 2004-12-22 | 2006-06-22 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA |
US20060134189A1 (en) * | 2004-11-17 | 2006-06-22 | Protiva Biotherapeutics, Inc | siRNA silencing of apolipoprotein B |
US20060166921A1 (en) * | 2005-01-07 | 2006-07-27 | Rachel Meyers | RNAi modulation of RSV and therapeutic uses thereof |
US20060172963A1 (en) * | 2005-02-01 | 2006-08-03 | Alcon, Inc. | RNAi-mediated inhibition of ocular hypertension targets |
US20060178297A1 (en) * | 2003-01-28 | 2006-08-10 | Troy Carol M | Systems and methods for silencing expression of a gene in a cell and uses thereof |
US20060178328A1 (en) * | 2002-11-26 | 2006-08-10 | Medtronic Inc. | Devices, systems and methods for improving memory and/or cognitive function through brain delivery of siRNA |
US20060189564A1 (en) * | 2004-10-22 | 2006-08-24 | Medtronic, Inc. | Methods and sequences to suppress pro-inflamatory cytokine actions locally to treat pain |
US20060205635A1 (en) * | 2005-03-14 | 2006-09-14 | Board Of Regents, The University Of Texas System | Antigene oligomers inhibit transcription |
US20060211637A1 (en) * | 2002-08-06 | 2006-09-21 | Intradigm Corporation | Methods of down regulating target gene expression in vivo by introduction of interfering rna |
US20060217324A1 (en) * | 2005-01-24 | 2006-09-28 | Juergen Soutschek | RNAi modulation of the Nogo-L or Nogo-R gene and uses thereof |
US20060223773A1 (en) * | 2005-03-11 | 2006-10-05 | Alcon, Inc. | RNAi-mediated inhibition of Frizzled Related Protein-1 for treatment of glaucoma |
US20060223749A1 (en) * | 2001-09-19 | 2006-10-05 | University Of South Florida | Inhibition of SHIP to enhance stem cell harvest and transplantation |
US20060240093A1 (en) * | 2003-07-16 | 2006-10-26 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering rna |
US20060240425A1 (en) * | 2002-09-30 | 2006-10-26 | Oncotherapy Science, Inc | Genes and polypeptides relating to myeloid leukemia |
US20060239971A1 (en) * | 2003-02-21 | 2006-10-26 | Mohapatra Shyam S | Vectors for regulating gene expression |
US20060257380A1 (en) * | 2002-09-19 | 2006-11-16 | Inst.Nat. De La Sante Et De La Recherche MED | Use of sirnas for gene silencing in antigen presenting cells |
US20060269530A1 (en) * | 2003-02-21 | 2006-11-30 | The Penn State Research Foundation | RNA interference compositions and methods |
US20060269519A1 (en) * | 2004-07-19 | 2006-11-30 | Baylor College Of Medicine | Modulation of cytokine signaling regulators and applications for immunotherapy |
US20060276635A1 (en) * | 2002-09-05 | 2006-12-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20060287259A1 (en) * | 2003-12-23 | 2006-12-21 | The Trustees Of The University Of Pennsylvania | Compositions and methods for combined therapy of disease |
US20060287269A1 (en) * | 2002-09-09 | 2006-12-21 | The Regents Of The University Of California | Short interfering nucleic acid hybrids and methods thereof |
US20060293256A1 (en) * | 2002-08-06 | 2006-12-28 | Masateru Yamada | Remedy or preventive for kidney disease and method of diagnosing kidney disease |
US20060292119A1 (en) * | 2005-06-23 | 2006-12-28 | Baylor College Of Medicine | Modulation of negative immune regulators and applications for immunotherapy |
US20070003575A1 (en) * | 2004-05-26 | 2007-01-04 | Itzhak Bentwich | Viral and viral associated MiRNAs and uses thereof |
US20070010468A1 (en) * | 2003-04-23 | 2007-01-11 | Georgetown University | Methods and compositions for the inhibition of stat5 in prostate cancer cells |
US20070037762A1 (en) * | 2002-07-24 | 2007-02-15 | Tolentino Michael J | COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOGENESIS |
US20070054873A1 (en) * | 2005-08-26 | 2007-03-08 | Protiva Biotherapeutics, Inc. | Glucocorticoid modulation of nucleic acid-mediated immune stimulation |
US20070087991A1 (en) * | 2002-02-13 | 2007-04-19 | Axordia Limited | Pluripotential stem cells |
US20070111227A1 (en) * | 2005-07-28 | 2007-05-17 | Green Pamela J | Small regulatory RNAs and methods of use |
US20070111963A1 (en) * | 2005-11-17 | 2007-05-17 | Board Of Regents, The University Of Texas System | Modulation of gene expression by oligomers targeted to chromosomal DNA |
US20070128640A1 (en) * | 2002-11-14 | 2007-06-07 | Dharmacon, Inc. | siRNA targeting ras-related nuclear protein |
US20070135370A1 (en) * | 2005-10-20 | 2007-06-14 | Protiva Biotherapeutics, Inc. | siRNA silencing of filovirus gene expression |
US20070135372A1 (en) * | 2005-11-02 | 2007-06-14 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
US20070141009A1 (en) * | 2003-01-03 | 2007-06-21 | Shaharyar Khan | Sirna mediated post-transriptional gene silencing of genes involved in alopecia |
US20070141601A1 (en) * | 2004-05-12 | 2007-06-21 | Dharmacon, Inc. | siRNA targeting cAMP-specific phosphodiesterase 4D |
US20070149468A1 (en) * | 2003-05-16 | 2007-06-28 | Jackson Aimee L | Methods and compositions for rna interference |
US20070149470A1 (en) * | 2004-09-10 | 2007-06-28 | Kaspar Roger L | Inhibition of viral gene expression using small interfering RNA |
US20070160586A1 (en) * | 2005-06-15 | 2007-07-12 | Children's Medical Center Corporation | Methods for extending the replicative lifespan of cells |
US20070161547A1 (en) * | 2003-06-03 | 2007-07-12 | Balkrishen Bhat | Modulation of survivin expression |
US20070161586A1 (en) * | 2004-01-16 | 2007-07-12 | Takeda Pharmaceutical Company Limited | Drug for preventing and treating atherosclerosis |
US20070180242A1 (en) * | 2006-01-30 | 2007-08-02 | Nagaraj Thadi M | GSM authentication in a CDMA network |
US20070202134A1 (en) * | 2004-02-23 | 2007-08-30 | Kufe Donald W | Muc1 Antagonist Enhancement of Death Receptor Ligand-Induced Apoptosis |
US20070232555A1 (en) * | 2004-03-26 | 2007-10-04 | Nariyoshi Shinomiya | C-Met Sirna Adenovirus Vectors Inhibit Cancer Cell Growth, Invasion and Tumorigenicity |
US20070238676A1 (en) * | 2003-12-04 | 2007-10-11 | Mohapatra Shyam S | Polynucleotides for Reducing Respiratory Syncytial Virus Gene Expression |
US20070238691A1 (en) * | 2006-03-29 | 2007-10-11 | Senesco Technologies, Inc. | Inhibition of HIV replication and expression of p24 with eIF-5A |
US20070243570A1 (en) * | 2003-05-19 | 2007-10-18 | Genecare Research Institute Co., Ltd | Apoptosis Inducer for Cancer Cell |
US20070244311A1 (en) * | 2002-11-14 | 2007-10-18 | Dharmacon, Inc. | siRNA targeting coatomer protein complex, subunit beta 2 (CPOB2) |
US20070258993A1 (en) * | 2003-11-12 | 2007-11-08 | The Austin Research Institute | Dna-Carrier Conjugate |
US20070259827A1 (en) * | 2006-01-25 | 2007-11-08 | University Of Massachusetts | Compositions and methods for enhancing discriminatory RNA interference |
US20070265220A1 (en) * | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
US20070269892A1 (en) * | 2006-05-18 | 2007-11-22 | Nastech Pharmaceutical Company Inc. | FORMULATIONS FOR INTRACELLULAR DELIVERY dsRNA |
US20070270369A1 (en) * | 2002-09-18 | 2007-11-22 | The Burnham Institute | Use of hepatitis b x-interacting protein (hbxip) in modulation of apoptosis |
US20070275923A1 (en) * | 2006-05-25 | 2007-11-29 | Nastech Pharmaceutical Company Inc. | CATIONIC PEPTIDES FOR siRNA INTRACELLULAR DELIVERY |
US20070275913A1 (en) * | 2006-04-12 | 2007-11-29 | Monia Brett P | Compositions and their uses directed to hepcidin |
US20080014191A1 (en) * | 2006-05-19 | 2008-01-17 | The Scripps Research Institute | Treatment of Protein Misfolding |
US20080039415A1 (en) * | 2006-08-11 | 2008-02-14 | Gregory Robert Stewart | Retrograde transport of sirna and therapeutic uses to treat neurologic disorders |
US20080039412A1 (en) * | 2004-02-10 | 2008-02-14 | Sirna Therapeutics, Inc. | Rna Interference Mediated Inhibition of Gene Expression Using Multifunctional Short Interfering Nucleic Acid (Multifunctional Sina) |
US20080039411A1 (en) * | 2004-02-23 | 2008-02-14 | Ulf Smith | Use Of Resistin Antisense Oligonucleotides And/Or Sirna Molecules In The Treatment Of Rheumatoid Arthritis |
US20080057062A1 (en) * | 2006-07-18 | 2008-03-06 | National Institute Of Advanced Industrial Science And Technology | Agent for Inducing senescence and apoptosis of cancer cell |
US20080070857A1 (en) * | 2005-02-14 | 2008-03-20 | Jun Nishihira | Pharmaceutical Agents for Preventing Metastasis of Cancer |
US20080069840A1 (en) * | 2005-01-06 | 2008-03-20 | Tzyy-Choou Wu | RNA Interference That Blocks Expression of Pro-Apoptotic Proteins Potentiates Immunity Induced by DNA and Transfected Dendritic Cell Vaccines |
US20080076731A1 (en) * | 2000-09-19 | 2008-03-27 | University Of South Florida | Control of NK cell function and survival by modulation of ship activity |
US20080102084A1 (en) * | 2005-01-26 | 2008-05-01 | Tzyy-Choou Wu | Anti-cancer DNA Vaccine Employing Plasmids Encoding Mutant Oncoprotein Antigen and Calreticulin |
US20080108584A1 (en) * | 2006-05-22 | 2008-05-08 | De Fougerolles Antonin | Compositions and methods for inhibiting expression of ikk-b gene |
US20080125384A1 (en) * | 2005-11-21 | 2008-05-29 | Shuewi Yang | Simultaneous silencing and restoration of gene function |
US20080153765A1 (en) * | 2004-03-22 | 2008-06-26 | Gewirtz Alan M | Methods of Use of Bcl-6-Derived Nucleotides to Induce Apoptosis |
US20080152654A1 (en) * | 2006-06-12 | 2008-06-26 | Exegenics, Inc., D/B/A Opko Health, Inc. | COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOGENESIS |
US20080167265A1 (en) * | 2007-01-09 | 2008-07-10 | Isis Pharmaceuticals Inc | Modulation of fr-alpha expression |
US20080167256A1 (en) * | 2004-03-31 | 2008-07-10 | Hidetoshi Sumimoto | Cancer Therapy Via the Inhibition of Skp-2 Expression |
US20080171719A1 (en) * | 2006-11-28 | 2008-07-17 | Alcon Manufacturing, Ltd. | RNAi-MEDIATED INHIBITION OF AQUAPORIN 1 FOR TREATMENT OF IOP-RELATED CONDITIONS |
US20080171051A1 (en) * | 2003-11-26 | 2008-07-17 | Patrick Gerard Johnston | Cancer Treatment |
US20080171906A1 (en) * | 2007-01-16 | 2008-07-17 | Everaerts Frank J L | Tissue performance via hydrolysis and cross-linking |
US20080171715A1 (en) * | 2004-11-12 | 2008-07-17 | David Brown | Methods and compositions involving mirna and mirna inhibitor molecules |
US20080176293A1 (en) * | 2005-07-25 | 2008-07-24 | Jacques Rohayem | RNA-Dependent RNA Polymerase, Methods And Kits For The Amplification And/Or Labelling Of RNA |
US20080177051A1 (en) * | 2002-11-14 | 2008-07-24 | Dharmacon, Inc. | siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B) |
US7422853B1 (en) * | 2002-10-04 | 2008-09-09 | Myriad Genetics, Inc. | RNA interference using a universal target |
US20080221059A1 (en) * | 2008-04-03 | 2008-09-11 | National Taiwan University | Novel treatment tool for cancer: rna interference of bcas2 |
US20080227967A1 (en) * | 2002-11-14 | 2008-09-18 | Dharmacon, Inc. | siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2) |
US20080242627A1 (en) * | 2000-08-02 | 2008-10-02 | University Of Southern California | Novel rna interference methods using dna-rna duplex constructs |
US20080249046A1 (en) * | 2006-06-09 | 2008-10-09 | Protiva Biotherapeutics, Inc. | MODIFIED siRNA MOLECULES AND USES THEREOF |
US20080249038A1 (en) * | 2003-10-07 | 2008-10-09 | Quark Biotech, Inc. | Bone Morphogenetic Protein (Bmp) 2A and Uses Thereof |
WO2008002678A3 (en) * | 2006-06-29 | 2008-10-16 | Univ Texas | Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use |
US20080253989A1 (en) * | 2004-10-22 | 2008-10-16 | Neuregenix Limited | Neuron Regeneration |
WO2008088836A3 (en) * | 2007-01-16 | 2008-10-16 | Burnham Inst Medical Research | Compositions and methods for treatment of colorectal cancer |
US20080255345A1 (en) * | 2006-11-21 | 2008-10-16 | Alnylam Pharmaceuticals, Inc. | IRNA Agents Targeting CCR5 Expressing Cells And Uses Thereof |
US20080260765A1 (en) * | 2007-03-15 | 2008-10-23 | Johns Hopkins University | HPV DNA Vaccines and Methods of Use Thereof |
WO2007127919A3 (en) * | 2006-04-28 | 2008-10-30 | Alnylam Pharmaceuticals Inc | Compositions and methods for inhibiting expression of a gene from the jc virus |
US20080268457A1 (en) * | 2002-11-14 | 2008-10-30 | Dharmacon, Inc. | siRNA targeting forkhead box P3 (FOXP3) |
US20080279844A1 (en) * | 2006-10-18 | 2008-11-13 | Kapil Mehta | Methods for Treating Cancer Targeting Transglutaminase |
US20080287386A1 (en) * | 2004-01-30 | 2008-11-20 | Quark Biotech, Inc. | Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases |
US20080299659A1 (en) * | 2007-03-02 | 2008-12-04 | Nastech Pharmaceutical Company Inc. | Nucleic acid compounds for inhibiting apob gene expression and uses thereof |
US20080319180A1 (en) * | 2002-11-14 | 2008-12-25 | Dharmacon, Inc. | siRNA targeting protein kinase N-3 (PKN-3) |
US20090005330A1 (en) * | 2004-08-31 | 2009-01-01 | Sylentis S.A. | Methods and Compositions to Inhibit P2x7 Receptor Expression |
US20090005548A1 (en) * | 2002-11-14 | 2009-01-01 | Dharmacon, Inc. | siRNA targeting nuclear receptor interacting protein 1 (NRIP1) |
US20090023675A1 (en) * | 2002-02-20 | 2009-01-22 | Sirna Therapeutics, Inc. | RNA Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (siNA) |
US20090022667A1 (en) * | 2007-05-15 | 2009-01-22 | Marco Peters | METHODS OF TREATING COGNITIVE DISORDERS BY INHIBITION OF Gpr12 |
US20090028862A1 (en) * | 2004-09-30 | 2009-01-29 | Arndt Gregory M | Emmprin antagonists and uses thereof |
US20090042826A1 (en) * | 2002-02-12 | 2009-02-12 | Quark Pharmaceuticals, Inc. | Use of the AXL receptor for diagnosis and treatment of renal disease |
US20090053298A1 (en) * | 2007-07-31 | 2009-02-26 | Sumitomo Chemical Company, Limited | Compositions and methods for inhibiting car gene expression by rna interference |
US20090061487A1 (en) * | 2006-09-08 | 2009-03-05 | Samuel Jotham Reich | Sirna and methods of manufacture |
US20090081789A1 (en) * | 2007-08-31 | 2009-03-26 | Greenville Hospital System | Activation of nuclear factor kappa B |
US20090093439A1 (en) * | 2002-02-20 | 2009-04-09 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF CHROMOSOME TRANSLOCATION GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20090093437A1 (en) * | 2002-02-20 | 2009-04-09 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF CHECKPOINT KINASE-1 (CHK-1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20090092988A1 (en) * | 2007-10-04 | 2009-04-09 | Schwartz Jacob C | Modulating Gene Expression with agRNA and Gapmers Targeting Antisense Transcripts |
US20090093435A1 (en) * | 2002-02-20 | 2009-04-09 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF GRB2 ASSOCIATED BINDING PROTEIN (GAB2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20090099111A1 (en) * | 2004-08-23 | 2009-04-16 | Sylentis S.A.U. | Methods and Compositions for the Treatment of Eye Disorders with Increased Intraocular Pressure |
US20090099116A1 (en) * | 2002-02-20 | 2009-04-16 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF FOS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20090098127A1 (en) * | 2004-07-12 | 2009-04-16 | Medical Research Fund Of Tel Aviv Sourasky Medical Center | Agents Capable of Downregulating an MSF-A DEPENDENT HIF-1ALPHA and Use Thereof in Cancer Treatment |
US20090118206A1 (en) * | 2003-09-12 | 2009-05-07 | University Of Massachusetts | Rna interference for the treatment of gain-of-function disorders |
US20090118489A1 (en) * | 2002-11-14 | 2009-05-07 | Dharmacon, Inc. | siRNA targeting nucleoporin 62kDa (Nup62) |
US20090118214A1 (en) * | 2007-11-07 | 2009-05-07 | Beeologics, Llc | Compositions for conferring tolerance to viral disease in social insects, and the use thereof |
US20090123572A1 (en) * | 2005-03-18 | 2009-05-14 | Shiseido Company, Ltd. | Method and Pharmaceutical Composition for Treating Psoriasis, Squamous Cell Carcinoma and/or Parakeratosis by Inhibiting Expression of Squamous Cell Carcinoma-Related Antigen |
US20090130212A1 (en) * | 2006-05-15 | 2009-05-21 | Physical Pharmaceutica, Llc | Composition and improved method for preparation of small particles |
US20090137508A1 (en) * | 2002-02-20 | 2009-05-28 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF POLYCOMB GROUP PROTEIN EZH2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20090137509A1 (en) * | 2002-02-20 | 2009-05-28 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF PROLIFERATION CELL NUCLEAR ANTIGEN (PCNA) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20090143321A1 (en) * | 2005-07-07 | 2009-06-04 | Avraham Hochberg | Nucleic acid agents for downregulating h19 and methods of using same |
US20090149407A1 (en) * | 2000-08-30 | 2009-06-11 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED TREATMENT OF ALZHEIMER'S DISEASE USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20090149403A1 (en) * | 2006-05-26 | 2009-06-11 | Protiva Biotherapeutics, Inc. | siRNA silencing of genes expressed in cancer |
US20090149377A1 (en) * | 2005-09-30 | 2009-06-11 | St. Jude Children's Research Hospital | METHODS FOR REGULATION OF p53 TRANSLATION AND FUNCTION |
US20090148471A1 (en) * | 2000-08-03 | 2009-06-11 | The Johns Hopkins University | Molecular Vaccine Linking an Endoplasmic Reticulum Chaperone Polypeptide to an Antigen |
US20090156531A1 (en) * | 2005-12-30 | 2009-06-18 | Institut Gustave Roussy | Use of Inhibitors of Scinderin and/or Ephrin-A1 for Treating Tumors |
US20090163407A1 (en) * | 2004-11-15 | 2009-06-25 | Mount Sinai School Of Medicine Of New York University | Compositions and methods for altering wnt autocrine signaling |
US20090192113A1 (en) * | 2003-08-28 | 2009-07-30 | Jan Weiler | Interfering RNA Duplex Having Blunt-Ends and 3`-Modifications |
US20090203138A1 (en) * | 2008-02-12 | 2009-08-13 | University Of Tennessee Research Foundation, Inc. | Small Interfering RNAs Targeting Feline Herpes Virus |
US20090203055A1 (en) * | 2005-04-18 | 2009-08-13 | Massachusetts Institute Of Technology | Compositions and methods for RNA interference with sialidase expression and uses thereof |
US20090203135A1 (en) * | 2007-04-23 | 2009-08-13 | Alnylam Pharmaceuticals, Inc. | Glycoconjugates of RNA Interference Agents |
US7579451B2 (en) | 2004-07-21 | 2009-08-25 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising a modified or non-natural nucleobase |
US20090227780A1 (en) * | 2002-11-14 | 2009-09-10 | Dharmacon, Inc. | siRNA targeting connexin 43 |
US20090226446A1 (en) * | 2006-04-06 | 2009-09-10 | Deutsches Krebsforschungszentrum Stiftung Des Offentilchen Rechts | Method to Inhibit the Propagation of an Undesired Cell Population |
US20090233983A1 (en) * | 2002-02-20 | 2009-09-17 | Sirna Therapeutics Inc. | RNA Interference Mediated Inhibition of Protein Tyrosine Phosphatase-1B (PTP-1B) Gene Expression Using Short Interfering RNA |
US20090238772A1 (en) * | 2007-12-13 | 2009-09-24 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for prevention or treatment of rsv infection |
US20090239814A1 (en) * | 2007-12-04 | 2009-09-24 | Alnylam Pharmaceuticals, Inc. | Carbohydrate Conjugates as Delivery Agents for Oligonucleotides |
US20090247613A1 (en) * | 2002-02-20 | 2009-10-01 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF B-CELL CLL/LYMPHOMA-2 (BCL2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20090247606A1 (en) * | 2001-08-28 | 2009-10-01 | Sirna Therapeutics, Inc. | RNA Interference Mediated Inhibition of Adenosine A1 Receptor (ADORA1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
US20090247607A1 (en) * | 2006-03-24 | 2009-10-01 | John Benson | dsRNA COMPOSITIONS AND METHODS FOR TREATING HPV INFECTION |
US20090247614A1 (en) * | 2007-12-04 | 2009-10-01 | Alnylam Pharmaceuticals, Inc. | Folate Conjugates |
US20090253772A1 (en) * | 2002-02-20 | 2009-10-08 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF CXCR4 GENE EXPRESSION USING SHORT INTERFERING NUCELEIC ACID (siNA) |
US20090258934A1 (en) * | 2005-11-04 | 2009-10-15 | Alnylam Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Nav1.8 GENE |
US7605249B2 (en) | 2002-11-26 | 2009-10-20 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
US20090275638A1 (en) * | 2008-04-17 | 2009-11-05 | Kevin Fitzgerald | Compositions and Methods for Inhibiting Expression of XBP-1 Gene |
US20090275635A1 (en) * | 2006-05-26 | 2009-11-05 | Medical Research Council | Screening method |
US7615618B2 (en) | 2004-06-30 | 2009-11-10 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising a non-phosphate backbone linkage |
US20090285861A1 (en) * | 2008-04-17 | 2009-11-19 | Tzyy-Choou Wu | Tumor cell-based cancer immunotherapeutic compositions and methods |
US7626014B2 (en) | 2004-04-27 | 2009-12-01 | Alnylam Pharmaceuticals | Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety |
US20090306182A1 (en) * | 2002-02-20 | 2009-12-10 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF MAP KINASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20090306356A1 (en) * | 2002-11-14 | 2009-12-10 | Dharmacon,Inc. | siRNA Targeting TNFalpha |
US7632932B2 (en) | 2004-08-04 | 2009-12-15 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase |
US20100003317A1 (en) * | 2008-03-27 | 2010-01-07 | Akin Akinc | Compositions and methods for mediating rnai in vivo |
US20100010066A1 (en) * | 2008-01-31 | 2010-01-14 | Kevin Fitzgerald | Optimized Methods For Delivery Of DSRNA Targeting The PCSK9 Gene |
US20100016405A1 (en) * | 2006-07-10 | 2010-01-21 | Alnylam Pharmaceuticals, Inc | Compositions and Methods for Inhibiting Expression of the MYC Gene |
US20100015707A1 (en) * | 2006-05-04 | 2010-01-21 | Francois Jean-Charles Natt | SHORT INTERFERING RIBONUCLEIC ACID (siRNA) FOR ORAL ADMINISTRATION |
US20100035966A1 (en) * | 2006-06-14 | 2010-02-11 | Rosetta Inpharmatics Llc | Methods and compositions for regulating cell cycle progression |
US7674778B2 (en) | 2004-04-30 | 2010-03-09 | Alnylam Pharmaceuticals | Oligonucleotides comprising a conjugate group linked through a C5-modified pyrimidine |
US20100069461A1 (en) * | 2005-11-09 | 2010-03-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of factor v leiden mutant gene |
US20100087508A1 (en) * | 2008-03-05 | 2010-04-08 | David Bumcrot | Compositions and Methods for Inhibiting Expression of Eg5 and VEGF Genes |
US7695902B2 (en) | 1996-06-06 | 2010-04-13 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides and ribonucleases for cleaving RNA |
US20100093831A1 (en) * | 2003-03-12 | 2010-04-15 | Vasgene Therapeutics, Inc. | Nucleic acid compounds for inhibiting angiogenesis and tumor growth |
US20100098664A1 (en) * | 2007-11-28 | 2010-04-22 | Mathieu Jean-Francois Desclaux | Lentiviral vectors allowing RNAi mediated inhibition of GFAP and vimentin expression |
US20100105759A1 (en) * | 2007-01-16 | 2010-04-29 | Abraham Hochberg | H19 silencing nucleic acid agents for treating rheumatoid arthritis |
US7709616B2 (en) | 2004-05-14 | 2010-05-04 | Rosetta Genomics Inc. | Micrornas and uses thereof |
US20100113564A1 (en) * | 2002-02-20 | 2010-05-06 | Mcswiggen James | RNA Interference Mediated Inhibition of Interleukin and Interleukin Receptor Gene Expression Using Short Interfering Nucleic Acid (siNA) |
US20100112686A1 (en) * | 2008-10-15 | 2010-05-06 | Qing Ge | Short hairpin rnas for inhibition of gene expression |
US20100113307A1 (en) * | 2002-11-14 | 2010-05-06 | Dharmacon, Inc. | siRNA targeting vascular endothelial growth factor (VEGF) |
US20100120893A1 (en) * | 2008-10-20 | 2010-05-13 | Dinah Wen-Yee Sah | Compositions and Methods for Inhibiting Expression of Transthyretin |
US20100130595A1 (en) * | 2008-08-25 | 2010-05-27 | Dean Nicholas M | Antisense oligonucleotides directed against connective tissue growth factor and uses thereof |
US20100129429A1 (en) * | 2005-11-07 | 2010-05-27 | British Columbia Cancer Agency | Inhibition of autophagy genes in cancer chemotherapy |
US20100136026A1 (en) * | 2007-09-26 | 2010-06-03 | Kerr William G | Ship Inhibition to Direct Hematopoietic Stem Cells and Induce Extramedullary Hematopoiesis |
US7732591B2 (en) | 2003-11-25 | 2010-06-08 | Medtronic, Inc. | Compositions, devices and methods for treatment of huntington's disease through intracranial delivery of sirna |
US20100144851A1 (en) * | 2002-02-20 | 2010-06-10 | Sirna Therapeutics, Inc. | RNA Interference Mediated Inhibition of Platelet-Derived Endothelial Cell Growth Factor (ECGF1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
US20100144842A1 (en) * | 2002-02-20 | 2010-06-10 | Sirna Therapeutics, Inc. | RNA Interference Mediated Inhibition of NOGO and NOGO Receptor Gene Expression Using Short Interfering Nucleic Acid (siNA) |
US20100144833A1 (en) * | 2004-10-22 | 2010-06-10 | Sailen Barik | RNAi Modulation Of RSV, PIV And Other Respiratory Viruses And Uses Thereof |
US20100151470A1 (en) * | 2007-05-01 | 2010-06-17 | University Of Massachusetts | Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy |
US7745418B2 (en) | 2001-10-12 | 2010-06-29 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting viral replication |
US20100168205A1 (en) * | 2008-10-23 | 2010-07-01 | Alnylam Pharmaceuticals, Inc. | Methods and Compositions for Prevention or Treatment of RSV Infection Using Modified Duplex RNA Molecules |
US20100166661A1 (en) * | 2008-12-11 | 2010-07-01 | Bojian Zheng | siRNA COMPOSITIONS AND METHODS FOR POTENTLY INHIBITING VIRAL INFECTION |
US20100168206A1 (en) * | 2008-12-10 | 2010-07-01 | Jared Gollob | GNAQ Targeted dsRNA Compositions And Methods For Inhibiting Expression |
US7750144B2 (en) | 2003-06-02 | 2010-07-06 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of RNA silencing |
US20100184824A1 (en) * | 2002-02-20 | 2010-07-22 | Sirna Therapeutics, Inc. | RNA Interference Mediated Inhibition of Interleukin and Interleukin Receptor Gene Expression Using Short Interfering Nucleic Acid (siNA) |
US20100183696A1 (en) * | 2007-01-30 | 2010-07-22 | Allergan, Inc | Treating Ocular Diseases Using Peroxisome Proliferator-Activated Receptor Delta Antagonists |
US20100184825A1 (en) * | 2002-02-20 | 2010-07-22 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Protein Tyrosine Phosphatase-1B (PTP-1B) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
US7763592B1 (en) | 2003-11-20 | 2010-07-27 | University Of South Florida | SHIP-deficiency to increase megakaryocyte progenitor production |
US20100190714A1 (en) * | 2007-06-15 | 2010-07-29 | Novatis Ag | RNAi Inhibition of Alpha-ENaC Expression |
US20100197773A1 (en) * | 2009-02-03 | 2010-08-05 | Birgit Bramlage | Compositions and methods for inhibiting expression of ptp1b genes |
US20100196403A1 (en) * | 2007-01-29 | 2010-08-05 | Jacob Hochman | Antibody conjugates for circumventing multi-drug resistance |
US20100204307A1 (en) * | 2006-09-21 | 2010-08-12 | Tomoko Nakayama | Compositions And Methods For Inhibiting Expression Of The HAMP Gene |
US20100204306A1 (en) * | 2007-12-14 | 2010-08-12 | Alnylam Pharmaceuticals, Inc. | Method of Treating Neurodegenerative Disease |
US7781575B2 (en) | 2002-11-14 | 2010-08-24 | Dharmacon, Inc. | siRNA targeting tumor protein 53 (p53) |
US20100216866A1 (en) * | 2004-09-24 | 2010-08-26 | Alnylam Pharmaceuticals, Inc. | RNAi Modulation of APOB and Uses Thereof |
US20100234446A1 (en) * | 2004-11-24 | 2010-09-16 | Philipp Hadwiger | RNAi Modulation of the BCR-ABL Fusion Gene and Uses Thereof |
US20100240441A1 (en) * | 2007-09-14 | 2010-09-23 | Konami Digital Entertainment Co., Ltd | Game system, and game apparatus and challenge notifying apparatus constituting the game system |
US20100240730A1 (en) * | 2002-02-20 | 2010-09-23 | Merck Sharp And Dohme Corp. | RNA Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (siNA) |
US20100249052A1 (en) * | 2007-03-26 | 2010-09-30 | Alnylam Pharmaceuticals, Inc. | Dsrna compositions and methods for treating hpv infections |
US20100249212A1 (en) * | 2000-08-02 | 2010-09-30 | University Of Southern California | Gene Silencing Using mRNA-cDNA Hybrids |
US7807646B1 (en) | 2003-11-20 | 2010-10-05 | University Of South Florida | SHIP-deficiency to increase megakaryocyte progenitor production |
US20100256218A1 (en) * | 2004-12-14 | 2010-10-07 | Olaf Heidenreich | RNAi MODULATION OF MLL-AF4 AND USES THEREOF |
US20100255023A1 (en) * | 2007-11-30 | 2010-10-07 | Si-Yi Chen | Dendritic cell vaccine compositions and uses of same |
US7812149B2 (en) | 1996-06-06 | 2010-10-12 | Isis Pharmaceuticals, Inc. | 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations |
US20100267810A1 (en) * | 2005-08-18 | 2010-10-21 | University Of Massachusetts | Methods and compositions for treating neurological disease |
US7819842B2 (en) | 2006-11-21 | 2010-10-26 | Medtronic, Inc. | Chronically implantable guide tube for repeated intermittent delivery of materials or fluids to targeted tissue sites |
US20100273863A1 (en) * | 2009-04-24 | 2010-10-28 | Board Of Regents, The University Of Texas System | Modulation of Gene Expression Using Oligomers That Target Gene Regions Downstream of 3' Untranslated Regions |
US20100280102A1 (en) * | 2003-06-13 | 2010-11-04 | Alnylam Pharmaceuticals | Double-stranded ribonucleic acid with increased effectiveness in an organism |
US20100278871A1 (en) * | 2003-05-05 | 2010-11-04 | Johns Hopkins University | Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein |
US7829694B2 (en) | 2002-11-26 | 2010-11-09 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
US20100286230A1 (en) * | 2005-10-20 | 2010-11-11 | Sylentis S.A.U. | Modulation of trpv expression levels |
US20100291188A1 (en) * | 2008-12-04 | 2010-11-18 | Musc Foundation For Research Development | Periostin Inhibitory Compositions for Myocardial Regeneration, Methods of Delivery, and Methods of Using Same |
US20100292305A1 (en) * | 2005-06-27 | 2010-11-18 | Akin Akinc | RNAi MODULATION OF HIF-1 AND THERAPUTIC USES THEREOF |
US20100298405A1 (en) * | 2005-10-28 | 2010-11-25 | Dinah Wen-Yee Sah | Compositions And Methods For Inhibiting Expression Of Huntingtin Gene |
US20100316703A1 (en) * | 2000-12-01 | 2010-12-16 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Rna interference mediating small rna molecules |
US20100330105A1 (en) * | 2006-08-22 | 2010-12-30 | John Hopkins University | Anticancer Combination Therapies |
US20110003879A1 (en) * | 2005-03-11 | 2011-01-06 | Vincent Mark D | Antisense oligonucleotides targeted to the coding region of thymidylate synthase and uses thereof |
US20110003882A1 (en) * | 2006-05-19 | 2011-01-06 | Alnylam Pharmaceuticals, Inc. | RNAi Modulation of AHA and Therapeutic Uses Thereof |
US20110015252A1 (en) * | 2009-06-15 | 2011-01-20 | Kevin Fitzgerald | Lipid formulated dsrna targeting the pcsk9 gene |
US20110020300A1 (en) * | 2009-05-15 | 2011-01-27 | Genentech, Inc. | Compositions and methods for inhibiting expression of glucocorticoid receptor (gcr) genes |
US7884086B2 (en) * | 2004-09-08 | 2011-02-08 | Isis Pharmaceuticals, Inc. | Conjugates for use in hepatocyte free uptake assays |
US20110034537A1 (en) * | 2008-02-12 | 2011-02-10 | De Fougerolles Antonin | Compositions and methods for inhibiting expression of cd45 gene |
US7888010B2 (en) | 2004-05-28 | 2011-02-15 | Asuragen, Inc. | Methods and compositions involving microRNA |
US20110038922A1 (en) * | 2005-06-16 | 2011-02-17 | Faron Pharmaceuticals Oy (A Finnish Company) | Compounds for treating or preventing amine oxidase related diseases or disorders |
US20110053226A1 (en) * | 2008-06-13 | 2011-03-03 | Riboxx Gmbh | Method for enzymatic synthesis of chemically modified rna |
US7902352B2 (en) | 2005-05-06 | 2011-03-08 | Medtronic, Inc. | Isolated nucleic acid duplex for reducing huntington gene expression |
US20110060031A1 (en) * | 2007-03-29 | 2011-03-10 | Alnylam Pharmaceuticals, Inc. | Compositions And Methods For Inhibiting Expression Of A Gene From The Ebola Virus |
WO2011035065A1 (en) | 2009-09-17 | 2011-03-24 | Nektar Therapeutics | Monoconjugated chitosans as delivery agents for small interfering nucleic acids |
US7923206B2 (en) * | 2004-11-22 | 2011-04-12 | Dharmacon, Inc. | Method of determining a cellular response to a biological agent |
US20110092565A1 (en) * | 2003-06-09 | 2011-04-21 | Alnylam Pharmaceuticals, Inc. | Method of treating neurodegenerative disease |
US20110098460A1 (en) * | 2001-07-23 | 2011-04-28 | Senesco Technologies, Inc. | SiRNA Useful to Suppress expression of eIF-5A1 |
US7935811B2 (en) | 2004-11-22 | 2011-05-03 | Dharmacon, Inc. | Apparatus and system having dry gene silencing compositions |
US20110110483A1 (en) * | 2009-11-06 | 2011-05-12 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for migrating fuel assemblies in a nuclear fission reactor |
US20110117088A1 (en) * | 2004-05-12 | 2011-05-19 | Simon Michael R | Composition and method for introduction of rna interference sequences into targeted cells and tissues |
US7951935B2 (en) | 2002-11-14 | 2011-05-31 | Dharmacon, Inc. | siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC) |
US20110142917A1 (en) * | 2008-06-06 | 2011-06-16 | Egvenia Alpert | Compositions and methods for treatment of ear disorders |
US20110150897A1 (en) * | 2006-10-11 | 2011-06-23 | Meyer Thomas F | Influenza targets |
US20110160277A1 (en) * | 2005-10-25 | 2011-06-30 | Sylentis S.A.U. | Modulation of 11 beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases |
US20110166199A1 (en) * | 2010-01-07 | 2011-07-07 | National Cheng Kung University | RNAi COMPOUND TARGETED TO THROMBOSPONDIN-1 AND APPLICATIONS THEREOF |
US20110172291A1 (en) * | 2003-09-12 | 2011-07-14 | University Of Massachusetts | Rna interference for the treatment of gain-of-function disorders |
US20110172286A1 (en) * | 2007-07-10 | 2011-07-14 | Neurim Pharmaceuticals (1991) Ltd. | Cd44 splice variants in neurodegenerative diseases |
US20110184041A1 (en) * | 2007-08-17 | 2011-07-28 | Richard Kremer | PTHrP, ITS ISOFORMS AND ANTAGONIST THERETO IN THE DIAGNOSIS AND TREATMENT OF DISEASE |
US20110184046A1 (en) * | 2008-07-11 | 2011-07-28 | Dinah Wen-Yee Sah | Compositions And Methods For Inhibiting Expression Of GSK-3 Genes |
US7988668B2 (en) | 2006-11-21 | 2011-08-02 | Medtronic, Inc. | Microsyringe for pre-packaged delivery of pharmaceuticals |
US20110190380A1 (en) * | 2008-10-23 | 2011-08-04 | Elena Feinstein | Methods for delivery of sirna to bone marrow cells and uses thereof |
US20110201667A1 (en) * | 2009-07-20 | 2011-08-18 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing ebola virus gene expression |
US20110207796A1 (en) * | 2008-02-13 | 2011-08-25 | Elan Pharma International Limited | Alpha-synuclein kinase |
US20110213328A1 (en) * | 2004-03-18 | 2011-09-01 | Medtronic, Inc. | Methods and Systems for Treatment of Neurological Diseases of the Central Nervous System |
US20110230542A1 (en) * | 2006-05-11 | 2011-09-22 | Pamela Tan | Compositions and Methods for Inhibiting Expression of the PCSK9 Gene |
US20110245325A1 (en) * | 2008-12-12 | 2011-10-06 | Kureha Corporation | Pharmaceutical composition for treatment of cancer and asthma |
US8058069B2 (en) | 2008-04-15 | 2011-11-15 | Protiva Biotherapeutics, Inc. | Lipid formulations for nucleic acid delivery |
US8058448B2 (en) | 2004-04-05 | 2011-11-15 | Alnylam Pharmaceuticals, Inc. | Processes and reagents for sulfurization of oligonucleotides |
US8058255B2 (en) | 2004-12-23 | 2011-11-15 | Applied Biosystems, Llc | Methods and compositions concerning siRNA's as mediators of RNA interference |
US8071562B2 (en) | 2007-12-01 | 2011-12-06 | Mirna Therapeutics, Inc. | MiR-124 regulated genes and pathways as targets for therapeutic intervention |
US20120004403A1 (en) * | 2002-02-20 | 2012-01-05 | Leonid Beigelman | RNA INTERFERENCE MEDIATED INHIBITION OF TNF AND TNF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US8198427B1 (en) | 2002-11-14 | 2012-06-12 | Dharmacon, Inc. | SiRNA targeting catenin, beta-1 (CTNNB1) |
US8222221B2 (en) | 2008-06-04 | 2012-07-17 | The Board Of Regents Of The University Of Texas System | Modulation of gene expression through endogenous small RNA targeting of gene promoters |
US20120202215A1 (en) * | 2005-11-24 | 2012-08-09 | Jichi Medical University | Mitochondrial function of prohibitin 2 (phb2) |
US8258111B2 (en) | 2008-05-08 | 2012-09-04 | The Johns Hopkins University | Compositions and methods related to miRNA modulation of neovascularization or angiogenesis |
US8258112B2 (en) | 2005-05-06 | 2012-09-04 | Medtronic, Inc | Methods and sequences to suppress primate huntington gene Expression |
US8283333B2 (en) | 2009-07-01 | 2012-10-09 | Protiva Biotherapeutics, Inc. | Lipid formulations for nucleic acid delivery |
US8288354B2 (en) * | 2005-12-28 | 2012-10-16 | The Scripps Research Institute | Natural antisense and non-coding RNA transcripts as drug targets |
US8293719B2 (en) | 2004-03-12 | 2012-10-23 | Alnylam Pharmaceuticals, Inc. | iRNA agents targeting VEGF |
US8324366B2 (en) | 2008-04-29 | 2012-12-04 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for delivering RNAI using lipoproteins |
US8324367B2 (en) | 2006-11-03 | 2012-12-04 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
US8334273B2 (en) | 2007-12-10 | 2012-12-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of factor VII gene |
US8361714B2 (en) | 2007-09-14 | 2013-01-29 | Asuragen, Inc. | Micrornas differentially expressed in cervical cancer and uses thereof |
DE102011118024A1 (de) | 2011-08-01 | 2013-02-07 | Technische Universität Dresden | Inhibitor der Expression der Pro-Caspase 1 |
US8394947B2 (en) | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
US20130065939A1 (en) * | 2009-09-23 | 2013-03-14 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing genes expressed in cancer |
US8444983B2 (en) | 2009-03-23 | 2013-05-21 | Quark Pharmaceuticals, Inc. | Composition of anti-ENDO180 antibodies and methods of use for the treatment of cancer and fibrotic diseases |
US20130131331A1 (en) * | 2004-11-19 | 2013-05-23 | Genecare Research Institute Co., Ltd. | Cancer-cell-specific cytostatic agent |
US8455455B1 (en) | 2010-03-31 | 2013-06-04 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing genes involved in hemorrhagic fever |
US8470792B2 (en) | 2008-12-04 | 2013-06-25 | Opko Pharmaceuticals, Llc. | Compositions and methods for selective inhibition of VEGF |
US20130224311A1 (en) * | 2010-03-19 | 2013-08-29 | University Of South Alabama | Methods and compositions for the treatment of cancer |
US8524680B2 (en) * | 2002-02-01 | 2013-09-03 | Applied Biosystems, Llc | High potency siRNAS for reducing the expression of target genes |
US8546554B2 (en) | 2008-09-25 | 2013-10-01 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gene |
US8569256B2 (en) | 2009-07-01 | 2013-10-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
US8569474B2 (en) | 2004-03-09 | 2013-10-29 | Isis Pharmaceuticals, Inc. | Double stranded constructs comprising one or more short strands hybridized to a longer strand |
US8592570B2 (en) | 2008-10-06 | 2013-11-26 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of an RNA from West Nile virus |
US8604183B2 (en) | 2002-11-05 | 2013-12-10 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
US20130331435A1 (en) * | 2002-05-23 | 2013-12-12 | Isis Pharmaceuticals, Inc. | Antisense modulation of kinesin-like 1 expression |
US8618277B2 (en) | 2002-02-20 | 2013-12-31 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20140010893A1 (en) * | 2010-05-12 | 2014-01-09 | University Of South Carolina | Methods for Affecting Homology-Directed DNA Double Stranded Break Repair |
US8648185B2 (en) | 2002-02-20 | 2014-02-11 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20140057960A1 (en) * | 2009-05-05 | 2014-02-27 | Medical Diagnostic Laboratories, Llc | Novel repressor on ifn-lambda promoter and sirna against zeb1 and blimp-1 to increase ifn-lambda gene activity |
US20140057962A1 (en) * | 2011-03-11 | 2014-02-27 | Surinder K. Batra | Compositions and Methods for the Treatment of Cancer |
US8664189B2 (en) | 2008-09-22 | 2014-03-04 | Rxi Pharmaceuticals Corporation | RNA interference in skin indications |
US8703930B2 (en) | 2004-04-09 | 2014-04-22 | Genecare Research Institute Co., Ltd. | Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes |
US8722641B2 (en) | 2010-01-29 | 2014-05-13 | St. Jude Children's Research Hospital | Oligonucleotides which inhibit p53 induction in response to cellular stress |
US20140135379A1 (en) * | 2007-06-29 | 2014-05-15 | Niigata University | Method of fixing and expressing physiologically active substance |
US20140179768A1 (en) * | 2011-06-21 | 2014-06-26 | Alnylam Pharmaceuticals, Inc. | ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
US8815818B2 (en) | 2008-07-18 | 2014-08-26 | Rxi Pharmaceuticals Corporation | Phagocytic cell delivery of RNAI |
US8822426B2 (en) | 2009-05-05 | 2014-09-02 | Beeologics Inc. | Prevention and treatment of nosema disease in bees |
US8859516B2 (en) | 2009-09-15 | 2014-10-14 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes |
US20140315973A1 (en) * | 2010-10-07 | 2014-10-23 | Agency For Science, Technology And Research | Parp-1 inhibitors |
US8871730B2 (en) | 2009-07-13 | 2014-10-28 | Somagenics Inc. | Chemical modification of short small hairpin RNAs for inhibition of gene expression |
US20140364485A1 (en) * | 2012-01-06 | 2014-12-11 | University Of South Alabama | Methods and compositions for the treatment of cancer |
US8957198B2 (en) | 2003-02-03 | 2015-02-17 | Medtronic, Inc. | Compositions, devices and methods for treatment of Huntington's disease through intracranial delivery of sirna |
US8962584B2 (en) | 2009-10-14 | 2015-02-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Compositions for controlling Varroa mites in bees |
US9006417B2 (en) | 2010-06-30 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
US9018187B2 (en) | 2009-07-01 | 2015-04-28 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
US9023820B2 (en) | 2009-01-26 | 2015-05-05 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing apolipoprotein C-III expression |
US9029338B2 (en) | 2009-08-14 | 2015-05-12 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus |
US9051570B2 (en) | 2007-05-22 | 2015-06-09 | Arcturus Therapeutics, Inc. | UNA oligomers for therapeutics |
US9051567B2 (en) | 2009-06-15 | 2015-06-09 | Tekmira Pharmaceuticals Corporation | Methods for increasing efficacy of lipid formulated siRNA |
US9057069B2 (en) | 2006-03-31 | 2015-06-16 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of Eg5 gene |
US9068184B2 (en) | 2011-06-21 | 2015-06-30 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of expression of protein C (PROC) genes |
US9074211B2 (en) | 2008-11-19 | 2015-07-07 | Rxi Pharmaceuticals Corporation | Inhibition of MAP4K4 through RNAI |
US9080171B2 (en) | 2010-03-24 | 2015-07-14 | RXi Parmaceuticals Corporation | Reduced size self-delivering RNAi compounds |
US9085638B2 (en) | 2007-03-07 | 2015-07-21 | The Johns Hopkins University | DNA vaccine enhancement with MHC class II activators |
US20150202223A1 (en) * | 2012-10-02 | 2015-07-23 | The General Hospital Corporation | Methods relating to dna-sensing pathway related conditions |
US9089610B2 (en) | 2008-08-19 | 2015-07-28 | Nektar Therapeutics | Complexes of small-interfering nucleic acids |
US9095504B2 (en) | 2010-03-24 | 2015-08-04 | Rxi Pharmaceuticals Corporation | RNA interference in ocular indications |
US9096636B2 (en) | 1996-06-06 | 2015-08-04 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
US9101643B2 (en) | 2009-11-03 | 2015-08-11 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR) |
US9133517B2 (en) | 2005-06-28 | 2015-09-15 | Medtronics, Inc. | Methods and sequences to preferentially suppress expression of mutated huntingtin |
US9139554B2 (en) | 2008-10-09 | 2015-09-22 | Tekmira Pharmaceuticals Corporation | Amino lipids and methods for the delivery of nucleic acids |
US9173894B2 (en) | 2011-02-02 | 2015-11-03 | Excaliard Pharamaceuticals, Inc. | Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (CTGF) |
US9181546B2 (en) | 2004-12-17 | 2015-11-10 | Beth Israel Deaconess Medical Center | Compositions for bacterial mediated gene silencing and methods of using same |
US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9187746B2 (en) | 2009-09-22 | 2015-11-17 | Alnylam Pharmaceuticals, Inc. | Dual targeting siRNA agents |
US9200276B2 (en) | 2009-06-01 | 2015-12-01 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotides for multivalent RNA interference, compositions and methods of use thereof |
US9228188B2 (en) | 2011-06-21 | 2016-01-05 | Alnylam Pharmaceuticals, Inc. | Compositions and method for inhibiting hepcidin antimicrobial peptide (HAMP) or HAMP-related gene expression |
US9228186B2 (en) | 2002-11-14 | 2016-01-05 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
US20160024504A1 (en) * | 2013-03-15 | 2016-01-28 | Constellation Pharmaceuticals, Inc. | Treating th2-mediated diseases by inhibition of bromodomains |
US20160032402A1 (en) * | 2013-03-15 | 2016-02-04 | Novartis Ag | Biomarkers associated with brm inhibition |
US9260715B2 (en) | 2007-01-16 | 2016-02-16 | The University Of Queensland | Method of inducing an immune response |
US9260471B2 (en) | 2010-10-29 | 2016-02-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
US9273356B2 (en) | 2006-05-24 | 2016-03-01 | Medtronic, Inc. | Methods and kits for linking polymorphic sequences to expanded repeat mutations |
US9315813B2 (en) | 2011-06-21 | 2016-04-19 | Alnylam Pharmaceuticals, Inc | Compositions and methods for inhibition of expression of apolipoprotein C-III (APOC3) genes |
US9340786B2 (en) | 2010-03-24 | 2016-05-17 | Rxi Pharmaceuticals Corporation | RNA interference in dermal and fibrotic indications |
US9375440B2 (en) | 2006-11-03 | 2016-06-28 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
US9399775B2 (en) | 2011-11-18 | 2016-07-26 | Alnylam Pharmaceuticals, Inc. | RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases |
US20160215285A1 (en) * | 2012-12-30 | 2016-07-28 | The Regents Of The University Of California | Methods of modulating compliance of the trabecular meshwork |
US9493774B2 (en) | 2009-01-05 | 2016-11-15 | Rxi Pharmaceuticals Corporation | Inhibition of PCSK9 through RNAi |
US9492386B2 (en) | 2002-06-28 | 2016-11-15 | Protiva Biotherapeutics, Inc. | Liposomal apparatus and manufacturing methods |
US9587240B2 (en) | 2001-01-09 | 2017-03-07 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
WO2017050848A1 (en) * | 2015-09-21 | 2017-03-30 | Oommen Oommen P | Nucleic acid molecules with enhanced activity |
US9611478B2 (en) | 2011-02-03 | 2017-04-04 | Mirna Therapeutics, Inc. | Synthetic mimics of miR-124 |
US9644241B2 (en) | 2011-09-13 | 2017-05-09 | Interpace Diagnostics, Llc | Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease |
US9642872B2 (en) | 2010-09-30 | 2017-05-09 | University Of Zurich | Treatment of B-cell lymphoma with microRNA |
US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20170152513A1 (en) * | 2008-09-15 | 2017-06-01 | Children's Medical Center Corporation | Modulation of bcl11a for treatment of hemoglobinopathies |
US9719092B2 (en) | 2002-11-14 | 2017-08-01 | Thermo Fisher Scientific Inc. | RNAi targeting CNTD2 |
US9719094B2 (en) | 2002-11-14 | 2017-08-01 | Thermo Fisher Scientific Inc. | RNAi targeting SEC61G |
US9745574B2 (en) | 2009-02-04 | 2017-08-29 | Rxi Pharmaceuticals Corporation | RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
US9771586B2 (en) | 2002-11-14 | 2017-09-26 | Thermo Fisher Scientific Inc. | RNAi targeting ZNF205 |
US9808479B2 (en) | 2012-09-05 | 2017-11-07 | Sylentis Sau | SiRNA and their use in methods and compositions for the treatment and / or prevention of eye conditions |
US9839649B2 (en) | 2002-11-14 | 2017-12-12 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
US9856475B2 (en) | 2014-03-25 | 2018-01-02 | Arcturus Therapeutics, Inc. | Formulations for treating amyloidosis |
US9879266B2 (en) | 2002-11-14 | 2018-01-30 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
US9982259B2 (en) | 2014-03-25 | 2018-05-29 | Arcturus Therapeutics, Inc. | Transthyretin allele selective UNA oligomers for gene silencing |
US10011836B2 (en) | 2002-11-14 | 2018-07-03 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
US10011837B2 (en) | 2014-03-04 | 2018-07-03 | Sylentis Sau | SiRNAs and their use in methods and compositions for the treatment and/or prevention of eye conditions |
US10011832B2 (en) | 2012-09-05 | 2018-07-03 | Sylentis Sau | SiRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
US20180195064A1 (en) * | 2015-06-30 | 2018-07-12 | Tadamitsu Kishimoto | Novel therapeutic agent for a lung disease and/or method for screening for the same |
US10060921B2 (en) | 2014-08-29 | 2018-08-28 | Alnylam Pharmaceuticals, Inc. | Methods of treating transthyretin (TTR) mediated amyloidosis |
US10131904B2 (en) | 2008-02-11 | 2018-11-20 | Rxi Pharmaceuticals Corporation | Modified RNAi polynucleotides and uses thereof |
US10208307B2 (en) | 2015-07-31 | 2019-02-19 | Alnylam Pharmaceuticals, Inc. | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases |
US10214745B2 (en) | 2012-03-15 | 2019-02-26 | The Scripps Research Institute | Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF |
US10246709B2 (en) | 2016-03-07 | 2019-04-02 | Arrowhead Pharmaceuticals, Inc. | Targeting ligands for therapeutic compounds |
US10287588B2 (en) | 2014-04-25 | 2019-05-14 | The Childrens's Medical Center Corporation | Compositions and methods to treating hemoglobinopathies |
US10294474B2 (en) | 2016-09-02 | 2019-05-21 | Arrowhead Pharmaceuticals, Inc. | Targeting ligands |
US10378012B2 (en) | 2014-07-29 | 2019-08-13 | Monsanto Technology Llc | Compositions and methods for controlling insect pests |
US10421964B2 (en) | 2015-07-23 | 2019-09-24 | Arcturus Therapeutics, Inc. | UNA oligomers and compositions for treating amyloidosis |
US10478500B2 (en) | 2014-10-10 | 2019-11-19 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression |
US10513703B2 (en) | 2014-11-10 | 2019-12-24 | Alnylam Pharmaceuticals, Inc. | Hepatitis B virus (HBV) iRNA compositions and methods of use thereof |
US10519447B2 (en) | 2015-04-01 | 2019-12-31 | Arcturus Therapeutics, Inc. | Therapeutic UNA oligomers and uses thereof |
US10570393B2 (en) | 2015-04-13 | 2020-02-25 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof |
US10590416B2 (en) | 2017-07-06 | 2020-03-17 | Arrowhead Pharmaceuticals, Inc. | RNAi agents for inhibiting expression of alpha-ENaC and methods of use |
US10597676B2 (en) | 2013-07-19 | 2020-03-24 | Monsanto Technology Llc | Compositions and methods for controlling Leptinotarsa |
US10597657B2 (en) | 2017-09-11 | 2020-03-24 | Arrowhead Pharmaceuticals, Inc. | RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3) |
US10653619B2 (en) | 2009-03-23 | 2020-05-19 | Medtronic, Inc. | Drug depots for treatment of pain and inflammation |
US10683500B2 (en) | 2014-03-25 | 2020-06-16 | Arcturus Therapeutics, Inc. | UNA oligomers having reduced off-target effects in gene silencing |
US10731157B2 (en) | 2015-08-24 | 2020-08-04 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotide nanoparticles for the modulation of gene expression and uses thereof |
US10808247B2 (en) | 2015-07-06 | 2020-10-20 | Phio Pharmaceuticals Corp. | Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach |
US10900039B2 (en) | 2014-09-05 | 2021-01-26 | Phio Pharmaceuticals Corp. | Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1 |
US10934550B2 (en) | 2013-12-02 | 2021-03-02 | Phio Pharmaceuticals Corp. | Immunotherapy of cancer |
US10968449B2 (en) | 2015-01-22 | 2021-04-06 | Monsanto Technology Llc | Compositions and methods for controlling Leptinotarsa |
US10982212B2 (en) | 2003-06-12 | 2021-04-20 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
US11001845B2 (en) | 2015-07-06 | 2021-05-11 | Phio Pharmaceuticals Corp. | Nucleic acid molecules targeting superoxide dismutase 1 (SOD1) |
US11021707B2 (en) | 2015-10-19 | 2021-06-01 | Phio Pharmaceuticals Corp. | Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA |
US11053500B2 (en) * | 2013-08-28 | 2021-07-06 | lonis Pharmaceuticals, Inc. | Modulation of prekallikrein (PKK) expression |
US20210238590A1 (en) * | 2018-06-14 | 2021-08-05 | University Of Utah Research Foundation | Staufen1 regulating agents and associated methods |
US11091770B2 (en) | 2014-04-01 | 2021-08-17 | Monsanto Technology Llc | Compositions and methods for controlling insect pests |
US11142766B2 (en) | 2014-11-17 | 2021-10-12 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof |
US11198869B2 (en) * | 2017-12-01 | 2021-12-14 | The Texas A&M University System | Angelman syndrome antisense treatment |
US11261447B2 (en) | 2017-07-13 | 2022-03-01 | Alnylam Pharmaceuticals, Inc. | Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
USRE48948E1 (en) | 2008-04-18 | 2022-03-01 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable polymer |
US11261441B2 (en) | 2017-03-29 | 2022-03-01 | Bluebird Bio, Inc. | Vectors and compositions for treating hemoglobinopathies |
US11279934B2 (en) | 2014-04-28 | 2022-03-22 | Phio Pharmaceuticals Corp. | Methods for treating cancer using nucleic acids targeting MDM2 or MYCN |
US11312962B2 (en) | 2015-07-10 | 2022-04-26 | Ionis Pharmaceuticals, Inc. | Modulators of diacyglycerol acyltransferase 2 (DGAT2) |
US11324820B2 (en) | 2017-04-18 | 2022-05-10 | Alnylam Pharmaceuticals, Inc. | Methods for the treatment of subjects having a hepatitis b virus (HBV) infection |
US11492623B2 (en) | 2018-08-13 | 2022-11-08 | Alnylam Pharmaceuticals, Inc. | Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof |
US11542493B2 (en) | 2012-11-27 | 2023-01-03 | The Children's Medical Center Corporation | Targeting BCL11A distal regulatory elements for fetal hemoglobin reinduction |
US11572543B2 (en) | 2015-05-08 | 2023-02-07 | The Children's Medical Center. Corporation | Targeting BCL11A enhancer functional regions for fetal hemoglobin reinduction |
US11591544B2 (en) | 2020-11-25 | 2023-02-28 | Akagera Medicines, Inc. | Ionizable cationic lipids |
US11613752B2 (en) | 2014-05-01 | 2023-03-28 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating PKK expression |
US11613751B2 (en) | 2021-03-04 | 2023-03-28 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof |
US11723912B2 (en) | 2016-12-08 | 2023-08-15 | University Of Utah Research Foundation | Staufen1 agents and associated methods |
US11788087B2 (en) | 2017-05-25 | 2023-10-17 | The Children's Medical Center Corporation | BCL11A guide delivery |
US11806360B2 (en) | 2017-09-19 | 2023-11-07 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for treating transthyretin (TTR) mediated amyloidosis |
US11959081B2 (en) | 2021-08-03 | 2024-04-16 | Alnylam Pharmaceuticals, Inc. | Transthyretin (TTR) iRNA compositions and methods of use thereof |
Families Citing this family (733)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0642589A4 (en) * | 1992-05-11 | 1997-05-21 | Ribozyme Pharm Inc | METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION. |
US20030206887A1 (en) * | 1992-05-14 | 2003-11-06 | David Morrissey | RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA) |
US5639647A (en) * | 1994-03-29 | 1997-06-17 | Ribozyme Pharmaceuticals, Inc. | 2'-deoxy-2'alkylnucleotide containing nucleic acid |
US20040219569A1 (en) * | 1999-07-06 | 2004-11-04 | Fruma Yehiely | Gene identification method |
AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
CZ295108B6 (cs) | 1998-03-20 | 2005-05-18 | Benitec Australia Ltd | Syntetický gen obsahující dispergovanou nebo cizorodou deoxyribonukleovou molekulu a genový konstrukt obsahující tento syntetický gen |
CA2326823A1 (en) * | 1998-04-20 | 1999-10-28 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid molecules with novel chemical compositions capable of modulating gene expression |
EP2314700A1 (en) | 1999-01-28 | 2011-04-27 | Medical College of Georgia Research Institute, Inc | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA |
DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
US7601494B2 (en) | 1999-03-17 | 2009-10-13 | The University Of North Carolina At Chapel Hill | Method of screening candidate compounds for susceptibility to biliary excretion |
EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
US6656698B1 (en) * | 1999-06-30 | 2003-12-02 | Millennium Pharmaceuticals, Inc. | 12832, a novel human kinase-like molecule and uses thereof |
US6423885B1 (en) | 1999-08-13 | 2002-07-23 | Commonwealth Scientific And Industrial Research Organization (Csiro) | Methods for obtaining modified phenotypes in plant cells |
DE10100586C1 (de) | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
US7829693B2 (en) * | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
DE10160151A1 (de) * | 2001-01-09 | 2003-06-26 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens |
US7179796B2 (en) | 2000-01-18 | 2007-02-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
US20050032733A1 (en) * | 2001-05-18 | 2005-02-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA) |
US20080039414A1 (en) * | 2002-02-20 | 2008-02-14 | Sima Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20070026394A1 (en) * | 2000-02-11 | 2007-02-01 | Lawrence Blatt | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies |
US8202846B2 (en) | 2000-03-16 | 2012-06-19 | Cold Spring Harbor Laboratory | Methods and compositions for RNA interference |
US20030084471A1 (en) * | 2000-03-16 | 2003-05-01 | David Beach | Methods and compositions for RNA interference |
EP1272630A2 (en) | 2000-03-16 | 2003-01-08 | Genetica, Inc. | Methods and compositions for rna interference |
ES2500923T3 (es) * | 2000-03-30 | 2014-10-01 | The Whitehead Institute For Biomedical Research | Mediadores específicos de secuencia de ARN de interferencia de ARN |
US20030190635A1 (en) * | 2002-02-20 | 2003-10-09 | Mcswiggen James A. | RNA interference mediated treatment of Alzheimer's disease using short interfering RNA |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US7767802B2 (en) | 2001-01-09 | 2010-08-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
CA2369944A1 (en) | 2001-01-31 | 2002-07-31 | Nucleonics Inc. | Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell |
US20050261219A1 (en) * | 2001-05-18 | 2005-11-24 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA) |
US20050159379A1 (en) * | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc | RNA interference mediated inhibition of gastric inhibitory polypeptide (GIP) and gastric inhibitory polypeptide receptor (GIPR) gene expression using short interfering nucleic acid (siNA) |
US20050233344A1 (en) * | 2001-05-18 | 2005-10-20 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of platelet derived growth factor (PDGF) and platelet derived growth factor receptor (PDGFR) gene expression using short interfering nucleic acid (siNA) |
US20050196767A1 (en) * | 2001-05-18 | 2005-09-08 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA) |
EP1627061B1 (en) * | 2001-05-18 | 2009-08-12 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) |
US20050196781A1 (en) * | 2001-05-18 | 2005-09-08 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of STAT3 gene expression using short interfering nucleic acid (siNA) |
US20050014172A1 (en) | 2002-02-20 | 2005-01-20 | Ivan Richards | RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA) |
US20050164968A1 (en) * | 2001-05-18 | 2005-07-28 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of ADAM33 gene expression using short interfering nucleic acid (siNA) |
US20050158735A1 (en) * | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of proliferating cell nuclear antigen (PCNA) gene expression using short interfering nucleic acid (siNA) |
US20060142225A1 (en) * | 2001-05-18 | 2006-06-29 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of cyclin dependent kinase-2 (CDK2) gene expression using short interfering nucleic acid (siNA) |
US20040198682A1 (en) * | 2001-11-30 | 2004-10-07 | Mcswiggen James | RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA) |
US20050143333A1 (en) * | 2001-05-18 | 2005-06-30 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA) |
US20050136436A1 (en) * | 2001-05-18 | 2005-06-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of G72 and D-amino acid oxidase (DAAO) gene expression using short interfering nucleic acid (siNA) |
US7109165B2 (en) * | 2001-05-18 | 2006-09-19 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
US7517864B2 (en) | 2001-05-18 | 2009-04-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US20050267058A1 (en) * | 2001-05-18 | 2005-12-01 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (sINA) |
US20080161256A1 (en) * | 2001-05-18 | 2008-07-03 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
US20050079610A1 (en) * | 2001-05-18 | 2005-04-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA) |
US20060211642A1 (en) * | 2001-05-18 | 2006-09-21 | Sirna Therapeutics, Inc. | RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA) |
US20050164967A1 (en) * | 2001-05-18 | 2005-07-28 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA) |
US20050233997A1 (en) * | 2001-05-18 | 2005-10-20 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA) |
US20050124569A1 (en) * | 2001-05-18 | 2005-06-09 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA) |
US20050288242A1 (en) * | 2001-05-18 | 2005-12-29 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA) |
US20060148743A1 (en) * | 2001-05-18 | 2006-07-06 | Vasant Jadhav | RNA interference mediated inhibition of histone deacetylase (HDAC) gene expression using short interfering nucleic acid (siNA) |
US20050176663A1 (en) * | 2001-05-18 | 2005-08-11 | Sima Therapeutics, Inc. | RNA interference mediated inhibition of protein tyrosine phosphatase type IVA (PRL3) gene expression using short interfering nucleic acid (siNA) |
US20050203040A1 (en) * | 2001-05-18 | 2005-09-15 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA) |
US20050222066A1 (en) * | 2001-05-18 | 2005-10-06 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US20050196765A1 (en) * | 2001-05-18 | 2005-09-08 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of checkpoint Kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA) |
US20050287128A1 (en) * | 2001-05-18 | 2005-12-29 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA) |
US20070270579A1 (en) * | 2001-05-18 | 2007-11-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
US20050153914A1 (en) * | 2001-05-18 | 2005-07-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of MDR P-glycoprotein gene expression using short interfering nucleic acid (siNA) |
US20050187174A1 (en) * | 2001-05-18 | 2005-08-25 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA) |
US20050164224A1 (en) * | 2001-05-18 | 2005-07-28 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA) |
US20050282188A1 (en) * | 2001-05-18 | 2005-12-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
US20090299045A1 (en) * | 2001-05-18 | 2009-12-03 | Sirna Therapeutics, Inc. | RNA Interference Mediated Inhibition Of Interleukin and Interleukin Gene Expression Using Short Interfering Nucleic Acid (siNA) |
US20030175950A1 (en) * | 2001-05-29 | 2003-09-18 | Mcswiggen James A. | RNA interference mediated inhibition of HIV gene expression using short interfering RNA |
US20080188430A1 (en) * | 2001-05-18 | 2008-08-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA) |
WO2003070743A1 (en) * | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF G72 AND D-AMINO ACID OXIDASE (DAAO) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20050256068A1 (en) * | 2001-05-18 | 2005-11-17 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA) |
US20050176666A1 (en) * | 2001-05-18 | 2005-08-11 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of GPRA and AAA1 gene expression using short interfering nucleic acid (siNA) |
WO2005014811A2 (en) * | 2003-08-08 | 2005-02-17 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF XIAP GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20070042983A1 (en) * | 2001-05-18 | 2007-02-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
US20050159378A1 (en) * | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA) |
US20050182007A1 (en) * | 2001-05-18 | 2005-08-18 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA) |
US20070093437A1 (en) * | 2001-05-18 | 2007-04-26 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of xiap gene expression using short interfering nucleic acid (sina) |
US20030124513A1 (en) * | 2001-05-29 | 2003-07-03 | Mcswiggen James | Enzymatic nucleic acid treatment of diseases or conditions related to levels of HIV |
US20050124566A1 (en) * | 2001-05-18 | 2005-06-09 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA) |
US20050159380A1 (en) * | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of angiopoietin gene expression using short interfering nucleic acid (siNA) |
US20050176664A1 (en) * | 2001-05-18 | 2005-08-11 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering nucleic acid (siNA) |
US20050119212A1 (en) * | 2001-05-18 | 2005-06-02 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of FAS and FASL gene expression using short interfering nucleic acid (siNA) |
US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
US20050209180A1 (en) * | 2001-05-18 | 2005-09-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA) |
WO2003070983A1 (en) * | 2002-02-20 | 2003-08-28 | Sirna Therapeutics, Inc | RNA INTERFERENCE MEDIATED INHIBITION OF PROTEIN KINASE C ALPHA (PKC-ALPHA) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20050137155A1 (en) * | 2001-05-18 | 2005-06-23 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of Parkinson disease using short interfering nucleic acid (siNA) |
US20050048529A1 (en) * | 2002-02-20 | 2005-03-03 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA) |
WO2003070897A2 (en) * | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | RNA INTERFERENCE MEDIATED INHIBITION OF TNF AND TNF RECEPTOR SUPERFAMILY GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20050148530A1 (en) | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US20050191618A1 (en) * | 2001-05-18 | 2005-09-01 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA) |
US20040019001A1 (en) * | 2002-02-20 | 2004-01-29 | Mcswiggen James A. | RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA |
US20050233996A1 (en) * | 2002-02-20 | 2005-10-20 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hairless (HR) gene expression using short interfering nucleic acid (siNA) |
US20050159382A1 (en) * | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA) |
US20050054596A1 (en) * | 2001-11-30 | 2005-03-10 | Mcswiggen James | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US8008472B2 (en) | 2001-05-29 | 2011-08-30 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA) |
US20050019915A1 (en) | 2001-06-21 | 2005-01-27 | Bennett C. Frank | Antisense modulation of superoxide dismutase 1, soluble expression |
WO2003000707A2 (en) | 2001-06-21 | 2003-01-03 | Isis Pharmaceuticals, Inc. | Antisense modulation of superoxide dismutase 1, soluble expression |
KR20040022449A (ko) | 2001-07-12 | 2004-03-12 | 유니버시티 오브 매사추세츠 | 유전자 불활성화를 매개하는 소형 간섭 rna의 생체내제조 |
US20030198627A1 (en) * | 2001-09-01 | 2003-10-23 | Gert-Jan Arts | siRNA knockout assay method and constructs |
US20050119202A1 (en) * | 2001-10-26 | 2005-06-02 | Roland Kreutzer | Medicament to treat a fibrotic disease |
DE10230996A1 (de) * | 2001-10-26 | 2003-07-17 | Ribopharma Ag | Medikament zur Behandlung eines Pankreaskarzinoms |
CN1604783A (zh) * | 2001-10-26 | 2005-04-06 | 里伯药品公司 | 通过rna干扰治疗纤维化疾病的药物 |
WO2003035870A1 (de) * | 2001-10-26 | 2003-05-01 | Ribopharma Ag | Medikament zur behandlung eines pankreaskarzinoms |
AU2002348163A1 (en) * | 2001-11-02 | 2003-05-19 | Intradigm Corporation | Therapeutic methods for nucleic acid delivery vehicles |
US20040138163A1 (en) * | 2002-05-29 | 2004-07-15 | Mcswiggen James | RNA interference mediated inhibition of vascular edothelial growth factor and vascular edothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US20070203333A1 (en) * | 2001-11-30 | 2007-08-30 | Mcswiggen James | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US20050075304A1 (en) * | 2001-11-30 | 2005-04-07 | Mcswiggen James | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US7294504B1 (en) | 2001-12-27 | 2007-11-13 | Allele Biotechnology & Pharmaceuticals, Inc. | Methods and compositions for DNA mediated gene silencing |
AU2003237616B2 (en) * | 2002-01-17 | 2007-07-05 | The University Of British Columbia | Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same |
DE10202419A1 (de) | 2002-01-22 | 2003-08-07 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens |
US7897753B2 (en) | 2002-02-20 | 2011-03-01 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of XIAP gene expression using short interfering nucleic acid (siNA) |
US7795422B2 (en) | 2002-02-20 | 2010-09-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA) |
US8067575B2 (en) | 2002-02-20 | 2011-11-29 | Merck, Sharp & Dohme Corp. | RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA) |
US7897752B2 (en) | 2002-02-20 | 2011-03-01 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of telomerase gene expression using short interfering nucleic acid (siNA) |
WO2003106476A1 (en) * | 2002-02-20 | 2003-12-24 | Sirna Therapeutics, Inc | Nucleic acid mediated inhibition of enterococcus infection and cytolysin toxin activity |
EP1499631A4 (en) * | 2002-02-20 | 2006-01-25 | Sirna Therapeutics Inc | RNA INTERFERENCE-ADMINISTRATIVE INHIBITION OF TGF-BETA AND TGF-BETA-RECEPTOR GENE EXPRESSION WITH SHORT-INTERFERENCE NUCLEIC ACID (SINA) |
US20050096284A1 (en) * | 2002-02-20 | 2005-05-05 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA) |
US7893248B2 (en) | 2002-02-20 | 2011-02-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA) |
US7667030B2 (en) | 2002-02-20 | 2010-02-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA) |
US7928220B2 (en) | 2002-02-20 | 2011-04-19 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA) |
US7700760B2 (en) | 2002-02-20 | 2010-04-20 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA) |
US7928219B2 (en) | 2002-02-20 | 2011-04-19 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (SINA) |
US7935812B2 (en) | 2002-02-20 | 2011-05-03 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA) |
US20090192105A1 (en) | 2002-02-20 | 2009-07-30 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF INTERCELLULAR ADHESION MOLECULE (ICAM) GENE EXPRESSION USING SHORT INTERFERING NUCELIC ACID (siNA) |
US8258288B2 (en) | 2002-02-20 | 2012-09-04 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA) |
EP1501853A4 (en) * | 2002-02-20 | 2005-11-16 | Sirna Therapeutics Inc | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION OF AN EPIDERMAL GROWTH FACTOR RECEPTOR USING SHORT INTERFERING NUCLEIC ACIDS |
US20090253774A1 (en) | 2002-02-20 | 2009-10-08 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF PLATELET DERIVED GROWTH FACTOR (PDGF) AND PLATELET DERIVED GROWTH FACTOR RECEPTOR (PDGFR) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
JP2005517427A (ja) | 2002-02-20 | 2005-06-16 | サーナ・セラピューティクス・インコーポレイテッド | 短干渉核酸(siNA)を用いるC型肝炎ウイルス(HCV)遺伝子発現のRNA干渉媒介性阻害 |
US20090099117A1 (en) | 2002-02-20 | 2009-04-16 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF MYOSTATIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2003072745A2 (en) * | 2002-02-22 | 2003-09-04 | Eshleman James R | Antigene locks and therapeutic uses thereof |
EP2277522B1 (en) * | 2002-03-01 | 2012-11-21 | UCB Manufacturing, Inc. | Methods for increasing or decreasing bone density and identifying molecules |
US7274703B2 (en) * | 2002-03-11 | 2007-09-25 | 3Com Corporation | Stackable network units with resiliency facility |
US7357928B2 (en) | 2002-04-08 | 2008-04-15 | University Of Louisville Research Foundation, Inc. | Method for the diagnosis and prognosis of malignant diseases |
AU2003239897A1 (en) | 2002-05-23 | 2003-12-12 | Ceptyr, Inc. | Modulation of ptp1b signal transduction by rna interference |
WO2003099298A1 (en) * | 2002-05-24 | 2003-12-04 | Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V. | Rna interference mediating small rna molecules |
US20040248094A1 (en) * | 2002-06-12 | 2004-12-09 | Ford Lance P. | Methods and compositions relating to labeled RNA molecules that reduce gene expression |
AU2003276666A1 (en) * | 2002-06-12 | 2003-12-31 | Ambion, Inc. | Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference |
US20100075423A1 (en) * | 2002-06-12 | 2010-03-25 | Life Technologies Corporation | Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference |
EP1513538A4 (en) * | 2002-06-14 | 2007-08-22 | Mirus Bio Corp | Novel methods for introducing polynucleotides into cells |
US20100009856A1 (en) * | 2002-06-21 | 2010-01-14 | Sinogenomax Sompany LTD. | Randomized dna libraries and double-stranded rna libraries, use and method of production thereof |
EP1520022B1 (en) * | 2002-07-10 | 2015-07-22 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Rna-interference by single-stranded rna molecules |
ES2695050T3 (es) * | 2002-08-05 | 2018-12-28 | Silence Therapeutics Gmbh | Nuevas formas adicionales de moléculas de ARN de interferencia |
AU2012216354B2 (en) * | 2002-08-05 | 2016-01-14 | Silence Therapeutics Gmbh | Further novel forms of interfering RNA molecules |
US20040241854A1 (en) | 2002-08-05 | 2004-12-02 | Davidson Beverly L. | siRNA-mediated gene silencing |
US20050042646A1 (en) | 2002-08-05 | 2005-02-24 | Davidson Beverly L. | RNA interference suppresion of neurodegenerative diseases and methods of use thereof |
AU2015264957B2 (en) * | 2002-08-05 | 2017-10-26 | Silence Therapeutics Gmbh | Further novel forms of interfering rna molecules |
US20080274989A1 (en) | 2002-08-05 | 2008-11-06 | University Of Iowa Research Foundation | Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof |
ES2389024T3 (es) | 2002-08-05 | 2012-10-22 | Silence Therapeutics Aktiengesellschaft | Moléculas de RNA interferentes de extremos romos |
EP1527176B2 (en) | 2002-08-05 | 2017-03-22 | Silence Therapeutics GmbH | Further novel forms of interfering rna molecules |
US20040029275A1 (en) * | 2002-08-10 | 2004-02-12 | David Brown | Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs |
PT1536827E (pt) * | 2002-08-14 | 2009-03-20 | Silence Therapeutics Ag | Utilização de proteína cinase n beta |
US20080260744A1 (en) | 2002-09-09 | 2008-10-23 | Omeros Corporation | G protein coupled receptors and uses thereof |
US20050020521A1 (en) | 2002-09-25 | 2005-01-27 | University Of Massachusetts | In vivo gene silencing by chemically modified and stable siRNA |
US20060160759A1 (en) * | 2002-09-28 | 2006-07-20 | Jianzhu Chen | Influenza therapeutic |
CA2500468A1 (en) * | 2002-09-28 | 2004-04-08 | Massachussets Institute Of Technology | Influenza therapeutic |
US9150606B2 (en) | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation |
US7696345B2 (en) | 2002-11-05 | 2010-04-13 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
WO2004043977A2 (en) * | 2002-11-05 | 2004-05-27 | Isis Pharmaceuticals, Inc. | 2’-fluoro substituted oligomeric compounds and compositions for use in gene modulations |
US9150605B2 (en) | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
DE10322662A1 (de) * | 2002-11-06 | 2004-10-07 | Grünenthal GmbH | Wirksame und stabile DNA-Enzyme |
US7250496B2 (en) | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
US7655785B1 (en) | 2002-11-14 | 2010-02-02 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof |
US10920226B2 (en) * | 2002-11-14 | 2021-02-16 | Thermo Fisher Scientific Inc. | siRNA targeting LDHA |
US8163896B1 (en) | 2002-11-14 | 2012-04-24 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
CA2506619A1 (en) | 2002-11-18 | 2004-08-19 | Thomas W. Hodge | Cell lines and host nucleic acid sequences related to infectious disease |
US7064337B2 (en) | 2002-11-19 | 2006-06-20 | The Regents Of The University Of California | Radiation detection system for portable gamma-ray spectroscopy |
DE10254214A1 (de) * | 2002-11-20 | 2004-06-09 | Beiersdorf Ag | Oligoribonukleotide zur Behandlung von degenerativen Hauterscheinungen durch RNA-Interferenz |
JP4526228B2 (ja) * | 2002-11-22 | 2010-08-18 | 隆 森田 | RNAiによる新規治療法および治療剤 |
US20060275762A1 (en) * | 2002-11-22 | 2006-12-07 | Bio- Think Tank Co., Ltd., | Method of detecting target base sequence of rna interference, method of designing polynucleotide base sequence causing rna interference, method of constructing double-stranded polynucleotide, method of regulating gene expression, base sequence processing apparatus, program for running base sequence processing method on comp |
WO2004048545A2 (en) * | 2002-11-26 | 2004-06-10 | University Of Massachusetts | DELIVERY OF siRNAs______________________________________________ |
US20130130231A1 (en) | 2002-11-26 | 2013-05-23 | Isaac Bentwich | Bioinformatically detectable group of novel viral regulatory genes and uses thereof |
US7696334B1 (en) | 2002-12-05 | 2010-04-13 | Rosetta Genomics, Ltd. | Bioinformatically detectable human herpesvirus 5 regulatory gene |
US7217807B2 (en) | 2002-11-26 | 2007-05-15 | Rosetta Genomics Ltd | Bioinformatically detectable group of novel HIV regulatory genes and uses thereof |
CN1301263C (zh) | 2002-12-18 | 2007-02-21 | 北京昭衍新药研究中心 | 一组抗hiv感染及防治艾滋病的核苷酸序列及其应用 |
KR101410692B1 (ko) | 2002-12-24 | 2014-06-24 | 리나트 뉴로사이언스 코프. | 항-ngf 항체 및 그것을 이용하는 방법 |
US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
CA2513623A1 (en) * | 2003-01-16 | 2004-08-05 | The Trustees Of The University Of Pennsylvania | Compositions and methods for sirna inhibition of icam-1 |
US7629323B2 (en) * | 2003-01-21 | 2009-12-08 | Northwestern University | Manipulation of neuronal ion channels |
EP1589931A2 (en) * | 2003-02-05 | 2005-11-02 | University of Massachusetts | RNAi TARGETING OF VIRUSES |
US20070104688A1 (en) | 2003-02-13 | 2007-05-10 | City Of Hope | Small interfering RNA mediated transcriptional gene silencing in mammalian cells |
US20040162235A1 (en) * | 2003-02-18 | 2004-08-19 | Trubetskoy Vladimir S. | Delivery of siRNA to cells using polyampholytes |
EP2191846A1 (en) | 2003-02-19 | 2010-06-02 | Rinat Neuroscience Corp. | Method for treating pain by administering a nerve growth factor antagonist and an NSAID and composition containing the same |
WO2004076629A2 (en) | 2003-02-27 | 2004-09-10 | Nucleonics Inc. | METHODS AND CONSTRUCTS FOR EVALUATION OF RNAi TARGETS AND EFFECTOR MOLECULES |
WO2004076663A1 (ja) * | 2003-02-27 | 2004-09-10 | National Institute Of Advanced Industrial Science And Technology | 哺乳動物細胞におけるdsRNAによるCpG配列へのメチル化誘導 |
EP3450559A1 (en) | 2003-03-07 | 2019-03-06 | Alnylam Pharmaceuticals, Inc. | Therapeutic compositions |
AU2004221760B2 (en) | 2003-03-21 | 2010-03-18 | Roche Innovation Center Copenhagen A/S | Short interfering RNA (siRNA) analogues |
US20040198640A1 (en) * | 2003-04-02 | 2004-10-07 | Dharmacon, Inc. | Stabilized polynucleotides for use in RNA interference |
ATE536408T1 (de) * | 2003-04-02 | 2011-12-15 | Dharmacon Inc | Modifizierte polynukleotide zur verwendung bei rna-interferenz |
JP4605799B2 (ja) * | 2003-04-02 | 2011-01-05 | ダーマコン, インコーポレイテッド | Rna干渉において使用するための修飾ポリヌクレオチド |
EP1631669A2 (en) * | 2003-04-09 | 2006-03-08 | Biodelivery Sciences International, Inc. | Cochleate compositions directed against expression of proteins |
CA2521464C (en) | 2003-04-09 | 2013-02-05 | Alnylam Pharmaceuticals, Inc. | Irna conjugates |
WO2004092383A2 (en) * | 2003-04-15 | 2004-10-28 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF SEVERE ACUTE RESPIRATORY SYNDROME (SARS) VIRUS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
DK1620544T3 (en) | 2003-04-17 | 2019-01-14 | Alnylam Pharmaceuticals Inc | MODIFIED iRNA AGENTS |
US7723509B2 (en) | 2003-04-17 | 2010-05-25 | Alnylam Pharmaceuticals | IRNA agents with biocleavable tethers |
US8017762B2 (en) | 2003-04-17 | 2011-09-13 | Alnylam Pharmaceuticals, Inc. | Modified iRNA agents |
US8796436B2 (en) | 2003-04-17 | 2014-08-05 | Alnylam Pharmaceuticals, Inc. | Modified iRNA agents |
US7851615B2 (en) | 2003-04-17 | 2010-12-14 | Alnylam Pharmaceuticals, Inc. | Lipophilic conjugated iRNA agents |
EP1625138A4 (en) | 2003-04-17 | 2010-06-23 | Alnylam Pharmaceuticals Inc | PROTECTED MONOMERS |
ATE516047T1 (de) | 2003-05-09 | 2011-07-15 | Diadexus Inc | Ovr110-antikörperzusammensetzungen und anwendungsverfahren |
WO2004101788A2 (en) | 2003-05-09 | 2004-11-25 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Small interfering rna libraries and methods of synthesis and use |
AU2003241409A1 (en) * | 2003-05-12 | 2005-01-21 | Potomac Pharmaceuticals, Inc. | Gene expression suppression agents |
US20050148531A1 (en) * | 2003-05-15 | 2005-07-07 | Todd Hauser | Modulation of gene expression using DNA-DNA hybrids |
CA2527301A1 (en) * | 2003-05-30 | 2004-12-09 | Nippon Shinyaku Co., Ltd. | Oligonucleic acid-bearing composite and pharmaceutical composition containing the composite |
EP1640452A4 (en) * | 2003-05-30 | 2009-12-23 | Nippon Shinyaku Co Ltd | OLIGOBICATENARY RNA INHIBITING BCL-2 EXPRESSION AND MEDICINAL COMPOSITION CONTAINING THE SAME |
EP1486564A1 (de) * | 2003-06-13 | 2004-12-15 | Ribopharma AG | SiRNA mit erhöhter Stabilität in Serum |
US7790691B2 (en) * | 2003-06-20 | 2010-09-07 | Isis Pharmaceuticals, Inc. | Double stranded compositions comprising a 3′-endo modified strand for use in gene modulation |
EP1692153A4 (en) * | 2003-07-03 | 2007-03-21 | Univ Pennsylvania | INHIBITION OF EXPRESSION OF SYK-KINASE |
WO2005010188A2 (en) * | 2003-07-21 | 2005-02-03 | Whitehead Institute For Biomedical Research | Rnas able to modulate chromatin silencing |
CA2533701A1 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
US7888497B2 (en) | 2003-08-13 | 2011-02-15 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof |
AU2004267425B2 (en) * | 2003-08-13 | 2010-10-21 | The Board Of Trustees Of The University Of Illinois | Silencing of TGF-beta receptor type II expression by sIRNA |
WO2005035759A2 (en) * | 2003-08-20 | 2005-04-21 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF HYPOXIA INDUCIBLE FACTOR 1 (HIF1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US8501705B2 (en) * | 2003-09-11 | 2013-08-06 | The Board Of Regents Of The University Of Texas System | Methods and materials for treating autoimmune and/or complement mediated diseases and conditions |
PE20050469A1 (es) | 2003-09-18 | 2005-09-10 | Lilly Co Eli | Modulacion de la expresion de eif4e |
AU2004276823A1 (en) * | 2003-09-22 | 2005-04-07 | Merck And Co., Inc | Synthetic lethal screen using RNA interference |
WO2005033310A1 (de) * | 2003-10-01 | 2005-04-14 | Grünenthal GmbH | Pim-1-spezifische dsrna-verbindungen |
US20050120415A1 (en) | 2003-10-09 | 2005-06-02 | E.I. Du Pont De Nemours And Company | Gene silencing |
WO2005045032A2 (en) * | 2003-10-20 | 2005-05-19 | Sima Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF EARLY GROWTH RESPONSE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2005045038A2 (en) * | 2003-10-23 | 2005-05-19 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF GPRA AND AAA1 GENE EXPRESSION USING SHORT NUCLEIC ACID (siNA) |
WO2005044981A2 (en) * | 2003-10-23 | 2005-05-19 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
CA2543954C (en) | 2003-10-27 | 2016-11-08 | Rosetta Inpharmatics Llc | Method of designing sirnas for gene silencing |
US8227434B1 (en) | 2003-11-04 | 2012-07-24 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Materials and methods for treating oncological disorders |
US20070275918A1 (en) * | 2003-11-07 | 2007-11-29 | The Board Of Trustees Of The University Of Illinois | Induction of Cellular Senescence by Cdk4 Disruption for Tumor Suppression and Regression |
JP2005168485A (ja) * | 2003-11-20 | 2005-06-30 | Tsutomu Suzuki | siRNAの設計方法 |
US20100145038A1 (en) * | 2003-11-24 | 2010-06-10 | Merck & Co., Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2005068630A1 (ja) * | 2003-12-16 | 2005-07-28 | National Institute Of Advanced Industrial Science And Technology | 干渉用二重鎖rna |
WO2005073378A1 (en) * | 2004-01-30 | 2005-08-11 | Santaris Pharma A/S | MODIFIED SHORT INTERFERING RNA (MODIFIED siRNA) |
ATE447024T1 (de) * | 2004-02-06 | 2009-11-15 | Dharmacon Inc | Stabilisierte rnas als transfektionskontrollen und silencing-reagentien |
US20060019914A1 (en) | 2004-02-11 | 2006-01-26 | University Of Tennessee Research Foundation | Inhibition of tumor growth and invasion by anti-matrix metalloproteinase DNAzymes |
CA2557426A1 (en) | 2004-02-24 | 2005-10-06 | Thomas W. Hodge | Rab9a, rab11a, and modulators thereof related to infectious disease |
US7691823B2 (en) * | 2004-03-05 | 2010-04-06 | University Of Massachusetts | RIP140 regulation of glucose transport |
JPWO2005095647A1 (ja) * | 2004-03-31 | 2008-02-21 | タカラバイオ株式会社 | siRNAのスクリーニング方法 |
KR101147147B1 (ko) | 2004-04-01 | 2012-05-25 | 머크 샤프 앤드 돔 코포레이션 | Rna 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드 |
CA2557532A1 (en) | 2004-04-23 | 2005-11-10 | Angela M. Christiano | Inhibition of hairless protein mrna |
US8029815B2 (en) | 2004-04-28 | 2011-10-04 | Elford Howard L | Methods for treating or preventing restenosis and other vascular proliferative disorders |
US7687616B1 (en) | 2004-05-14 | 2010-03-30 | Rosetta Genomics Ltd | Small molecules modulating activity of micro RNA oligonucleotides and micro RNA targets and uses thereof |
WO2005110464A2 (en) * | 2004-05-14 | 2005-11-24 | Oregon Health & Science University | Irx5 inhibition as treatment for hyperproliferative disorders |
US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
JP2008500364A (ja) * | 2004-05-25 | 2008-01-10 | キメラコア, インコーポレイテッド | 自己集合性ナノ粒子薬物送達システム |
EP1602926A1 (en) | 2004-06-04 | 2005-12-07 | University of Geneva | Novel means and methods for the treatment of hearing loss and phantom hearing |
US20090215860A1 (en) * | 2004-06-17 | 2009-08-27 | The Regents Of The University Of California | Compositions and methods for regulating gene transcription |
US20060030538A1 (en) * | 2004-07-21 | 2006-02-09 | Medtronic, Inc. | Methods for reducing or preventing localized fibrosis using SiRNA |
WO2006020231A2 (en) * | 2004-07-21 | 2006-02-23 | Medtronic, Inc. | Medical devices and methods for reducing localized fibrosis |
CA2579574A1 (en) | 2004-07-23 | 2007-01-04 | The University Of North Carolina At Chapel Hill | Methods and materials for determining pain sensitivity and predicting and treating related disorders |
EP2990410A1 (en) | 2004-08-10 | 2016-03-02 | Alnylam Pharmaceuticals Inc. | Chemically modified oligonucleotides |
PL1791568T3 (pl) | 2004-08-16 | 2013-01-31 | Quark Pharmaceuticals Inc | Terapeutyczne zastosowania inhibitorów RTP801 |
US7323310B2 (en) | 2004-08-31 | 2008-01-29 | Qiagen North American Holdings, Inc. | Methods and compositions for RNA amplification and detection using an RNA-dependent RNA-polymerase |
FI20041204A0 (fi) | 2004-09-16 | 2004-09-16 | Riikka Lund | Menetelmät immuunivälitteisiin sairauksiin liittyvien uusien kohdegeenien hyödyntämiseksi |
MX2007003795A (es) | 2004-09-28 | 2007-07-11 | Quark Biotech Inc | Oligoribonucleotidos y metodos de uso de los mismos para tratamiento de la alopecia, insuficiencia renal aguda y otras enfermedades. |
NZ582988A (en) | 2004-10-21 | 2011-07-29 | Venganza Inc | Methods and materials for conferring resistance to pests and pathogens of plants |
US20060110440A1 (en) * | 2004-10-22 | 2006-05-25 | Kiminobu Sugaya | Method and system for biasing cellular development |
EP2311530A2 (en) | 2004-10-27 | 2011-04-20 | Vanderbilt University | Mammalian genes involved in infection |
EP2371954A1 (en) * | 2004-10-27 | 2011-10-05 | Schering Corporation | Compositions and methods for short interfering nucleic acid inhibition of NAv1.8 |
CA2580363A1 (en) * | 2004-10-28 | 2006-05-11 | Idexx Laboratories, Inc. | Compositions for controlled delivery of pharmaceutically active compounds |
WO2007001448A2 (en) | 2004-11-04 | 2007-01-04 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
US20060105052A1 (en) * | 2004-11-15 | 2006-05-18 | Acar Havva Y | Cationic nanoparticle having an inorganic core |
EP2189469B1 (en) * | 2004-11-18 | 2015-09-16 | The Board Of Trustees Of The University Of Illinois | Multicistronic siRNA constructs to inhibit tumors |
US7923207B2 (en) | 2004-11-22 | 2011-04-12 | Dharmacon, Inc. | Apparatus and system having dry gene silencing pools |
US20060160110A1 (en) * | 2004-12-02 | 2006-07-20 | Takayuki Mizutani | Methods of designing small interfering RNAs, antisense polynucleotides, and other hybridizing polynucleotides |
WO2006060779A2 (en) * | 2004-12-03 | 2006-06-08 | Case Western Reserve University | Novel methods, compositions and devices for inducing neovascularization |
GB0427916D0 (en) * | 2004-12-21 | 2005-01-19 | Astrazeneca Ab | Method |
TWI386225B (zh) | 2004-12-23 | 2013-02-21 | Alcon Inc | 用於治療眼睛病症的結締組織生長因子(CTGF)RNA干擾(RNAi)抑制技術 |
US8852472B2 (en) | 2004-12-27 | 2014-10-07 | Silence Therapeutics Gmbh | Coated lipid complexes and their use |
WO2006074108A2 (en) * | 2004-12-30 | 2006-07-13 | Hauser Todd M | Compositions and methods for modulating gene expression using self-protected oligonucleotides |
EP1841793B1 (en) | 2005-01-07 | 2010-03-31 | Diadexus, Inc. | Ovr110 antibody compositions and methods of use |
US8088579B2 (en) | 2005-02-14 | 2012-01-03 | University Of Iowa Research Foundation | Complement factor H for diagnosis of age-related macular degeneration |
US8859749B2 (en) | 2005-03-08 | 2014-10-14 | Qiagen Gmbh | Modified short interfering RNA |
GB0505081D0 (en) * | 2005-03-14 | 2005-04-20 | Genomica Sau | Downregulation of interleukin-12 expression by means of rnai technology |
WO2006105361A2 (en) * | 2005-03-31 | 2006-10-05 | Calando Pharmaceuticals, Inc. | Inhibitors of ribonucleotide reductase subunit 2 and uses thereof |
WO2007008300A2 (en) * | 2005-05-31 | 2007-01-18 | ECOLE POLYTECHNIQUE FéDéRALE DE LAUSANNE | Triblock copolymers for cytoplasmic delivery of gene-based drugs |
US20070048293A1 (en) * | 2005-05-31 | 2007-03-01 | The Trustees Of The University Of Pennsylvania | Manipulation of PTEN in T cells as a strategy to modulate immune responses |
EP1885739A4 (en) * | 2005-06-01 | 2010-02-10 | Univ Duke | METHOD FOR INHIBITING INTERNAL HYPERPLASIA |
CN101213300B (zh) * | 2005-06-01 | 2013-01-23 | 聚加转染股份有限公司 | 用于rna干扰的寡核苷酸及其生物学应用 |
CN100445381C (zh) * | 2005-06-10 | 2008-12-24 | 中国人民解放军军事医学科学院基础医学研究所 | 带有单链polyA尾巴的siRNA分子制备方法和应用 |
US20100266574A1 (en) * | 2005-06-10 | 2010-10-21 | Orna Mor | Oligoribonucleotides and Methods of Use Thereof for Treatment of Fibrotic Conditions and Other Diseases |
WO2006138145A1 (en) | 2005-06-14 | 2006-12-28 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
US8703769B2 (en) | 2005-07-15 | 2014-04-22 | The University Of North Carolina At Chapel Hill | Use of EGFR inhibitors to prevent or treat obesity |
US7919583B2 (en) | 2005-08-08 | 2011-04-05 | Discovery Genomics, Inc. | Integration-site directed vector systems |
US20070213257A1 (en) * | 2005-08-12 | 2007-09-13 | Nastech Pharmaceutical Company Inc. | Compositions and methods for complexes of nucleic acids and peptides |
US8501703B2 (en) | 2005-08-30 | 2013-08-06 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds for modulation of splicing |
WO2007030167A1 (en) * | 2005-09-02 | 2007-03-15 | Nastech Pharmaceutical Company Inc. | Modification of double-stranded ribonucleic acid molecules |
WO2007033058A2 (en) * | 2005-09-13 | 2007-03-22 | Trustees Of Dartmouth College | Compositions and methods for regulating rna translation via cd154 ca-dinucleotide repeat |
EP1931789B1 (en) | 2005-09-20 | 2016-05-04 | BASF Plant Science GmbH | Methods for controlling gene expression using ta-siran |
FR2890859B1 (fr) * | 2005-09-21 | 2012-12-21 | Oreal | Oligonucleotide d'arn double brin inhibant l'expression de la tyrosinase |
US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
US8080534B2 (en) | 2005-10-14 | 2011-12-20 | Phigenix, Inc | Targeting PAX2 for the treatment of breast cancer |
US8076307B2 (en) * | 2005-10-27 | 2011-12-13 | National University Corporation NARA Institute of Science and Technology | Formation/elongation of axon by inhibiting the expression or function of Singar and application to nerve regeneration |
US8603991B2 (en) | 2005-11-18 | 2013-12-10 | Gradalis, Inc. | Individualized cancer therapy |
US8916530B2 (en) | 2005-11-18 | 2014-12-23 | Gradalis, Inc. | Individualized cancer therapy |
US9267937B2 (en) | 2005-12-15 | 2016-02-23 | Massachusetts Institute Of Technology | System for screening particles |
AU2006337093B2 (en) * | 2005-12-22 | 2013-03-14 | Opko Pharmaceuticals, Llc. | Compositions and methods for regulating complement system |
AR057252A1 (es) * | 2005-12-27 | 2007-11-21 | Alcon Mfg Ltd | Inhibicion de rho quinasa mediada por arni para el tratamiento de trastornos oculares |
US8673873B1 (en) * | 2005-12-28 | 2014-03-18 | Alcon Research, Ltd. | RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders |
BRPI0707290A2 (pt) | 2006-01-17 | 2011-08-16 | Biolex Therapeutics Inc | composições e métodos para humanização e otimização de n-glicanas em plantas |
US20090060921A1 (en) * | 2006-01-17 | 2009-03-05 | Biolex Therapeutics, Inc. | Glycan-optimized anti-cd20 antibodies |
DOP2007000015A (es) | 2006-01-20 | 2007-08-31 | Quark Biotech Inc | Usos terapéuticos de inhibidores de rtp801 |
ES2683846T3 (es) | 2006-01-20 | 2018-09-28 | Cell Signaling Technology, Inc. | ROS quinasa mutante y de translocación en el carcinoma pulmonar no microcítico humano |
US20120208824A1 (en) | 2006-01-20 | 2012-08-16 | Cell Signaling Technology, Inc. | ROS Kinase in Lung Cancer |
US7825099B2 (en) | 2006-01-20 | 2010-11-02 | Quark Pharmaceuticals, Inc. | Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes |
US20090176977A1 (en) * | 2006-01-27 | 2009-07-09 | Joacim Elmen | Lna modified phosphorothiolated oligonucleotides |
WO2007091269A2 (en) * | 2006-02-08 | 2007-08-16 | Quark Pharmaceuticals, Inc. | NOVEL TANDEM siRNAS |
US7910566B2 (en) | 2006-03-09 | 2011-03-22 | Quark Pharmaceuticals Inc. | Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA |
FI20060246A0 (fi) | 2006-03-16 | 2006-03-16 | Jukka Westermarck | Uusi kasvua stimuloiva proteiini ja sen käyttö |
US20100056441A1 (en) * | 2006-03-17 | 2010-03-04 | Costa Robert H | Method for Inhibiting Angiogenesis |
AU2007229161B2 (en) | 2006-03-23 | 2012-07-12 | Roche Innovation Center Copenhagen A/S | Small internally segmented interfering RNA |
FR2898908A1 (fr) | 2006-03-24 | 2007-09-28 | Agronomique Inst Nat Rech | Procede de preparation de cellules aviaires differenciees et genes impliques dans le maintien de la pluripotence |
CA2648099C (en) | 2006-03-31 | 2012-05-29 | The Brigham And Women's Hospital, Inc | System for targeted delivery of therapeutic agents |
US9044461B2 (en) | 2006-04-07 | 2015-06-02 | The Research Foundation Of State University Of New York | Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency |
US8524454B2 (en) | 2006-04-07 | 2013-09-03 | The Research Foundation Of State University Of New York | Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency |
CA2648581A1 (en) * | 2006-04-07 | 2008-09-12 | Chimeros, Inc. | Compositions and methods for treating b- cell malignancies |
CN101460634A (zh) * | 2006-04-13 | 2009-06-17 | 康乃尔研究基金会有限公司 | 用于靶向c-rel的方法和组合物 |
ES2561406T3 (es) | 2006-04-14 | 2016-02-26 | Cell Signaling Technology, Inc. | Defectos de genes y quinasa ALK mutante en tumores sólidos humanos |
WO2007120847A2 (en) | 2006-04-14 | 2007-10-25 | Massachusetts Institute Of Technology | Identifying and modulating molecular pathways that mediate nervous system plasticity |
CN101573141B (zh) | 2006-05-15 | 2016-05-04 | 麻省理工学院 | 用于功能性颗粒的聚合物 |
EP2026843A4 (en) | 2006-06-09 | 2011-06-22 | Quark Pharmaceuticals Inc | THERAPEUTIC USES OF RTP801L INHIBITORS |
WO2007150030A2 (en) | 2006-06-23 | 2007-12-27 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
GB0613753D0 (en) * | 2006-07-11 | 2006-08-23 | Norwegian Radium Hospital Res | Method |
SG173371A1 (en) | 2006-07-13 | 2011-08-29 | Univ Iowa Res Found | Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration |
CN102321626B (zh) | 2006-07-21 | 2014-12-10 | 赛伦斯治疗有限公司 | 用于抑制蛋白激酶3表达的方法 |
DE102006039479A1 (de) | 2006-08-23 | 2008-03-06 | Febit Biotech Gmbh | Programmierbare Oligonukleotidsynthese |
EP2076599A2 (en) * | 2006-09-19 | 2009-07-08 | Asuragen, Inc. | Mir-200 regulated genes and pathways as targets for therapeutic intervention |
CA2663962A1 (en) * | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | Mir-15, mir-26, mir-31,mir-145, mir-147, mir-188, mir-215, mir-216, mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention |
WO2008036841A2 (en) | 2006-09-22 | 2008-03-27 | Dharmacon, Inc. | Tripartite oligonucleotide complexes and methods for gene silencing by rna interference |
JP2010507387A (ja) | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | 新規のsiRNAおよびその使用方法 |
EP2061901A2 (en) | 2006-10-31 | 2009-05-27 | Noxxon Pharma AG | Methods for detection of a single- or double-stranded nucleic acid molecule |
ATE508191T1 (de) | 2006-11-01 | 2011-05-15 | Medical Res And Infrastructure Fund Of The Tel Aviv Sourasky Medical Ct | Adipozytenspezifische konstrukte und verfahren zur hemmung der expression von blutplättchen-typ- 12-lipoxygenase |
US8252526B2 (en) * | 2006-11-09 | 2012-08-28 | Gradalis, Inc. | ShRNA molecules and methods of use thereof |
US8906874B2 (en) | 2006-11-09 | 2014-12-09 | Gradalis, Inc. | Bi-functional shRNA targeting Stathmin 1 and uses thereof |
US8758998B2 (en) | 2006-11-09 | 2014-06-24 | Gradalis, Inc. | Construction of bifunctional short hairpin RNA |
EP2087912B1 (en) * | 2006-11-22 | 2017-05-10 | The University of Tokyo | Sirna carrier using disulfide-bridged polymeric micelle |
EP2101813B1 (en) | 2006-11-27 | 2014-04-02 | Patrys Limited | Novel glycosylated peptide target in neoplastic cells |
EP2962697A1 (en) | 2006-11-27 | 2016-01-06 | diaDexus, Inc. | Ovr110 antibody compositions and methods of use |
WO2008067526A2 (en) * | 2006-11-30 | 2008-06-05 | University Of Southern California Usc Stevens | Compositions and methods of sphingosine kinase inhibitors in radiation therapy of various cancers |
WO2008073920A2 (en) * | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Mir-21 regulated genes and pathways as targets for therapeutic intervention |
EP2104737B1 (en) * | 2006-12-08 | 2013-04-10 | Asuragen, INC. | Functions and targets of let-7 micro rnas |
EA200900782A1 (ru) * | 2006-12-14 | 2009-12-30 | Новартис Аг | Композиции и способы, предназначенные для лечения мышечных и сердечно-сосудистых нарушений |
US20090175827A1 (en) * | 2006-12-29 | 2009-07-09 | Byrom Mike W | miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION |
US9896511B2 (en) | 2007-01-10 | 2018-02-20 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies |
CN102099367A (zh) * | 2007-01-17 | 2011-06-15 | 蒙特利尔临床研究所 | 具有季碳中心的核苷和核苷酸类似物以及其使用方法 |
CA2676143A1 (en) | 2007-01-26 | 2008-07-31 | University Of Louisville Research Foundation, Inc. | Modification of exosomal components for use as a vaccine |
KR101488800B1 (ko) | 2007-02-09 | 2015-02-04 | 노오쓰웨스턴 유니버시티 | 세포내 타겟 검출용 입자 |
WO2008098165A2 (en) | 2007-02-09 | 2008-08-14 | Massachusetts Institute Of Technology | Oscillating cell culture bioreactor |
DE102007008596B4 (de) * | 2007-02-15 | 2010-09-02 | Friedrich-Schiller-Universität Jena | Biologisch wirksame Moleküle auf Grundlage von PNA und siRNA, Verfahren zu deren zellspezifischen Aktivierung sowie Applikationskit zur Verabreichung |
AU2008218813B2 (en) | 2007-02-20 | 2014-04-17 | Monsanto Technology, Llc | Invertebrate microRNAs |
EP2137205A2 (en) | 2007-02-26 | 2009-12-30 | Quark Pharmaceuticals, Inc. | Inhibitors of rtp801 and their use in disease treatment |
US20100292301A1 (en) * | 2007-02-28 | 2010-11-18 | Elena Feinstein | Novel sirna structures |
WO2008109518A1 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting wnt gene expression and uses thereof |
WO2008109034A2 (en) * | 2007-03-02 | 2008-09-12 | The Trustees Of The University Of Pennsylvania | Modulating pdx-1 with pcif1, methods and uses thereof |
US7812002B2 (en) | 2007-03-21 | 2010-10-12 | Quark Pharmaceuticals, Inc. | Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer |
BRPI0809130A8 (pt) | 2007-03-21 | 2021-11-03 | Brookhaven Science Ass Llc | Composições combinadas hairpin-antissenso e métodos para modulação da expressão |
EP2144600A4 (en) | 2007-04-04 | 2011-03-16 | Massachusetts Inst Technology | POLY (AMINIC ACID) TARGET MOLECULES |
WO2008124634A1 (en) | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Polymer-encapsulated reverse micelles |
WO2008124165A2 (en) * | 2007-04-09 | 2008-10-16 | Chimeros, Inc. | Self-assembling nanoparticle drug delivery system |
CA2678055C (en) | 2007-04-10 | 2016-02-16 | Qiagen Gmbh | Rna interference tags |
AU2008242842B2 (en) * | 2007-04-17 | 2014-06-05 | Baxter Healthcare Sa | Nucleic acid microparticles for pulmonary delivery |
EP2155860B1 (en) | 2007-05-03 | 2014-08-27 | The Brigham and Women's Hospital, Inc. | Multipotent stem cells and uses thereof |
JP5296328B2 (ja) * | 2007-05-09 | 2013-09-25 | 独立行政法人理化学研究所 | 1本鎖環状rnaおよびその製造方法 |
KR20100017422A (ko) * | 2007-05-15 | 2010-02-16 | 헬리콘 테라퓨틱스 인코퍼레이티드 | 작은 간섭 RNA(siRNA)를 이용하여 기억 형성에 관여하는 유전자를 확인하는 방법 |
US20090131354A1 (en) * | 2007-05-22 | 2009-05-21 | Bader Andreas G | miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION |
DK2160464T3 (da) | 2007-05-30 | 2014-08-04 | Univ Northwestern | Nukleinsyrefunktionaliserede nanopartikler til terapeutiske anvendelser |
US8158677B2 (en) | 2007-06-01 | 2012-04-17 | The Trustees Of Princeton University | Treatment of viral infections by modulation of host cell metabolic pathways |
US9051391B2 (en) | 2007-06-11 | 2015-06-09 | Takara Bio Inc. | Method for expression of specific gene |
US20100273854A1 (en) * | 2007-06-15 | 2010-10-28 | Hagar Kalinski | Compositions and methods for inhibiting nadph oxidase expression |
US8785408B2 (en) | 2007-06-27 | 2014-07-22 | Quark Pharmaceuticals, Inc. | Compositions and methods for reducing or protecting against delayed graft function (DGF) |
EA201000085A1 (ru) * | 2007-07-05 | 2010-10-29 | Новартис Аг | dsPHK, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ИНФЕКЦИИ |
US8828960B2 (en) * | 2007-07-17 | 2014-09-09 | Idexx Laboratories, Inc. | Amino acid vitamin ester compositions for controlled delivery of pharmaceutically active compounds |
US9526707B2 (en) | 2007-08-13 | 2016-12-27 | Howard L. Elford | Methods for treating or preventing neuroinflammation or autoimmune diseases |
US20100286378A1 (en) * | 2007-08-27 | 2010-11-11 | Boston Biomedical, Inc. | Composition of Asymmetric RNA Duplex As MicroRNA Mimetic or Inhibitor |
US8637477B2 (en) * | 2007-08-30 | 2014-01-28 | Akshaya Bio Inc. | Antigenic compositions and use of same in the targeted delivery of nucleic acids |
WO2009033027A2 (en) | 2007-09-05 | 2009-03-12 | Medtronic, Inc. | Suppression of scn9a gene expression and/or function for the treatment of pain |
JP2010539245A (ja) * | 2007-09-14 | 2010-12-16 | 日東電工株式会社 | 薬物担体 |
DK2548962T3 (en) | 2007-09-19 | 2016-04-11 | Applied Biosystems Llc | Sirna sequence-independent modification formats to reduce off-target phenotype effects in RNAI and stabilized forms thereof |
WO2009042625A1 (en) * | 2007-09-25 | 2009-04-02 | Idexx Laboratories, Inc. | Pharmaceutical compositions for administering oligonucleotides |
HUE034775T2 (hu) | 2007-09-28 | 2018-02-28 | Pfizer | Rákos sejt célzása nanorészecskék alkalmazásával |
US20120082659A1 (en) * | 2007-10-02 | 2012-04-05 | Hartmut Land | Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations |
BRPI0817605A2 (pt) * | 2007-10-03 | 2017-05-09 | Quark Pharmaceuticals Inc | novas estruturas de sirna |
EP2620157A3 (en) | 2007-10-12 | 2013-10-16 | Massachusetts Institute of Technology | Vaccine nanotechnology |
EP3072963B1 (en) | 2007-10-18 | 2020-04-01 | Cell Signaling Technology, Inc. | Translocation and mutant ros kinase in human non-small cell lung carcinoma |
CA2706317C (en) | 2007-12-03 | 2017-06-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Doc1 compositions and methods for treating cancer |
US20110105584A1 (en) * | 2007-12-12 | 2011-05-05 | Elena Feinstein | Rtp80il sirna compounds and methods of use thereof |
US8614311B2 (en) | 2007-12-12 | 2013-12-24 | Quark Pharmaceuticals, Inc. | RTP801L siRNA compounds and methods of use thereof |
US7845686B2 (en) * | 2007-12-17 | 2010-12-07 | S & B Technical Products, Inc. | Restrained pipe joining system for plastic pipe |
KR100949791B1 (ko) * | 2007-12-18 | 2010-03-30 | 이동기 | 오프-타겟 효과를 최소화하고 RNAi 기구를 포화시키지않는 신규한 siRNA 구조 및 그 용도 |
US20090192114A1 (en) * | 2007-12-21 | 2009-07-30 | Dmitriy Ovcharenko | miR-10 Regulated Genes and Pathways as Targets for Therapeutic Intervention |
WO2009090639A2 (en) * | 2008-01-15 | 2009-07-23 | Quark Pharmaceuticals, Inc. | Sirna compounds and methods of use thereof |
EP2260110B1 (en) * | 2008-02-08 | 2014-11-12 | Asuragen, INC. | miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS |
US8188060B2 (en) | 2008-02-11 | 2012-05-29 | Dharmacon, Inc. | Duplex oligonucleotides with enhanced functionality in gene regulation |
DE102009043743B4 (de) | 2009-03-13 | 2016-10-13 | Friedrich-Schiller-Universität Jena | Zellspezifisch wirksame Moleküle auf Grundlage von siRNA sowie Applikationskits zu deren Herstellung und Verwendung |
WO2009103067A2 (en) * | 2008-02-14 | 2009-08-20 | The Children's Hospital Of Philadelphia | Compositions and methods to treat asthma |
EP2268832A2 (en) * | 2008-03-06 | 2011-01-05 | Asuragen, INC. | Microrna markers for recurrence of colorectal cancer |
CA2718520C (en) * | 2008-03-17 | 2020-01-07 | The Board Of Regents Of The University Of Texas System | Identification of micro-rnas involved in neuromuscular synapse maintenance and regeneration |
WO2009116037A2 (en) * | 2008-03-20 | 2009-09-24 | Quark Pharmaceuticals, Inc. | NOVEL siRNA COMPOUNDS FOR INHIBITING RTP801 |
EP2271757A2 (en) * | 2008-03-26 | 2011-01-12 | Asuragen, INC. | Compositions and methods related to mir-16 and therapy of prostate cancer |
ES2605618T3 (es) * | 2008-03-31 | 2017-03-15 | National Institute Of Advanced Industrial Science And Technology | ARN de doble cadena, modificado con lípidos con elevado efecto de interferencia por ARN |
US20090258928A1 (en) * | 2008-04-08 | 2009-10-15 | Asuragen, Inc. | Methods and compositions for diagnosing and modulating human papillomavirus (hpv) |
WO2009126933A2 (en) | 2008-04-11 | 2009-10-15 | Alnylam Pharmaceuticals, Inc. | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
EP2271368B1 (en) | 2008-04-11 | 2018-12-05 | Cedars-Sinai Medical Center | Poly(beta malic acid) with pendant leu-leu-leu tripeptide for effective cytoplasmic drug delivery |
EP2285385A4 (en) * | 2008-04-15 | 2013-01-16 | Quark Pharmaceuticals Inc | COMPOUNDS BASED ON RNSI TO INHIBIT NRF2 |
CA2721870C (en) | 2008-04-21 | 2020-12-22 | Tissue Regeneration Therapeutics, Inc. | Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents |
US8173616B2 (en) * | 2008-05-02 | 2012-05-08 | The Brigham And Women's Hospital, Inc. | RNA-induced translational silencing and cellular apoptosis |
US20090291073A1 (en) * | 2008-05-20 | 2009-11-26 | Ward Keith W | Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same |
US20100009451A1 (en) * | 2008-05-30 | 2010-01-14 | Sigma Aldrich Company | Compositions and methods for specifically silencing a target nucleic acid |
US20090305611A1 (en) * | 2008-06-06 | 2009-12-10 | Flow International Corporation | Device and method for improving accuracy of a high-pressure fluid jet apparatus |
WO2010005741A1 (en) * | 2008-06-16 | 2010-01-14 | Georgia Tech Research Corporation | Nanogels for cellular delivery of therapeutics |
TWI455944B (zh) | 2008-07-01 | 2014-10-11 | Daiichi Sankyo Co Ltd | 雙股多核苷酸 |
US8309791B2 (en) | 2008-07-16 | 2012-11-13 | Recombinectics, Inc. | Method for producing a transgenic pig using a hyper-methylated transposon |
US8039658B2 (en) * | 2008-07-25 | 2011-10-18 | Air Products And Chemicals, Inc. | Removal of trace arsenic impurities from triethylphosphate (TEPO) |
WO2010014857A2 (en) * | 2008-07-30 | 2010-02-04 | University Of Massachusetts | Chromosome therapy |
WO2011028218A1 (en) | 2009-09-02 | 2011-03-10 | Alnylam Pharmaceuticals, Inc. | Process for triphosphate oligonucleotide synthesis |
US8962580B2 (en) | 2008-09-23 | 2015-02-24 | Alnylam Pharmaceuticals, Inc. | Chemical modifications of monomers and oligonucleotides with cycloaddition |
WO2010042292A1 (en) * | 2008-10-08 | 2010-04-15 | Trustees Of Dartmouth College | Method for selectively inhibiting the activity of acat1 in the treatment of alzheimer's disease |
US9388414B2 (en) | 2008-10-08 | 2016-07-12 | Trustees Of Dartmouth College | Method for selectively inhibiting ACAT1 in the treatment of neurodegenerative diseases |
US9388413B2 (en) | 2008-10-08 | 2016-07-12 | Trustees Of Dartmouth College | Method for selectively inhibiting ACAT1 in the treatment of neurodegenerative diseases |
US9149492B2 (en) | 2008-10-08 | 2015-10-06 | Trustees Of Dartmouth College | Method for selectively inhibiting ACAT1 in the treatment of alzheimer's disease |
US8802646B2 (en) * | 2008-10-08 | 2014-08-12 | Trustees Of Dartmouth College | Method for selectively inhibiting the activity of ACAT1 in the treatment of alzheimer's disease |
US8343498B2 (en) | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
US8343497B2 (en) | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
US8591905B2 (en) | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
US9458472B2 (en) * | 2008-10-15 | 2016-10-04 | Massachusetts Institute Of Technology | Detection and destruction of cancer cells using programmed genetic vectors |
MX359674B (es) | 2008-11-10 | 2018-10-05 | Alnylam Pharmaceuticals Inc | Lipidos y composiciones novedosas para el suministro de terapeuticos. |
WO2010056737A2 (en) * | 2008-11-11 | 2010-05-20 | Mirna Therapeutics, Inc. | Methods and compositions involving mirnas in cancer stem cells |
PT2365804E (pt) * | 2008-11-13 | 2015-09-16 | Modgene Llc | Redução da carga da beta-amiloide em tecido não cerebral |
EP2373308A2 (en) | 2008-11-21 | 2011-10-12 | Isis Pharmaceuticals, Inc. | Combination therapy for the treatment of cancer |
US9139827B2 (en) | 2008-11-24 | 2015-09-22 | Northwestern University | Polyvalent RNA-nanoparticle compositions |
EP2191834A1 (en) * | 2008-11-26 | 2010-06-02 | Centre National De La Recherche Scientifique (Cnrs) | Compositions and methods for treating retrovirus infections |
CN104673798B (zh) | 2008-12-03 | 2018-03-20 | 阿克丘勒斯治疗公司 | UsiRNA复合物 |
UA109108C2 (uk) | 2008-12-09 | 2015-07-27 | Дженентек, Інк. | Антитіло до pd-l1 та його застосування для посилення функції t-клітин |
EP2370175A2 (en) | 2008-12-16 | 2011-10-05 | Bristol-Myers Squibb Company | Methods of inhibiting quiescent tumor proliferation |
US20110288155A1 (en) | 2008-12-18 | 2011-11-24 | Elena Feinstein | Sirna compounds and methods of use thereof |
JP5592897B2 (ja) | 2008-12-26 | 2014-09-17 | サムヤン バイオファーマシューティカルズ コーポレイション | アニオン性薬物含有薬剤学的組成物及びその製造方法 |
US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
WO2010083532A1 (en) * | 2009-01-19 | 2010-07-22 | The Research Foundaton Of State University Of New York | Fatty acid binding proteins as drug targets for modulation of endocannabinoids |
CA2750044A1 (en) * | 2009-01-20 | 2010-07-29 | Vib Vzw | Phd2 inhibition for blood vessel normalization, and uses thereof |
PL2881402T3 (pl) | 2009-02-12 | 2017-10-31 | Cell Signaling Technology Inc | Ekspresja zmutowanej ROS w ludzkim raku wątroby |
JP2012518401A (ja) * | 2009-02-24 | 2012-08-16 | リボックス・ゲーエムベーハー | 低分子干渉rnaの改善された設計 |
AU2010221419B2 (en) | 2009-03-02 | 2015-10-01 | Alnylam Pharmaceuticals, Inc. | Nucleic acid chemical modifications |
CN102439151A (zh) * | 2009-03-19 | 2012-05-02 | 默沙东公司 | 使用短干扰核酸(siNA)的RNA干扰介导的BTB和CNC同系物1,碱性亮氨酸拉链转录因子1(Bach1)基因表达的抑制 |
WO2010120874A2 (en) | 2009-04-14 | 2010-10-21 | Chimeros, Inc. | Chimeric therapeutics, compositions, and methods for using same |
US8367350B2 (en) | 2009-04-29 | 2013-02-05 | Morehouse School Of Medicine | Compositions and methods for diagnosis, prognosis and management of malaria |
US9255266B2 (en) * | 2009-05-06 | 2016-02-09 | Rutgers, The State University Of New Jersey | RNA targeting in alpha-synucleinopathies |
CA2762524A1 (en) * | 2009-05-18 | 2011-01-13 | Ensysce Biosciences, Inc. | Carbon nanotubes complexed with multiple bioactive agents and methods related thereto |
US20120128673A1 (en) | 2009-05-20 | 2012-05-24 | Schering Corporation | Modulation of pilr receptors to treat microbial infections |
US20100304995A1 (en) * | 2009-05-22 | 2010-12-02 | Li Shen | Arrays and Methods for Reverse Genetic Functional Analysis |
WO2010140024A1 (en) * | 2009-06-03 | 2010-12-09 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods for diagnosing and treating a renal disease in an individual |
CN102458099B (zh) | 2009-06-05 | 2015-08-19 | 佛罗里达大学研究基金公司 | 甘蔗木质素生物合成基因的分离和靶向抑制 |
EP3276004B1 (en) | 2009-06-08 | 2020-03-18 | Quark Pharmaceuticals, Inc. | Methods for treating chronic kidney disease |
KR102205886B1 (ko) | 2009-06-10 | 2021-01-21 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
CN102803496A (zh) | 2009-06-10 | 2012-11-28 | 淡马锡生命科学研究院有限公司 | 用于棉花中基因功能性分析的病毒诱导的基因沉默(vigs) |
US20100323018A1 (en) * | 2009-06-17 | 2010-12-23 | Massachusetts Institute Of Technology | Branched DNA/RNA monomers and uses thereof |
US20100324124A1 (en) * | 2009-06-17 | 2010-12-23 | Massachusetts Institute Of Technology | Compositions and methods relating to DNA-based particles |
GB0910723D0 (en) * | 2009-06-22 | 2009-08-05 | Sylentis Sau | Novel drugs for inhibition of gene expression |
ES2629167T3 (es) | 2009-07-20 | 2017-08-07 | Bristol-Myers Squibb Company | Combinación de anticuerpo anti-CTLA4 con etopósido para el tratamiento sinérgico de enfermedades proliferativas |
CA2769822C (en) | 2009-08-13 | 2019-02-19 | The Johns Hopkins University | Methods of modulating immune function |
EP2470217B1 (en) | 2009-08-24 | 2020-10-07 | Phigenix, Inc. | Targeting pax2 for the treatment of breast cancer |
WO2011031600A1 (en) | 2009-09-10 | 2011-03-17 | Schering Corporation | Use of il-33 antagonists to treat fibrotic disease |
EP2295543A1 (en) | 2009-09-11 | 2011-03-16 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for the preparation of an influenza virus |
WO2011032100A1 (en) | 2009-09-11 | 2011-03-17 | Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Inhibitors of kshv vil6 and human il6 |
US20150025122A1 (en) | 2009-10-12 | 2015-01-22 | Larry J. Smith | Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro |
US9376690B2 (en) | 2009-10-30 | 2016-06-28 | Northwestern University | Templated nanoconjugates |
WO2011057171A1 (en) | 2009-11-08 | 2011-05-12 | Quark Pharmaceuticals, Inc. | METHODS FOR DELIVERY OF siRNA TO THE SPINAL CORD AND THERAPIES ARISING THEREFROM |
US9260517B2 (en) | 2009-11-17 | 2016-02-16 | Musc Foundation For Research Development | Human monoclonal antibodies to human nucleolin |
AU2010324658A1 (en) | 2009-11-26 | 2012-05-03 | Quark Pharmaceuticals, Inc. | siRNA compounds comprising terminal substitutions |
EP3296398A1 (en) | 2009-12-07 | 2018-03-21 | Arbutus Biopharma Corporation | Compositions for nucleic acid delivery |
ES2562499T3 (es) * | 2009-12-09 | 2016-03-04 | Nitto Denko Corporation | Modulación de la expresión de HSP47 |
WO2011072091A1 (en) | 2009-12-09 | 2011-06-16 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the cns |
WO2011072240A1 (en) | 2009-12-10 | 2011-06-16 | Cedars-Sinai Medical Center | Drug delivery of temozolomide for systemic based treatment of cancer |
EP2336171A1 (en) | 2009-12-11 | 2011-06-22 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Novel targets for the treatment of proliferative diseases |
WO2011084357A1 (en) | 2009-12-17 | 2011-07-14 | Schering Corporation | Modulation of pilr to treat immune disorders |
KR101605932B1 (ko) | 2009-12-18 | 2016-03-24 | 노파르티스 아게 | Hsf1-관련 질환을 치료하기 위한 유기 조성물 |
US20130017223A1 (en) | 2009-12-18 | 2013-01-17 | The University Of British Columbia | Methods and compositions for delivery of nucleic acids |
CN102917709B (zh) | 2009-12-23 | 2018-04-24 | 格兰达利斯有限公司 | 弗林蛋白酶敲减和gm-csf增强的(fang)癌症疫苗 |
US8933046B2 (en) | 2009-12-23 | 2015-01-13 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Influenza targets |
US20130023578A1 (en) | 2009-12-31 | 2013-01-24 | Samyang Biopharmaceuticals Corporation | siRNA for inhibition of c-Met expression and anticancer composition containing the same |
WO2011084193A1 (en) | 2010-01-07 | 2011-07-14 | Quark Pharmaceuticals, Inc. | Oligonucleotide compounds comprising non-nucleotide overhangs |
ES2664866T3 (es) * | 2010-01-11 | 2018-04-23 | Curna, Inc. | Tratamiento de enfermedades relacionadas con la globulina fijadora de hormonas sexuales (shbg) mediante inhibición del transcrito antisentido natural a shbg |
WO2011088058A1 (en) * | 2010-01-12 | 2011-07-21 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expressions of factor vii and pten genes |
DE102010004957A1 (de) | 2010-01-14 | 2011-07-21 | Universitätsklinikum Jena, 07743 | Biologisch wirksame Moleküle zur Beeinflussung von Virus-, Bakterien-, Parasiten-infizierten Zellen und/oder Tumorzellen und Verfahren zu deren Anwendung |
WO2011100131A2 (en) | 2010-01-28 | 2011-08-18 | Alnylam Pharmacuticals, Inc. | Monomers and oligonucleotides comprising cycloaddition adduct(s) |
WO2011094580A2 (en) | 2010-01-28 | 2011-08-04 | Alnylam Pharmaceuticals, Inc. | Chelated copper for use in the preparation of conjugated oligonucleotides |
JP2013519869A (ja) | 2010-02-10 | 2013-05-30 | ノバルティス アーゲー | 筋肉成長のための方法および化合物 |
WO2011123621A2 (en) | 2010-04-01 | 2011-10-06 | Alnylam Pharmaceuticals Inc. | 2' and 5' modified monomers and oligonucleotides |
US10913767B2 (en) | 2010-04-22 | 2021-02-09 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising acyclic and abasic nucleosides and analogs |
WO2011133868A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | Conformationally restricted dinucleotide monomers and oligonucleotides |
WO2011133658A1 (en) | 2010-04-22 | 2011-10-27 | Boston Medical Center Corporation | Compositions and methods for targeting and delivering therapeutics into cells |
WO2011133871A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | 5'-end derivatives |
CA2994063A1 (en) | 2010-04-29 | 2011-11-10 | Ionis Pharmaceuticals, Inc. | Modulation of transthyretin expression |
WO2011137363A1 (en) | 2010-04-30 | 2011-11-03 | Allergan, Inc. | Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase |
EP2566967B1 (en) | 2010-05-04 | 2016-07-06 | The Brigham and Women's Hospital, Inc. | Cadherin-11 antagonist for the treatment of fibrosis |
AU2011258156B2 (en) | 2010-05-26 | 2016-11-24 | Selecta Biosciences, Inc. | Multivalent synthetic nanocarrier vaccines |
EP2390327A1 (en) | 2010-05-27 | 2011-11-30 | Sylentis S.A. | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
DE102010022937A1 (de) | 2010-06-04 | 2011-12-08 | Universitätsklinikum Jena | Zellspezifisch aktivierbare biologisch wirksame Moleküle auf Grundlage von siRNA, Verfahren zu deren Aktivierung sowie Applikationskit zur Verabreichung |
US20130236968A1 (en) | 2010-06-21 | 2013-09-12 | Alnylam Pharmaceuticals, Inc. | Multifunctional copolymers for nucleic acid delivery |
WO2011163436A1 (en) | 2010-06-24 | 2011-12-29 | Quark Pharmaceuticals, Inc. | Double stranded rna compounds to rhoa and use thereof |
US20130202652A1 (en) | 2010-07-30 | 2013-08-08 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
US20130323269A1 (en) | 2010-07-30 | 2013-12-05 | Muthiah Manoharan | Methods and compositions for delivery of active agents |
US20120101108A1 (en) | 2010-08-06 | 2012-04-26 | Cell Signaling Technology, Inc. | Anaplastic Lymphoma Kinase In Kidney Cancer |
WO2012027206A1 (en) | 2010-08-24 | 2012-03-01 | Merck Sharp & Dohme Corp. | SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER |
WO2012051491A1 (en) | 2010-10-14 | 2012-04-19 | The United States Of America, As Represented By The Secretary National Institutes Of Health | Compositions and methods for controlling neurotropic viral pathogenesis by micro-rna targeting |
ES2732929T3 (es) * | 2010-10-22 | 2019-11-26 | Olix Pharmaceuticals Inc | Moléculas de ácido nucleico que inducen interferencia de ARN y usos de las mismas |
WO2012071436A1 (en) | 2010-11-24 | 2012-05-31 | Genentech, Inc. | Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants |
AU2011338682B2 (en) | 2010-12-06 | 2017-04-27 | Quark Pharmaceuticals, Inc. | Double stranded oligonucleotide compounds comprising threose modifications |
US10202615B2 (en) | 2010-12-10 | 2019-02-12 | Vanderbilt University | Mammalian genes involved in toxicity and infection |
US9617542B2 (en) * | 2010-12-14 | 2017-04-11 | The United States of America, as representd by The Secretary of Agriculture | Lepidopteran moth control using double-stranded RNA constructs |
US9623041B2 (en) | 2010-12-30 | 2017-04-18 | Cedars-Sinai Medical Center | Polymalic acid-based nanobiopolymer compositions |
ES2808529T3 (es) | 2011-01-10 | 2021-03-01 | Univ Michigan Regents | Inhibidor del factor de células madre |
US20150018408A1 (en) | 2013-07-10 | 2015-01-15 | The Regents Of The University Of Michigan | Therapeutic antibodies and uses thereof |
DK3202760T3 (da) | 2011-01-11 | 2019-11-25 | Alnylam Pharmaceuticals Inc | Pegylerede lipider og deres anvendelse til lægemiddelfremføring |
DE102011009470A1 (de) | 2011-01-21 | 2012-08-09 | Friedrich-Schiller-Universität Jena | Biologisch wirksame Nukleotid-Moleküle zur gezielten Abtötung von Zellen, Verwendung derselben sowie Applikationskit |
US9796979B2 (en) | 2011-03-03 | 2017-10-24 | Quark Pharmaceuticals Inc. | Oligonucleotide modulators of the toll-like receptor pathway |
EP2681315B1 (en) | 2011-03-03 | 2017-05-03 | Quark Pharmaceuticals, Inc. | Oligonucleotide modulators of the toll-like receptor pathway |
US20140303013A1 (en) | 2011-03-15 | 2014-10-09 | University Of Utah Research Foundation | Methods of diagnosing and treating vascular associated maculopathy and symptoms thereof |
US9458456B2 (en) * | 2011-04-01 | 2016-10-04 | University Of South Alabama | Methods and compositions for the diagnosis, classification, and treatment of cancer |
EP2686342A2 (en) | 2011-04-12 | 2014-01-22 | The Government of The United States of America, as represented by The Secretary, Department of Health and Human Services | Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use |
KR101839177B1 (ko) | 2011-04-13 | 2018-03-15 | 아이오니스 파마수티컬즈, 인코포레이티드 | Ptpib 발현의 안티센스 조절 |
WO2012142622A1 (en) * | 2011-04-15 | 2012-10-18 | Molecular Transfer, Inc. | Agents for improved delivery of nucleic acids to eukaryotic cells |
US8716257B2 (en) * | 2011-04-15 | 2014-05-06 | Sutter West Bay Hospitals | CMV gene products promote cancer stem cell growth |
CA2836898A1 (en) | 2011-05-20 | 2012-11-29 | Government Of The United States, As Represented By The Secretary, Department Of Health And Human Services | Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof |
ES2690557T3 (es) | 2011-06-02 | 2018-11-21 | University Of Louisville Research Foundation, Inc. | Nanopartículas conjugadas a un agente antinucleolina |
US20140227293A1 (en) | 2011-06-30 | 2014-08-14 | Trustees Of Boston University | Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1) |
WO2013001372A2 (en) | 2011-06-30 | 2013-01-03 | University Of Oslo | Methods and compositions for inhibition of activation of regulatory t cells |
HUE030501T2 (en) | 2011-07-06 | 2017-05-29 | Sykehuset Sorlandet Hf | EGFR Targeted Therapy |
WO2013006861A1 (en) | 2011-07-07 | 2013-01-10 | University Of Georgia Research Foundation, Inc. | Sorghum grain shattering gene and uses thereof in altering seed dispersal |
US8853181B2 (en) | 2011-07-21 | 2014-10-07 | Albert Einstein College Of Medicine Of Yeshiva University | Fidgetin-like 2 as a target to enhance wound healing |
US9120858B2 (en) | 2011-07-22 | 2015-09-01 | The Research Foundation Of State University Of New York | Antibodies to the B12-transcobalamin receptor |
WO2013034653A1 (en) | 2011-09-06 | 2013-03-14 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | The mirna-212/132 family as a therapeutic target |
AU2012305714A1 (en) | 2011-09-09 | 2014-03-27 | Biomed Realty, L.P. | Methods and compositions for controlling assembly of viral proteins |
US9701623B2 (en) | 2011-09-27 | 2017-07-11 | Alnylam Pharmaceuticals, Inc. | Di-aliphatic substituted pegylated lipids |
US9951349B2 (en) | 2011-09-27 | 2018-04-24 | Yale University | Compositions and methods for transient expression of recombinant RNA |
ES2745373T3 (es) | 2011-10-18 | 2020-03-02 | Dicerna Pharmaceuticals Inc | Lípidos catiónicos de amina y uso de los mismos |
US20140323549A1 (en) | 2011-11-08 | 2014-10-30 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the nervous system |
US9006199B2 (en) * | 2011-11-14 | 2015-04-14 | Silenseed Ltd. | Methods and compositions for treating prostate cancer |
WO2013082529A1 (en) | 2011-12-02 | 2013-06-06 | Yale University | Enzymatic synthesis of poly(amine-co-esters) and methods of use thereof for gene delivery |
JP2015509085A (ja) | 2012-01-01 | 2015-03-26 | キュービーアイ エンタープライゼズ リミテッドQbi Enterprises Ltd. | 治療剤および診断剤の選択的送達のためのendo180を標的とする粒子 |
BR112014016870A2 (pt) | 2012-01-09 | 2017-06-27 | Huesken Dieter | composições orgânicas para tratar doenças relacionadas com beta-catenina |
KR20140111673A (ko) | 2012-01-12 | 2014-09-19 | 쿠아크 파마수티칼스 인코퍼레이티드 | 청력 및 균형 장애를 치료하기 위한 조합요법 |
US20150126438A1 (en) | 2012-01-24 | 2015-05-07 | Beth Israel Deaconess Medical Center, Inc. | Novel ChREBP Isoforms and Methods Using the Same |
WO2013138463A1 (en) | 2012-03-14 | 2013-09-19 | University Of Central Florida Research Foundation, Inc. | Neurofibromatoses therapeutic agents and screening for same |
ES2655842T3 (es) | 2012-04-18 | 2018-02-21 | Cell Signaling Technology, Inc. | EGFR y ROS1 en el cáncer |
WO2013166043A1 (en) | 2012-05-02 | 2013-11-07 | Children's Hospital Medical Center | Rejuvenation of precursor cells |
EP3453762B1 (en) | 2012-05-02 | 2021-04-21 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) compositions |
ES2716818T3 (es) | 2012-05-22 | 2019-06-17 | Olix Pharmaceuticals Inc | Molécula de ácido nucleico inductora de interferencias de arn capaz de penetrar en las células y uso de la misma |
WO2014006227A1 (en) | 2012-07-06 | 2014-01-09 | Institut Gustave-Roussy | Simultaneous detection of cannibalism and senescence as prognostic marker for cancer |
WO2014018375A1 (en) | 2012-07-23 | 2014-01-30 | Xenon Pharmaceuticals Inc. | Cyp8b1 and uses thereof in therapeutic and diagnostic methods |
AU2013308519A1 (en) * | 2012-08-31 | 2015-04-09 | The General Hospital Corporation | Biotin complexes for treatment and diagnosis of Alzheimer's disease |
AU2013315524B2 (en) | 2012-09-12 | 2019-01-31 | Quark Pharmaceuticals, Inc. | Double-stranded oligonucleotide molecules to p53 and methods of use thereof |
CA2880290C (en) | 2012-09-12 | 2020-10-27 | Quark Pharmaceuticals, Inc. | Double-stranded oligonucleotide molecules targeting p53 and methods of use thereof |
PL2897620T3 (pl) | 2012-09-21 | 2020-11-02 | Intensity Therapeutics, Inc | Sposób leczenia nowotworu złośliwego |
WO2014055825A1 (en) | 2012-10-04 | 2014-04-10 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | A formulation of mycobacterial components as an adjuvant for inducing th17 responses |
WO2014068072A1 (en) | 2012-10-31 | 2014-05-08 | Institut Gustave-Roussy | Identification, assessment and therapy of essential thrombocythemia with resistance to jak2 inhibitors |
CN105051192B (zh) * | 2012-11-13 | 2020-04-17 | 科迪艾克生物科学公司 | 治疗剂的递送 |
DE102012022596B4 (de) | 2012-11-15 | 2017-05-04 | Friedrich-Schiller-Universität Jena | Neue zellspezifisch wirksame Nukleotid-Moleküle und Applikationskit zu deren Anwendung |
DK2920201T3 (da) | 2012-11-15 | 2020-04-14 | Apellis Pharmaceuticals Inc | Langtidsvirkende compstatin-analoger og relaterede sammensætninger og fremgangsmåder |
WO2014093688A1 (en) | 2012-12-12 | 2014-06-19 | 1Massachusetts Institute Of Technology | Compositions and methods for functional nucleic acid delivery |
CA2891855A1 (en) | 2012-12-21 | 2014-06-26 | Sykehuset Sorlandet Hf | Egfr targeted therapy of neurological disorders and pain |
US10258682B2 (en) | 2013-01-16 | 2019-04-16 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Attenuated chlamydia vaccine |
DE102013003869B4 (de) | 2013-02-27 | 2016-11-24 | Friedrich-Schiller-Universität Jena | Verfahren zur gezielten Abtötung von Zellen durch zur mRNA-Anbindung ausgerichtete Nukleotid-Moleküle sowie Nukleotid-Moleküle und Applikationskit für solche Verwendung |
EP2968149B1 (en) | 2013-03-14 | 2024-05-08 | Dicerna Pharmaceuticals, Inc. | Process for formulating an anionic agent |
US10308687B2 (en) | 2013-03-15 | 2019-06-04 | Apellis Pharmaceuticals, Inc. | Cell-penetrating compstatin analogs and uses thereof |
EP2978446B1 (en) | 2013-03-27 | 2020-03-04 | The General Hospital Corporation | Anti-cd33 antibody for use in treating alzheimer's disease |
CA2912801A1 (en) | 2013-05-17 | 2014-11-20 | Medimmune, Llc | Receptors for b7-h4 |
EP3013424A4 (en) | 2013-06-25 | 2017-03-29 | University of Canberra | Methods and compositions for modulating cancer stem cells |
TW201534578A (zh) | 2013-07-08 | 2015-09-16 | Daiichi Sankyo Co Ltd | 新穎脂質 |
US10711106B2 (en) | 2013-07-25 | 2020-07-14 | The University Of Chicago | High aspect ratio nanofibril materials |
WO2015015496A1 (en) | 2013-07-31 | 2015-02-05 | Qbi Enterprises Ltd. | Sphingolipid-polyalkylamine-oligonucleotide compounds |
EP3027223A1 (en) | 2013-07-31 | 2016-06-08 | QBI Enterprises Ltd. | Methods of use of sphingolipid polyalkylamine oligonucleotide compounds |
ES2959451T3 (es) | 2013-09-11 | 2024-02-26 | Eagle Biologics Inc | Formulaciones proteicas líquidas que contienen organofosfatos |
ES2851724T3 (es) | 2013-09-18 | 2021-09-08 | Epiaxis Therapeutics Pty Ltd | Modulación de células madre |
JP6694811B2 (ja) | 2013-10-04 | 2020-05-20 | ノバルティス アーゲー | RNA干渉に使用するためのRNAi剤用の3’末端キャップ |
US10519446B2 (en) | 2013-10-04 | 2019-12-31 | Novartis Ag | Organic compounds to treat hepatitis B virus |
EP2865756A1 (en) | 2013-10-22 | 2015-04-29 | Sylentis, S.A.U. | siRNA and their use in methods and compositions for inhibiting the expression of the FLAP gene. |
EP2865758A1 (en) | 2013-10-22 | 2015-04-29 | Sylentis, S.A.U. | siRNA and their use in methods and compositions for inhibiting the expression of the ORAI1 gene |
EP2865757A1 (en) | 2013-10-22 | 2015-04-29 | Sylentis, S.A.U. | siRNA and their use in methods and compositions for inhibiting the expression of the PDK1 gene. |
US10004814B2 (en) | 2013-11-11 | 2018-06-26 | Sirna Therapeutics, Inc. | Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety |
WO2015077566A1 (en) | 2013-11-21 | 2015-05-28 | Huang Zhen | Methods for structural determination of selenium derivatized nucleic acid complexes |
US10150965B2 (en) | 2013-12-06 | 2018-12-11 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA |
CN104830906B (zh) | 2014-02-12 | 2018-09-04 | 北京维通达生物技术有限公司 | 一种重编程获得功能性人肝脏实质细胞的方法 |
WO2015136001A1 (en) | 2014-03-11 | 2015-09-17 | Cellectis | Method for generating t-cells compatible for allogenic transplantation |
WO2015140330A1 (en) * | 2014-03-20 | 2015-09-24 | Oommen Varghese | Improved small interfering ribonucleic acid molecules |
AU2015240761B2 (en) | 2014-04-01 | 2019-09-12 | Biogen Ma Inc. | Compositions for modulating SOD-1 expression |
CN106456771B9 (zh) | 2014-05-02 | 2021-07-20 | 国家儿童医院研究所 | 用于抗lyst免疫调节的组合物和方法 |
WO2015175545A1 (en) | 2014-05-12 | 2015-11-19 | The Johns Hopkins University | Highly stable biodegradable gene vector platforms for overcoming biological barriers |
JP6763780B2 (ja) | 2014-05-12 | 2020-09-30 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 合成脳浸透遺伝子ベクターの操作 |
WO2015184105A1 (en) | 2014-05-29 | 2015-12-03 | Trustees Of Dartmouth College | Method for selectively inhibiting acat1 in the treatment of neurodegenerative diseases |
CA2953216C (en) | 2014-06-04 | 2020-12-22 | Exicure, Inc. | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
CN104120127B (zh) * | 2014-07-01 | 2016-09-21 | 清华大学 | 分离的寡核苷酸及其应用 |
WO2016019126A1 (en) | 2014-07-30 | 2016-02-04 | The Research Foundation For The State University Of New York | System and method for delivering genetic material or protein to cells |
US20200230251A1 (en) | 2014-08-14 | 2020-07-23 | Friedrich-Schiller-Universitaet Jena | Peptide for use in the reduction of side effects in the form of immunostimulatory reactions/effects |
CA2958704A1 (en) | 2014-08-25 | 2016-03-03 | University Of Canberra | Compositions for modulating cancer stem cells and uses therefor |
US11390885B2 (en) | 2014-09-15 | 2022-07-19 | Children's Medical Center Corporation | Methods and compositions to increase somatic cell nuclear transfer (SCNT) efficiency by removing histone H3-lysine trimethylation |
US20170296561A1 (en) | 2014-09-25 | 2017-10-19 | Cold Spring Harbor Laboratory | Treatment of rett syndrome |
KR102497368B1 (ko) | 2014-10-01 | 2023-02-10 | 이글 바이올로직스 인코포레이티드 | 점도-저하제를 함유하는 폴리삭카라이드 및 핵산 제형 |
AU2015330731B2 (en) | 2014-10-10 | 2020-07-09 | Idera Pharmaceuticals, Inc. | Treatment of cancer using TLR9 agonist with checkpoint inhibitors |
US20170304459A1 (en) | 2014-10-10 | 2017-10-26 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for inhalation delivery of conjugated oligonucleotide |
WO2016060919A1 (en) | 2014-10-14 | 2016-04-21 | The Board Of Regents Of The University Of Texas System | Allele selective inhibition of mutant c9orf72 foci expression by duplex rnas targeting the expanded hexanucleotide repeat |
WO2016061642A1 (en) | 2014-10-22 | 2016-04-28 | Katholieke Universiteit Leuven Ku Leuven Research & Development | Modulating adipose tissue and adipogenesis |
AU2015346281B2 (en) | 2014-11-12 | 2021-12-02 | Nmc, Inc. | Transgenic plants with engineered redox sensitive modulation of photosynthetic antenna complex pigments and methods for making the same |
WO2016081621A1 (en) | 2014-11-18 | 2016-05-26 | Yale University | Formulations for targeted release of agents under low ph conditions and methods of use thereof |
CA2968531A1 (en) | 2014-11-21 | 2016-05-26 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
WO2016094374A1 (en) * | 2014-12-09 | 2016-06-16 | The Board Of Regents Of The University Of Texas System | Compositions and mentods for treatment of friedreich's ataxia |
US20180002702A1 (en) * | 2014-12-26 | 2018-01-04 | Nitto Denko Corporation | Methods and compositions for treating malignant tumors associated with kras mutation |
US10264976B2 (en) | 2014-12-26 | 2019-04-23 | The University Of Akron | Biocompatible flavonoid compounds for organelle and cell imaging |
US10792299B2 (en) | 2014-12-26 | 2020-10-06 | Nitto Denko Corporation | Methods and compositions for treating malignant tumors associated with kras mutation |
WO2016168197A1 (en) | 2015-04-15 | 2016-10-20 | Yale University | Compositions for enhancing delivery of agents across the blood brain barrier and methods of use thereof |
WO2016179394A1 (en) | 2015-05-05 | 2016-11-10 | Malik Mohammad Tariq | Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents |
US10933049B2 (en) | 2015-06-03 | 2021-03-02 | The University Of Queensland | Mobilizing agents and uses therefor |
WO2016201323A1 (en) | 2015-06-10 | 2016-12-15 | Board Of Regents, The University Of Texas System | Use of exosomes for the treatment of disease |
MA44908A (fr) | 2015-09-08 | 2018-07-18 | Sylentis Sau | Molécules d'arnsi et leur utilisation dans des procédés et des compositions pour inhiber l'expression du gène nrarp |
US10086063B2 (en) | 2015-09-23 | 2018-10-02 | Regents Of The University Of Minnesota | Methods of making and using live attenuated viruses |
US10548959B2 (en) | 2015-09-23 | 2020-02-04 | Massachusetts Institute Of Technology | Compositions and methods for modified dendrimer nanoparticle delivery |
US10383935B2 (en) | 2015-09-23 | 2019-08-20 | Regents Of The University Of Minnesota | Methods of making and using live attenuated viruses |
EP3356415B1 (en) | 2015-09-29 | 2024-05-01 | Amgen Inc. | Asgr inhibitors for reduzing cholesterol levels |
JOP20210043A1 (ar) * | 2015-10-01 | 2017-06-16 | Arrowhead Pharmaceuticals Inc | تراكيب وأساليب لتثبيط تعبير جيني للـ lpa |
EP3359555B1 (en) | 2015-10-07 | 2023-12-20 | Apellis Pharmaceuticals, Inc. | Dosing regimens |
KR20180071362A (ko) | 2015-11-16 | 2018-06-27 | 올릭스 주식회사 | MyD88 또는 TLR3을 타겟팅하는 RNA 복합체를 이용한 연령-관련 황반 변성의 치료 |
WO2017095751A1 (en) | 2015-12-02 | 2017-06-08 | Partikula Llc | Compositions and methods for modulating cancer cell metabolism |
WO2017100193A1 (en) | 2015-12-10 | 2017-06-15 | Fibrogen, Inc. | Methods for treatment of motor neuron diseases |
EP3391875B1 (en) | 2015-12-18 | 2021-11-03 | Samyang Holdings Corporation | Method for preparing polymeric micelle containing anionic drug |
BR102017001164A2 (pt) | 2016-01-26 | 2019-03-06 | Embrapa - Empresa Brasileira De Pesquisa Agropecuária | Composições de rna de fita dupla para controle de diaphorina citri e métodos de uso. |
US10478503B2 (en) | 2016-01-31 | 2019-11-19 | University Of Massachusetts | Branched oligonucleotides |
KR20180104692A (ko) | 2016-02-02 | 2018-09-21 | 올릭스 주식회사 | Angpt2 및 pdgfb를 표적화하는 rna 복합체를 사용하는 혈관신생 관련 질환의 치료 |
KR20180104075A (ko) | 2016-02-02 | 2018-09-19 | 올릭스 주식회사 | IL4Rα, TRPA1, 또는 F2RL1을 표적화하는 RNA 복합체를 사용한 아토피 피부염 및 천식의 치료 |
US20170360815A1 (en) | 2016-02-25 | 2017-12-21 | Applied Biological Laboratories, Inc. | Compositions and methods for protecting against airborne pathogens and irritants |
AU2017224113B2 (en) | 2016-02-25 | 2022-04-21 | Applied Biological Laboratories, Inc. | Compositions and methods for protecting against airborne pathogens and irritants |
WO2017147594A1 (en) | 2016-02-26 | 2017-08-31 | Yale University | COMPOSITIONS AND METHODS OF USING piRNAS IN CANCER DIAGNOSTICS AND THERAPEUTICS |
US20210189062A1 (en) | 2016-03-01 | 2021-06-24 | Alexion Pharmaceuticals, Inc. | Biodegradable activated polymers for therapeutic delivery |
WO2017152073A1 (en) | 2016-03-04 | 2017-09-08 | University Of Louisville Research Foundation, Inc. | Methods and compositions for ex vivo expansion of very small embryonic-like stem cells (vsels) |
CN109310885B (zh) | 2016-03-15 | 2022-05-31 | 梅尔莎纳医疗公司 | NaPi2b靶向抗体-药物缀合物及其使用方法 |
MA45349A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Acides nucléiques egfr et leurs utilisations |
MA45469A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Acides nucléiques de bêta-caténine et leurs utilisations |
MA45470A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Acides nucléiques kras et leurs utilisations |
WO2017173453A1 (en) | 2016-04-01 | 2017-10-05 | The Brigham And Women's Hospital, Inc. | Stimuli-responsive nanoparticles for biomedical applications |
MA45328A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
WO2017176894A1 (en) | 2016-04-06 | 2017-10-12 | Ohio State Innovation Foundation | Rna ligand-displaying exosomes for specific delivery of therapeutics to cell by rna nanotechnology |
US10301628B2 (en) | 2016-04-11 | 2019-05-28 | Olix Pharmaceuticals, Inc. | Treatment of idiopathic pulmonary fibrosis using RNA complexes that target connective tissue growth factor |
US11234994B2 (en) * | 2016-04-14 | 2022-02-01 | Benitec Biopharma Limited | Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof |
EP3448997B1 (en) | 2016-04-27 | 2020-10-14 | Massachusetts Institute of Technology | Stable nanoscale nucleic acid assemblies and methods thereof |
WO2017197128A1 (en) | 2016-05-11 | 2017-11-16 | Yale University | Poly(amine-co-ester) nanoparticles and methods of use thereof |
KR101916652B1 (ko) | 2016-06-29 | 2018-11-08 | 올릭스 주식회사 | 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도 |
BR112019000015A2 (pt) | 2016-06-30 | 2019-04-24 | Oncorus, Inc. | distribuição por vírus oncolítico pseudotipado de polipeptídeos terapêuticos |
RU2627179C1 (ru) * | 2016-07-28 | 2017-08-03 | федеральное государственное бюджетное учреждение "Федеральный научно-исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | ТЕСТ-СИСТЕМА ДЛЯ ОПРЕДЕЛЕНИЯ РНК ИНТЕРФЕРОНА λ, ИНТЕРЛЕЙКИНА IL23 И ПРОТИВОВИРУСНОГО БЕЛКА MxA |
EP3519582A1 (en) | 2016-07-29 | 2019-08-07 | Danmarks Tekniske Universitet | Methods for decoupling cell growth from production of biochemicals and recombinant polypeptides |
JP2019524787A (ja) | 2016-08-03 | 2019-09-05 | エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド | Tlr9標的治療薬 |
WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
CA3033756A1 (en) | 2016-09-02 | 2018-03-08 | Dicerna Pharmaceuticals, Inc. | 4'-phosphate analogs and oligonucleotides comprising the same |
US10933081B2 (en) | 2016-09-21 | 2021-03-02 | Alnylam Pharmaceuticals, Inc. | Myostatin iRNA compositions and methods of use thereof |
EP3521430A4 (en) * | 2016-09-29 | 2020-05-20 | National University Corporation Tokyo Medical and Dental University | DOUBLE-STRANDED NUCLEIC ACID COMPLEX WITH OVERHEAD |
WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
US11135307B2 (en) | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
WO2018112470A1 (en) | 2016-12-16 | 2018-06-21 | The Brigham And Women's Hospital, Inc. | Co-delivery of nucleic acids for simultaneous suppression and expression of target genes |
KR20190098748A (ko) | 2017-01-10 | 2019-08-22 | 애로우헤드 파마슈티컬스 인코포레이티드 | 알파-1 항트립신 (AAT) RNAi 작용제, AAT RNAi 작용제를 포함하는 조성물, 및 사용 방법 |
CN110770343A (zh) | 2017-02-10 | 2020-02-07 | 成均馆大学校产学协力团 | 用于rna干扰的长双链rna |
US10934547B2 (en) * | 2017-02-20 | 2021-03-02 | Northwestern University | Use of trinucleotide repeat RNAs to treat cancer |
DE102017103383A1 (de) | 2017-02-20 | 2018-08-23 | aReNA-Bio GbR (vertretungsberechtigter Gesellschafter: Dr. Heribert Bohlen, 50733 Köln) | System und Verfahren zur Zelltyp-spezifischen Translation von RNA-Molekülen in Eukaryoten |
TW201834697A (zh) | 2017-02-28 | 2018-10-01 | 美商梅爾莎納醫療公司 | Her2標靶抗體-藥物結合物之組合療法 |
KR20190139931A (ko) | 2017-04-07 | 2019-12-18 | 아펠리스 파마슈티컬스 인코포레이티드 | 투여 요법 및 관련 조성물 및 방법 |
AU2018251209B2 (en) | 2017-04-14 | 2021-11-04 | Arizona Board Of Regents On Behalf Of The University Of Arizonia | Compositions and methods for treating pulmonary fibrosis |
WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
US10844377B2 (en) * | 2017-06-23 | 2020-11-24 | University Of Massachusetts | Two-tailed self-delivering siRNA |
US11110114B2 (en) | 2017-07-17 | 2021-09-07 | Oxford University Innovation Limited | Dinucleotides |
US11104700B2 (en) | 2017-07-17 | 2021-08-31 | Oxford University Innovation Limited | Oligonucleotides |
WO2019068326A1 (en) | 2017-10-05 | 2019-04-11 | Université D'aix-Marseille | INHIBITORS OF LSD1 FOR THE TREATMENT AND PREVENTION OF CARDIOMYOPATHIES |
SG11202003488WA (en) | 2017-10-20 | 2020-05-28 | Dicerna Pharmaceuticals Inc | Methods for treating hepatitis b infection |
WO2019100053A1 (en) | 2017-11-20 | 2019-05-23 | University Of Georgia Research Foundation, Inc. | Compositions and methods for modulating hif-2α to improve muscle generation and repair |
US11638760B2 (en) | 2017-11-27 | 2023-05-02 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
MX2020005860A (es) | 2017-12-06 | 2020-09-09 | Avidity Biosciences Inc | Composiciones y metodos de tratamiento de atrofia muscular y distrofia miotonica. |
CA3086485A1 (en) | 2017-12-21 | 2019-06-27 | Alnylam Pharmaceuticals, Inc. | Chirally-enriched double-stranded rna agents |
JP2021506883A (ja) | 2017-12-21 | 2021-02-22 | メルサナ セラピューティクス インコーポレイテッド | ピロロベンゾジアゼピン抗体結合体 |
US10960086B2 (en) | 2017-12-28 | 2021-03-30 | Augusta University Research Institute, Inc. | Aptamer compositions and methods of use thereof |
US11865081B2 (en) | 2017-12-29 | 2024-01-09 | Virogin Biotech Canada Ltd. | Oncolytic viral delivery of therapeutic polypeptides |
CA3084829A1 (en) | 2018-01-05 | 2019-07-11 | Dicerna Pharmaceuticals, Inc. | Reducing beta-catenin and ido expression to potentiate immunotherapy |
AU2019209324A1 (en) | 2018-01-16 | 2020-07-09 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting ALDH2 expression |
KR20200108315A (ko) | 2018-02-09 | 2020-09-17 | 제넨테크, 인크. | Tmem106b의 발현을 조절하기 위한 올리고뉴클레오티드 |
JP2021522815A (ja) | 2018-05-07 | 2021-09-02 | ロシュ イノベーション センター コペンハーゲン エーエス | 超並列シーケンシングを用いるlnaオリゴヌクレオチド治療法の品質管理法 |
CA3100995A1 (en) | 2018-05-10 | 2019-11-14 | The University Of Manchester | Methods for assessing macular degeneration |
EP3846797A4 (en) | 2018-09-04 | 2022-06-08 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | USE OF DELTA-TOCOTRIENOL FOR THE TREATMENT OF CANCER |
EP3847650A1 (en) | 2018-09-06 | 2021-07-14 | The Broad Institute, Inc. | Nucleic acid assemblies for use in targeted delivery |
MX2021004906A (es) | 2018-10-29 | 2021-09-10 | Mersana Therapeutics Inc | Conjugados de anticuerpo modificado con cisteína-fármaco con enlazadores que contienen péptidos. |
KR20210132661A (ko) | 2019-02-12 | 2021-11-04 | 다이서나 파마수이티컬, 인크. | Cyp27a1의 발현을 억제하기 위한 방법 및 조성물 |
CA3134486A1 (en) | 2019-03-29 | 2020-10-08 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for the treatment of kras associated diseases or disorders |
US20220170025A1 (en) | 2019-04-04 | 2022-06-02 | Dicerna Pharmaceuticals Inc. | Compositions and methods for inhibiting gene expression in the central nervous system |
US11814464B2 (en) | 2019-04-29 | 2023-11-14 | Yale University | Poly(amine-co-ester) polymers and polyplexes with modified end groups and methods of use thereof |
CN113795581A (zh) | 2019-05-03 | 2021-12-14 | 迪克纳制药公司 | 具有缩短的有义链的双链核酸抑制剂分子 |
US20200369759A1 (en) | 2019-05-23 | 2020-11-26 | Fibrogen, Inc. | Methods of treatment of muscular dystrophies |
JP2022538868A (ja) | 2019-06-26 | 2022-09-06 | バイオーケストラ カンパニー, リミテッド | ミセルナノ粒子及びその使用 |
CN115151275A (zh) | 2019-08-30 | 2022-10-04 | 耶鲁大学 | 用于向细胞递送核酸的组合物和方法 |
TW202123973A (zh) | 2019-09-10 | 2021-07-01 | 日商第一三共股份有限公司 | 用於肝臟遞送之GalNAc-寡核苷酸結合物及製造方法 |
IL291841A (en) | 2019-10-02 | 2022-06-01 | Dicerna Pharmaceuticals Inc | Chemical modifications of tiny interfering rna with minimal fluoride content |
US11355185B2 (en) | 2019-11-26 | 2022-06-07 | Cypress Semiconductor Corporation | Silicon-oxide-nitride-oxide-silicon multi-level non-volatile memory device and methods of fabrication thereof |
WO2021130270A1 (en) | 2019-12-24 | 2021-07-01 | F. Hoffmann-La Roche Ag | Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv |
CA3163490A1 (en) | 2019-12-24 | 2021-07-01 | F. Hoffman-La Roche Ag | Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv |
CA3166420A1 (en) | 2020-01-14 | 2021-07-22 | Synthekine, Inc. | Il2 orthologs and methods of use |
US20210222128A1 (en) | 2020-01-22 | 2021-07-22 | Massachusetts Institute Of Technology | Inducible tissue constructs and uses thereof |
WO2021173965A1 (en) | 2020-02-28 | 2021-09-02 | Massachusetts Institute Of Technology | Identification of variable influenza residues and uses thereof |
CN116096889A (zh) | 2020-03-18 | 2023-05-09 | 迪克纳制药公司 | 用于抑制angptl3表达的组合物和方法 |
AU2021237465A1 (en) | 2020-03-19 | 2022-10-13 | Avidity Biosciences, Inc. | Compositions and methods of treating Facioscapulohumeral muscular dystrophy |
US11446387B2 (en) | 2020-03-27 | 2022-09-20 | Avidity Biosciences, Inc. | Compositions and methods of treating muscle dystrophy |
CA3176356A1 (en) | 2020-04-22 | 2021-10-28 | Anne BROOKS | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
JP2023531444A (ja) | 2020-06-19 | 2023-07-24 | イェール ユニバーシティー | 改変された末端基および増強された肺送達を有するポリ(アミン-co-エステル)ポリマー |
WO2021255262A1 (en) | 2020-06-19 | 2021-12-23 | Sylentis Sau | siRNA AND COMPOSITIONS FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF VIRUS DISEASES |
US20220031633A1 (en) | 2020-07-28 | 2022-02-03 | Yale University | Poly(amine-co-ester) polymeric particles for selective pulmonary delivery |
TW202221120A (zh) | 2020-08-04 | 2022-06-01 | 美商黛瑟納製藥公司 | 用於治療代謝症候群之組成物及方法 |
KR20230061389A (ko) | 2020-08-04 | 2023-05-08 | 다이서나 파마수이티컬, 인크. | 올리고뉴클레오티드의 전신 전달 |
JP2023538284A (ja) | 2020-08-04 | 2023-09-07 | ダイセルナ ファーマシューティカルズ, インコーポレイテッド | Plp1発現を阻害するための組成物及び方法 |
CA3185348A1 (en) | 2020-08-05 | 2022-02-10 | Bob Dale Brown | Compositions and methods for inhibiting lpa expression |
CA3190794A1 (en) | 2020-08-05 | 2022-02-10 | Soren Ottosen | Oligonucleotide treatment of hepatitis b patients |
EP4204002A1 (en) | 2020-08-31 | 2023-07-05 | Yale University | Compositions and methods for delivery of nucleic acids to cells |
EP3964204A1 (en) | 2020-09-08 | 2022-03-09 | Université d'Aix-Marseille | Lsd1 inhibitors for use in the treatment and prevention of fibrosis of tissues |
EP4214515A1 (en) | 2020-09-16 | 2023-07-26 | Complement Therapeutics Limited | Complementome assay |
CN117295753A (zh) | 2020-12-04 | 2023-12-26 | 基那奥生物公司 | 用于将核酸递送到细胞的组合物和方法 |
EP4015634A1 (en) | 2020-12-15 | 2022-06-22 | Sylentis, S.A.U. | Sirna and compositions for prophylactic and therapeutic treatment of virus diseases |
CN117202894A (zh) | 2021-03-31 | 2023-12-08 | 胭脂红治疗私人有限公司 | 负载至少两个不同核酸的细胞外囊泡 |
BR112023017367A2 (pt) | 2021-04-12 | 2023-12-12 | Boehringer Ingelheim Int | Composições e métodos para inibição de ceto-hexoquinase (khk) |
AR125351A1 (es) | 2021-04-14 | 2023-07-12 | Dicerna Pharmaceuticals Inc | Composiciones y métodos para modular la expresión de pnpla3 |
KR102644654B1 (ko) | 2021-04-19 | 2024-03-07 | 노보 노르디스크 에이/에스 | 핵 수용체 서브패밀리 1 그룹 h 구성원 3(nr1h3) 발현을 억제하기 위한 조성물 및 방법 |
JP7463621B2 (ja) | 2021-05-28 | 2024-04-08 | ノヴォ ノルディスク アー/エス | ミトコンドリアアミドキシム還元成分1(marc1)発現を阻害するための組成物および方法 |
CA3221935A1 (en) | 2021-05-29 | 2022-12-08 | 1Globe Health Institute Llc | Asymmetric short duplex dna as a novel gene silencing technology and use thereof |
EP4347828A1 (en) | 2021-05-29 | 2024-04-10 | 1Globe Health Institute LLC | Short duplex dna as a novel gene silencing technology and use thereof |
WO2022271786A1 (en) | 2021-06-23 | 2022-12-29 | University Of Massachusetts | Optimized anti-flt1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders |
CA3229305A1 (en) | 2021-08-16 | 2023-02-23 | Vib Vzw | Oligonucleotides for modulating synaptogyrin-3 expression |
US20230107967A1 (en) | 2021-08-25 | 2023-04-06 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting alpha-1 antitrypsin expression |
WO2023049743A1 (en) | 2021-09-21 | 2023-03-30 | The Johns Hopkins University | Dendrimer conjugates of small molecule biologics for intracellular delivery |
WO2023083906A2 (en) | 2021-11-11 | 2023-05-19 | F. Hoffmann-La Roche Ag | Pharmaceutical combinations for treatment of hbv |
US20240043846A1 (en) | 2021-11-19 | 2024-02-08 | Kist (Korea Institute Of Science And Technology) | Therapeutic Compounds for Red Blood Cell-Mediated Delivery of an Active Pharmaceutical Ingredient to a Target Cell |
AU2022402155A1 (en) | 2021-12-01 | 2024-05-09 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for modulating apoc3 expression |
WO2023118546A2 (en) | 2021-12-23 | 2023-06-29 | Boehringer Ingelheim International Gmbh | METHODS AND MOLECULES FOR RNA INTERFERENCE (RNAi) |
WO2023159189A1 (en) | 2022-02-18 | 2023-08-24 | Yale University | Branched poly(amine-co-ester) polymers for more efficient nucleic expression |
GB202203627D0 (en) | 2022-03-16 | 2022-04-27 | Univ Manchester | Agents for treating complement-related disorders |
WO2023192872A1 (en) | 2022-03-28 | 2023-10-05 | Massachusetts Institute Of Technology | Rna scaffolded wireframe origami and methods thereof |
GB202204884D0 (en) | 2022-04-04 | 2022-05-18 | Fondo Ricerca Medica S R I | Sirna targeting kcna1 |
US20230374522A1 (en) | 2022-04-15 | 2023-11-23 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for modulating scap activity |
WO2023201369A1 (en) | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | Til expansion processes using specific cytokine combinations and/or akti treatment |
US20230416742A1 (en) | 2022-05-12 | 2023-12-28 | Dicerna Phrmaceuticals, Inc. | Compositions and methods for inhibiting mapt expression |
US20230416743A1 (en) | 2022-05-13 | 2023-12-28 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting snca expression |
TW202400193A (zh) | 2022-06-24 | 2024-01-01 | 丹麥商諾佛 儂迪克股份有限公司 | 抑制跨膜絲胺酸蛋白酶6(tmprss6)表現的組成物及方法 |
WO2024040041A1 (en) | 2022-08-15 | 2024-02-22 | Dicerna Pharmaceuticals, Inc. | Regulation of activity of rnai molecules |
WO2024081736A2 (en) | 2022-10-11 | 2024-04-18 | Yale University | Compositions and methods of using cell-penetrating antibodies |
Citations (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4469863A (en) * | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
US5208149A (en) * | 1983-10-20 | 1993-05-04 | The Research Foundation Of State University Of New York | Nucleic acid constructs containing stable stem and loop structures |
US5457189A (en) * | 1989-12-04 | 1995-10-10 | Isis Pharmaceuticals | Antisense oligonucleotide inhibition of papillomavirus |
US5514577A (en) * | 1990-02-26 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide therapies for modulating the effects of herpes viruses |
US5576208A (en) * | 1991-06-14 | 1996-11-19 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide inhibition of the RAS gene |
US5578716A (en) * | 1993-12-01 | 1996-11-26 | Mcgill University | DNA methyltransferase antisense oligonucleotides |
US5580859A (en) * | 1989-03-21 | 1996-12-03 | Vical Incorporated | Delivery of exogenous DNA sequences in a mammal |
US5594122A (en) * | 1993-06-23 | 1997-01-14 | Genesys Pharma Inc. | Antisense oligonucleotides targeted against human immunodeficiency virus |
US5624803A (en) * | 1993-10-14 | 1997-04-29 | The Regents Of The University Of California | In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom |
US5624808A (en) * | 1995-03-28 | 1997-04-29 | Becton Dickinson And Company | Method for identifying cells committed to apoptosis by determining cellular phosphotyrosine content |
US5670633A (en) * | 1990-01-11 | 1997-09-23 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides that detect and modulate gene expression |
US5672695A (en) * | 1990-10-12 | 1997-09-30 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Modified ribozymes |
US5712257A (en) * | 1987-08-12 | 1998-01-27 | Hem Research, Inc. | Topically active compositions of mismatched dsRNAs |
US5770580A (en) * | 1992-04-13 | 1998-06-23 | Baylor College Of Medicine | Somatic gene therapy to cells associated with fluid spaces |
US5795715A (en) * | 1991-12-18 | 1998-08-18 | Cis Bio International | Process for preparing double-stranded RNA, and its applications |
US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
US5814500A (en) * | 1996-10-31 | 1998-09-29 | The Johns Hopkins University School Of Medicine | Delivery construct for antisense nucleic acids and methods of use |
US5898031A (en) * | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
US5908779A (en) * | 1993-12-01 | 1999-06-01 | University Of Connecticut | Targeted RNA degradation using nuclear antisense RNA |
US5919722A (en) * | 1987-02-25 | 1999-07-06 | Exxon Chemical Patents Inc. | Zeolite L catalyst |
US5972704A (en) * | 1992-05-14 | 1999-10-26 | Ribozyme Pharmaceuticals, Inc. | HIV nef targeted ribozymes |
US5998203A (en) * | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
US6001990A (en) * | 1994-05-10 | 1999-12-14 | The General Hospital Corporation | Antisense inhibition of hepatitis C virus |
US6057153A (en) * | 1995-01-13 | 2000-05-02 | Yale University | Stabilized external guide sequences |
US6225290B1 (en) * | 1996-09-19 | 2001-05-01 | The Regents Of The University Of California | Systemic gene therapy by intestinal cell transformation |
US20020086356A1 (en) * | 2000-03-30 | 2002-07-04 | Whitehead Institute For Biomedical Research | RNA sequence-specific mediators of RNA interference |
US20020114784A1 (en) * | 1999-01-28 | 2002-08-22 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA |
US20020132257A1 (en) * | 2001-01-31 | 2002-09-19 | Tony Giordano | Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell |
US20020137210A1 (en) * | 1999-12-09 | 2002-09-26 | Churikov Nikolai Andreevich | Method for modifying genetic characteristics of an organism |
US20020160393A1 (en) * | 2000-12-28 | 2002-10-31 | Symonds Geoffrey P. | Double-stranded RNA-mediated gene suppression |
US20020162126A1 (en) * | 2000-03-16 | 2002-10-31 | David Beach | Methods and compositions for RNA interference |
US6475726B1 (en) * | 1998-01-09 | 2002-11-05 | Cubist Pharmaceuticals, Inc. | Method for identifying validated target and assay combinations for drug development |
US6476205B1 (en) * | 1989-10-24 | 2002-11-05 | Isis Pharmaceuticals, Inc. | 2′ Modified oligonucleotides |
US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
US6531647B1 (en) * | 1997-09-22 | 2003-03-11 | Plant Bioscience Limited | Gene silencing methods |
US20030064945A1 (en) * | 1997-01-31 | 2003-04-03 | Saghir Akhtar | Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors |
US20030068301A1 (en) * | 1992-05-14 | 2003-04-10 | Kenneth Draper | Method and reagent for inhibiting hepatitis B virus replication |
US20030084471A1 (en) * | 2000-03-16 | 2003-05-01 | David Beach | Methods and compositions for RNA interference |
US20030140362A1 (en) * | 2001-06-08 | 2003-07-24 | Dennis Macejak | In vivo models for screening inhibitors of hepatitis B virus |
US20030148985A1 (en) * | 2001-12-05 | 2003-08-07 | David Morrissey | Methods and reagents for the inhibition of hepatitis B virus replication |
US20030153521A1 (en) * | 2001-05-29 | 2003-08-14 | Mcswiggen James | Nucleic acid treatment of diseases or conditions related to levels of Ras |
US20030171311A1 (en) * | 1998-04-27 | 2003-09-11 | Lawrence Blatt | Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection |
US20030180756A1 (en) * | 2002-03-21 | 2003-09-25 | Yang Shi | Compositions and methods for suppressing eukaryotic gene expression |
US20030190654A1 (en) * | 2002-01-22 | 2003-10-09 | Ribopharma | Double-stranded RNA (dsRNA) and method of use for inhibiting expression of a fusion gene |
US6635805B1 (en) * | 1997-02-14 | 2003-10-21 | Plant Bioscience Limited | Methods and DNA constructs for gene silencing in transgenic plants |
US20030206887A1 (en) * | 1992-05-14 | 2003-11-06 | David Morrissey | RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA) |
US20040002153A1 (en) * | 1999-07-21 | 2004-01-01 | Monia Brett P. | Modulation of PTEN expression via oligomeric compounds |
US20040001811A1 (en) * | 2001-01-09 | 2004-01-01 | Ribopharma Ag | Compositions and methods for inhibiting expression of anti-apoptotic genes |
US20040006035A1 (en) * | 2001-05-29 | 2004-01-08 | Dennis Macejak | Nucleic acid mediated disruption of HIV fusogenic peptide interactions |
US20040005593A1 (en) * | 2002-03-06 | 2004-01-08 | Rigel Pharmaceuticals, Inc. | Novel method for delivery and intracellular synthesis of siRNA molecules |
US20040019001A1 (en) * | 2002-02-20 | 2004-01-29 | Mcswiggen James A. | RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA |
US20040038921A1 (en) * | 2001-10-26 | 2004-02-26 | Ribopharma Ag | Composition and method for inhibiting expression of a target gene |
US20040054156A1 (en) * | 1992-05-14 | 2004-03-18 | Kenneth Draper | Method and reagent for inhibiting hepatitis B viral replication |
US20040053876A1 (en) * | 2002-03-26 | 2004-03-18 | The Regents Of The University Of Michigan | siRNAs and uses therof |
US20040053875A1 (en) * | 1999-01-30 | 2004-03-18 | Ribopharma Ag | Method and medicament for inhibiting the expression of a given gene |
US20040096843A1 (en) * | 2002-02-14 | 2004-05-20 | Rossi John J. | Methods for producing interfering RNA molecules in mammalian cells and therapeutic uses for such molecules |
US6753139B1 (en) * | 1999-10-27 | 2004-06-22 | Plant Bioscience Limited | Gene silencing |
US20040121348A1 (en) * | 2001-10-26 | 2004-06-24 | Ribopharma Ag | Compositions and methods for treating pancreatic cancer |
US20040137471A1 (en) * | 2002-09-18 | 2004-07-15 | Timothy Vickers | Efficient reduction of target RNA's by single-and double-stranded oligomeric compounds |
US20040175703A1 (en) * | 1999-11-24 | 2004-09-09 | Ribopharma Ag | Compositions and methods for inhibiting expression of a target gene |
US20040192626A1 (en) * | 2002-02-20 | 2004-09-30 | Mcswiggen James | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20040191905A1 (en) * | 2002-11-22 | 2004-09-30 | University Of Massachusetts | Modulation of HIV replication by RNA interference |
US20040203145A1 (en) * | 2002-08-07 | 2004-10-14 | University Of Massachusetts | Compositions for RNA interference and methods of use thereof |
US20040214330A1 (en) * | 1999-04-07 | 2004-10-28 | Waterhouse Peter Michael | Methods and means for obtaining modified phenotypes |
US20040224328A1 (en) * | 2003-01-15 | 2004-11-11 | Hans Prydz | siRNA screening method |
US20040231016A1 (en) * | 2003-02-19 | 2004-11-18 | Commonwealth Scientific And Industrial Research Organization | Efficient gene silencing in plants using short dsRNA sequences |
US20040229266A1 (en) * | 2000-12-01 | 2004-11-18 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | RNA interference mediating small RNA molecules |
US20040241854A1 (en) * | 2002-08-05 | 2004-12-02 | Davidson Beverly L. | siRNA-mediated gene silencing |
US20040248835A1 (en) * | 2001-10-26 | 2004-12-09 | Anja Krebs | Use of a double-stranded ribonucleic acid for treating an infection with a positivestrand rna-virus |
US20040248296A1 (en) * | 2002-03-20 | 2004-12-09 | Beresford Paul J. | HIV therapeutic |
US20050282765A1 (en) * | 1996-10-04 | 2005-12-22 | The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland | Enzyme having S-adenosyl-L-homocysteine hydrolase (AHCY) type activity |
US7232806B2 (en) * | 2001-09-28 | 2007-06-19 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | MicroRNA molecules |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2003006A (en) * | 1933-04-11 | 1935-05-28 | Michelson Barnett Samuel | Water tank cover |
IE66830B1 (en) | 1987-08-12 | 1996-02-07 | Hem Res Inc | Topically active compositions of double-stranded RNAs |
KR927003044A (ko) | 1990-01-11 | 1992-12-17 | 크리스토퍼 케이. 미라벨리 | Rna 활성과 유전자 발현을 검출하고 조절하는 조성물 및 그 방법 |
FR2675803B1 (fr) | 1991-04-25 | 1996-09-06 | Genset Sa | Oligonucleotides fermes, antisens et sens et leurs applications. |
JP3530186B2 (ja) | 1992-03-05 | 2004-05-24 | アイシス・ファーマシューティカルス・インコーポレーテッド | 共有架橋オリゴヌクレオチド |
JPH08501928A (ja) * | 1992-07-02 | 1996-03-05 | ハイブライドン インコーポレイテッド | 治療剤としての自己安定化オリゴヌクレオチド |
US5652355A (en) | 1992-07-23 | 1997-07-29 | Worcester Foundation For Experimental Biology | Hybrid oligonucleotide phosphorothioates |
WO1994015645A1 (en) | 1992-12-31 | 1994-07-21 | Texas Biotechnology Corporation | Antisense molecules directed against genes of the raf oncogene family |
US6056704A (en) | 1993-03-03 | 2000-05-02 | Ide; Masatake | Foot-pressure massage stand |
EP0616026A1 (en) | 1993-03-19 | 1994-09-21 | The Procter & Gamble Company | Concentrated cleaning compositions |
FR2710074B1 (fr) | 1993-09-15 | 1995-12-08 | Rhone Poulenc Rorer Sa | Gène GRB3-3, ses variants et leurs utilisations. |
WO1995013834A1 (en) | 1993-11-16 | 1995-05-26 | Genta, Incorporated | Chimeric oligonucleoside compounds |
US5674683A (en) | 1995-03-21 | 1997-10-07 | Research Corporation Technologies, Inc. | Stem-loop and circular oligonucleotides and method of using |
EP1489184A1 (en) | 1995-06-07 | 2004-12-22 | Inex Pharmaceutical Corp. | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
CA2239976A1 (en) * | 1995-09-20 | 1997-03-27 | Paul A. Zamecnik | Antisense oligonucleotide chemotherapy for benign hyperplasia or cancer of the prostate |
DK0882061T3 (da) | 1996-02-14 | 2004-09-27 | Isis Pharmaceuticals Inc | Sukkermodificerede gapped oligonukleotider |
EP0910634A2 (en) | 1996-04-17 | 1999-04-28 | Hoechst Marion Roussel Deutschland GmbH | ANTISENSE INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEgF/VPF) EXPRESSION |
DE19618797C2 (de) | 1996-05-10 | 2000-03-23 | Bertling Wolf | Vehikel zum Transport molekularer Substanz |
US20040266706A1 (en) | 2002-11-05 | 2004-12-30 | Muthiah Manoharan | Cross-linked oligomeric compounds and their use in gene modulation |
DE19631919C2 (de) | 1996-08-07 | 1998-07-16 | Deutsches Krebsforsch | Anti-Sinn-RNA mit Sekundärstruktur |
WO1998026062A2 (en) | 1996-12-12 | 1998-06-18 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Synthetic antisense oligodeoxynucleotides and pharmaceutical compositions containing them |
US6218142B1 (en) * | 1997-03-05 | 2001-04-17 | Michael Wassenegger | Nucleic acid molecules encoding polypeptides having the enzymatic activity of an RNA-directed RNA polymerase (RDRP) |
GB9710475D0 (en) | 1997-05-21 | 1997-07-16 | Zeneca Ltd | Gene silencing |
IL135000A0 (en) | 1997-09-12 | 2001-05-20 | Exiqon As | Bi- and tri-cyclic nucleoside, nucleotide and oligonucleotide analogues |
US20030083272A1 (en) | 1997-09-19 | 2003-05-01 | Lahive & Cockfield, Llp | Sense mrna therapy |
CZ295108B6 (cs) | 1998-03-20 | 2005-05-18 | Benitec Australia Ltd | Syntetický gen obsahující dispergovanou nebo cizorodou deoxyribonukleovou molekulu a genový konstrukt obsahující tento syntetický gen |
AUPP249298A0 (en) * | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
ATE507299T1 (de) | 1998-04-08 | 2011-05-15 | Commw Scient Ind Res Org | Verfahren und mittel zum erhalt von veränderten phänotypen |
CA2326823A1 (en) | 1998-04-20 | 1999-10-28 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid molecules with novel chemical compositions capable of modulating gene expression |
AR020078A1 (es) | 1998-05-26 | 2002-04-10 | Syngenta Participations Ag | Metodo para alterar la expresion de un gen objetivo en una celula de planta |
GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
AU1408300A (en) | 1998-11-24 | 2000-06-13 | Hisamitsu Pharmaceutical Co. Inc. | Hiv infection inhibitors |
AU1830000A (en) | 1998-11-30 | 2000-06-19 | Ribogene, Inc. | Methods and compositions for identification of inhibitors of ribosome assembly |
US6939712B1 (en) | 1998-12-29 | 2005-09-06 | Impedagen, Llc | Muting gene activity using a transgenic nucleic acid |
WO2000063364A2 (en) | 1999-04-21 | 2000-10-26 | American Home Products Corporation | Methods and compositions for inhibiting the function of polynucleotide sequences |
GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
DE10160151A1 (de) | 2001-01-09 | 2003-06-26 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens |
WO2001068826A2 (en) | 2000-03-14 | 2001-09-20 | Syngenta Participations Ag | Protoporphyrinogen oxidase ('protox') genes |
ES2500923T3 (es) | 2000-03-30 | 2014-10-01 | The Whitehead Institute For Biomedical Research | Mediadores específicos de secuencia de ARN de interferencia de ARN |
JP4901051B2 (ja) | 2000-05-30 | 2012-03-21 | ジョンソン アンド ジョンソン リサーチ プロプライアトリー リミテッド | RNAiを増強する因子を使用することによって遺伝子抑制を媒介する方法 |
WO2003103600A2 (en) | 2002-06-05 | 2003-12-18 | Invitrogen Corporation | Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites |
NZ526194A (en) | 2000-12-08 | 2004-10-29 | Invitrogen Corp | Methods of covalently linking, in one or both strands, two or more double stranded nucleotide sequences using one or more topoisomerases |
WO2003035869A1 (de) | 2001-10-26 | 2003-05-01 | Ribopharma Ag | Verwendung einer doppelsträngigen ribonukleinsäure zur gezielten hemmung der expression eines vorgegebenen zielgens |
US7423142B2 (en) * | 2001-01-09 | 2008-09-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
EP1263250B1 (de) | 2001-06-01 | 2004-03-24 | Mobilkom Austria Aktiengesellschaft & Co KG | Verfahren zur Bestimmung des Standortes einer Mobilstation in einem Mobilfunksystem |
DE10163098B4 (de) | 2001-10-12 | 2005-06-02 | Alnylam Europe Ag | Verfahren zur Hemmung der Replikation von Viren |
DE10154113A1 (de) | 2001-11-03 | 2003-05-15 | Opel Adam Ag | Frontstruktur eines Kraftfahrzeuges |
WO2003064621A2 (en) | 2002-02-01 | 2003-08-07 | Ambion, Inc. | HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES |
WO2003099298A1 (en) | 2002-05-24 | 2003-12-04 | Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V. | Rna interference mediating small rna molecules |
AU2003276666A1 (en) | 2002-06-12 | 2003-12-31 | Ambion, Inc. | Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference |
EP1520022B1 (en) | 2002-07-10 | 2015-07-22 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Rna-interference by single-stranded rna molecules |
EP1527176B2 (en) | 2002-08-05 | 2017-03-22 | Silence Therapeutics GmbH | Further novel forms of interfering rna molecules |
US20050020521A1 (en) | 2002-09-25 | 2005-01-27 | University Of Massachusetts | In vivo gene silencing by chemically modified and stable siRNA |
AU2003291755A1 (en) | 2002-11-05 | 2004-06-07 | Isis Pharmaceuticals, Inc. | Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use |
PT2284266E (pt) | 2002-11-14 | 2013-12-17 | Thermo Fisher Scient Biosciences Inc | Siarn contra tp53 |
AU2003295539A1 (en) | 2002-11-15 | 2004-06-15 | University Of Massachusetts | Allele-targeted rna interference |
WO2004063375A1 (en) | 2003-01-15 | 2004-07-29 | Hans Prydz | OPTIMIZING siRNA BY RNAi ANTISENSE |
WO2004065600A2 (en) | 2003-01-17 | 2004-08-05 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Rna interference by palindromic or modified rna molecules |
EP2314687B1 (en) | 2003-01-17 | 2017-12-27 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inducible small interfering rna (sirna) expression constructs for targeted gene silencing |
CN1768139A (zh) | 2003-02-10 | 2006-05-03 | 独立行政法人产业技术总合研究所 | 通过dna干扰调控基因的表达 |
DK1633767T3 (en) | 2003-06-02 | 2019-03-25 | Univ Massachusetts | METHODS AND COMPOSITIONS FOR MANAGING THE EFFECT OF RNA SILENCING |
US6998203B2 (en) * | 2003-08-01 | 2006-02-14 | Intel Corporation | Proximity correcting lithography mask blanks |
CA2594334A1 (en) | 2005-01-07 | 2006-07-13 | Alnylam Pharmaceuticals, Inc. | Rnai modulation of rsv and therapeutic uses thereof |
JP6348063B2 (ja) | 2011-07-08 | 2018-06-27 | インテヴァ プロダクツ, エルエルシーInteva Products, Llc | 車両内装部材にステッチを施す方法 |
-
2001
- 2001-11-29 EP EP07014533A patent/EP1873259B1/en not_active Expired - Lifetime
- 2001-11-29 US US10/433,050 patent/US20040259247A1/en not_active Abandoned
- 2001-11-29 SI SI200130787T patent/SI1407044T2/en unknown
- 2001-11-29 KR KR1020037006978A patent/KR100872437B1/ko active IP Right Grant
- 2001-11-29 DK DK14176605.5T patent/DK2813582T3/en active
- 2001-11-29 CZ CZ2011452A patent/CZ308053B6/cs not_active IP Right Cessation
- 2001-11-29 ES ES17160119T patent/ES2728168T3/es not_active Expired - Lifetime
- 2001-11-29 PL PL365784A patent/PL218876B1/pl unknown
- 2001-11-29 EP EP10179952.6A patent/EP2348133B1/en not_active Expired - Lifetime
- 2001-11-29 CZ CZ20031839A patent/CZ302719B6/cs not_active IP Right Cessation
- 2001-11-29 EP EP01985833.1A patent/EP1407044B2/en not_active Expired - Lifetime
- 2001-11-29 CN CNB018209009A patent/CN100523215C/zh not_active Expired - Lifetime
- 2001-11-29 TR TR2004/01292T patent/TR200401292T3/xx unknown
- 2001-11-29 NZ NZ525888A patent/NZ525888A/en not_active IP Right Cessation
- 2001-11-29 BR BRPI0115814A patent/BRPI0115814B8/pt not_active IP Right Cessation
- 2001-11-29 AU AU2002235744A patent/AU2002235744B8/en not_active Expired
- 2001-11-29 JP JP2002546670A patent/JP4095895B2/ja not_active Expired - Lifetime
- 2001-11-29 CA CA2429814A patent/CA2429814C/en not_active Expired - Lifetime
- 2001-11-29 WO PCT/EP2001/013968 patent/WO2002044321A2/en active Application Filing
- 2001-11-29 DE DE60130583.3T patent/DE60130583T3/de not_active Expired - Lifetime
- 2001-11-29 ES ES01985833.1T patent/ES2215494T5/es not_active Expired - Lifetime
- 2001-11-29 RU RU2003119457/13A patent/RU2322500C2/ru active
- 2001-11-29 HU HU0302557A patent/HU230458B1/hu unknown
- 2001-11-29 DK DK01985833.1T patent/DK1407044T4/en active
- 2001-11-29 KR KR1020087011582A patent/KR100909681B1/ko active IP Right Grant
- 2001-11-29 AT AT01985833T patent/ATE373724T2/de active
- 2001-11-29 PT PT01985833T patent/PT1407044E/pt unknown
- 2001-11-29 MX MXPA03004836A patent/MXPA03004836A/es active IP Right Grant
- 2001-11-29 IL IL15599101A patent/IL155991A0/xx unknown
-
2003
- 2003-05-19 IL IL155991A patent/IL155991A/en active IP Right Grant
- 2003-05-21 ZA ZA200303929A patent/ZA200303929B/xx unknown
- 2003-05-30 NO NO20032464A patent/NO333713B1/no not_active IP Right Cessation
-
2004
- 2004-04-27 US US10/832,248 patent/US7078196B2/en not_active Expired - Lifetime
- 2004-04-27 US US10/832,257 patent/US20050026278A1/en not_active Abandoned
- 2004-04-27 US US10/832,432 patent/US7056704B2/en not_active Expired - Lifetime
-
2005
- 2005-06-02 US US11/142,865 patent/US20050234006A1/en not_active Abandoned
- 2005-06-02 US US11/142,866 patent/US20050234007A1/en not_active Abandoned
-
2006
- 2006-11-24 JP JP2006317758A patent/JP4494392B2/ja not_active Expired - Lifetime
- 2006-12-06 US US11/634,138 patent/US20080269147A1/en not_active Abandoned
- 2006-12-06 US US11/634,129 patent/US20070093445A1/en not_active Abandoned
-
2007
- 2007-07-19 AU AU2007203385A patent/AU2007203385B2/en not_active Expired
- 2007-08-16 RU RU2007131270/10A patent/RU2470073C2/ru active
-
2008
- 2008-05-07 HK HK08105073.1A patent/HK1110631A1/xx not_active IP Right Cessation
- 2008-10-29 US US12/260,443 patent/US20090155174A1/en not_active Abandoned
-
2009
- 2009-08-07 US US12/537,632 patent/US20100010207A1/en not_active Abandoned
- 2009-08-07 US US12/537,602 patent/US8372968B2/en not_active Expired - Lifetime
- 2009-09-11 JP JP2009210276A patent/JP6189576B2/ja not_active Expired - Lifetime
- 2009-12-02 US US12/591,829 patent/US8853384B2/en not_active Expired - Fee Related
-
2010
- 2010-01-06 US US12/683,081 patent/US8362231B2/en not_active Expired - Lifetime
- 2010-01-06 US US12/683,070 patent/US8933044B2/en not_active Expired - Fee Related
- 2010-03-03 JP JP2010046471A patent/JP5749892B2/ja not_active Expired - Lifetime
- 2010-05-14 HK HK10104709.2A patent/HK1139181A1/xx not_active IP Right Cessation
- 2010-06-02 HK HK10105414.5A patent/HK1139433A1/xx not_active IP Right Cessation
- 2010-06-04 US US12/794,071 patent/US8765930B2/en not_active Expired - Fee Related
- 2010-06-21 US US12/819,444 patent/US8796016B2/en not_active Expired - Fee Related
- 2010-07-12 US US12/834,311 patent/US8445237B2/en not_active Expired - Lifetime
- 2010-07-13 US US12/835,086 patent/US8778902B2/en not_active Expired - Fee Related
- 2010-07-19 US US12/838,786 patent/US8329463B2/en not_active Expired - Lifetime
- 2010-08-19 IL IL207727A patent/IL207727A/en active IP Right Grant
- 2010-08-19 AU AU2010212438A patent/AU2010212438B2/en not_active Expired
- 2010-09-10 US US12/879,300 patent/US8993745B2/en not_active Expired - Fee Related
- 2010-10-04 US US12/897,374 patent/US8895718B2/en not_active Expired - Fee Related
-
2012
- 2012-12-21 US US13/725,262 patent/US8895721B2/en not_active Expired - Fee Related
-
2013
- 2013-02-14 NO NO20130246A patent/NO335426B1/no not_active IP Right Cessation
-
2014
- 2014-09-03 US US14/476,465 patent/US9567582B2/en not_active Expired - Lifetime
- 2014-12-12 JP JP2014251819A patent/JP6325974B2/ja not_active Expired - Lifetime
-
2015
- 2015-06-05 HK HK15105362.2A patent/HK1204798A1/xx not_active IP Right Cessation
-
2016
- 2016-12-22 US US15/388,681 patent/US10633656B2/en not_active Expired - Lifetime
-
2017
- 2017-07-05 CY CY20171100721T patent/CY1119062T1/el unknown
-
2020
- 2020-02-28 US US16/805,072 patent/US20200299693A1/en not_active Abandoned
-
2021
- 2021-05-18 LT LTPA2021005C patent/LTPA2021005I1/lt unknown
Patent Citations (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4469863A (en) * | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
US5208149A (en) * | 1983-10-20 | 1993-05-04 | The Research Foundation Of State University Of New York | Nucleic acid constructs containing stable stem and loop structures |
US5919722A (en) * | 1987-02-25 | 1999-07-06 | Exxon Chemical Patents Inc. | Zeolite L catalyst |
US5712257A (en) * | 1987-08-12 | 1998-01-27 | Hem Research, Inc. | Topically active compositions of mismatched dsRNAs |
US5580859A (en) * | 1989-03-21 | 1996-12-03 | Vical Incorporated | Delivery of exogenous DNA sequences in a mammal |
US6476205B1 (en) * | 1989-10-24 | 2002-11-05 | Isis Pharmaceuticals, Inc. | 2′ Modified oligonucleotides |
US5457189A (en) * | 1989-12-04 | 1995-10-10 | Isis Pharmaceuticals | Antisense oligonucleotide inhibition of papillomavirus |
US5670633A (en) * | 1990-01-11 | 1997-09-23 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides that detect and modulate gene expression |
US5514577A (en) * | 1990-02-26 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide therapies for modulating the effects of herpes viruses |
US5672695A (en) * | 1990-10-12 | 1997-09-30 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Modified ribozymes |
US5576208A (en) * | 1991-06-14 | 1996-11-19 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide inhibition of the RAS gene |
US5795715A (en) * | 1991-12-18 | 1998-08-18 | Cis Bio International | Process for preparing double-stranded RNA, and its applications |
US5770580A (en) * | 1992-04-13 | 1998-06-23 | Baylor College Of Medicine | Somatic gene therapy to cells associated with fluid spaces |
US5972704A (en) * | 1992-05-14 | 1999-10-26 | Ribozyme Pharmaceuticals, Inc. | HIV nef targeted ribozymes |
US20030068301A1 (en) * | 1992-05-14 | 2003-04-10 | Kenneth Draper | Method and reagent for inhibiting hepatitis B virus replication |
US20040054156A1 (en) * | 1992-05-14 | 2004-03-18 | Kenneth Draper | Method and reagent for inhibiting hepatitis B viral replication |
US20030206887A1 (en) * | 1992-05-14 | 2003-11-06 | David Morrissey | RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA) |
US5594122A (en) * | 1993-06-23 | 1997-01-14 | Genesys Pharma Inc. | Antisense oligonucleotides targeted against human immunodeficiency virus |
US5624803A (en) * | 1993-10-14 | 1997-04-29 | The Regents Of The University Of California | In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom |
US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
US5908779A (en) * | 1993-12-01 | 1999-06-01 | University Of Connecticut | Targeted RNA degradation using nuclear antisense RNA |
US5578716A (en) * | 1993-12-01 | 1996-11-26 | Mcgill University | DNA methyltransferase antisense oligonucleotides |
US6001990A (en) * | 1994-05-10 | 1999-12-14 | The General Hospital Corporation | Antisense inhibition of hepatitis C virus |
US6057153A (en) * | 1995-01-13 | 2000-05-02 | Yale University | Stabilized external guide sequences |
US5624808A (en) * | 1995-03-28 | 1997-04-29 | Becton Dickinson And Company | Method for identifying cells committed to apoptosis by determining cellular phosphotyrosine content |
US5998203A (en) * | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
US6107094A (en) * | 1996-06-06 | 2000-08-22 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides and ribonucleases for cleaving RNA |
US5898031A (en) * | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
US6225290B1 (en) * | 1996-09-19 | 2001-05-01 | The Regents Of The University Of California | Systemic gene therapy by intestinal cell transformation |
US20050282765A1 (en) * | 1996-10-04 | 2005-12-22 | The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland | Enzyme having S-adenosyl-L-homocysteine hydrolase (AHCY) type activity |
US5814500A (en) * | 1996-10-31 | 1998-09-29 | The Johns Hopkins University School Of Medicine | Delivery construct for antisense nucleic acids and methods of use |
US20030064945A1 (en) * | 1997-01-31 | 2003-04-03 | Saghir Akhtar | Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors |
US6635805B1 (en) * | 1997-02-14 | 2003-10-21 | Plant Bioscience Limited | Methods and DNA constructs for gene silencing in transgenic plants |
US6531647B1 (en) * | 1997-09-22 | 2003-03-11 | Plant Bioscience Limited | Gene silencing methods |
US20030051263A1 (en) * | 1997-12-23 | 2003-03-13 | The Carnegie Institution Of Washington | Genetic inhibition by double-stranded RNA |
US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
US20030055020A1 (en) * | 1997-12-23 | 2003-03-20 | The Carnegie Institution Of Washington | Genetic inhibition by double-stranded RNA |
US20030056235A1 (en) * | 1997-12-23 | 2003-03-20 | The Carnegie Institution Of Washington | Genetic inhibition by double-stranded RNA |
US6475726B1 (en) * | 1998-01-09 | 2002-11-05 | Cubist Pharmaceuticals, Inc. | Method for identifying validated target and assay combinations for drug development |
US20030171311A1 (en) * | 1998-04-27 | 2003-09-11 | Lawrence Blatt | Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection |
US20020114784A1 (en) * | 1999-01-28 | 2002-08-22 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA |
US20040072779A1 (en) * | 1999-01-30 | 2004-04-15 | Ribopharma Ag | Method and medicament for inhibiting the expression of a given gene |
US20040102408A1 (en) * | 1999-01-30 | 2004-05-27 | Ribopharma Ag | Method and medicament for inhibiting the expression of a given gene |
US20040053875A1 (en) * | 1999-01-30 | 2004-03-18 | Ribopharma Ag | Method and medicament for inhibiting the expression of a given gene |
US20040214330A1 (en) * | 1999-04-07 | 2004-10-28 | Waterhouse Peter Michael | Methods and means for obtaining modified phenotypes |
US20040002153A1 (en) * | 1999-07-21 | 2004-01-01 | Monia Brett P. | Modulation of PTEN expression via oligomeric compounds |
US20040221337A1 (en) * | 1999-10-27 | 2004-11-04 | Baulcombe David C. | Gene silencing |
US6753139B1 (en) * | 1999-10-27 | 2004-06-22 | Plant Bioscience Limited | Gene silencing |
US20040175703A1 (en) * | 1999-11-24 | 2004-09-09 | Ribopharma Ag | Compositions and methods for inhibiting expression of a target gene |
US20020137210A1 (en) * | 1999-12-09 | 2002-09-26 | Churikov Nikolai Andreevich | Method for modifying genetic characteristics of an organism |
US20040086884A1 (en) * | 2000-03-16 | 2004-05-06 | Genetica, Inc. | Methods and compositions for RNA interference |
US20040018999A1 (en) * | 2000-03-16 | 2004-01-29 | David Beach | Methods and compositions for RNA interference |
US20030084471A1 (en) * | 2000-03-16 | 2003-05-01 | David Beach | Methods and compositions for RNA interference |
US20020162126A1 (en) * | 2000-03-16 | 2002-10-31 | David Beach | Methods and compositions for RNA interference |
US20070003961A1 (en) * | 2000-03-30 | 2007-01-04 | Whitehead Institute For Biomedical Research | RNA sequence-specific mediators of RNA interference |
US20070003963A1 (en) * | 2000-03-30 | 2007-01-04 | Whitehead Institute For Biomedical Research | RNA sequence-specific mediators of RNA interference |
US20030108923A1 (en) * | 2000-03-30 | 2003-06-12 | Whitehead Institute For Biomedical Research | RNA sequence-specific mediators of RNA interference |
US20080132461A1 (en) * | 2000-03-30 | 2008-06-05 | Whitehead Institute For Biomedical Research | RNA sequence-specific mediators of RNA interference |
US20070003962A1 (en) * | 2000-03-30 | 2007-01-04 | Whitehead Institute For Biomedical Research | RNA sequence-specific mediators of RNA interference |
US20020086356A1 (en) * | 2000-03-30 | 2002-07-04 | Whitehead Institute For Biomedical Research | RNA sequence-specific mediators of RNA interference |
US20070003960A1 (en) * | 2000-03-30 | 2007-01-04 | Whitehead Institute For Biomedical Research | RNA sequence-specific mediators of RNA interference |
US20050234006A1 (en) * | 2000-12-01 | 2005-10-20 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | RNA interference mediating small RNA molecules |
US20070093445A1 (en) * | 2000-12-01 | 2007-04-26 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E. V. | RNA interference mediating small RNA molecules |
US20050234007A1 (en) * | 2000-12-01 | 2005-10-20 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | RNA interference mediating small RNA molecules |
US20050026278A1 (en) * | 2000-12-01 | 2005-02-03 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | RNA interference mediating small RNA molecules |
US20040259248A1 (en) * | 2000-12-01 | 2004-12-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | RNA interference mediating small RNA molecules |
US7056704B2 (en) * | 2000-12-01 | 2006-06-06 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | RNA interference mediating small RNA molecules |
US20040229266A1 (en) * | 2000-12-01 | 2004-11-18 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | RNA interference mediating small RNA molecules |
US7078196B2 (en) * | 2000-12-01 | 2006-07-18 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften, E.V. | RNA interference mediating small RNA molecules |
US20020160393A1 (en) * | 2000-12-28 | 2002-10-31 | Symonds Geoffrey P. | Double-stranded RNA-mediated gene suppression |
US20040001811A1 (en) * | 2001-01-09 | 2004-01-01 | Ribopharma Ag | Compositions and methods for inhibiting expression of anti-apoptotic genes |
US20020132257A1 (en) * | 2001-01-31 | 2002-09-19 | Tony Giordano | Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell |
US20030153521A1 (en) * | 2001-05-29 | 2003-08-14 | Mcswiggen James | Nucleic acid treatment of diseases or conditions related to levels of Ras |
US20040006035A1 (en) * | 2001-05-29 | 2004-01-08 | Dennis Macejak | Nucleic acid mediated disruption of HIV fusogenic peptide interactions |
US20030140362A1 (en) * | 2001-06-08 | 2003-07-24 | Dennis Macejak | In vivo models for screening inhibitors of hepatitis B virus |
US7232806B2 (en) * | 2001-09-28 | 2007-06-19 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | MicroRNA molecules |
US20040038921A1 (en) * | 2001-10-26 | 2004-02-26 | Ribopharma Ag | Composition and method for inhibiting expression of a target gene |
US20040248835A1 (en) * | 2001-10-26 | 2004-12-09 | Anja Krebs | Use of a double-stranded ribonucleic acid for treating an infection with a positivestrand rna-virus |
US20040126791A1 (en) * | 2001-10-26 | 2004-07-01 | Ribopharma Ag | Compositions and methods for treating trail-resistant cancer cells |
US20040121348A1 (en) * | 2001-10-26 | 2004-06-24 | Ribopharma Ag | Compositions and methods for treating pancreatic cancer |
US20030148985A1 (en) * | 2001-12-05 | 2003-08-07 | David Morrissey | Methods and reagents for the inhibition of hepatitis B virus replication |
US20030190654A1 (en) * | 2002-01-22 | 2003-10-09 | Ribopharma | Double-stranded RNA (dsRNA) and method of use for inhibiting expression of a fusion gene |
US20040096843A1 (en) * | 2002-02-14 | 2004-05-20 | Rossi John J. | Methods for producing interfering RNA molecules in mammalian cells and therapeutic uses for such molecules |
US20040192626A1 (en) * | 2002-02-20 | 2004-09-30 | Mcswiggen James | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20040019001A1 (en) * | 2002-02-20 | 2004-01-29 | Mcswiggen James A. | RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA |
US20040005593A1 (en) * | 2002-03-06 | 2004-01-08 | Rigel Pharmaceuticals, Inc. | Novel method for delivery and intracellular synthesis of siRNA molecules |
US20040248296A1 (en) * | 2002-03-20 | 2004-12-09 | Beresford Paul J. | HIV therapeutic |
US20030180756A1 (en) * | 2002-03-21 | 2003-09-25 | Yang Shi | Compositions and methods for suppressing eukaryotic gene expression |
US20040053876A1 (en) * | 2002-03-26 | 2004-03-18 | The Regents Of The University Of Michigan | siRNAs and uses therof |
US20040241854A1 (en) * | 2002-08-05 | 2004-12-02 | Davidson Beverly L. | siRNA-mediated gene silencing |
US20040203145A1 (en) * | 2002-08-07 | 2004-10-14 | University Of Massachusetts | Compositions for RNA interference and methods of use thereof |
US20040137471A1 (en) * | 2002-09-18 | 2004-07-15 | Timothy Vickers | Efficient reduction of target RNA's by single-and double-stranded oligomeric compounds |
US20040191905A1 (en) * | 2002-11-22 | 2004-09-30 | University Of Massachusetts | Modulation of HIV replication by RNA interference |
US20040224328A1 (en) * | 2003-01-15 | 2004-11-11 | Hans Prydz | siRNA screening method |
US20040231016A1 (en) * | 2003-02-19 | 2004-11-18 | Commonwealth Scientific And Industrial Research Organization | Efficient gene silencing in plants using short dsRNA sequences |
Cited By (1247)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9096636B2 (en) | 1996-06-06 | 2015-08-04 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
US7812149B2 (en) | 1996-06-06 | 2010-10-12 | Isis Pharmaceuticals, Inc. | 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations |
US7695902B2 (en) | 1996-06-06 | 2010-04-13 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides and ribonucleases for cleaving RNA |
US20040086845A1 (en) * | 1999-10-20 | 2004-05-06 | Tzyy-Choou Wu | Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen |
US8128922B2 (en) | 1999-10-20 | 2012-03-06 | Johns Hopkins University | Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen |
US9758551B2 (en) | 1999-10-20 | 2017-09-12 | The Johns Hopkins University | Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen |
US8263569B2 (en) | 1999-10-27 | 2012-09-11 | Plant Biosciences Limited | Gene silencing |
US20040221337A1 (en) * | 1999-10-27 | 2004-11-04 | Baulcombe David C. | Gene silencing |
US8258285B2 (en) | 1999-10-27 | 2012-09-04 | Plant Bioscience Limited | RNA molecules and vectors for gene silencing |
US8097710B2 (en) | 1999-10-27 | 2012-01-17 | Plant Bioscience Limited | Gene silencing |
US20090286254A1 (en) * | 1999-10-27 | 2009-11-19 | David Charles Baulcombe | Gene silencing |
US20050102709A1 (en) * | 1999-10-27 | 2005-05-12 | Plant Bioscience Limited | RNA molecules and vectors for gene silencing |
US20050102710A1 (en) * | 1999-10-27 | 2005-05-12 | Plant Bioscience Limited | Cells and animals produced by gene silencing |
US8779236B2 (en) | 1999-10-27 | 2014-07-15 | Plant Bioscience Limited | Gene silencing |
US20060168669A1 (en) * | 1999-10-27 | 2006-07-27 | Baulcombe David C | Gene silencing |
US20080312176A1 (en) * | 1999-10-27 | 2008-12-18 | David Charles Baulcombe | Gene silencing |
US7704688B2 (en) | 1999-10-27 | 2010-04-27 | Plant Bioscience Limited | Methods of detecting silencing mammalian cells |
US20090288182A1 (en) * | 1999-10-27 | 2009-11-19 | David Charles Baulcombe | Gene silencing |
US8299235B2 (en) | 1999-10-27 | 2012-10-30 | Plant Bioscience Limited | RNA molecules and vectors for gene silencing |
US8349607B2 (en) | 1999-10-27 | 2013-01-08 | Plant Bioscience Limited | Gene silencing |
US8759102B2 (en) | 1999-10-27 | 2014-06-24 | Plant Bioscience Limited | Short RNA producing gene silencing in cells |
US8420391B2 (en) | 2000-03-30 | 2013-04-16 | University Of Massachusetts | RNA sequence-specific mediators of RNA interference |
US9193753B2 (en) | 2000-03-30 | 2015-11-24 | University Of Massachusetts | RNA sequence-specific mediators of RNA interference |
US20070003962A1 (en) * | 2000-03-30 | 2007-01-04 | Whitehead Institute For Biomedical Research | RNA sequence-specific mediators of RNA interference |
US8742092B2 (en) | 2000-03-30 | 2014-06-03 | University Of Massachusetts | RNA sequence-specific mediators of RNA interference |
US8394628B2 (en) | 2000-03-30 | 2013-03-12 | University Of Massachusetts | RNA sequence-specific mediators of RNA interference |
US20020086356A1 (en) * | 2000-03-30 | 2002-07-04 | Whitehead Institute For Biomedical Research | RNA sequence-specific mediators of RNA interference |
US8790922B2 (en) | 2000-03-30 | 2014-07-29 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | RNA sequence-specific mediators of RNA interference |
US20090186843A1 (en) * | 2000-03-30 | 2009-07-23 | Whitehead Institute For Biomedical Research | RNA sequence-specific mediators of RNA interference |
US10472625B2 (en) | 2000-03-30 | 2019-11-12 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | RNA sequence-specific mediators of RNA interference |
US9012621B2 (en) | 2000-03-30 | 2015-04-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | RNA sequence-specific mediators of RNA interference |
US8632997B2 (en) | 2000-03-30 | 2014-01-21 | University Of Massachusetts | RNA sequence-specific mediators of RNA interference |
US9012138B2 (en) | 2000-03-30 | 2015-04-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | RNA sequence-specific mediators of RNA interference |
US8552171B2 (en) * | 2000-03-30 | 2013-10-08 | University Of Massachusetts | RNA sequence-specific mediators of RNA interference |
US20030108923A1 (en) * | 2000-03-30 | 2003-06-12 | Whitehead Institute For Biomedical Research | RNA sequence-specific mediators of RNA interference |
US20080132461A1 (en) * | 2000-03-30 | 2008-06-05 | Whitehead Institute For Biomedical Research | RNA sequence-specific mediators of RNA interference |
US20070003963A1 (en) * | 2000-03-30 | 2007-01-04 | Whitehead Institute For Biomedical Research | RNA sequence-specific mediators of RNA interference |
US20070003961A1 (en) * | 2000-03-30 | 2007-01-04 | Whitehead Institute For Biomedical Research | RNA sequence-specific mediators of RNA interference |
US20070003960A1 (en) * | 2000-03-30 | 2007-01-04 | Whitehead Institute For Biomedical Research | RNA sequence-specific mediators of RNA interference |
US20120029061A1 (en) * | 2000-03-30 | 2012-02-02 | Thomas Tuschl | Rna sequence-specific mediators of rna interference |
US8372969B2 (en) | 2000-08-02 | 2013-02-12 | University Of Southern California | RNA interference methods using DNA-RNA duplex constructs |
US8080652B2 (en) * | 2000-08-02 | 2011-12-20 | University Of Southern California | Gene silencing using mRNA-cDNA hybrids |
US20100249212A1 (en) * | 2000-08-02 | 2010-09-30 | University Of Southern California | Gene Silencing Using mRNA-cDNA Hybrids |
US20080242627A1 (en) * | 2000-08-02 | 2008-10-02 | University Of Southern California | Novel rna interference methods using dna-rna duplex constructs |
US20110098461A1 (en) * | 2000-08-02 | 2011-04-28 | University Of Southern California | Novel RNA Interference Methods Using DNA-RNA Duplex Constructs |
US20090148471A1 (en) * | 2000-08-03 | 2009-06-11 | The Johns Hopkins University | Molecular Vaccine Linking an Endoplasmic Reticulum Chaperone Polypeptide to an Antigen |
US8007781B2 (en) | 2000-08-03 | 2011-08-30 | The Johns Hopkins University | Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen |
US20090149407A1 (en) * | 2000-08-30 | 2009-06-11 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED TREATMENT OF ALZHEIMER'S DISEASE USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US7662951B2 (en) * | 2000-08-30 | 2010-02-16 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA) |
US8017765B2 (en) | 2000-08-30 | 2011-09-13 | Merck Sharp & Dohme Corp. | RNA interference mediated treatment of alzheimer's disease using short interfering nucleic acid (siNA) |
US20100168208A1 (en) * | 2000-08-30 | 2010-07-01 | Sima Therapeutics, Inc. | RNA INTERFERENCE MEDIATED TREATMENT OF ALZHEIMER'S DISEASE USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US7713945B2 (en) * | 2000-09-19 | 2010-05-11 | University Of South Florida | Control of NK cell function and survival by modulation of SHIP activity |
US20080076731A1 (en) * | 2000-09-19 | 2008-03-27 | University Of South Florida | Control of NK cell function and survival by modulation of ship activity |
US8163710B2 (en) | 2000-09-19 | 2012-04-24 | University Of South Florida | Reduction of graft-versus-host disease by modulation of SHIP activity |
US20100144841A1 (en) * | 2000-09-19 | 2010-06-10 | University Of South Florida | Control of nk cell function and survival by modulation of ship activity |
US8329463B2 (en) | 2000-12-01 | 2012-12-11 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | RNA interference mediating small RNA molecules |
US10633656B2 (en) | 2000-12-01 | 2020-04-28 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | RNA interference mediating small RNA molecules |
US8372968B2 (en) | 2000-12-01 | 2013-02-12 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | RNA interference mediating small RNA molecules |
US8853384B2 (en) | 2000-12-01 | 2014-10-07 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | RNA interference mediating small RNA molecules |
US20110070162A1 (en) * | 2000-12-01 | 2011-03-24 | Max-Phanck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Rna interference mediating small rna molecules |
US8796016B2 (en) | 2000-12-01 | 2014-08-05 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | RNA interference mediating small RNA molecules |
US8933044B2 (en) | 2000-12-01 | 2015-01-13 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | RNA interference mediating small RNA molecules |
US20110054159A1 (en) * | 2000-12-01 | 2011-03-03 | Maxplanck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Rna interference mediating small rna molecules |
US8993745B2 (en) | 2000-12-01 | 2015-03-31 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | RNA interference mediating small RNA molecules |
US20100316703A1 (en) * | 2000-12-01 | 2010-12-16 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Rna interference mediating small rna molecules |
US20110014123A1 (en) * | 2000-12-01 | 2011-01-20 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | RNA interference mediating small RNA molecules |
US20110027883A1 (en) * | 2000-12-01 | 2011-02-03 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Rna interference mediating small rna molecules |
US8445237B2 (en) | 2000-12-01 | 2013-05-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | RNA interference mediating small RNA molecules |
US8765930B2 (en) | 2000-12-01 | 2014-07-01 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | RNA interference mediating small RNA molecules |
US8895721B2 (en) | 2000-12-01 | 2014-11-25 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | RNA interference mediating small RNA molecules |
US8895718B2 (en) | 2000-12-01 | 2014-11-25 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | RNA interference mediating small RNA molecules |
US20110065773A1 (en) * | 2000-12-01 | 2011-03-17 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Rna interference mediating small rna molecules |
US20110065109A1 (en) * | 2000-12-01 | 2011-03-17 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Rna interference mediating small rna molecules |
US8778902B2 (en) | 2000-12-01 | 2014-07-15 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | RNA interference mediating small RNA molecules |
US8362231B2 (en) | 2000-12-01 | 2013-01-29 | Max-Planck-Gesellschaft zur Föderung der Wissenschaften E.V. | RNA interference mediating small RNA molecules |
US20110112283A1 (en) * | 2000-12-01 | 2011-05-12 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Rna interference mediating small rna molecules |
US9587240B2 (en) | 2001-01-09 | 2017-03-07 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
US20050239731A1 (en) * | 2001-05-18 | 2005-10-27 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of MAP kinase gene expression using short interfering nucleic acid (siNA) |
US20050159381A1 (en) * | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of chromosome translocation gene expression using short interfering nucleic acid (siNA) |
US20050176024A1 (en) * | 2001-05-18 | 2005-08-11 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of epidermal growth factor receptor (EGFR) gene expression using short interfering nucleic acid (siNA) |
US20050176025A1 (en) * | 2001-05-18 | 2005-08-11 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA) |
US8772469B2 (en) * | 2001-07-12 | 2014-07-08 | Sanofi-Aventis Deutschland Gmbh | Synthetic double-stranded oligonucleotides for specific inhibition of gene expression |
US20030139585A1 (en) * | 2001-07-12 | 2003-07-24 | Eugen Uhlmann | Synthetic double-stranded oligonucleotides for specific inhibition of gene expression |
US10517887B2 (en) | 2001-07-23 | 2019-12-31 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for RNAi mediated inhibition of gene expression in mammals |
US20130066058A1 (en) * | 2001-07-23 | 2013-03-14 | John E. Thompson | Use of Antisense Oligonucleotides or siRNA to Suppress Expression of eIF-5A1 |
US20090264505A1 (en) * | 2001-07-23 | 2009-10-22 | Kay Mark A | Methods and compositions for rnai mediated inhibition of gene expression in mammals |
US20110098460A1 (en) * | 2001-07-23 | 2011-04-28 | Senesco Technologies, Inc. | SiRNA Useful to Suppress expression of eIF-5A1 |
US20030139363A1 (en) * | 2001-07-23 | 2003-07-24 | Kay Mark A. | Methods and compositions for RNAi mediated inhibition of viral gene expression in mammals |
US9018179B2 (en) | 2001-07-23 | 2015-04-28 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for RNAi mediated inhibition of gene expression in mammals |
US20100099740A1 (en) * | 2001-07-23 | 2010-04-22 | Kay Mark A | Methods and compositions for rnai mediated inhibition of gene expression in mammals |
US8242256B2 (en) * | 2001-07-23 | 2012-08-14 | Senesco Technologies, Inc. | siRNA useful to supress expression of EIF-5A1 |
US20030153519A1 (en) * | 2001-07-23 | 2003-08-14 | Kay Mark A. | Methods and compositions for RNAi mediated inhibition of gene expression in mammals |
US10590418B2 (en) * | 2001-07-23 | 2020-03-17 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for RNAi mediated inhibition of gene expression in mammals |
US20090247606A1 (en) * | 2001-08-28 | 2009-10-01 | Sirna Therapeutics, Inc. | RNA Interference Mediated Inhibition of Adenosine A1 Receptor (ADORA1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
US20100305191A1 (en) * | 2001-08-28 | 2010-12-02 | Mcswiggen James | Rna interference mediated inhibition of adenosine a1 receptor (adora1) gene expression using short interfering rna |
US7691821B2 (en) | 2001-09-19 | 2010-04-06 | University Of South Florida | Inhibition of SHIP to enhance stem cell harvest and transplantation |
US20060223749A1 (en) * | 2001-09-19 | 2006-10-05 | University Of South Florida | Inhibition of SHIP to enhance stem cell harvest and transplantation |
US20050074757A1 (en) * | 2001-10-12 | 2005-04-07 | Ribopharma Ag | Compositions and methods for inhibiting expression of a mutant gene |
US7348314B2 (en) * | 2001-10-12 | 2008-03-25 | Alnylam Europe Ag | Compositions and methods for inhibiting viral replication |
US7763590B2 (en) * | 2001-10-12 | 2010-07-27 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a mutant gene |
US7745418B2 (en) | 2001-10-12 | 2010-06-29 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting viral replication |
US20040091457A1 (en) * | 2001-10-12 | 2004-05-13 | Ribopharma Ag | Compositions and methods for inhibiting viral replication |
US20030157030A1 (en) * | 2001-11-02 | 2003-08-21 | Insert Therapeutics, Inc. | Methods and compositions for therapeutic use of rna interference |
US20040063654A1 (en) * | 2001-11-02 | 2004-04-01 | Davis Mark E. | Methods and compositions for therapeutic use of RNA interference |
US20090304798A1 (en) * | 2001-11-02 | 2009-12-10 | Insert Therapeutics, Inc. | Methods and compositions for therapeutic use of RNA interference |
US20050004064A1 (en) * | 2001-11-21 | 2005-01-06 | Mitsubishi Chemical Corporation | Method of inhibiting gene expression |
US20050148526A1 (en) * | 2002-01-23 | 2005-07-07 | Kisielow Malgorzata A. | Methods of obtaining isoform specific expression in mammalian cells |
US9592250B2 (en) | 2002-02-01 | 2017-03-14 | Life Technologies Corporation | Double-stranded oligonucleotides |
US9777275B2 (en) | 2002-02-01 | 2017-10-03 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
US10036025B2 (en) | 2002-02-01 | 2018-07-31 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
US10106793B2 (en) | 2002-02-01 | 2018-10-23 | Life Technologies Corporation | Double-stranded oligonucleotides |
US10626398B2 (en) | 2002-02-01 | 2020-04-21 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
US8815821B2 (en) | 2002-02-01 | 2014-08-26 | Life Technologies Corporation | Double-stranded oligonucleotides |
US10196640B1 (en) | 2002-02-01 | 2019-02-05 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
US20040054155A1 (en) * | 2002-02-01 | 2004-03-18 | Sequitur, Inc. | Oligonucleotide compositions with enhanced efficiency |
US9796978B1 (en) | 2002-02-01 | 2017-10-24 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
US20040014956A1 (en) * | 2002-02-01 | 2004-01-22 | Sequitur, Inc. | Double-stranded oligonucleotides |
US20060009409A1 (en) * | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
US20150099797A1 (en) * | 2002-02-01 | 2015-04-09 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
US8524680B2 (en) * | 2002-02-01 | 2013-09-03 | Applied Biosystems, Llc | High potency siRNAS for reducing the expression of target genes |
US20050096289A1 (en) * | 2002-02-07 | 2005-05-05 | Hans Prydz | Methods and compositions for modulating tissue factor |
US20090042826A1 (en) * | 2002-02-12 | 2009-02-12 | Quark Pharmaceuticals, Inc. | Use of the AXL receptor for diagnosis and treatment of renal disease |
US20070087991A1 (en) * | 2002-02-13 | 2007-04-19 | Axordia Limited | Pluripotential stem cells |
US20040096843A1 (en) * | 2002-02-14 | 2004-05-20 | Rossi John J. | Methods for producing interfering RNA molecules in mammalian cells and therapeutic uses for such molecules |
US8076071B2 (en) | 2002-02-14 | 2011-12-13 | City Of Hope | Methods for producing interfering RNA molecules in mammalian cells and therapeutic uses for such molecules |
US8106181B2 (en) | 2002-02-14 | 2012-01-31 | City Of Hope | Methods for producing interfering RNA molecules in mammalian cells and therapeutic uses for such molecules |
US9181584B2 (en) | 2002-02-14 | 2015-11-10 | City Of Hope | Methods for producing interfering RNA molecules in mammalian cells and therapeutic uses for such molecules |
US8927519B2 (en) | 2002-02-14 | 2015-01-06 | City Of Hope | Methods for producing interfering RNA molecules in mammalian cells and therapeutic uses for such molecules |
US20110003307A1 (en) * | 2002-02-14 | 2011-01-06 | City Of Hope | Methods for producing interfering rna molecules in mammalian cells and therapeutic uses for such molecules |
US7820632B2 (en) * | 2002-02-14 | 2010-10-26 | City Of Hope | Methods for producing interfering RNA molecules in mammalian cells and therapeutic uses for such molecules |
US9957517B2 (en) | 2002-02-20 | 2018-05-01 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US7956178B2 (en) * | 2002-02-20 | 2011-06-07 | Mcswiggen James | RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acid (siNA) |
US10889815B2 (en) | 2002-02-20 | 2021-01-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20090093439A1 (en) * | 2002-02-20 | 2009-04-09 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF CHROMOSOME TRANSLOCATION GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20090023675A1 (en) * | 2002-02-20 | 2009-01-22 | Sirna Therapeutics, Inc. | RNA Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (siNA) |
US20090306182A1 (en) * | 2002-02-20 | 2009-12-10 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF MAP KINASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20090093437A1 (en) * | 2002-02-20 | 2009-04-09 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF CHECKPOINT KINASE-1 (CHK-1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20090099116A1 (en) * | 2002-02-20 | 2009-04-16 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF FOS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US8013143B2 (en) * | 2002-02-20 | 2011-09-06 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA) |
US8648185B2 (en) | 2002-02-20 | 2014-02-11 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20060281175A1 (en) * | 2002-02-20 | 2006-12-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20100240730A1 (en) * | 2002-02-20 | 2010-09-23 | Merck Sharp And Dohme Corp. | RNA Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (siNA) |
US20100227911A1 (en) * | 2002-02-20 | 2010-09-09 | Mcswiggen James | RNA INTERFERENCE MEDIATED INHIBITION OF CHROMOSOME TRANSLOCATION GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20070167393A1 (en) * | 2002-02-20 | 2007-07-19 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) |
US20100228018A1 (en) * | 2002-02-20 | 2010-09-09 | Mcswiggen James | RNA INTERFERENCE MEDIATED INHIBITION OF PROLIFERATING CELL NUCLEAR ANTIGEN (PCNA) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US10662428B2 (en) | 2002-02-20 | 2020-05-26 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
US8846894B2 (en) | 2002-02-20 | 2014-09-30 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9771588B2 (en) | 2002-02-20 | 2017-09-26 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9738899B2 (en) | 2002-02-20 | 2017-08-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9732344B2 (en) | 2002-02-20 | 2017-08-15 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US8618277B2 (en) | 2002-02-20 | 2013-12-31 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20100184825A1 (en) * | 2002-02-20 | 2010-07-22 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Protein Tyrosine Phosphatase-1B (PTP-1B) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
US20090137508A1 (en) * | 2002-02-20 | 2009-05-28 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF POLYCOMB GROUP PROTEIN EZH2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20090137509A1 (en) * | 2002-02-20 | 2009-05-28 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF PROLIFERATION CELL NUCLEAR ANTIGEN (PCNA) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20100184824A1 (en) * | 2002-02-20 | 2010-07-22 | Sirna Therapeutics, Inc. | RNA Interference Mediated Inhibition of Interleukin and Interleukin Receptor Gene Expression Using Short Interfering Nucleic Acid (siNA) |
US20050142578A1 (en) * | 2002-02-20 | 2005-06-30 | Sirn Therapeutics, Inc. | RNA interference mediated target discovery and target validation using short interfering nucleic acid (siNA) |
US7897755B2 (en) * | 2002-02-20 | 2011-03-01 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA) |
US7897756B2 (en) * | 2002-02-20 | 2011-03-01 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of NOGO and NOGO receptor gene expression using short interfering nucleic acid (siNA) |
US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US7662952B2 (en) * | 2002-02-20 | 2010-02-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acid (siNA) |
US20120004403A1 (en) * | 2002-02-20 | 2012-01-05 | Leonid Beigelman | RNA INTERFERENCE MEDIATED INHIBITION OF TNF AND TNF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US7897757B2 (en) * | 2002-02-20 | 2011-03-01 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA) |
US20060293271A1 (en) * | 2002-02-20 | 2006-12-28 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20090093435A1 (en) * | 2002-02-20 | 2009-04-09 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF GRB2 ASSOCIATED BINDING PROTEIN (GAB2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US7667029B2 (en) * | 2002-02-20 | 2010-02-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of checkpoint kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA) |
US10000754B2 (en) | 2002-02-20 | 2018-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US7910725B2 (en) * | 2002-02-20 | 2011-03-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA) |
US20100144842A1 (en) * | 2002-02-20 | 2010-06-10 | Sirna Therapeutics, Inc. | RNA Interference Mediated Inhibition of NOGO and NOGO Receptor Gene Expression Using Short Interfering Nucleic Acid (siNA) |
US20100144851A1 (en) * | 2002-02-20 | 2010-06-10 | Sirna Therapeutics, Inc. | RNA Interference Mediated Inhibition of Platelet-Derived Endothelial Cell Growth Factor (ECGF1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
US20040219671A1 (en) * | 2002-02-20 | 2004-11-04 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of parkinson disease using short interfering nucleic acid (siNA) |
US7910724B2 (en) * | 2002-02-20 | 2011-03-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA) |
US20100130592A1 (en) * | 2002-02-20 | 2010-05-27 | Sirna Therapeutics, Inc. | RNA Interference Mediated Inhibition of GRB2 Associated Binding Protein (GAB2) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
US7923549B2 (en) * | 2002-02-20 | 2011-04-12 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA) |
US7989612B2 (en) | 2002-02-20 | 2011-08-02 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US7928218B2 (en) | 2002-02-20 | 2011-04-19 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA) |
US20090233983A1 (en) * | 2002-02-20 | 2009-09-17 | Sirna Therapeutics Inc. | RNA Interference Mediated Inhibition of Protein Tyrosine Phosphatase-1B (PTP-1B) Gene Expression Using Short Interfering RNA |
US20090247613A1 (en) * | 2002-02-20 | 2009-10-01 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF B-CELL CLL/LYMPHOMA-2 (BCL2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20100113564A1 (en) * | 2002-02-20 | 2010-05-06 | Mcswiggen James | RNA Interference Mediated Inhibition of Interleukin and Interleukin Receptor Gene Expression Using Short Interfering Nucleic Acid (siNA) |
US8232383B2 (en) | 2002-02-20 | 2012-07-31 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20090253772A1 (en) * | 2002-02-20 | 2009-10-08 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF CXCR4 GENE EXPRESSION USING SHORT INTERFERING NUCELEIC ACID (siNA) |
US20040192626A1 (en) * | 2002-02-20 | 2004-09-30 | Mcswiggen James | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US10351852B2 (en) | 2002-02-20 | 2019-07-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US7855284B2 (en) | 2002-02-20 | 2010-12-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of checkpoint kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA) |
US20100099743A1 (en) * | 2002-02-20 | 2010-04-22 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF CHECKPOINT KINASE-1 (CHK-1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20040005593A1 (en) * | 2002-03-06 | 2004-01-08 | Rigel Pharmaceuticals, Inc. | Novel method for delivery and intracellular synthesis of siRNA molecules |
US20040248296A1 (en) * | 2002-03-20 | 2004-12-09 | Beresford Paul J. | HIV therapeutic |
US20060003915A1 (en) * | 2002-04-18 | 2006-01-05 | Karina Drumm | Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification |
US8946180B2 (en) | 2002-04-18 | 2015-02-03 | Opko Pharmaceuticals, Llc | Means and methods for the specific modulation of target genes in the CNS and the eye and methods for their identification |
US20110021605A1 (en) * | 2002-04-18 | 2011-01-27 | Schulte Ralf Wilhelm | Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye |
US8202845B2 (en) | 2002-04-18 | 2012-06-19 | Acuity Pharmaceuticals, Inc. | Means and methods for the specific modulation of target genes in the CNS and the eye and methods for their identification |
US9850485B2 (en) | 2002-05-03 | 2017-12-26 | Duke University | Method of regulating gene expression |
US10233451B2 (en) | 2002-05-03 | 2019-03-19 | Duke University | Method of regulating gene expression |
US20040053411A1 (en) * | 2002-05-03 | 2004-03-18 | Duke University | Method of regulating gene expression |
US9267145B2 (en) | 2002-05-03 | 2016-02-23 | Duke University | Method of regulating gene expression |
US8409796B2 (en) | 2002-05-03 | 2013-04-02 | Duke University | Method of regulating gene expression |
US9856476B2 (en) | 2002-05-03 | 2018-01-02 | Duke University | Method of regulating gene expression |
US8137910B2 (en) | 2002-05-03 | 2012-03-20 | Duke University | Method of regulating gene expression |
US8865884B2 (en) * | 2002-05-23 | 2014-10-21 | Isis Pharmaceuticals, Inc. | Antisense modulation of kinesin-like 1 expression |
US20130331435A1 (en) * | 2002-05-23 | 2013-12-12 | Isis Pharmaceuticals, Inc. | Antisense modulation of kinesin-like 1 expression |
US20060058252A1 (en) * | 2002-06-26 | 2006-03-16 | Clawson Gary A | Methods and materials for treating human papillomavirus infections |
US7704965B2 (en) * | 2002-06-26 | 2010-04-27 | The Penn State Research Foundation | Methods and materials for treating human papillomavirus infections |
US9492386B2 (en) | 2002-06-28 | 2016-11-15 | Protiva Biotherapeutics, Inc. | Liposomal apparatus and manufacturing methods |
US11298320B2 (en) | 2002-06-28 | 2022-04-12 | Arbutus Biopharma Corporation | Liposomal apparatus and manufacturing methods |
US11318098B2 (en) | 2002-06-28 | 2022-05-03 | Arbutus Biopharma Corporation | Liposomal apparatus and manufacturing methods |
US9504651B2 (en) | 2002-06-28 | 2016-11-29 | Protiva Biotherapeutics, Inc. | Lipid compositions for nucleic acid delivery |
US9150863B2 (en) | 2002-07-24 | 2015-10-06 | The Trustees Of The University Of Pennsylvania | Compositions and methods for siRNA inhibition of angiogenesis |
US20070037762A1 (en) * | 2002-07-24 | 2007-02-15 | Tolentino Michael J | COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOGENESIS |
US8946403B2 (en) | 2002-07-24 | 2015-02-03 | The Trustees Of The University Of Pennsylvania | Compositions and methods for siRNA inhibition of angiogenesis |
US8541384B2 (en) | 2002-07-24 | 2013-09-24 | The Trustees Of The University Of Pennsylvania | Compositions and methods for siRNA inhibition of angiogenesis |
US8546345B2 (en) | 2002-07-24 | 2013-10-01 | The Trustees Of The University Of Pennsylvania | Compositions and methods for siRNA inhibition of angiogenesis |
US20080269155A1 (en) * | 2002-08-06 | 2008-10-30 | Toray Industries Inc. | Remedy or preventive for kidney disease and method of diagnosing kidney disease |
US20060293256A1 (en) * | 2002-08-06 | 2006-12-28 | Masateru Yamada | Remedy or preventive for kidney disease and method of diagnosing kidney disease |
US20060211637A1 (en) * | 2002-08-06 | 2006-09-21 | Intradigm Corporation | Methods of down regulating target gene expression in vivo by introduction of interfering rna |
US8729036B2 (en) | 2002-08-07 | 2014-05-20 | University Of Massachusetts | Compositions for RNA interference and methods of use thereof |
US9611472B2 (en) | 2002-08-07 | 2017-04-04 | University Of Massachusetts | Compositions for RNA interference and methods of use thereof |
US20040203145A1 (en) * | 2002-08-07 | 2004-10-14 | University Of Massachusetts | Compositions for RNA interference and methods of use thereof |
US8252918B2 (en) * | 2002-08-21 | 2012-08-28 | The University Of British Columbia | RNAi probes targeting cancer-related proteins |
US20080274996A1 (en) * | 2002-08-21 | 2008-11-06 | The University Of British Columbia | RNAi Probes Targeting Cancer-Related Proteins |
US7820635B2 (en) | 2002-08-21 | 2010-10-26 | The University Of British Columbia | RNAi probes targeting cancer-related proteins |
US20060178329A1 (en) * | 2002-08-21 | 2006-08-10 | The University Of British Columbia | RNAi probes targeting cancer-related proteins |
US20040096882A1 (en) * | 2002-08-21 | 2004-05-20 | Martin Gleave | RNAi probes targeting cancer-related proteins |
US9487777B2 (en) | 2002-08-21 | 2016-11-08 | The University Of British Columbia | RNAi probes targeting cancer-related proteins |
US7964717B2 (en) * | 2002-08-21 | 2011-06-21 | The University Of British Columbia | RNAi probes targeting cancer-related proteins |
US20110009472A1 (en) * | 2002-08-21 | 2011-01-13 | The University Of British Columbia | RNAi Probes Targeting Cancer-Related Proteins |
US8759308B2 (en) | 2002-08-21 | 2014-06-24 | The University Of British Columbia | RNAi probes targeting cancer-related proteins |
US7923547B2 (en) * | 2002-09-05 | 2011-04-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US7956176B2 (en) | 2002-09-05 | 2011-06-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20070004664A1 (en) * | 2002-09-05 | 2007-01-04 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20060276635A1 (en) * | 2002-09-05 | 2006-12-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20060287269A1 (en) * | 2002-09-09 | 2006-12-21 | The Regents Of The University Of California | Short interfering nucleic acid hybrids and methods thereof |
US7655634B2 (en) * | 2002-09-18 | 2010-02-02 | The Burnham Institute | Use of hepatitis B X-interacting protein (HBXIP) in modulation of apoptosis |
US20070270369A1 (en) * | 2002-09-18 | 2007-11-22 | The Burnham Institute | Use of hepatitis b x-interacting protein (hbxip) in modulation of apoptosis |
US20100190195A1 (en) * | 2002-09-18 | 2010-07-29 | The Burnham Institute | Use of Hepatitis B X-Interacting Protein (HBXIP) in Modulation of Apoptosis |
US20060257380A1 (en) * | 2002-09-19 | 2006-11-16 | Inst.Nat. De La Sante Et De La Recherche MED | Use of sirnas for gene silencing in antigen presenting cells |
US20090124567A1 (en) * | 2002-09-28 | 2009-05-14 | Jianzhu Chen | Influenza Therapeutic |
US20090106852A1 (en) * | 2002-09-28 | 2009-04-23 | Massachusetts Institute Of Technology | Influenza Therapeutic |
US20040242518A1 (en) * | 2002-09-28 | 2004-12-02 | Massachusetts Institute Of Technology | Influenza therapeutic |
US20060240425A1 (en) * | 2002-09-30 | 2006-10-26 | Oncotherapy Science, Inc | Genes and polypeptides relating to myeloid leukemia |
US7422853B1 (en) * | 2002-10-04 | 2008-09-09 | Myriad Genetics, Inc. | RNA interference using a universal target |
US20090048111A1 (en) * | 2002-10-04 | 2009-02-19 | Myriad Genetics, Incorporated | Rna interference using a universal target |
US7521431B2 (en) * | 2002-11-01 | 2009-04-21 | The Trustees Of The University Of Pennsylvania | Compositions and methods for siRNA inhibition of HIF-1 alpha |
US20040180357A1 (en) * | 2002-11-01 | 2004-09-16 | The Trustees Of The University Of Pennsylvania | Compositions and methods for siRNA inhibition of HIF-1 alpha |
US7645744B2 (en) | 2002-11-01 | 2010-01-12 | The Trustees Of The University Of Pennsylvania | Compositions and methods for siRNA inhibition of HIF-1 alpha |
US20100136101A1 (en) * | 2002-11-01 | 2010-06-03 | The Trustees Of The University Of Pennsylvania | Compositions and methods for sirna inhibition of hif-1 alpha |
US8236775B2 (en) | 2002-11-01 | 2012-08-07 | The Trustees Of The University Of Pennsylvania | Compositions and methods for siRNA inhibition of HIF-1 α |
US7892793B2 (en) | 2002-11-04 | 2011-02-22 | University Of Massachusetts | Allele-specific RNA interference |
US20060128650A1 (en) * | 2002-11-04 | 2006-06-15 | University Of Massachusetts | Allele-specific RNA interference |
US8604183B2 (en) | 2002-11-05 | 2013-12-10 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
US20080076908A1 (en) * | 2002-11-14 | 2008-03-27 | Dharmacon, Inc. | siRNA targeting nuclear receptors |
US10765695B2 (en) | 2002-11-14 | 2020-09-08 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
US8232386B2 (en) | 2002-11-14 | 2012-07-31 | Dharmacon, Inc. | SiRNA targeting apolipoprotein B (APOB) |
US8222396B2 (en) | 2002-11-14 | 2012-07-17 | Dharmacon, Inc. | SiRNA targeting proto-oncogene MET |
US9771586B2 (en) | 2002-11-14 | 2017-09-26 | Thermo Fisher Scientific Inc. | RNAi targeting ZNF205 |
US20090082556A1 (en) * | 2002-11-14 | 2009-03-26 | Dharmacon, Inc. | siRNA targeting TATA box binding protein (TBP)-associated factor (TAF1) |
US7511132B2 (en) * | 2002-11-14 | 2009-03-31 | Dharmacon, Inc. | Functional and hyperfunctional siRNA directed against Bcl-2 |
US20090088563A1 (en) * | 2002-11-14 | 2009-04-02 | Dharmacon, Inc. | siRNA targeting Transducin (beta)-like 3 (TBL3) |
US7514550B2 (en) * | 2002-11-14 | 2009-04-07 | Dharmacon, Inc. | siRNA targeting myeloid cell leukemia sequence 1 |
US9777270B2 (en) | 2002-11-14 | 2017-10-03 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
US9839649B2 (en) | 2002-11-14 | 2017-12-12 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
US8217162B2 (en) | 2002-11-14 | 2012-07-10 | Dharmacon, Inc. | siRNA targeting interleukin-1 receptor-associated kinase 4(IRAK4) |
US20090005548A1 (en) * | 2002-11-14 | 2009-01-01 | Dharmacon, Inc. | siRNA targeting nuclear receptor interacting protein 1 (NRIP1) |
US8198427B1 (en) | 2002-11-14 | 2012-06-12 | Dharmacon, Inc. | SiRNA targeting catenin, beta-1 (CTNNB1) |
US8232385B2 (en) | 2002-11-14 | 2012-07-31 | Dharmacon, Inc. | siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B) |
US8236942B2 (en) | 2002-11-14 | 2012-08-07 | Dharmacon, Inc. | SiRNA targeting glucagon receptor (GCGR) |
US8247169B2 (en) | 2002-11-14 | 2012-08-21 | Dharmacon, Inc. | SiRNA targeting diacylglycerol O-acyltransferase homolog 2 (DGAT2) |
US8138329B2 (en) | 2002-11-14 | 2012-03-20 | Dharmacon, Inc. | siRNA targeting connective tissue growth factor (CTGF) |
US20120010106A1 (en) * | 2002-11-14 | 2012-01-12 | Dharmacon, Inc. | siRNA targeting myeloid differentiation primary response gene (88) (MYD88) |
US8093370B2 (en) | 2002-11-14 | 2012-01-10 | Dharmacon, Inc. | siRNA targeting spleen tyrosine kinase |
US8090542B2 (en) | 2002-11-14 | 2012-01-03 | Dharmacon Inc. | Functional and hyperfunctional siRNA |
US20050245475A1 (en) * | 2002-11-14 | 2005-11-03 | Dharmacon, Inc. | Functional and hyperfunctional siRNA directed against Bcl-2 |
US20080319180A1 (en) * | 2002-11-14 | 2008-12-25 | Dharmacon, Inc. | siRNA targeting protein kinase N-3 (PKN-3) |
US20050246794A1 (en) * | 2002-11-14 | 2005-11-03 | Dharmacon Inc. | Functional and hyperfunctional siRNA |
US8293887B2 (en) | 2002-11-14 | 2012-10-23 | Dharmacon, Inc. | SiRNA targeting beta secretase (BACE) |
US8071754B2 (en) | 2002-11-14 | 2011-12-06 | Dharmacon, Inc. | siRNA targeting apolipoprotein B (APOB) |
US20090118489A1 (en) * | 2002-11-14 | 2009-05-07 | Dharmacon, Inc. | siRNA targeting nucleoporin 62kDa (Nup62) |
US20080306015A1 (en) * | 2002-11-14 | 2008-12-11 | Dharmacon, Inc. | siRNA targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) |
US9879266B2 (en) | 2002-11-14 | 2018-01-30 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
US8067576B2 (en) | 2002-11-14 | 2011-11-29 | Dharmacon, Inc. | siRNA targeting serine/threonine kinase 12 (STK12 or aurora B kinase) |
US9719094B2 (en) | 2002-11-14 | 2017-08-01 | Thermo Fisher Scientific Inc. | RNAi targeting SEC61G |
US20080293595A1 (en) * | 2002-11-14 | 2008-11-27 | Dharmacon, Inc. | siRNA targeting protein tyrosine phosphatase-1B (PTP1B) |
US20080293593A1 (en) * | 2002-11-14 | 2008-11-27 | Dharmacon, Inc. | siRNA targeting casitas B cell lymphoma-B (CBL-B) |
US8304528B2 (en) | 2002-11-14 | 2012-11-06 | Dharmacon, Inc. | SiRNA targeting fructose-1, 6-bisphosphatase 1 (FBP1) |
US9719092B2 (en) | 2002-11-14 | 2017-08-01 | Thermo Fisher Scientific Inc. | RNAi targeting CNTD2 |
US8039610B2 (en) | 2002-11-14 | 2011-10-18 | Dharmacon, Inc. | siRNA targeting superoxide dismutase 1 (SOD1) |
US8314229B2 (en) | 2002-11-14 | 2012-11-20 | Dharmacon, Inc. | siRNA targeting tie-2 |
US8030474B2 (en) | 2002-11-14 | 2011-10-04 | Dharmacon, Inc. | siRNA targeting cyclin-dependent kinase 4 (CDK4) |
US20080268457A1 (en) * | 2002-11-14 | 2008-10-30 | Dharmacon, Inc. | siRNA targeting forkhead box P3 (FOXP3) |
US20090149644A1 (en) * | 2002-11-14 | 2009-06-11 | Dharmacon Inc. | siRNA Targeting KRAS |
US8030476B2 (en) | 2002-11-14 | 2011-10-04 | Dharmacon, Inc. | siRNA targeting gremlin |
US20090156797A1 (en) * | 2002-11-14 | 2009-06-18 | Dharmacon, Inc. | siRNA Targeting Hypoxia-inducible Factor 1 |
US7550572B2 (en) * | 2002-11-14 | 2009-06-23 | Dharmacon, Inc. | siRNA targeting cell division cycle 20 homolog (CDC20) |
US8022199B2 (en) | 2002-11-14 | 2011-09-20 | Dharmacon, Inc. | SiRNA targeting myeloid differentiation primary response gene (88) (MYD88) |
US20090163702A1 (en) * | 2002-11-14 | 2009-06-25 | Dharmacon Inc. | siRNA targeting Myeloid cell leukemia sequence 1 |
US20090163701A1 (en) * | 2002-11-14 | 2009-06-25 | Dharmacon Inc. | siRNA targeting tumor necrosis factor receptor superfamily member 1A |
US8022198B2 (en) | 2002-11-14 | 2011-09-20 | Dharmacon, Inc. | siRNA targeting histamine receptor H1 |
US20050255487A1 (en) * | 2002-11-14 | 2005-11-17 | Dharmacon, Inc. | Methods and compositions for selecting siRNA of improved functionality |
US8013145B2 (en) | 2002-11-14 | 2011-09-06 | Dharmacon, Inc. | SiRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B) |
US20090191625A1 (en) * | 2002-11-14 | 2009-07-30 | Dharmacon, Inc. | siRNA targeting connective tissue growth factor (CTGF) |
US8008474B2 (en) | 2002-11-14 | 2011-08-30 | Dharmacon, Inc. | siRNA targeting KRAS |
US10011836B2 (en) | 2002-11-14 | 2018-07-03 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
US7999097B2 (en) | 2002-11-14 | 2011-08-16 | Dharmacon, Inc. | siRNA targeting beta secretase (BACE) |
US8000902B2 (en) | 2002-11-14 | 2011-08-16 | Dharmacon, Inc. | Methods and compositions for selecting siRNA of improved functionality |
US7985854B2 (en) | 2002-11-14 | 2011-07-26 | Dharmacon, Inc. | siRNA targeting TATA box binding protein (TBP)-associated factor (TAF1) |
US7576197B2 (en) | 2002-11-14 | 2009-08-18 | Dharmacon, Inc. | SiRNA targeting KRAS |
US7576196B2 (en) | 2002-11-14 | 2009-08-18 | Dharmacon, Inc. | siRNA targeting transducin (beta)-like 3 (TBL3) |
US7977471B2 (en) | 2002-11-14 | 2011-07-12 | Dharmacon, Inc. | siRNA targeting TNFα |
US7582746B2 (en) | 2002-11-14 | 2009-09-01 | Dharmacon, Inc. | siRNA targeting complement component 3 (C3) |
US20090227780A1 (en) * | 2002-11-14 | 2009-09-10 | Dharmacon, Inc. | siRNA targeting connexin 43 |
US8426579B2 (en) * | 2002-11-14 | 2013-04-23 | Dharmacon, Inc. | SiRNA targeting myeloid differentiation primary response gene (88) (MYD88) |
US7589191B2 (en) | 2002-11-14 | 2009-09-15 | Dharmacon, Inc. | siRNA targeting hypoxia-inducible factor 1 |
US20080227967A1 (en) * | 2002-11-14 | 2008-09-18 | Dharmacon, Inc. | siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2) |
US8461326B2 (en) | 2002-11-14 | 2013-06-11 | Dharmacon, Inc. | SiRNA targeting connective tissue growth factor (CTGF) |
US7592442B2 (en) | 2002-11-14 | 2009-09-22 | Dharmacon, Inc. | siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2) |
US7592444B2 (en) | 2002-11-14 | 2009-09-22 | Dharmacon, Inc. | siRNA targeting myeloid cell leukemia sequence 1 |
US20130210676A1 (en) * | 2002-11-14 | 2013-08-15 | Dharmacon, Inc. | siRNA Targeting Myeloid Differentiation Primary Response Gene (88) (MYD88) |
US7951935B2 (en) | 2002-11-14 | 2011-05-31 | Dharmacon, Inc. | siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC) |
US7592443B2 (en) | 2002-11-14 | 2009-09-22 | Dharmacon, Inc. | siRNA targeting interleukin-1 receptor-associated kinase 4 (IRAK4) |
US20110105363A1 (en) * | 2002-11-14 | 2011-05-05 | Dharmacon, Inc. | siRNA targeting TNFa |
US20080177051A1 (en) * | 2002-11-14 | 2008-07-24 | Dharmacon, Inc. | siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B) |
US7935813B2 (en) | 2002-11-14 | 2011-05-03 | Dharmacon, Inc. | siRNA target hypoxia-inducible factor 1 |
US7595389B2 (en) | 2002-11-14 | 2009-09-29 | Dharmacon, Inc. | siRNA targeting casitas B cell lymphoma-B (CBL-B) |
US7897754B2 (en) | 2002-11-14 | 2011-03-01 | Dharmacon, Inc. | SiRNA targeting ras-related nuclear protein RAN |
US7893247B2 (en) | 2002-11-14 | 2011-02-22 | Dharmacon, Inc. | siRNA targeting spleen tyrosine kinase |
US8633306B2 (en) | 2002-11-14 | 2014-01-21 | Thermo Fisher Scientific Biosciences Inc. | SiRNA targeting histamine receptor H1 |
US20070031844A1 (en) * | 2002-11-14 | 2007-02-08 | Anastasia Khvorova | Functional and hyperfunctional siRNA |
US20100323922A1 (en) * | 2002-11-14 | 2010-12-23 | Dharmacon, Inc. | siRNA targeting TATA box binding protein (TBP)-associated factor (TAF1) |
US7598369B2 (en) | 2002-11-14 | 2009-10-06 | Dharmacon, Inc. | siRNA targeting histamine receptor H1 |
US7598370B2 (en) | 2002-11-14 | 2009-10-06 | Dharmacon, Inc. | siRNA targeting polo-like kinase-1 (PLK-1) |
US20090253776A1 (en) * | 2002-11-14 | 2009-10-08 | Dharmacon, Inc. | siRNA targeting gremlin |
US7855186B2 (en) | 2002-11-14 | 2010-12-21 | Dharmacon, Inc. | siRNA targeting TIE-2 |
US20070072823A1 (en) * | 2002-11-14 | 2007-03-29 | Dharmacon Inc. | siRNA targeting survivin |
US20070088154A1 (en) * | 2002-11-14 | 2007-04-19 | Dharmacon Inc. | siRNA targeting complement factor B |
US11198870B2 (en) | 2002-11-14 | 2021-12-14 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
US7605252B2 (en) * | 2002-11-14 | 2009-10-20 | Dharmacon, Inc. | siRNA targeting kinase insert domain receptor (KDR) |
US20070128640A1 (en) * | 2002-11-14 | 2007-06-07 | Dharmacon, Inc. | siRNA targeting ras-related nuclear protein |
US20070134698A1 (en) * | 2002-11-14 | 2007-06-14 | Dharmacon, Inc. | siRNA targeting histamine receptor H1 |
US7608706B2 (en) * | 2002-11-14 | 2009-10-27 | Dharmacon, Inc. | siRNA targeting ras-related nuclear protein |
US7608707B2 (en) * | 2002-11-14 | 2009-10-27 | Dharmacon, Inc. | siRNA targeting survivin |
US7612196B2 (en) | 2002-11-14 | 2009-11-03 | Dharmacon, Inc. | siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B) |
US10233449B2 (en) | 2002-11-14 | 2019-03-19 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
US9228186B2 (en) | 2002-11-14 | 2016-01-05 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
US7833989B2 (en) | 2002-11-14 | 2010-11-16 | Dharmacon, Inc. | siRNA targeting connective tissue growth factor (CTGF) |
US7615541B2 (en) | 2002-11-14 | 2009-11-10 | Dharmacon, Inc. | siRNA targeting TIE-2 |
US7619081B2 (en) * | 2002-11-14 | 2009-11-17 | Dharmacon, Inc. | siRNA targeting coatomer protein complex, subunit beta 2 (COPB2) |
US7834170B2 (en) | 2002-11-14 | 2010-11-16 | Dharmacon, Inc. | Functional and hyperfunctional siRNA |
US20070134697A1 (en) * | 2002-11-14 | 2007-06-14 | Dharmacon, Inc. | siRNA targeting TIE-2 |
US20080132691A1 (en) * | 2002-11-14 | 2008-06-05 | Dharmacon, Inc. | siRNA targeting kinase insert domain receptor (KDR) |
US7829696B2 (en) | 2002-11-14 | 2010-11-09 | Dharmacon, Inc. | siRNA targeting amyloid beta (A4) precursor protein (APP) |
US20070141602A1 (en) * | 2002-11-14 | 2007-06-21 | Dharmacon, Inc. | siRNA targeting aquaporin 4 |
US20080114162A1 (en) * | 2002-11-14 | 2008-05-15 | Dharmacon Inc. | Functional and hyperfunctional siRNA directed against Bcl-2 |
US20090306356A1 (en) * | 2002-11-14 | 2009-12-10 | Dharmacon,Inc. | siRNA Targeting TNFalpha |
US20080113378A1 (en) * | 2002-11-14 | 2008-05-15 | Dharmacon, Inc. | siRNA targeting interleukin-1 receptor-associated kinase 4 (IRAK4) |
US7632938B2 (en) | 2002-11-14 | 2009-12-15 | Dharmacon, Inc. | siRNA targeting superoxide dismutase 1 (SOD1) |
US7632939B2 (en) | 2002-11-14 | 2009-12-15 | Dharmacon, Inc. | siRNA targeting proto-oncogene MET |
US7820809B2 (en) | 2002-11-14 | 2010-10-26 | Dharmacon, Inc. | Functional and hyperfunctional siRNA directed against Bcl-2 |
US7635771B2 (en) | 2002-11-14 | 2009-12-22 | Dharmacon, Inc. | siRNA targeting amyloid beta (A4) precursor protein (APP) |
US7635770B2 (en) | 2002-11-14 | 2009-12-22 | Dharmacon, Inc. | siRNA targeting protein kinase N-3 (PKN-3) |
US7816512B2 (en) | 2002-11-14 | 2010-10-19 | Dharmacon, Inc. | siRNA targeting proto-oncogene MET |
US7807819B2 (en) | 2002-11-14 | 2010-10-05 | Dharmacon, Inc. | siRNA targeting survivin |
US20090325818A1 (en) * | 2002-11-14 | 2009-12-31 | Dharmacon, Inc. | siRNA targeting interleukin-1 receptor-associated kinase 4 (IRAK4) |
US7642349B2 (en) | 2002-11-14 | 2010-01-05 | Dharmacon, Inc. | siRNA targeting TATA box binding protein (TBP)-associated factor (TAF1) |
US20100248990A1 (en) * | 2002-11-14 | 2010-09-30 | Dharmacon, Inc. | siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2) |
US7803933B2 (en) | 2002-11-14 | 2010-09-28 | Dharmacon, Inc. | siRNA targeting TATA box binding protein (TBP)-associated factor (TAF1) |
US7795421B2 (en) | 2002-11-14 | 2010-09-14 | Dharmacon, Inc. | siRNA targeting apolipoprotein B (APOB) |
US20080113370A1 (en) * | 2002-11-14 | 2008-05-15 | Dharmacon, Inc. | siRNA targeting apolipoprotein B (APOB) |
US20080113375A1 (en) * | 2002-11-14 | 2008-05-15 | Dharmacon, Inc. | siRNA targeting superoxide dismutase 1 (SOD1) |
US20080113371A1 (en) * | 2002-11-14 | 2008-05-15 | Dharmacon, Inc. | siRNA targeting beta secretase (BACE) |
US7795420B2 (en) | 2002-11-14 | 2010-09-14 | Dharmacon, Inc. | Functional and hyperfunctional siRNA directed against Bcl-2 |
US20100016176A1 (en) * | 2002-11-14 | 2010-01-21 | Dharmacon. Inc. | siRNA targeting histamine receptor H1 |
US10696968B2 (en) | 2002-11-14 | 2020-06-30 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
US20100022413A1 (en) * | 2002-11-14 | 2010-01-28 | Dharmacon, Inc. | siRNA targeting Ras-related nuclear protein RAN |
US20100022763A1 (en) * | 2002-11-14 | 2010-01-28 | Dharmacon, Inc. | siRNA targeting kinase insert domain receptor (KDR) |
US20070185320A1 (en) * | 2002-11-14 | 2007-08-09 | Dharmacon, Inc. | siRNA targeting cell division cycle 20 homolog (CDC20) |
US20080113377A1 (en) * | 2002-11-14 | 2008-05-15 | Dharmacon, Inc. | siRNA Targeting proto-oncogene MET |
US7655789B2 (en) | 2002-11-14 | 2010-02-02 | Dharmacon, Inc. | siRNA targeting transient receptor potential cation channel, subfamily V, member 1 (TRPV1) |
US7781575B2 (en) | 2002-11-14 | 2010-08-24 | Dharmacon, Inc. | siRNA targeting tumor protein 53 (p53) |
US20080113373A1 (en) * | 2002-11-14 | 2008-05-15 | Dharmacon, Inc. | siRNA targeting amyloid beta (A4) precursor protein (APP) |
US20080113374A1 (en) * | 2002-11-14 | 2008-05-15 | Dharmacon, Inc. | siRNA targeting fructose-1,6-bisphosphatase 1 (FBP1) |
US7662950B2 (en) * | 2002-11-14 | 2010-02-16 | Dharmacon, Inc. | siRNA targeting myeloid differentiation primary response gene (88) (MYD88) |
US7666853B2 (en) | 2002-11-14 | 2010-02-23 | Dharmacon, Inc. | siRNA targeting connective tissue growth factor (CTGF) |
US20080113376A1 (en) * | 2002-11-14 | 2008-05-15 | Dharmacon, Inc. | siRNA targeting myeloid differentiation primary response gene (88) (MYD88) |
US8883998B2 (en) * | 2002-11-14 | 2014-11-11 | Thermo Fisher Scientific Inc. | siRNA targeting myeloid differentiation primary response gene (88) (MYD88) |
US20100062951A1 (en) * | 2002-11-14 | 2010-03-11 | Dharmacon, Inc. | siRNA targeting TIE-2 |
US7678896B2 (en) | 2002-11-14 | 2010-03-16 | Dharmacon, Inc. | siRNA targeting serine/threonine kinase 12 (STK12 or aurora B kinase) |
US20080113369A1 (en) * | 2002-11-14 | 2008-05-15 | Dharmacon, Inc. | siRNA targeting diacylglycerol O-acyltransferase homolog 2 (DGAT2) |
US20100075869A1 (en) * | 2002-11-14 | 2010-03-25 | Dharmacon, Inc. | siRNA targeting TATA box binding protein (TBP)-associated factor (TAF1) |
US20080113372A1 (en) * | 2002-11-14 | 2008-05-15 | Dharmacon, Inc. | siRNA targeting glucagon receptor (GCGR) |
US20100190971A1 (en) * | 2002-11-14 | 2010-07-29 | Dharmacon, Inc. | siRNA Targeting Diacylglycerol O-Acyltransferase Homolog 2 (DGAT2) |
US7691998B2 (en) | 2002-11-14 | 2010-04-06 | Dharmacon, Inc. | siRNA targeting nucleoporin 62kDa (Nup62) |
US7691997B2 (en) | 2002-11-14 | 2010-04-06 | Dharmacon, Inc. | Functional and hyperfunctional siRNA |
US20080108802A1 (en) * | 2002-11-14 | 2008-05-08 | Dharmacon Inc. | Functional and hyperfunctional siRNA directed against Bcl-2 |
US20080108803A1 (en) * | 2002-11-14 | 2008-05-08 | Dharmacon Inc. | Functional and hyperfunctional siRNA directed against Bcl-2 |
US7696344B2 (en) | 2002-11-14 | 2010-04-13 | Dharmacon, Inc. | siRNA targeting complement factor B |
US20070207974A1 (en) * | 2002-11-14 | 2007-09-06 | Dharmacon Inc. | Functional and hyperfunctional siRNA |
US20070219362A1 (en) * | 2002-11-14 | 2007-09-20 | Dharmacon, Inc. | siRNA targeting azurocidin 1 (Cartionic Antimicrobial protein 37) |
US20100099578A1 (en) * | 2002-11-14 | 2010-04-22 | Dharmacon, Inc. | siRNA Targeting Fructose-1, 6-bisphosphatase 1 (FBP1) |
US20080097090A1 (en) * | 2002-11-14 | 2008-04-24 | Dharmacon Inc. | Functional and hyperfunctional siRNA directed against Bcl-2 |
US20070244311A1 (en) * | 2002-11-14 | 2007-10-18 | Dharmacon, Inc. | siRNA targeting coatomer protein complex, subunit beta 2 (CPOB2) |
US20080091001A1 (en) * | 2002-11-14 | 2008-04-17 | Dharmacon Inc. | Functional and hyperfunctional siRNA directed against Bcl-2 |
US20080091003A1 (en) * | 2002-11-14 | 2008-04-17 | Dharmacon Inc. | Functional and hyperfunctional siRNA directed against Bcl-2 |
US20080090997A1 (en) * | 2002-11-14 | 2008-04-17 | Dharmacon, Inc. | siRNA targeting complement component 3 (C3) |
US20070265438A1 (en) * | 2002-11-14 | 2007-11-15 | Dharmacon, Inc. | siRNA targeting polo-like kinase-1 (PLK-1) |
US20070276135A1 (en) * | 2002-11-14 | 2007-11-29 | Dharmacon, Inc. | siRNA targeting dual specificity phosphate 5 (DUSP5) |
US7709629B2 (en) | 2002-11-14 | 2010-05-04 | Dharmacon, Inc. | siRNA targeting diacylglycerol O-acyltransferase homolog 2 (DGAT2) |
US7745611B2 (en) | 2002-11-14 | 2010-06-29 | Dharmacon, Inc. | siRNA targeting KRAS |
US20100113760A1 (en) * | 2002-11-14 | 2010-05-06 | Dharmacon, Inc. | siRNA targeting myeloid differentiation primary response gene (88) (MYD88) |
US20080085998A1 (en) * | 2002-11-14 | 2008-04-10 | Dharmacon, Inc. | siRNA targeting transient receptor potential cation channel, subfamily V, member 1 (TRPV1) |
US7745612B2 (en) | 2002-11-14 | 2010-06-29 | Dharmacon, Inc. | siRNA targeting interleukin-1 receptor-associated kinase 4 (IRAK4) |
US20100113307A1 (en) * | 2002-11-14 | 2010-05-06 | Dharmacon, Inc. | siRNA targeting vascular endothelial growth factor (VEGF) |
US20100113306A1 (en) * | 2002-11-14 | 2010-05-06 | Dharmacon, Inc. | siRNA Targeting connective tissue growth factor (CTGF) |
US8222395B2 (en) | 2002-11-14 | 2012-07-17 | Dharmacon, Inc. | siRNA targeting kinase insert domain receptor (KDR) |
US20080071073A1 (en) * | 2002-11-14 | 2008-03-20 | Dharmacon, Inc. | siRNA targeting ubiquitin ligases |
US7745610B2 (en) | 2002-11-14 | 2010-06-29 | Dharmacon, Inc. | siRNA targeting cyclin dependent kinase 11 (CDK11) |
US7741470B2 (en) | 2002-11-14 | 2010-06-22 | Dharmacon, Inc. | siRNA targeting gremlin |
US20070276136A1 (en) * | 2002-11-14 | 2007-11-29 | Dharmacon, Inc. | siRNA targeting serine/threonine kinase 12 (STK12 or aurora B kinase) |
US20080064865A1 (en) * | 2002-11-14 | 2008-03-13 | Dharmacon, Inc. | siRNA targeting cyclin dependent kinase 11 (CDK11) |
US7737267B2 (en) | 2002-11-14 | 2010-06-15 | Dharmacon, Inc. | siRNA targeting hypoxia-inducible factor 1 |
US20100144552A1 (en) * | 2002-11-14 | 2010-06-10 | Dharmacon, Inc. | siRNA targeting serine/threonine kinase 12 (STK12 or aurora B kinase) |
US20040191905A1 (en) * | 2002-11-22 | 2004-09-30 | University Of Massachusetts | Modulation of HIV replication by RNA interference |
US7618948B2 (en) * | 2002-11-26 | 2009-11-17 | Medtronic, Inc. | Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA |
US20060178328A1 (en) * | 2002-11-26 | 2006-08-10 | Medtronic Inc. | Devices, systems and methods for improving memory and/or cognitive function through brain delivery of siRNA |
US8058251B2 (en) | 2002-11-26 | 2011-11-15 | Kaemmerer William F | Devices, systems and methods for improving memory and/or cognitive function through brain delivery of siRNA |
US8119611B2 (en) | 2002-11-26 | 2012-02-21 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of SIRNA |
US7605249B2 (en) | 2002-11-26 | 2009-10-20 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
US8618069B2 (en) | 2002-11-26 | 2013-12-31 | Medtronic, Inc. | Devices, systems and methods for improving memory and/or cognitive function through brain delivery of siRNA |
US8415319B2 (en) | 2002-11-26 | 2013-04-09 | Medtronic, Inc. | Devices, systems and methods for improving memory and/or cognitive function through brain delivery of siRNA |
US7829694B2 (en) | 2002-11-26 | 2010-11-09 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
US20070141009A1 (en) * | 2003-01-03 | 2007-06-21 | Shaharyar Khan | Sirna mediated post-transriptional gene silencing of genes involved in alopecia |
US20060178297A1 (en) * | 2003-01-28 | 2006-08-10 | Troy Carol M | Systems and methods for silencing expression of a gene in a cell and uses thereof |
US20040147027A1 (en) * | 2003-01-28 | 2004-07-29 | Troy Carol M. | Complex for facilitating delivery of dsRNA into a cell and uses thereof |
US8957198B2 (en) | 2003-02-03 | 2015-02-17 | Medtronic, Inc. | Compositions, devices and methods for treatment of Huntington's disease through intracranial delivery of sirna |
US20050009042A1 (en) * | 2003-02-10 | 2005-01-13 | Aventis Pharma S.A. | Oligonucleotides which inhibit expression of the OB-RGRP protein and method for detecting compounds which modify the interaction between proteins of the OB-RGRP family and the leptin receptor |
US7884084B2 (en) * | 2003-02-10 | 2011-02-08 | Aventis Pharma S.A. | Oligonucleotides which inhibit expression of the OB-RGRP protein |
US8796235B2 (en) | 2003-02-21 | 2014-08-05 | University Of South Florida | Methods for attenuating dengue virus infection |
US20060239971A1 (en) * | 2003-02-21 | 2006-10-26 | Mohapatra Shyam S | Vectors for regulating gene expression |
US20060269530A1 (en) * | 2003-02-21 | 2006-11-30 | The Penn State Research Foundation | RNA interference compositions and methods |
US20050164212A1 (en) * | 2003-03-06 | 2005-07-28 | Todd Hauser | Modulation of gene expression using DNA-RNA hybrids |
US20080085999A1 (en) * | 2003-03-06 | 2008-04-10 | Oligoengine, Inc. | Modulation of gene expression using dna-rna hybrids |
US20100093831A1 (en) * | 2003-03-12 | 2010-04-15 | Vasgene Therapeutics, Inc. | Nucleic acid compounds for inhibiting angiogenesis and tumor growth |
US7994305B2 (en) * | 2003-04-18 | 2011-08-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for siRNA inhibition of angiopoietin 1 and 2 and their receptor Tie2 |
US20040248174A1 (en) * | 2003-04-18 | 2004-12-09 | Thetrustees Of The University Of Pennsylvania | Compositions and methods for siRNA inhibition of angiopoietin 1and 2 and their receptor Tie2 |
US20070010468A1 (en) * | 2003-04-23 | 2007-01-11 | Georgetown University | Methods and compositions for the inhibition of stat5 in prostate cancer cells |
US20100278871A1 (en) * | 2003-05-05 | 2010-11-04 | Johns Hopkins University | Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein |
US9701725B2 (en) | 2003-05-05 | 2017-07-11 | The Johns Hopkins University | Anti-cancer DNA vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein |
US20070149468A1 (en) * | 2003-05-16 | 2007-06-28 | Jackson Aimee L | Methods and compositions for rna interference |
US8609830B2 (en) * | 2003-05-16 | 2013-12-17 | Merck Sharp & Dohme Corp. | Methods and compositions for RNA interference |
US20100168209A1 (en) * | 2003-05-19 | 2010-07-01 | Genecare Research Institute Co., Ltd. | Apoptosis inducer for cancer cell |
US20070243570A1 (en) * | 2003-05-19 | 2007-10-18 | Genecare Research Institute Co., Ltd | Apoptosis Inducer for Cancer Cell |
US8809296B2 (en) | 2003-05-19 | 2014-08-19 | Genecare Research Institute Co., Ltd. | Apoptosis inducer for cancer cell |
US8299044B2 (en) | 2003-05-19 | 2012-10-30 | Genecare Research Institute Co., Ltd. | Apoptosis inducer for cancer cell |
US7459547B2 (en) | 2003-06-02 | 2008-12-02 | University Of Massachusetts | Methods and compositions for controlling efficacy of RNA silencing |
US11459562B2 (en) | 2003-06-02 | 2022-10-04 | University Of Massachusetts | Methods and compositions for controlling efficacy of RNA silencing |
US9121018B2 (en) | 2003-06-02 | 2015-09-01 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of RNA silencing |
US20100317105A1 (en) * | 2003-06-02 | 2010-12-16 | University Of Massachusetts | Methods and compositions for controlling efficacy of RNA silencing |
US7732593B2 (en) | 2003-06-02 | 2010-06-08 | University Of Massachusetts | Methods and compositions for controlling efficacy of RNA silencing |
US8329892B2 (en) | 2003-06-02 | 2012-12-11 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of RNA silencing |
US20100184826A1 (en) * | 2003-06-02 | 2010-07-22 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of rna silencing |
US7772203B2 (en) | 2003-06-02 | 2010-08-10 | University Of Massachusetts | Methods and compositions for controlling efficacy of RNA silencing |
US20050181382A1 (en) * | 2003-06-02 | 2005-08-18 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of RNAi |
US10364429B2 (en) | 2003-06-02 | 2019-07-30 | University Of Massachusetts | Methods and compositions for controlling efficacy of RNA silencing |
US20100184828A1 (en) * | 2003-06-02 | 2010-07-22 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of rna silencing |
US8309705B2 (en) | 2003-06-02 | 2012-11-13 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of RNA silencing |
US20090098614A1 (en) * | 2003-06-02 | 2009-04-16 | Zamore Phillip D | Methods and Compositions for controlling Efficacy of RNA Silencing |
US20110152347A1 (en) * | 2003-06-02 | 2011-06-23 | University Of Massachusetts | Methods and compositions for controlling efficacy of RNA silencing |
US8309704B2 (en) | 2003-06-02 | 2012-11-13 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of RNAi |
US8304530B2 (en) | 2003-06-02 | 2012-11-06 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of RNA silencing |
US20100184827A1 (en) * | 2003-06-02 | 2010-07-22 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of rna silencing |
US20080318896A1 (en) * | 2003-06-02 | 2008-12-25 | University Of Massachusetts | Methods and Compositions for Controlling of Efficacy of RNA Silencing |
US7750144B2 (en) | 2003-06-02 | 2010-07-06 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of RNA silencing |
US20050037988A1 (en) * | 2003-06-02 | 2005-02-17 | University Of Massachusetts | Methods and compositions for controlling efficacy of RNA silencing |
US10604754B2 (en) | 2003-06-02 | 2020-03-31 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of RNA silencing |
US20090203896A1 (en) * | 2003-06-03 | 2009-08-13 | Balkrishen Bhat | Modulation of survivin expression |
US7541344B2 (en) * | 2003-06-03 | 2009-06-02 | Eli Lilly And Company | Modulation of survivin expression |
US20050019918A1 (en) * | 2003-06-03 | 2005-01-27 | Hidetoshi Sumimoto | Treatment of cancer by inhibiting BRAF expression |
US20070161547A1 (en) * | 2003-06-03 | 2007-07-12 | Balkrishen Bhat | Modulation of survivin expression |
US20110092565A1 (en) * | 2003-06-09 | 2011-04-21 | Alnylam Pharmaceuticals, Inc. | Method of treating neurodegenerative disease |
US10982212B2 (en) | 2003-06-12 | 2021-04-20 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
US20100280102A1 (en) * | 2003-06-13 | 2010-11-04 | Alnylam Pharmaceuticals | Double-stranded ribonucleic acid with increased effectiveness in an organism |
WO2005044976A3 (en) * | 2003-06-20 | 2006-02-23 | Isis Pharmaceuticals Inc | Oligomeric compounds for use in gene modulation |
US20050256071A1 (en) * | 2003-07-15 | 2005-11-17 | California Institute Of Technology | Inhibitor nucleic acids |
US20050136430A1 (en) * | 2003-07-15 | 2005-06-23 | California Institute Of Technology | Inhibitor nucleic acids |
US20060240093A1 (en) * | 2003-07-16 | 2006-10-26 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering rna |
US7982027B2 (en) * | 2003-07-16 | 2011-07-19 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering RNA |
US20100311810A1 (en) * | 2003-08-18 | 2010-12-09 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
US8883997B2 (en) | 2003-08-18 | 2014-11-11 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
US7825235B2 (en) | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
US8258289B2 (en) | 2003-08-18 | 2012-09-04 | Isis Pharmaceuticals, Inc | Modulation of diacylglycerol acyltransferase 2 expression |
US20050272680A1 (en) * | 2003-08-18 | 2005-12-08 | Sanjay Bhanot | Modulation of diacylglycerol acyltransferase 2 expression |
US20050043524A1 (en) * | 2003-08-18 | 2005-02-24 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
US7732590B2 (en) * | 2003-08-18 | 2010-06-08 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
US20050136437A1 (en) * | 2003-08-25 | 2005-06-23 | Nastech Pharmaceutical Company Inc. | Nanoparticles for delivery of nucleic acids and stable double-stranded RNA |
US20060142230A1 (en) * | 2003-08-25 | 2006-06-29 | Nastech Pharmaceutical Company Inc. | Double-stranded ribonucleic acid molecules having ribothymidine |
US20060160123A1 (en) * | 2003-08-25 | 2006-07-20 | Nastech Pharmaceutical Company Inc. | Method of minimizing off-target effects of siRNA molecules |
US20060122137A1 (en) * | 2003-08-25 | 2006-06-08 | Nastech Pharmaceutical Company Inc. | 5'-methylpyrimidine and 2'-O-methyl ribonucleotide modified double-stranded ribonucleic acid molecules |
US20070155658A1 (en) * | 2003-08-25 | 2007-07-05 | Nastech Pharmaceutical Company Inc. | Nanoparticles for delivery of nucleic acids and stable double-stranded rna |
US20090192113A1 (en) * | 2003-08-28 | 2009-07-30 | Jan Weiler | Interfering RNA Duplex Having Blunt-Ends and 3`-Modifications |
US8097716B2 (en) | 2003-08-28 | 2012-01-17 | Novartis Ag | Interfering RNA duplex having blunt-ends and 3′-modifications |
US11299734B2 (en) | 2003-09-12 | 2022-04-12 | University Of Massachusetts | RNA interference for the treatment of gain-of-function disorders |
US20110172291A1 (en) * | 2003-09-12 | 2011-07-14 | University Of Massachusetts | Rna interference for the treatment of gain-of-function disorders |
US9434943B2 (en) | 2003-09-12 | 2016-09-06 | University Of Massachusetts | RNA interference for the treatment of gain-of-function disorders |
US7947658B2 (en) | 2003-09-12 | 2011-05-24 | University Of Massachusetts | RNA interference for the treatment of gain-of-function disorders |
US20090118206A1 (en) * | 2003-09-12 | 2009-05-07 | University Of Massachusetts | Rna interference for the treatment of gain-of-function disorders |
US10344277B2 (en) | 2003-09-12 | 2019-07-09 | University Of Massachusetts | RNA interference for the treatment of gain-of-function disorders |
US8680063B2 (en) | 2003-09-12 | 2014-03-25 | University Of Massachusetts | RNA interference for the treatment of gain-of-function disorders |
US20080249038A1 (en) * | 2003-10-07 | 2008-10-09 | Quark Biotech, Inc. | Bone Morphogenetic Protein (Bmp) 2A and Uses Thereof |
US20070258993A1 (en) * | 2003-11-12 | 2007-11-08 | The Austin Research Institute | Dna-Carrier Conjugate |
US7763592B1 (en) | 2003-11-20 | 2010-07-27 | University Of South Florida | SHIP-deficiency to increase megakaryocyte progenitor production |
US7807646B1 (en) | 2003-11-20 | 2010-10-05 | University Of South Florida | SHIP-deficiency to increase megakaryocyte progenitor production |
US20110064704A1 (en) * | 2003-11-20 | 2011-03-17 | University Of South Florida | Ship-deficiency to increase megakaryocyte and platelet production |
US20100260730A1 (en) * | 2003-11-20 | 2010-10-14 | University Of South Florida | SHIP-Deficiency to Increase Megakaryocyte Progenitor Production |
US8008273B2 (en) | 2003-11-20 | 2011-08-30 | University Of South Florida | SHIP-deficiency to increase megakaryocyte progenitor production |
US20050208658A1 (en) * | 2003-11-21 | 2005-09-22 | The University Of Maryland | RNA interference mediated inhibition of 11beta hydroxysteriod dehydrogenase-1 (11beta HSD-1) gene expression |
US7732591B2 (en) | 2003-11-25 | 2010-06-08 | Medtronic, Inc. | Compositions, devices and methods for treatment of huntington's disease through intracranial delivery of sirna |
US8685946B2 (en) | 2003-11-26 | 2014-04-01 | Universiy of Massachusetts | Sequence-specific inhibition of small RNA function |
US20050227256A1 (en) * | 2003-11-26 | 2005-10-13 | Gyorgy Hutvagner | Sequence-specific inhibition of small RNA function |
US8598143B2 (en) * | 2003-11-26 | 2013-12-03 | University Of Massachusetts | Sequence-specific inhibition of small RNA function |
US9334497B2 (en) | 2003-11-26 | 2016-05-10 | University Of Massachusetts | Sequence-specific inhibition of small RNA function |
US20080171051A1 (en) * | 2003-11-26 | 2008-07-17 | Patrick Gerard Johnston | Cancer Treatment |
US20090083873A1 (en) * | 2003-11-26 | 2009-03-26 | Uinversity Of Massachusetts | Sequence-specific inhibition of small rna function |
US11359196B2 (en) | 2003-11-26 | 2022-06-14 | University Of Massachusetts | Sequence-specific inhibition of small RNA function |
US20070238676A1 (en) * | 2003-12-04 | 2007-10-11 | Mohapatra Shyam S | Polynucleotides for Reducing Respiratory Syncytial Virus Gene Expression |
US9089590B2 (en) | 2003-12-04 | 2015-07-28 | University Of South Florida | Polynucleotides for reducing respiratory syncytial virus gene expression |
US20050234000A1 (en) * | 2003-12-12 | 2005-10-20 | Mitchell Gordon S | SiRNA delivery into mammalian nerve cells |
US9879253B2 (en) | 2003-12-22 | 2018-01-30 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA |
US10385339B2 (en) | 2003-12-22 | 2019-08-20 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA |
US7807814B2 (en) * | 2003-12-23 | 2010-10-05 | The Trustees Of The University Of Pennsylvania | Compositions and methods for combined therapy of disease |
US20060287259A1 (en) * | 2003-12-23 | 2006-12-21 | The Trustees Of The University Of Pennsylvania | Compositions and methods for combined therapy of disease |
US20070161586A1 (en) * | 2004-01-16 | 2007-07-12 | Takeda Pharmaceutical Company Limited | Drug for preventing and treating atherosclerosis |
US20090082303A1 (en) * | 2004-01-16 | 2009-03-26 | Takeda Pharmaceutical Company Limited | Drug for preventing and treating atherosclerosis |
US7939652B2 (en) * | 2004-01-30 | 2011-05-10 | Quark Pharmaceuticals Inc. | Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases |
US20080287386A1 (en) * | 2004-01-30 | 2008-11-20 | Quark Biotech, Inc. | Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases |
US8198258B2 (en) | 2004-01-30 | 2012-06-12 | Quark Pharmaceuticals Inc. | Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases |
US7858769B2 (en) * | 2004-02-10 | 2010-12-28 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional siNA) |
US20110118335A1 (en) * | 2004-02-10 | 2011-05-19 | Vasant Jadhav | RNA Interference Mediated Inhibition Of Gene Expression Using Multifunctional Short Interfering Nucleic Acid (Multifunctional siNA) |
US20080039412A1 (en) * | 2004-02-10 | 2008-02-14 | Sirna Therapeutics, Inc. | Rna Interference Mediated Inhibition of Gene Expression Using Multifunctional Short Interfering Nucleic Acid (Multifunctional Sina) |
US20050273868A1 (en) * | 2004-02-17 | 2005-12-08 | University Of Massachusetts | Methods and compositions for enhancing RISC activity in vitro and in vivo |
US20060069050A1 (en) * | 2004-02-17 | 2006-03-30 | University Of Massachusetts | Methods and compositions for mediating gene silencing |
US20070202134A1 (en) * | 2004-02-23 | 2007-08-30 | Kufe Donald W | Muc1 Antagonist Enhancement of Death Receptor Ligand-Induced Apoptosis |
US20080039411A1 (en) * | 2004-02-23 | 2008-02-14 | Ulf Smith | Use Of Resistin Antisense Oligonucleotides And/Or Sirna Molecules In The Treatment Of Rheumatoid Arthritis |
US8569474B2 (en) | 2004-03-09 | 2013-10-29 | Isis Pharmaceuticals, Inc. | Double stranded constructs comprising one or more short strands hybridized to a longer strand |
US8293719B2 (en) | 2004-03-12 | 2012-10-23 | Alnylam Pharmaceuticals, Inc. | iRNA agents targeting VEGF |
US20050202075A1 (en) * | 2004-03-12 | 2005-09-15 | Pardridge William M. | Delivery of genes encoding short hairpin RNA using receptor-specific nanocontainers |
US8796444B2 (en) | 2004-03-15 | 2014-08-05 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
US20070265220A1 (en) * | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
US9518262B2 (en) | 2004-03-15 | 2016-12-13 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
US20050277610A1 (en) * | 2004-03-15 | 2005-12-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
US8658356B2 (en) | 2004-03-15 | 2014-02-25 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
EP2514758A1 (en) * | 2004-03-15 | 2012-10-24 | City of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
US20090325285A1 (en) * | 2004-03-15 | 2009-12-31 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded rna |
US9365849B2 (en) | 2004-03-15 | 2016-06-14 | Integrated Dna Technologies, Inc. | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
US10106792B2 (en) | 2004-03-15 | 2018-10-23 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
US8084599B2 (en) | 2004-03-15 | 2011-12-27 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
US9988630B2 (en) | 2004-03-15 | 2018-06-05 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
US20090326046A1 (en) * | 2004-03-15 | 2009-12-31 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded rna |
US8691786B2 (en) | 2004-03-15 | 2014-04-08 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
US20100004436A1 (en) * | 2004-03-15 | 2010-01-07 | Integrated Dna Technologies, Inc. | Methods and compositions for the specific inhibition of gene expression by double-stranded rna |
US20100004318A1 (en) * | 2004-03-15 | 2010-01-07 | Integrated Dna Technologies, Inc. | Methods and compositions for the specific inhibition of gene expression by double-stranded rna |
US8809515B2 (en) | 2004-03-15 | 2014-08-19 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
US20110213328A1 (en) * | 2004-03-18 | 2011-09-01 | Medtronic, Inc. | Methods and Systems for Treatment of Neurological Diseases of the Central Nervous System |
US7851452B2 (en) * | 2004-03-22 | 2010-12-14 | The Trustees Of The University Of Pennsylvania | Methods of use of bcl-6-derived nucleotides to induce apoptosis |
US20050272682A1 (en) * | 2004-03-22 | 2005-12-08 | Evers Bernard M | SiRNA targeting PI3K signal transduction pathway and siRNA-based therapy |
US20080153765A1 (en) * | 2004-03-22 | 2008-06-26 | Gewirtz Alan M | Methods of Use of Bcl-6-Derived Nucleotides to Induce Apoptosis |
US8802639B2 (en) * | 2004-03-26 | 2014-08-12 | Curis, Inc. | RNA interference modulators of hedgehog signaling and uses thereof |
US20070232555A1 (en) * | 2004-03-26 | 2007-10-04 | Nariyoshi Shinomiya | C-Met Sirna Adenovirus Vectors Inhibit Cancer Cell Growth, Invasion and Tumorigenicity |
US7872117B2 (en) * | 2004-03-26 | 2011-01-18 | Van Andel Research Institute | c-met siRNA adenovirus vectors inhibit cancer cell growth, invasion and tumorigenicity |
US20050256076A1 (en) * | 2004-03-26 | 2005-11-17 | Curis, Inc. | RNA interference modulators of hedgehog signaling and uses thereof |
US20080167256A1 (en) * | 2004-03-31 | 2008-07-10 | Hidetoshi Sumimoto | Cancer Therapy Via the Inhibition of Skp-2 Expression |
US8058448B2 (en) | 2004-04-05 | 2011-11-15 | Alnylam Pharmaceuticals, Inc. | Processes and reagents for sulfurization of oligonucleotides |
US8063198B2 (en) | 2004-04-05 | 2011-11-22 | Alnylam Pharmaceuticals, Inc. | Processes and reagents for desilylation of oligonucleotides |
US8431693B2 (en) | 2004-04-05 | 2013-04-30 | Alnylam Pharmaceuticals, Inc. | Process for desilylation of oligonucleotides |
US8703930B2 (en) | 2004-04-09 | 2014-04-22 | Genecare Research Institute Co., Ltd. | Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes |
US20060078902A1 (en) * | 2004-04-15 | 2006-04-13 | Michaeline Bunting | Method and compositions for RNA interference |
US20060014289A1 (en) * | 2004-04-20 | 2006-01-19 | Nastech Pharmaceutical Company Inc. | Methods and compositions for enhancing delivery of double-stranded RNA or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells |
US8470988B2 (en) | 2004-04-27 | 2013-06-25 | Alnylam Pharmaceuticals, Inc. | Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety |
US7626014B2 (en) | 2004-04-27 | 2009-12-01 | Alnylam Pharmaceuticals | Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety |
US20100197899A1 (en) * | 2004-04-27 | 2010-08-05 | Alnylam Pharmaceuticals, Inc. | Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety |
US7674778B2 (en) | 2004-04-30 | 2010-03-09 | Alnylam Pharmaceuticals | Oligonucleotides comprising a conjugate group linked through a C5-modified pyrimidine |
US20060040882A1 (en) * | 2004-05-04 | 2006-02-23 | Lishan Chen | Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells |
US7605250B2 (en) | 2004-05-12 | 2009-10-20 | Dharmacon, Inc. | siRNA targeting cAMP-specific phosphodiesterase 4D |
US20060030003A1 (en) * | 2004-05-12 | 2006-02-09 | Simon Michael R | Composition and method for introduction of RNA interference sequences into targeted cells and tissues |
US20070207491A1 (en) * | 2004-05-12 | 2007-09-06 | Dharmacon, Inc. | siRNA targeting minichromosome maintenance deficient 4 (MCM4) |
US20110117088A1 (en) * | 2004-05-12 | 2011-05-19 | Simon Michael R | Composition and method for introduction of rna interference sequences into targeted cells and tissues |
US20070141601A1 (en) * | 2004-05-12 | 2007-06-21 | Dharmacon, Inc. | siRNA targeting cAMP-specific phosphodiesterase 4D |
US20050260214A1 (en) * | 2004-05-12 | 2005-11-24 | Simon Michael R | Composition and method for introduction of RNA interference sequences into targeted cells and tissues |
US7709616B2 (en) | 2004-05-14 | 2010-05-04 | Rosetta Genomics Inc. | Micrornas and uses thereof |
US8455633B2 (en) | 2004-05-26 | 2013-06-04 | Rosetta Genomics Ltd. | Viral and viral associated mirnas and uses thereof |
US20070003575A1 (en) * | 2004-05-26 | 2007-01-04 | Itzhak Bentwich | Viral and viral associated MiRNAs and uses thereof |
US7795419B2 (en) | 2004-05-26 | 2010-09-14 | Rosetta Genomics Ltd. | Viral and viral associated miRNAs and uses thereof |
US10047388B2 (en) | 2004-05-28 | 2018-08-14 | Asuragen, Inc. | Methods and compositions involving MicroRNA |
US8465914B2 (en) | 2004-05-28 | 2013-06-18 | Asuragen, Inc. | Method and compositions involving microRNA |
US7919245B2 (en) | 2004-05-28 | 2011-04-05 | Asuragen, Inc. | Methods and compositions involving microRNA |
US7888010B2 (en) | 2004-05-28 | 2011-02-15 | Asuragen, Inc. | Methods and compositions involving microRNA |
US8003320B2 (en) | 2004-05-28 | 2011-08-23 | Asuragen, Inc. | Methods and compositions involving MicroRNA |
US8568971B2 (en) | 2004-05-28 | 2013-10-29 | Asuragen, Inc. | Methods and compositions involving microRNA |
US8394947B2 (en) | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
US7745651B2 (en) | 2004-06-07 | 2010-06-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use |
US7799565B2 (en) | 2004-06-07 | 2010-09-21 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering RNA |
US9926560B2 (en) | 2004-06-07 | 2018-03-27 | Protiva Biotherapeutics, Inc. | Lipid encapsulating interfering RNA |
US20110060032A1 (en) * | 2004-06-07 | 2011-03-10 | Protiva Biotherapeutics, Inc. | Lipid encapsulating interfering rna |
US20060008910A1 (en) * | 2004-06-07 | 2006-01-12 | Protiva Biotherapeuties, Inc. | Lipid encapsulated interfering RNA |
US20060083780A1 (en) * | 2004-06-07 | 2006-04-20 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use |
US9181545B2 (en) | 2004-06-07 | 2015-11-10 | Protiva Biotherapeutics, Inc. | Lipid encapsulating interfering RNA |
US20060008907A1 (en) * | 2004-06-09 | 2006-01-12 | The Curators Of The University Of Missouri | Control of gene expression via light activated RNA interference |
US20060051815A1 (en) * | 2004-06-25 | 2006-03-09 | The J. David Gladstone Institutes | Methods of treating smooth muscle cell disorders |
US20100022624A1 (en) * | 2004-06-25 | 2010-01-28 | Verdin Eric M | Methods of Treating Smooth Muscle Cell Disorders |
US8114853B2 (en) | 2004-06-25 | 2012-02-14 | The J. David Gladstone Institutes | Methods of treating smooth muscle cell disorders |
US7615618B2 (en) | 2004-06-30 | 2009-11-10 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising a non-phosphate backbone linkage |
US8013136B2 (en) | 2004-06-30 | 2011-09-06 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising a non-phosphate backbone linkage |
US7723512B2 (en) | 2004-06-30 | 2010-05-25 | Alnylam Pharmaceuticals | Oligonucleotides comprising a non-phosphate backbone linkage |
US20060025366A1 (en) * | 2004-07-02 | 2006-02-02 | Protiva Biotherapeutics, Inc. | Immunostimulatory siRNA molecules and uses therefor |
US7807815B2 (en) | 2004-07-02 | 2010-10-05 | Protiva Biotherapeutics, Inc. | Compositions comprising immunostimulatory siRNA molecules and DLinDMA or DLenDMA |
US8143228B2 (en) * | 2004-07-12 | 2012-03-27 | Medical Research Fund Of Tel Aviv Sourasky Medical Center | Agents capable of downregulating an MSF-A dependent HIF-1α and use thereof in cancer treatment |
US8785373B2 (en) | 2004-07-12 | 2014-07-22 | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center | Agents capable of downregulating an MSF-A-dependent HIF-1alpha and use thereof in cancer treatment |
US20090098127A1 (en) * | 2004-07-12 | 2009-04-16 | Medical Research Fund Of Tel Aviv Sourasky Medical Center | Agents Capable of Downregulating an MSF-A DEPENDENT HIF-1ALPHA and Use Thereof in Cancer Treatment |
US7868158B2 (en) | 2004-07-19 | 2011-01-11 | Baylor College Of Medicine | Modulation of cytokine signaling regulators and applications for immunotherapy |
US20060269519A1 (en) * | 2004-07-19 | 2006-11-30 | Baylor College Of Medicine | Modulation of cytokine signaling regulators and applications for immunotherapy |
US7579451B2 (en) | 2004-07-21 | 2009-08-25 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising a modified or non-natural nucleobase |
US7772387B2 (en) | 2004-07-21 | 2010-08-10 | Alnylam Pharmaceuticals | Oligonucleotides comprising a modified or non-natural nucleobase |
US7632932B2 (en) | 2004-08-04 | 2009-12-15 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase |
US7893224B2 (en) | 2004-08-04 | 2011-02-22 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase |
WO2006020557A2 (en) * | 2004-08-10 | 2006-02-23 | Immusol, Inc. | Methods of using or identifying agents that inhibit cancer growth |
WO2006020557A3 (en) * | 2004-08-10 | 2007-08-16 | Immusol Inc | Methods of using or identifying agents that inhibit cancer growth |
US20060063181A1 (en) * | 2004-08-13 | 2006-03-23 | Green Pamela J | Method for identification and quantification of short or small RNA molecules |
US20090105176A1 (en) * | 2004-08-23 | 2009-04-23 | Sylentis S.A.U. | Methods and Compositions for the Treatment of Eye Disorders with Increased Intraocular Pressure |
US8247386B2 (en) * | 2004-08-23 | 2012-08-21 | Sylentis Sau | Methods and compositions for the treatment of eye disorders with increased intraocular pressure |
US8389490B2 (en) | 2004-08-23 | 2013-03-05 | Sylentis S.A.U. | Methods and compositions for the treatment of eye disorders with increased intraocular pressure |
US20090099111A1 (en) * | 2004-08-23 | 2009-04-16 | Sylentis S.A.U. | Methods and Compositions for the Treatment of Eye Disorders with Increased Intraocular Pressure |
US8252758B2 (en) * | 2004-08-23 | 2012-08-28 | Sylentis S.A.U. | Methods and compositions for the treatment of eye disorders with increased intraocular pressure |
US20090099113A1 (en) * | 2004-08-23 | 2009-04-16 | Sylentis S.A.U | Methods and Compositions for the Treatment of Eye Disorders with Increased Intraocular Pressure |
US20100331394A1 (en) * | 2004-08-23 | 2010-12-30 | Sylentis S.A.U. | Methods and Compositions for the Treatment of Eye Disorders with Increased Intraocular Pressure |
US8951982B2 (en) | 2004-08-23 | 2015-02-10 | Sylentis S.A.U. | Methods and compositions for the treatment of eye disorders with increased intraocular pressure |
US8258110B2 (en) * | 2004-08-23 | 2012-09-04 | Sylentis S.A.U. | Methods and compositions for the treatment of eye disorders with increased intraocular pressure |
US7902169B2 (en) | 2004-08-23 | 2011-03-08 | Sylentis S.A.U. | Methods and compositions for the treatment of eye disorders with increased intraocular pressure |
US20100022623A1 (en) * | 2004-08-23 | 2010-01-28 | Sylentis S.A.U. | Methods and Compositions for the Treatment of Eye Disorders with Increased Intraocular Pressure |
US20090099114A1 (en) * | 2004-08-23 | 2009-04-16 | Sylentis S.A.U. | Methods and Compositions for the Treatment of Eye Disorders with Increased Intraocular Pressure |
US8252759B2 (en) * | 2004-08-23 | 2012-08-28 | Sylentis S.A.U. | Methods and compositions for the treatment of eye disorders with increased intraocular pressure |
US8030284B2 (en) | 2004-08-23 | 2011-10-04 | Sylentis S.A.U. | Treatment of eye disorders characterized by an elevated intraocular pressure by siRNAs |
US20090099112A1 (en) * | 2004-08-23 | 2009-04-16 | Sylentis S.A.U. | Methods and Compositions for the Treatment of Eye Disorders with Increased Intraocular Pressure |
US8198250B2 (en) * | 2004-08-23 | 2012-06-12 | Sylentis S.A.U. | Methods and compositions for the treatment of eye disorders with increased intraocular pressure |
US8247387B2 (en) * | 2004-08-23 | 2012-08-21 | Sylentis S.A.U. | Methods and compositions for the treatment of eye disorders with increased intraocular pressure |
US20090105175A1 (en) * | 2004-08-23 | 2009-04-23 | Sylentis S.A.U. | Methods and Compositions for the Treatment of Eye Disorders with Increased Intraocular Pressure |
US20090005330A1 (en) * | 2004-08-31 | 2009-01-01 | Sylentis S.A. | Methods and Compositions to Inhibit P2x7 Receptor Expression |
US20090264501A9 (en) * | 2004-08-31 | 2009-10-22 | Sylentis S.A. | Methods and Compositions to Inhibit P2x7 Receptor Expression |
US7884086B2 (en) * | 2004-09-08 | 2011-02-08 | Isis Pharmaceuticals, Inc. | Conjugates for use in hepatocyte free uptake assays |
US20090170794A1 (en) * | 2004-09-10 | 2009-07-02 | Somagenics Inc. | Small interfering rnas that efficiently inhibit viral expression and methods of use thereof |
US8426380B2 (en) | 2004-09-10 | 2013-04-23 | Somagenics, Inc. | Inhibition of viral gene expression using small interfering RNA |
US20070149470A1 (en) * | 2004-09-10 | 2007-06-28 | Kaspar Roger L | Inhibition of viral gene expression using small interfering RNA |
US7902351B2 (en) * | 2004-09-10 | 2011-03-08 | Somagenics Inc. | Inhibition of viral gene expression using small interfering RNA |
US8569374B2 (en) | 2004-09-16 | 2013-10-29 | The Trustees Of The University Of Pennsylvania | NADPH oxidase inhibition pharmacotherapies for obstructive sleep apnea syndrome and its associated morbidities |
WO2006033965A3 (en) * | 2004-09-16 | 2006-12-21 | Univ Pennsylvania | Nadph oxidase inhibition pharmacotherapies for obstructive sleep apnea syndrome and its associated morbidities |
US20060154856A1 (en) * | 2004-09-16 | 2006-07-13 | Veasey Sigrid C | NADPH oxidase inhibition pharmacotherapies for Obstructive Sleep Apnea syndrome and its associated morbidities |
WO2006033965A2 (en) * | 2004-09-16 | 2006-03-30 | The Trustees Of The University Of Pennsylvania | Nadph oxidase inhibition pharmacotherapies for obstructive sleep apnea syndrome and its associated morbidities |
US9187747B2 (en) | 2004-09-24 | 2015-11-17 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of ApoB and uses thereof |
US8592571B2 (en) | 2004-09-24 | 2013-11-26 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of APOB and uses thereof |
US20100216866A1 (en) * | 2004-09-24 | 2010-08-26 | Alnylam Pharmaceuticals, Inc. | RNAi Modulation of APOB and Uses Thereof |
US8188061B2 (en) | 2004-09-24 | 2012-05-29 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of APOB and uses thereof |
US20100113332A1 (en) * | 2004-09-27 | 2010-05-06 | Nastech Pharmaceutical Company Inc. | Method of treating an inflammatory disease by double stranded ribonucleic acid |
US20090028862A1 (en) * | 2004-09-30 | 2009-01-29 | Arndt Gregory M | Emmprin antagonists and uses thereof |
US20060089324A1 (en) * | 2004-10-22 | 2006-04-27 | Sailen Barik | RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof |
US7790878B2 (en) | 2004-10-22 | 2010-09-07 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof |
US20080253989A1 (en) * | 2004-10-22 | 2008-10-16 | Neuregenix Limited | Neuron Regeneration |
US20110021606A1 (en) * | 2004-10-22 | 2011-01-27 | South Alabama Medical Science Foundation | RNAi Modulation of RSV, PIV and Other Respiratory Viruses and Uses Thereof |
US7592322B2 (en) | 2004-10-22 | 2009-09-22 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof |
US7943755B2 (en) * | 2004-10-22 | 2011-05-17 | Neuregenix Limited | Neuron regeneration |
US20100144833A1 (en) * | 2004-10-22 | 2010-06-10 | Sailen Barik | RNAi Modulation Of RSV, PIV And Other Respiratory Viruses And Uses Thereof |
US20060089323A1 (en) * | 2004-10-22 | 2006-04-27 | Sailen Barik | RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof |
US8598134B2 (en) * | 2004-10-22 | 2013-12-03 | South Alabama Medical Science Foundation | RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof |
US20060189564A1 (en) * | 2004-10-22 | 2006-08-24 | Medtronic, Inc. | Methods and sequences to suppress pro-inflamatory cytokine actions locally to treat pain |
US20060094676A1 (en) * | 2004-10-29 | 2006-05-04 | Ronit Lahav | Compositions and methods for treating cancer using compositions comprising an inhibitor of endothelin receptor activity |
US9447414B2 (en) | 2004-11-12 | 2016-09-20 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
US20080171715A1 (en) * | 2004-11-12 | 2008-07-17 | David Brown | Methods and compositions involving mirna and mirna inhibitor molecules |
US7960359B2 (en) | 2004-11-12 | 2011-06-14 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
US8765709B2 (en) | 2004-11-12 | 2014-07-01 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
US8946177B2 (en) | 2004-11-12 | 2015-02-03 | Mima Therapeutics, Inc | Methods and compositions involving miRNA and miRNA inhibitor molecules |
US8173611B2 (en) | 2004-11-12 | 2012-05-08 | Asuragen Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
US8058250B2 (en) | 2004-11-12 | 2011-11-15 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
US9506061B2 (en) | 2004-11-12 | 2016-11-29 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
US8809287B2 (en) * | 2004-11-15 | 2014-08-19 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for altering Wnt autocrine signaling |
US20090163407A1 (en) * | 2004-11-15 | 2009-06-25 | Mount Sinai School Of Medicine Of New York University | Compositions and methods for altering wnt autocrine signaling |
US20060134189A1 (en) * | 2004-11-17 | 2006-06-22 | Protiva Biotherapeutics, Inc | siRNA silencing of apolipoprotein B |
US20130131331A1 (en) * | 2004-11-19 | 2013-05-23 | Genecare Research Institute Co., Ltd. | Cancer-cell-specific cytostatic agent |
US7923206B2 (en) * | 2004-11-22 | 2011-04-12 | Dharmacon, Inc. | Method of determining a cellular response to a biological agent |
US7935811B2 (en) | 2004-11-22 | 2011-05-03 | Dharmacon, Inc. | Apparatus and system having dry gene silencing compositions |
US7994307B2 (en) | 2004-11-24 | 2011-08-09 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of the BCR-ABL fusion gene and uses thereof |
US20100234446A1 (en) * | 2004-11-24 | 2010-09-16 | Philipp Hadwiger | RNAi Modulation of the BCR-ABL Fusion Gene and Uses Thereof |
US8034793B2 (en) | 2004-12-14 | 2011-10-11 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of MLL-AF4 and uses thereof |
US20100256218A1 (en) * | 2004-12-14 | 2010-10-07 | Olaf Heidenreich | RNAi MODULATION OF MLL-AF4 AND USES THEREOF |
US9181546B2 (en) | 2004-12-17 | 2015-11-10 | Beth Israel Deaconess Medical Center | Compositions for bacterial mediated gene silencing and methods of using same |
US20060134787A1 (en) * | 2004-12-22 | 2006-06-22 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA |
US8058255B2 (en) | 2004-12-23 | 2011-11-15 | Applied Biosystems, Llc | Methods and compositions concerning siRNA's as mediators of RNA interference |
US20080069840A1 (en) * | 2005-01-06 | 2008-03-20 | Tzyy-Choou Wu | RNA Interference That Blocks Expression of Pro-Apoptotic Proteins Potentiates Immunity Induced by DNA and Transfected Dendritic Cell Vaccines |
US9011866B2 (en) * | 2005-01-06 | 2015-04-21 | The Johns Hopkins University | RNA interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by DNA and transfected dendritic cell vaccines |
US8263572B2 (en) | 2005-01-07 | 2012-09-11 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of RSV and therapeutic uses thereof |
US8158773B2 (en) | 2005-01-07 | 2012-04-17 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of RSV and therapeutic uses thereof |
US8859750B2 (en) | 2005-01-07 | 2014-10-14 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of RSV and therapeutic uses thereof |
US20060166921A1 (en) * | 2005-01-07 | 2006-07-27 | Rachel Meyers | RNAi modulation of RSV and therapeutic uses thereof |
US20090240043A1 (en) * | 2005-01-07 | 2009-09-24 | Alnylam Pharmaceuticals, Inc. | RNAi MODULATION OF RSV AND THERAPEUTIC USES THEREOF |
US7507809B2 (en) * | 2005-01-07 | 2009-03-24 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of RSV and therapeutic uses thereof |
US20060258608A1 (en) * | 2005-01-07 | 2006-11-16 | Rachel Meyers | RNAi modulation of RSV and therapeutic uses thereof |
US20090233984A1 (en) * | 2005-01-07 | 2009-09-17 | Alnylam Pharmaceuticals, Inc. | RNAi Modulation of RSV and Therapeutic Uses Thereof |
WO2006074346A3 (en) * | 2005-01-07 | 2007-07-05 | Alnylam Pharmaceuticals Inc | RNAi MODULATION OF RSV AND THERAPEUTIC USES THEREOF |
US7981869B2 (en) | 2005-01-07 | 2011-07-19 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of RSV and therapeutic uses thereof |
US7517865B2 (en) * | 2005-01-07 | 2009-04-14 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of RSV and therapeutic uses thereof |
US20060217324A1 (en) * | 2005-01-24 | 2006-09-28 | Juergen Soutschek | RNAi modulation of the Nogo-L or Nogo-R gene and uses thereof |
US20080102084A1 (en) * | 2005-01-26 | 2008-05-01 | Tzyy-Choou Wu | Anti-cancer DNA Vaccine Employing Plasmids Encoding Mutant Oncoprotein Antigen and Calreticulin |
US7592324B2 (en) * | 2005-02-01 | 2009-09-22 | Alcon, Inc. | RNAi-mediated inhibition of ocular targets |
US20110124708A1 (en) * | 2005-02-01 | 2011-05-26 | Alcon Inc. | Rnai-mediated inhibition of ocular hypertension targets |
US20060172963A1 (en) * | 2005-02-01 | 2006-08-03 | Alcon, Inc. | RNAi-mediated inhibition of ocular hypertension targets |
US20060172965A1 (en) * | 2005-02-01 | 2006-08-03 | Alcon, Inc. | RNAi-mediated inhibition of ocular targets |
US20080070857A1 (en) * | 2005-02-14 | 2008-03-20 | Jun Nishihira | Pharmaceutical Agents for Preventing Metastasis of Cancer |
US20110190381A1 (en) * | 2005-03-11 | 2011-08-04 | Alcon Inc. | Rnai-mediated inhibition of frizzled related protein-1 for treatment of glaucoma |
US20110003879A1 (en) * | 2005-03-11 | 2011-01-06 | Vincent Mark D | Antisense oligonucleotides targeted to the coding region of thymidylate synthase and uses thereof |
US9550994B2 (en) | 2005-03-11 | 2017-01-24 | Arrowhead Pharmaceuticals, Inc. | RNAI-mediated inhibition of frizzled related protein-1 for treatment of glaucoma |
US20060223773A1 (en) * | 2005-03-11 | 2006-10-05 | Alcon, Inc. | RNAi-mediated inhibition of Frizzled Related Protein-1 for treatment of glaucoma |
US9040494B2 (en) | 2005-03-11 | 2015-05-26 | Novartis Ag | RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma |
US7947660B2 (en) * | 2005-03-11 | 2011-05-24 | Alcon, Inc. | RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma |
US8173617B2 (en) | 2005-03-11 | 2012-05-08 | Novartis Ag | RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma |
US8999943B2 (en) * | 2005-03-14 | 2015-04-07 | Board Of Regents, The University Of Texas System | Antigene oligomers inhibit transcription |
US20060205635A1 (en) * | 2005-03-14 | 2006-09-14 | Board Of Regents, The University Of Texas System | Antigene oligomers inhibit transcription |
US20090123572A1 (en) * | 2005-03-18 | 2009-05-14 | Shiseido Company, Ltd. | Method and Pharmaceutical Composition for Treating Psoriasis, Squamous Cell Carcinoma and/or Parakeratosis by Inhibiting Expression of Squamous Cell Carcinoma-Related Antigen |
US7829547B2 (en) * | 2005-03-18 | 2010-11-09 | Shiseido Company, Ltd. | Method and pharmaceutical composition for treating psoriasis, squamous cell carcinoma and/or parakeratosis by inhibiting expression of squamous cell carcinoma-related antigen |
US20090203055A1 (en) * | 2005-04-18 | 2009-08-13 | Massachusetts Institute Of Technology | Compositions and methods for RNA interference with sialidase expression and uses thereof |
US8258112B2 (en) | 2005-05-06 | 2012-09-04 | Medtronic, Inc | Methods and sequences to suppress primate huntington gene Expression |
US7902352B2 (en) | 2005-05-06 | 2011-03-08 | Medtronic, Inc. | Isolated nucleic acid duplex for reducing huntington gene expression |
US20070160586A1 (en) * | 2005-06-15 | 2007-07-12 | Children's Medical Center Corporation | Methods for extending the replicative lifespan of cells |
US7838503B2 (en) * | 2005-06-15 | 2010-11-23 | Children's Medical Center Corporation | Methods for extending the replicative lifespan of cells |
US20110038922A1 (en) * | 2005-06-16 | 2011-02-17 | Faron Pharmaceuticals Oy (A Finnish Company) | Compounds for treating or preventing amine oxidase related diseases or disorders |
US7868159B2 (en) * | 2005-06-23 | 2011-01-11 | Baylor College Of Medicine | Modulation of negative immune regulators and applications for immunotherapy |
US20060292119A1 (en) * | 2005-06-23 | 2006-12-28 | Baylor College Of Medicine | Modulation of negative immune regulators and applications for immunotherapy |
US20100292305A1 (en) * | 2005-06-27 | 2010-11-18 | Akin Akinc | RNAi MODULATION OF HIF-1 AND THERAPUTIC USES THEREOF |
US9133517B2 (en) | 2005-06-28 | 2015-09-15 | Medtronics, Inc. | Methods and sequences to preferentially suppress expression of mutated huntingtin |
US8067573B2 (en) * | 2005-07-07 | 2011-11-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Nucleic acid agents for downregulating H19 and methods of using same |
US20090143321A1 (en) * | 2005-07-07 | 2009-06-04 | Avraham Hochberg | Nucleic acid agents for downregulating h19 and methods of using same |
US8067574B2 (en) | 2005-07-07 | 2011-11-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Nucleic acid agents for downregulating H19, and methods of using same |
US20090203121A1 (en) * | 2005-07-07 | 2009-08-13 | Avraham Hochberg | Nucleic acid agents for downregulating h19, and methods of using same |
US20080176293A1 (en) * | 2005-07-25 | 2008-07-24 | Jacques Rohayem | RNA-Dependent RNA Polymerase, Methods And Kits For The Amplification And/Or Labelling Of RNA |
US20070111227A1 (en) * | 2005-07-28 | 2007-05-17 | Green Pamela J | Small regulatory RNAs and methods of use |
US9914924B2 (en) | 2005-08-18 | 2018-03-13 | University Of Massachusetts | Methods and compositions for treating neurological disease |
US20100267810A1 (en) * | 2005-08-18 | 2010-10-21 | University Of Massachusetts | Methods and compositions for treating neurological disease |
US20070054873A1 (en) * | 2005-08-26 | 2007-03-08 | Protiva Biotherapeutics, Inc. | Glucocorticoid modulation of nucleic acid-mediated immune stimulation |
US20110160286A1 (en) * | 2005-09-30 | 2011-06-30 | University Of Massachusetts | Allele-specific rna interference |
US8933043B2 (en) * | 2005-09-30 | 2015-01-13 | St. Jude Children's Research Hospital | Methods for regulation of p53 translation and function |
US8309533B2 (en) | 2005-09-30 | 2012-11-13 | University Of Massachusetts | Allele-specific RNA interference |
US20090149377A1 (en) * | 2005-09-30 | 2009-06-11 | St. Jude Children's Research Hospital | METHODS FOR REGULATION OF p53 TRANSLATION AND FUNCTION |
WO2007047692A3 (en) * | 2005-10-19 | 2007-08-02 | Medtronic Inc | Devices, systems and methods for improving memory and/or cognitive function through brain delivery of sirna |
US20110177131A1 (en) * | 2005-10-20 | 2011-07-21 | Protiva Biotherapeutics, Inc. | siRNA SILENCING OF FILOVIRUS GENE EXPRESSION |
US8354385B2 (en) | 2005-10-20 | 2013-01-15 | Sylentis S.A.U. | Modulation of TRPV expression levels |
US7838658B2 (en) * | 2005-10-20 | 2010-11-23 | Ian Maclachlan | siRNA silencing of filovirus gene expression |
US20100286230A1 (en) * | 2005-10-20 | 2010-11-11 | Sylentis S.A.U. | Modulation of trpv expression levels |
US20070135370A1 (en) * | 2005-10-20 | 2007-06-14 | Protiva Biotherapeutics, Inc. | siRNA silencing of filovirus gene expression |
US8188057B2 (en) | 2005-10-25 | 2012-05-29 | Sylentis S.A.U. | Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases |
US20110160277A1 (en) * | 2005-10-25 | 2011-06-30 | Sylentis S.A.U. | Modulation of 11 beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases |
US8080532B2 (en) | 2005-10-28 | 2011-12-20 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of Huntingtin gene |
US20100298405A1 (en) * | 2005-10-28 | 2010-11-25 | Dinah Wen-Yee Sah | Compositions And Methods For Inhibiting Expression Of Huntingtin Gene |
US8314075B2 (en) | 2005-10-28 | 2012-11-20 | Alynylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of huntingtin gene |
US8188263B2 (en) | 2005-11-02 | 2012-05-29 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
US8101741B2 (en) * | 2005-11-02 | 2012-01-24 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
US8513403B2 (en) | 2005-11-02 | 2013-08-20 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
US20070135372A1 (en) * | 2005-11-02 | 2007-06-14 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
US9074208B2 (en) | 2005-11-02 | 2015-07-07 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
US20110124711A1 (en) * | 2005-11-04 | 2011-05-26 | Alnylam Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Nav1.8 GENE |
US20090258934A1 (en) * | 2005-11-04 | 2009-10-15 | Alnylam Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Nav1.8 GENE |
US7902168B2 (en) | 2005-11-04 | 2011-03-08 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of Nav1.8 gene |
US20100129429A1 (en) * | 2005-11-07 | 2010-05-27 | British Columbia Cancer Agency | Inhibition of autophagy genes in cancer chemotherapy |
US8076308B2 (en) * | 2005-11-07 | 2011-12-13 | British Columbia Cancer Agency | Inhibition of autophagy genes in cancer chemotherapy |
US8658782B2 (en) | 2005-11-09 | 2014-02-25 | Alynylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of factor V |
US10501740B2 (en) | 2005-11-09 | 2019-12-10 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of factor V |
US9441225B2 (en) | 2005-11-09 | 2016-09-13 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of factor V |
US20110130443A1 (en) * | 2005-11-09 | 2011-06-02 | Hans-Peter Vornlocher | Compositions And Methods For Inhibiting Expression Of Factor V Leiden Mutant Gene |
US20100069461A1 (en) * | 2005-11-09 | 2010-03-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of factor v leiden mutant gene |
US8324181B2 (en) | 2005-11-17 | 2012-12-04 | Board Of Regents, The University Of Texas System | Modulation of gene expression by oligomers targeted to chromosomal DNA |
US7709456B2 (en) | 2005-11-17 | 2010-05-04 | Board Of Regents, The University Of Texas System | Modulation of gene expression by oligomers targeted to chromosomal DNA |
US20070111963A1 (en) * | 2005-11-17 | 2007-05-17 | Board Of Regents, The University Of Texas System | Modulation of gene expression by oligomers targeted to chromosomal DNA |
US20080125384A1 (en) * | 2005-11-21 | 2008-05-29 | Shuewi Yang | Simultaneous silencing and restoration of gene function |
US20120202215A1 (en) * | 2005-11-24 | 2012-08-09 | Jichi Medical University | Mitochondrial function of prohibitin 2 (phb2) |
US9803195B2 (en) | 2005-12-28 | 2017-10-31 | The Scripps Research Institute | Natural antisense and non-coding RNA transcripts as drug targets |
US10472627B2 (en) | 2005-12-28 | 2019-11-12 | The Scripps Research Institute | Natural antisense and non-coding RNA transcripts as drug targets |
US8288354B2 (en) * | 2005-12-28 | 2012-10-16 | The Scripps Research Institute | Natural antisense and non-coding RNA transcripts as drug targets |
US20090156531A1 (en) * | 2005-12-30 | 2009-06-18 | Institut Gustave Roussy | Use of Inhibitors of Scinderin and/or Ephrin-A1 for Treating Tumors |
US8058252B2 (en) * | 2005-12-30 | 2011-11-15 | Institut Gustave Roussy | Use of inhibitors of scinderin and/or ephrin-A1 for treating tumors |
US20070259827A1 (en) * | 2006-01-25 | 2007-11-08 | University Of Massachusetts | Compositions and methods for enhancing discriminatory RNA interference |
US20070180242A1 (en) * | 2006-01-30 | 2007-08-02 | Nagaraj Thadi M | GSM authentication in a CDMA network |
US20090247607A1 (en) * | 2006-03-24 | 2009-10-01 | John Benson | dsRNA COMPOSITIONS AND METHODS FOR TREATING HPV INFECTION |
US7956177B2 (en) * | 2006-03-24 | 2011-06-07 | Alnylam Pharmaceuticals, Inc. | dsRNA compositions and methods for treating HPV infection |
US20110230546A1 (en) * | 2006-03-24 | 2011-09-22 | John Benson | dsRNA COMPOSITIONS AND METHODS FOR TREATING HPV INFECTION |
US20070238691A1 (en) * | 2006-03-29 | 2007-10-11 | Senesco Technologies, Inc. | Inhibition of HIV replication and expression of p24 with eIF-5A |
US9057069B2 (en) | 2006-03-31 | 2015-06-16 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of Eg5 gene |
US20090226446A1 (en) * | 2006-04-06 | 2009-09-10 | Deutsches Krebsforschungszentrum Stiftung Des Offentilchen Rechts | Method to Inhibit the Propagation of an Undesired Cell Population |
US20070275913A1 (en) * | 2006-04-12 | 2007-11-29 | Monia Brett P | Compositions and their uses directed to hepcidin |
US8076306B2 (en) * | 2006-04-12 | 2011-12-13 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to hepcidin |
US8058257B2 (en) | 2006-04-28 | 2011-11-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a gene from the JC virus |
US20090062225A1 (en) * | 2006-04-28 | 2009-03-05 | Pamela Tan | Compositions and methods for inhibiting expression of a gene from the jc virus |
US7691824B2 (en) | 2006-04-28 | 2010-04-06 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a gene from the JC virus |
US8410261B2 (en) | 2006-04-28 | 2013-04-02 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a gene from the JC virus |
US20100227915A1 (en) * | 2006-04-28 | 2010-09-09 | Pamela Tan | Compositions and methods for inhibiting expression of a gene from the jc virus |
US9012624B2 (en) | 2006-04-28 | 2015-04-21 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a gene from the JC virus |
WO2007127919A3 (en) * | 2006-04-28 | 2008-10-30 | Alnylam Pharmaceuticals Inc | Compositions and methods for inhibiting expression of a gene from the jc virus |
US8344128B2 (en) | 2006-05-04 | 2013-01-01 | Novartis Ag | Short interfering ribonucleic acid (siRNA) for oral administration |
US9493771B2 (en) | 2006-05-04 | 2016-11-15 | Novartis Ag | Short interfering ribonucleic acid (siRNA) for oral administration |
US20100015707A1 (en) * | 2006-05-04 | 2010-01-21 | Francois Jean-Charles Natt | SHORT INTERFERING RIBONUCLEIC ACID (siRNA) FOR ORAL ADMINISTRATION |
US8404832B2 (en) | 2006-05-04 | 2013-03-26 | Novartis Ag | Short interfering ribonucleic acid (siRNA) for oral administration |
US8957041B2 (en) | 2006-05-04 | 2015-02-17 | Novartis Ag | Short interfering ribonucleic acid (siRNA) for oral administration |
US8404831B2 (en) | 2006-05-04 | 2013-03-26 | Novartis Ag | Short interfering ribonucleic acid (siRNA) for oral administration |
US8084600B2 (en) | 2006-05-04 | 2011-12-27 | Novartis Ag | Short interfering ribonucleic acid (siRNA) with improved pharmacological properties |
US9260718B2 (en) | 2006-05-11 | 2016-02-16 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the PCSK9 gene |
US20110230542A1 (en) * | 2006-05-11 | 2011-09-22 | Pamela Tan | Compositions and Methods for Inhibiting Expression of the PCSK9 Gene |
US8222222B2 (en) | 2006-05-11 | 2012-07-17 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the PCSK9 gene |
US9822365B2 (en) | 2006-05-11 | 2017-11-21 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the PCSK9 gene |
US10501742B2 (en) | 2006-05-11 | 2019-12-10 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the PCSK9 gene |
US8809292B2 (en) | 2006-05-11 | 2014-08-19 | Alnylam Pharmaceuticals, Inc | Compositions and methods for inhibiting expression of the PCSK9 gene |
US20090130212A1 (en) * | 2006-05-15 | 2009-05-21 | Physical Pharmaceutica, Llc | Composition and improved method for preparation of small particles |
US20070269892A1 (en) * | 2006-05-18 | 2007-11-22 | Nastech Pharmaceutical Company Inc. | FORMULATIONS FOR INTRACELLULAR DELIVERY dsRNA |
US20080014191A1 (en) * | 2006-05-19 | 2008-01-17 | The Scripps Research Institute | Treatment of Protein Misfolding |
WO2007137237A3 (en) * | 2006-05-19 | 2008-12-18 | Scripps Research Inst | Treatment of protein misfolding |
US20110003882A1 (en) * | 2006-05-19 | 2011-01-06 | Alnylam Pharmaceuticals, Inc. | RNAi Modulation of AHA and Therapeutic Uses Thereof |
US8114984B2 (en) | 2006-05-19 | 2012-02-14 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of Aha and therapeutic uses thereof |
US9000143B2 (en) * | 2006-05-22 | 2015-04-07 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of IKK-B gene |
US20080108584A1 (en) * | 2006-05-22 | 2008-05-08 | De Fougerolles Antonin | Compositions and methods for inhibiting expression of ikk-b gene |
US7888498B2 (en) * | 2006-05-22 | 2011-02-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of IKK-B gene |
US20110112178A1 (en) * | 2006-05-22 | 2011-05-12 | Alnylam Pharmaceuticals, Inc. | Compositions And Methods For Inhibiting Expression Of IKK-B Gene |
US9273356B2 (en) | 2006-05-24 | 2016-03-01 | Medtronic, Inc. | Methods and kits for linking polymorphic sequences to expanded repeat mutations |
US20070275923A1 (en) * | 2006-05-25 | 2007-11-29 | Nastech Pharmaceutical Company Inc. | CATIONIC PEPTIDES FOR siRNA INTRACELLULAR DELIVERY |
US20090149403A1 (en) * | 2006-05-26 | 2009-06-11 | Protiva Biotherapeutics, Inc. | siRNA silencing of genes expressed in cancer |
US9074202B2 (en) * | 2006-05-26 | 2015-07-07 | Medical Research Council | Method of inhibiting human Trabid |
US8598333B2 (en) | 2006-05-26 | 2013-12-03 | Alnylam Pharmaceuticals, Inc. | SiRNA silencing of genes expressed in cancer |
US20090275635A1 (en) * | 2006-05-26 | 2009-11-05 | Medical Research Council | Screening method |
US7915399B2 (en) | 2006-06-09 | 2011-03-29 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
US20080249046A1 (en) * | 2006-06-09 | 2008-10-09 | Protiva Biotherapeutics, Inc. | MODIFIED siRNA MOLECULES AND USES THEREOF |
US20080152654A1 (en) * | 2006-06-12 | 2008-06-26 | Exegenics, Inc., D/B/A Opko Health, Inc. | COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOGENESIS |
US9200275B2 (en) * | 2006-06-14 | 2015-12-01 | Merck Sharp & Dohme Corp. | Methods and compositions for regulating cell cycle progression |
US20100035966A1 (en) * | 2006-06-14 | 2010-02-11 | Rosetta Inpharmatics Llc | Methods and compositions for regulating cell cycle progression |
WO2008002678A3 (en) * | 2006-06-29 | 2008-10-16 | Univ Texas | Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use |
US20100016405A1 (en) * | 2006-07-10 | 2010-01-21 | Alnylam Pharmaceuticals, Inc | Compositions and Methods for Inhibiting Expression of the MYC Gene |
US8124752B2 (en) | 2006-07-10 | 2012-02-28 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the MYC gene |
US20080057062A1 (en) * | 2006-07-18 | 2008-03-06 | National Institute Of Advanced Industrial Science And Technology | Agent for Inducing senescence and apoptosis of cancer cell |
US20080039415A1 (en) * | 2006-08-11 | 2008-02-14 | Gregory Robert Stewart | Retrograde transport of sirna and therapeutic uses to treat neurologic disorders |
US20100330105A1 (en) * | 2006-08-22 | 2010-12-30 | John Hopkins University | Anticancer Combination Therapies |
US20090061487A1 (en) * | 2006-09-08 | 2009-03-05 | Samuel Jotham Reich | Sirna and methods of manufacture |
US7872118B2 (en) | 2006-09-08 | 2011-01-18 | Opko Ophthalmics, Llc | siRNA and methods of manufacture |
US20110143400A1 (en) * | 2006-09-08 | 2011-06-16 | Opko Ophthalmics, Llc | Sirna and methods of manufacture |
US8470799B2 (en) | 2006-09-21 | 2013-06-25 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the HAMP gene |
US8791250B2 (en) | 2006-09-21 | 2014-07-29 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the HAMP gene |
US20100204307A1 (en) * | 2006-09-21 | 2010-08-12 | Tomoko Nakayama | Compositions And Methods For Inhibiting Expression Of The HAMP Gene |
US8163711B2 (en) | 2006-09-21 | 2012-04-24 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the HAMP gene |
US9506067B2 (en) | 2006-09-21 | 2016-11-29 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the HAMP gene |
US8268799B2 (en) | 2006-09-21 | 2012-09-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the HAMP gene |
US9090895B2 (en) | 2006-09-21 | 2015-07-28 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the HAMP gene |
US20110150897A1 (en) * | 2006-10-11 | 2011-06-23 | Meyer Thomas F | Influenza targets |
US8299040B2 (en) * | 2006-10-18 | 2012-10-30 | Board Of Regents, The University Of Texas System | Methods for treating cancer targeting transglutaminase |
US20080279844A1 (en) * | 2006-10-18 | 2008-11-13 | Kapil Mehta | Methods for Treating Cancer Targeting Transglutaminase |
US9375440B2 (en) | 2006-11-03 | 2016-06-28 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
US8324367B2 (en) | 2006-11-03 | 2012-12-04 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
US7819842B2 (en) | 2006-11-21 | 2010-10-26 | Medtronic, Inc. | Chronically implantable guide tube for repeated intermittent delivery of materials or fluids to targeted tissue sites |
US20080255345A1 (en) * | 2006-11-21 | 2008-10-16 | Alnylam Pharmaceuticals, Inc. | IRNA Agents Targeting CCR5 Expressing Cells And Uses Thereof |
US8034921B2 (en) | 2006-11-21 | 2011-10-11 | Alnylam Pharmaceuticals, Inc. | IRNA agents targeting CCR5 expressing cells and uses thereof |
US7988668B2 (en) | 2006-11-21 | 2011-08-02 | Medtronic, Inc. | Microsyringe for pre-packaged delivery of pharmaceuticals |
US20080171719A1 (en) * | 2006-11-28 | 2008-07-17 | Alcon Manufacturing, Ltd. | RNAi-MEDIATED INHIBITION OF AQUAPORIN 1 FOR TREATMENT OF IOP-RELATED CONDITIONS |
US20080167265A1 (en) * | 2007-01-09 | 2008-07-10 | Isis Pharmaceuticals Inc | Modulation of fr-alpha expression |
US7754698B2 (en) * | 2007-01-09 | 2010-07-13 | Isis Pharmaceuticals, Inc. | Modulation of FR-alpha expression |
US20080171906A1 (en) * | 2007-01-16 | 2008-07-17 | Everaerts Frank J L | Tissue performance via hydrolysis and cross-linking |
US20100105759A1 (en) * | 2007-01-16 | 2010-04-29 | Abraham Hochberg | H19 silencing nucleic acid agents for treating rheumatoid arthritis |
WO2008088836A3 (en) * | 2007-01-16 | 2008-10-16 | Burnham Inst Medical Research | Compositions and methods for treatment of colorectal cancer |
US7928083B2 (en) | 2007-01-16 | 2011-04-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | H19 silencing nucleic acid agents for treating rheumatoid arthritis |
US20090074785A1 (en) * | 2007-01-16 | 2009-03-19 | Smith Jeffrey W | Compositions and methods for treatment of colorectal cancer |
US9260715B2 (en) | 2007-01-16 | 2016-02-16 | The University Of Queensland | Method of inducing an immune response |
US20100196403A1 (en) * | 2007-01-29 | 2010-08-05 | Jacob Hochman | Antibody conjugates for circumventing multi-drug resistance |
US20100183696A1 (en) * | 2007-01-30 | 2010-07-22 | Allergan, Inc | Treating Ocular Diseases Using Peroxisome Proliferator-Activated Receptor Delta Antagonists |
US8729042B2 (en) * | 2007-01-30 | 2014-05-20 | Allergan, Inc. | Treating ocular diseases using peroxisome proliferator—activated receptor delta antagonists |
US20120136041A1 (en) * | 2007-01-30 | 2012-05-31 | Allergan, Inc. | Treating Ocular Diseases Using Peroxisome Proliferator-Activated Receptor Delta Antagonists |
US20080299659A1 (en) * | 2007-03-02 | 2008-12-04 | Nastech Pharmaceutical Company Inc. | Nucleic acid compounds for inhibiting apob gene expression and uses thereof |
US9085638B2 (en) | 2007-03-07 | 2015-07-21 | The Johns Hopkins University | DNA vaccine enhancement with MHC class II activators |
US20080260765A1 (en) * | 2007-03-15 | 2008-10-23 | Johns Hopkins University | HPV DNA Vaccines and Methods of Use Thereof |
US20100249052A1 (en) * | 2007-03-26 | 2010-09-30 | Alnylam Pharmaceuticals, Inc. | Dsrna compositions and methods for treating hpv infections |
US8735369B2 (en) | 2007-03-29 | 2014-05-27 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a gene from the Ebola virus |
US20110060031A1 (en) * | 2007-03-29 | 2011-03-10 | Alnylam Pharmaceuticals, Inc. | Compositions And Methods For Inhibiting Expression Of A Gene From The Ebola Virus |
US20110201671A1 (en) * | 2007-03-29 | 2011-08-18 | Alnylam Pharmaceuticals, Inc. | Compositions And Methods For Inhibiting Expression Of A Gene From The Ebola Virus |
US8354390B2 (en) | 2007-03-29 | 2013-01-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a gene from the ebola virus |
US9187516B2 (en) | 2007-03-29 | 2015-11-17 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a gene from the Ebola virus |
US7973020B2 (en) | 2007-03-29 | 2011-07-05 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a gene from the ebola virus |
US20090203135A1 (en) * | 2007-04-23 | 2009-08-13 | Alnylam Pharmaceuticals, Inc. | Glycoconjugates of RNA Interference Agents |
US10131907B2 (en) | 2007-04-23 | 2018-11-20 | Alnylam Pharmaceuticals, Inc. | Glycoconjugates of RNA interference agents |
US8877917B2 (en) * | 2007-04-23 | 2014-11-04 | Alnylam Pharmaceuticals, Inc. | Glycoconjugates of RNA interference agents |
US9873875B2 (en) | 2007-05-01 | 2018-01-23 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
US20100151470A1 (en) * | 2007-05-01 | 2010-06-17 | University Of Massachusetts | Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy |
US9441227B2 (en) | 2007-05-01 | 2016-09-13 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
US10233450B2 (en) | 2007-05-01 | 2019-03-19 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
US20090029466A1 (en) * | 2007-05-01 | 2009-01-29 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded rna |
US20100240734A1 (en) * | 2007-05-01 | 2010-09-23 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded rna |
US8883996B2 (en) | 2007-05-01 | 2014-11-11 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
US7968524B2 (en) * | 2007-05-15 | 2011-06-28 | Helicon Therapeutics, Inc. | Methods of enhancing long term memory formation by inhibition of Gpr12 |
US20090022667A1 (en) * | 2007-05-15 | 2009-01-22 | Marco Peters | METHODS OF TREATING COGNITIVE DISORDERS BY INHIBITION OF Gpr12 |
US9944929B2 (en) | 2007-05-22 | 2018-04-17 | Arcturus Therapeutics, Inc. | UNA single stranded oligomers for therapeutics |
US10457945B2 (en) | 2007-05-22 | 2019-10-29 | Arcturus Therapeutics, Inc. | UNA oligomers for therapeutics with prolonged stability |
US9297009B2 (en) | 2007-05-22 | 2016-03-29 | Arcturus Therapeutics, Inc. | UNA oligomers targeting micro-RNA for therapeutics |
US9051570B2 (en) | 2007-05-22 | 2015-06-09 | Arcturus Therapeutics, Inc. | UNA oligomers for therapeutics |
US9303260B2 (en) | 2007-05-22 | 2016-04-05 | Arcturus Therapeutics, Inc. | UNA duplex oligomers for therapeutics |
US20100210513A1 (en) * | 2007-06-15 | 2010-08-19 | Novartis Ag | RNAi Inhibition of Alpha-ENaC Expression |
US20100190714A1 (en) * | 2007-06-15 | 2010-07-29 | Novatis Ag | RNAi Inhibition of Alpha-ENaC Expression |
US9074212B2 (en) * | 2007-06-15 | 2015-07-07 | Arrowhead Research Corporation | RNAi inhibition of alpha-ENaC expression |
US8119612B2 (en) * | 2007-06-15 | 2012-02-21 | Novartis Ag | RNAi inhibition of alpha-ENaC expression |
US20100216972A1 (en) * | 2007-06-15 | 2010-08-26 | Novartis Ag | RNAi Inhibition of Alpha-ENaC Expression |
US7939508B2 (en) * | 2007-06-15 | 2011-05-10 | Novartis Ag | RNAi inhibition of alpha-ENaC expression |
US20100210514A1 (en) * | 2007-06-15 | 2010-08-19 | Novartis Ag | RNAi Inhibition of Alpha-ENaC Expression |
US20100216971A1 (en) * | 2007-06-15 | 2010-08-26 | Novartis Ag | RNAi Inhibition of Alpha-ENaC Expression |
US9914927B2 (en) | 2007-06-15 | 2018-03-13 | Arrowhead Pharmaceuticals, Inc. | RNAi inhibition of alpha-ENaC expression |
US8168606B2 (en) * | 2007-06-15 | 2012-05-01 | Novartis Ag | RNAi inhibition of alpha-ENaC expression |
US11208662B2 (en) | 2007-06-15 | 2021-12-28 | Arrowhead Pharmaceuticals, Inc. | RNAi inhibition of alpha-ENaC expression |
US9476052B2 (en) | 2007-06-15 | 2016-10-25 | Arrowhead Pharmaceuticals, Inc. | RNAi inhibition of alpha-ENaC expression |
US7943592B2 (en) * | 2007-06-15 | 2011-05-17 | Novartis Ag | RNAi inhibition of alpha-ENaC expression |
US10544418B2 (en) | 2007-06-15 | 2020-01-28 | Arrowhead Pharmaceuticals, Inc. | RNAi inhibition of alpha-ENaC expression |
US20140135379A1 (en) * | 2007-06-29 | 2014-05-15 | Niigata University | Method of fixing and expressing physiologically active substance |
US10689650B2 (en) | 2007-06-29 | 2020-06-23 | Stelic Institute & Co. | Method of fixing and expressing physiologically active substance |
US11485974B2 (en) | 2007-06-29 | 2022-11-01 | Stelic Institute & Co. | Method of fixing and expressing physiologically active substance |
US9018180B2 (en) * | 2007-07-10 | 2015-04-28 | Neurim Pharmaceuticals (1991) Ltd. | CD44 splice variants in neurodegenerative diseases |
US20110172286A1 (en) * | 2007-07-10 | 2011-07-14 | Neurim Pharmaceuticals (1991) Ltd. | Cd44 splice variants in neurodegenerative diseases |
US9416166B2 (en) | 2007-07-10 | 2016-08-16 | Neurim Pharmaceuticals (1991) Ltd. | CD44 splice variants in neurodegenerative diseases |
US20090053298A1 (en) * | 2007-07-31 | 2009-02-26 | Sumitomo Chemical Company, Limited | Compositions and methods for inhibiting car gene expression by rna interference |
US7816338B2 (en) * | 2007-07-31 | 2010-10-19 | Sumitomo Chemical Company, Limited | Compositions and methods for inhibiting car gene expression by RNA interference |
US20110184041A1 (en) * | 2007-08-17 | 2011-07-28 | Richard Kremer | PTHrP, ITS ISOFORMS AND ANTAGONIST THERETO IN THE DIAGNOSIS AND TREATMENT OF DISEASE |
US8501929B2 (en) * | 2007-08-17 | 2013-08-06 | Biochrom Pharma Inc. | PTHrP, its isoforms and antagonist thereto in the diagnosis and treatment of disease |
US20090081789A1 (en) * | 2007-08-31 | 2009-03-26 | Greenville Hospital System | Activation of nuclear factor kappa B |
US9080215B2 (en) | 2007-09-14 | 2015-07-14 | Asuragen, Inc. | MicroRNAs differentially expressed in cervical cancer and uses thereof |
US20100240441A1 (en) * | 2007-09-14 | 2010-09-23 | Konami Digital Entertainment Co., Ltd | Game system, and game apparatus and challenge notifying apparatus constituting the game system |
US8361714B2 (en) | 2007-09-14 | 2013-01-29 | Asuragen, Inc. | Micrornas differentially expressed in cervical cancer and uses thereof |
US20100136026A1 (en) * | 2007-09-26 | 2010-06-03 | Kerr William G | Ship Inhibition to Direct Hematopoietic Stem Cells and Induce Extramedullary Hematopoiesis |
US20090092988A1 (en) * | 2007-10-04 | 2009-04-09 | Schwartz Jacob C | Modulating Gene Expression with agRNA and Gapmers Targeting Antisense Transcripts |
US8507457B2 (en) | 2007-11-07 | 2013-08-13 | Beeologics Inc. | Compositions for conferring tolerance to viral disease in social insects, and the use thereof |
US10888579B2 (en) | 2007-11-07 | 2021-01-12 | Beeologics Inc. | Compositions for conferring tolerance to viral disease in social insects, and the use thereof |
US20090118214A1 (en) * | 2007-11-07 | 2009-05-07 | Beeologics, Llc | Compositions for conferring tolerance to viral disease in social insects, and the use thereof |
US8097712B2 (en) | 2007-11-07 | 2012-01-17 | Beelogics Inc. | Compositions for conferring tolerance to viral disease in social insects, and the use thereof |
US20100098664A1 (en) * | 2007-11-28 | 2010-04-22 | Mathieu Jean-Francois Desclaux | Lentiviral vectors allowing RNAi mediated inhibition of GFAP and vimentin expression |
US20100255023A1 (en) * | 2007-11-30 | 2010-10-07 | Si-Yi Chen | Dendritic cell vaccine compositions and uses of same |
US8324369B2 (en) | 2007-11-30 | 2012-12-04 | Baylor College Of Medicine | Dendritic cell vaccine compositions and uses of same |
US8071562B2 (en) | 2007-12-01 | 2011-12-06 | Mirna Therapeutics, Inc. | MiR-124 regulated genes and pathways as targets for therapeutic intervention |
US10806791B2 (en) | 2007-12-04 | 2020-10-20 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
US9352048B2 (en) | 2007-12-04 | 2016-05-31 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
US20090239814A1 (en) * | 2007-12-04 | 2009-09-24 | Alnylam Pharmaceuticals, Inc. | Carbohydrate Conjugates as Delivery Agents for Oligonucleotides |
US11110174B2 (en) | 2007-12-04 | 2021-09-07 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
US8106022B2 (en) | 2007-12-04 | 2012-01-31 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
US9814777B2 (en) | 2007-12-04 | 2017-11-14 | Arbutus Biopharma Corporation | Targeting lipids |
US11666653B2 (en) | 2007-12-04 | 2023-06-06 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
US9370582B2 (en) | 2007-12-04 | 2016-06-21 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
US8450467B2 (en) | 2007-12-04 | 2013-05-28 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
US20090247608A1 (en) * | 2007-12-04 | 2009-10-01 | Alnylam Pharmaceuticals, Inc. | Targeting Lipids |
US8507455B2 (en) | 2007-12-04 | 2013-08-13 | Alnylam Pharmaceuticals, Inc. | Folate conjugates |
US20090247614A1 (en) * | 2007-12-04 | 2009-10-01 | Alnylam Pharmaceuticals, Inc. | Folate Conjugates |
US9867882B2 (en) | 2007-12-04 | 2018-01-16 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
US8828956B2 (en) | 2007-12-04 | 2014-09-09 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
US9370581B2 (en) | 2007-12-04 | 2016-06-21 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
US8664193B2 (en) | 2007-12-10 | 2014-03-04 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of factor VII gene |
US8334273B2 (en) | 2007-12-10 | 2012-12-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of factor VII gene |
US9062310B2 (en) | 2007-12-10 | 2015-06-23 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of factor VII gene |
US8410073B2 (en) | 2007-12-13 | 2013-04-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for prevention or treatment of RSV infection |
US20090238772A1 (en) * | 2007-12-13 | 2009-09-24 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for prevention or treatment of rsv infection |
US9127277B2 (en) | 2007-12-13 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for prevention or treatment of RSV infection |
US20100204306A1 (en) * | 2007-12-14 | 2010-08-12 | Alnylam Pharmaceuticals, Inc. | Method of Treating Neurodegenerative Disease |
US20100010066A1 (en) * | 2008-01-31 | 2010-01-14 | Kevin Fitzgerald | Optimized Methods For Delivery Of DSRNA Targeting The PCSK9 Gene |
US10131904B2 (en) | 2008-02-11 | 2018-11-20 | Rxi Pharmaceuticals Corporation | Modified RNAi polynucleotides and uses thereof |
US10633654B2 (en) | 2008-02-11 | 2020-04-28 | Phio Pharmaceuticals Corp. | Modified RNAi polynucleotides and uses thereof |
US8288525B2 (en) | 2008-02-12 | 2012-10-16 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of CD45 gene |
US20090203138A1 (en) * | 2008-02-12 | 2009-08-13 | University Of Tennessee Research Foundation, Inc. | Small Interfering RNAs Targeting Feline Herpes Virus |
US7977321B2 (en) * | 2008-02-12 | 2011-07-12 | University Of Tennessee Research Foundation | Small interfering RNAs targeting feline herpes virus |
US8912316B2 (en) | 2008-02-12 | 2014-12-16 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of CD45 gene |
US20110034537A1 (en) * | 2008-02-12 | 2011-02-10 | De Fougerolles Antonin | Compositions and methods for inhibiting expression of cd45 gene |
US20110207796A1 (en) * | 2008-02-13 | 2011-08-25 | Elan Pharma International Limited | Alpha-synuclein kinase |
US20100087508A1 (en) * | 2008-03-05 | 2010-04-08 | David Bumcrot | Compositions and Methods for Inhibiting Expression of Eg5 and VEGF Genes |
US9006197B2 (en) | 2008-03-05 | 2015-04-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of Eg5 and VEGF genes |
US20100003317A1 (en) * | 2008-03-27 | 2010-01-07 | Akin Akinc | Compositions and methods for mediating rnai in vivo |
US8148344B2 (en) | 2008-03-27 | 2012-04-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for mediating RNAi in vivo |
US20080221059A1 (en) * | 2008-04-03 | 2008-09-11 | National Taiwan University | Novel treatment tool for cancer: rna interference of bcas2 |
US7718631B2 (en) * | 2008-04-03 | 2010-05-18 | National Taiwan University | Treatment tool for cancer: RNA interference of BCAS2 |
US8822668B2 (en) | 2008-04-15 | 2014-09-02 | Protiva Biotherapeutics, Inc. | Lipid formulations for nucleic acid delivery |
US9364435B2 (en) | 2008-04-15 | 2016-06-14 | Protiva Biotherapeutics, Inc. | Lipid formulations for nucleic acid delivery |
US8492359B2 (en) | 2008-04-15 | 2013-07-23 | Protiva Biotherapeutics, Inc. | Lipid formulations for nucleic acid delivery |
US8058069B2 (en) | 2008-04-15 | 2011-11-15 | Protiva Biotherapeutics, Inc. | Lipid formulations for nucleic acid delivery |
US11141378B2 (en) | 2008-04-15 | 2021-10-12 | Arbutus Biopharma Corporation | Lipid formulations for nucleic acid delivery |
US20090285861A1 (en) * | 2008-04-17 | 2009-11-19 | Tzyy-Choou Wu | Tumor cell-based cancer immunotherapeutic compositions and methods |
US8765932B2 (en) | 2008-04-17 | 2014-07-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of XBP-1 gene |
US20090275638A1 (en) * | 2008-04-17 | 2009-11-05 | Kevin Fitzgerald | Compositions and Methods for Inhibiting Expression of XBP-1 Gene |
US7875711B2 (en) | 2008-04-17 | 2011-01-25 | Alnylam Pharamaceuticals, Inc. | Compositions and methods for inhibiting expression of XBP-1 gene |
US8344126B2 (en) | 2008-04-17 | 2013-01-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of XBP-1 gene |
US20110152350A1 (en) * | 2008-04-17 | 2011-06-23 | Kevin Fitzgerald | Compositions and Methods for Inhibiting Expression of XBP-1 Gene |
USRE48948E1 (en) | 2008-04-18 | 2022-03-01 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable polymer |
US8324366B2 (en) | 2008-04-29 | 2012-12-04 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for delivering RNAI using lipoproteins |
US8258111B2 (en) | 2008-05-08 | 2012-09-04 | The Johns Hopkins University | Compositions and methods related to miRNA modulation of neovascularization or angiogenesis |
US9540645B2 (en) | 2008-05-08 | 2017-01-10 | The John Hopkins University | Compositions and methods related to miRNA modulation of neovascularization or angiogenesis |
US9365852B2 (en) | 2008-05-08 | 2016-06-14 | Mirna Therapeutics, Inc. | Compositions and methods related to miRNA modulation of neovascularization or angiogenesis |
US8222221B2 (en) | 2008-06-04 | 2012-07-17 | The Board Of Regents Of The University Of Texas System | Modulation of gene expression through endogenous small RNA targeting of gene promoters |
US8431692B2 (en) | 2008-06-06 | 2013-04-30 | Quark Pharmaceuticals, Inc. | Compositions and methods for treatment of ear disorders |
US9089591B2 (en) | 2008-06-06 | 2015-07-28 | Quark Pharmaceuticals, Inc. | Compositions and methods for treatment of ear disorders |
US20110142917A1 (en) * | 2008-06-06 | 2011-06-16 | Egvenia Alpert | Compositions and methods for treatment of ear disorders |
US20110053226A1 (en) * | 2008-06-13 | 2011-03-03 | Riboxx Gmbh | Method for enzymatic synthesis of chemically modified rna |
US20110184046A1 (en) * | 2008-07-11 | 2011-07-28 | Dinah Wen-Yee Sah | Compositions And Methods For Inhibiting Expression Of GSK-3 Genes |
US9029525B2 (en) | 2008-07-11 | 2015-05-12 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of GSK-3 genes |
US8815818B2 (en) | 2008-07-18 | 2014-08-26 | Rxi Pharmaceuticals Corporation | Phagocytic cell delivery of RNAI |
US9433684B2 (en) | 2008-08-19 | 2016-09-06 | Nektar Therapeutics | Conjugates of small-interfering nucleic acids |
US9089610B2 (en) | 2008-08-19 | 2015-07-28 | Nektar Therapeutics | Complexes of small-interfering nucleic acids |
US9688987B2 (en) | 2008-08-25 | 2017-06-27 | Excaliard Pharmaceuticals, Inc. | Antisense oligonucleotides directed against connective tissue growth factor and uses thereof |
US9096851B2 (en) | 2008-08-25 | 2015-08-04 | Excaliard Pharmaceuticals, Inc. | Antisense oligonucleotides directed against connective tissue growth factor and uses thereof |
US20190323013A1 (en) * | 2008-08-25 | 2019-10-24 | Excaliard Pharmaceuticals, Inc. | Antisense oligonucleotides directed against connective tissue growth factor and uses thereof |
US8772260B2 (en) | 2008-08-25 | 2014-07-08 | Isis Pharmaceuticals, Inc | Methods for inhibiting expression of connective tissue growth factor |
US20100130595A1 (en) * | 2008-08-25 | 2010-05-27 | Dean Nicholas M | Antisense oligonucleotides directed against connective tissue growth factor and uses thereof |
US8252762B2 (en) * | 2008-08-25 | 2012-08-28 | Excaliard Pharmaceuticals, Inc. | Antisense oligonucleotides directed against connective tissue growth factor and uses thereof |
US10266826B2 (en) | 2008-09-15 | 2019-04-23 | Children's Medical Center Corporation | Modulation of BCL11A for treatment of hemoglobinopathies |
US20170152513A1 (en) * | 2008-09-15 | 2017-06-01 | Children's Medical Center Corporation | Modulation of bcl11a for treatment of hemoglobinopathies |
US10570392B2 (en) | 2008-09-15 | 2020-02-25 | The Children's Medical Center Corporation | Modulation of BCL11A for treatment of hemoglobinopathies |
US9885041B2 (en) * | 2008-09-15 | 2018-02-06 | The Children's Medical Center Corporation | Modulation of BCL11A for treatment of hemoglobinopathies |
US11396654B2 (en) | 2008-09-22 | 2022-07-26 | Phio Pharmaceuticals Corp. | Neutral nanotransporters |
US10876119B2 (en) | 2008-09-22 | 2020-12-29 | Phio Pharmaceuticals Corp. | Reduced size self-delivering RNAI compounds |
US10041073B2 (en) | 2008-09-22 | 2018-08-07 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering RNAi compounds |
US9175289B2 (en) | 2008-09-22 | 2015-11-03 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering RNAi compounds |
US8664189B2 (en) | 2008-09-22 | 2014-03-04 | Rxi Pharmaceuticals Corporation | RNA interference in skin indications |
US10774330B2 (en) | 2008-09-22 | 2020-09-15 | Phio Pharmaceuticals Corp. | Reduced size self-delivering RNAI compounds |
US8796443B2 (en) | 2008-09-22 | 2014-08-05 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering RNAi compounds |
US10815485B2 (en) | 2008-09-22 | 2020-10-27 | Phio Pharmaceuticals Corp. | RNA interference in skin indications |
US9303259B2 (en) | 2008-09-22 | 2016-04-05 | Rxi Pharmaceuticals Corporation | RNA interference in skin indications |
US10138485B2 (en) | 2008-09-22 | 2018-11-27 | Rxi Pharmaceuticals Corporation | Neutral nanotransporters |
US9938530B2 (en) | 2008-09-22 | 2018-04-10 | Rxi Pharmaceuticals Corporation | RNA interference in skin indications |
US10472628B2 (en) | 2008-09-25 | 2019-11-12 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gene |
US9868950B2 (en) | 2008-09-25 | 2018-01-16 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of serum amyloid A gene |
US8546554B2 (en) | 2008-09-25 | 2013-10-01 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gene |
US11149273B2 (en) | 2008-09-25 | 2021-10-19 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of serum amyloid A gene |
US11884919B2 (en) | 2008-09-25 | 2024-01-30 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene |
US9206421B2 (en) | 2008-09-25 | 2015-12-08 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of serum amyloid A gene |
US9200282B2 (en) * | 2008-10-06 | 2015-12-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of an RNA from west nile virus |
US8592570B2 (en) | 2008-10-06 | 2013-11-26 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of an RNA from West Nile virus |
US20140051747A1 (en) * | 2008-10-06 | 2014-02-20 | Alnylam Pharmaceuticals, Inc. | Compositions and Methods for Inhibiting Expression of an RNA from West Nile Virus |
US9139554B2 (en) | 2008-10-09 | 2015-09-22 | Tekmira Pharmaceuticals Corporation | Amino lipids and methods for the delivery of nucleic acids |
US10653780B2 (en) | 2008-10-09 | 2020-05-19 | The University Of British Columbia | Amino lipids and methods for the delivery of nucleic acids |
US8283460B2 (en) | 2008-10-15 | 2012-10-09 | Somagenics, Inc. | Short hairpin RNAs for inhibition of gene expression |
US8779115B2 (en) | 2008-10-15 | 2014-07-15 | Somagenics Inc. | Short hairpin RNAs for inhibition of gene expression |
US20100112686A1 (en) * | 2008-10-15 | 2010-05-06 | Qing Ge | Short hairpin rnas for inhibition of gene expression |
US8741866B2 (en) | 2008-10-20 | 2014-06-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of transthyretin |
US20100120893A1 (en) * | 2008-10-20 | 2010-05-13 | Dinah Wen-Yee Sah | Compositions and Methods for Inhibiting Expression of Transthyretin |
US10240152B2 (en) | 2008-10-20 | 2019-03-26 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of transthyretin |
US9234196B2 (en) | 2008-10-20 | 2016-01-12 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of transthyretin |
US8168775B2 (en) | 2008-10-20 | 2012-05-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of transthyretin |
US20100168205A1 (en) * | 2008-10-23 | 2010-07-01 | Alnylam Pharmaceuticals, Inc. | Methods and Compositions for Prevention or Treatment of RSV Infection Using Modified Duplex RNA Molecules |
US20110190380A1 (en) * | 2008-10-23 | 2011-08-04 | Elena Feinstein | Methods for delivery of sirna to bone marrow cells and uses thereof |
US11254940B2 (en) | 2008-11-19 | 2022-02-22 | Phio Pharmaceuticals Corp. | Inhibition of MAP4K4 through RNAi |
US9074211B2 (en) | 2008-11-19 | 2015-07-07 | Rxi Pharmaceuticals Corporation | Inhibition of MAP4K4 through RNAI |
US20100291188A1 (en) * | 2008-12-04 | 2010-11-18 | Musc Foundation For Research Development | Periostin Inhibitory Compositions for Myocardial Regeneration, Methods of Delivery, and Methods of Using Same |
US8470792B2 (en) | 2008-12-04 | 2013-06-25 | Opko Pharmaceuticals, Llc. | Compositions and methods for selective inhibition of VEGF |
US8889644B2 (en) | 2008-12-10 | 2014-11-18 | Alnylam Pharmaceuticals, Inc. | GNAQ targeted dsRNA compositions and methods for inhibiting expression |
US9566295B2 (en) | 2008-12-10 | 2017-02-14 | Alnylam Pharmaceuticals, Inc. | GNAQ targeted dsRNA compositions and methods for inhibiting expression |
US8324368B2 (en) | 2008-12-10 | 2012-12-04 | Alnylam Pharmaceuticals, Inc. | GNAQ targeted dsRNA compositions and methods for inhibiting expression |
US10954516B2 (en) | 2008-12-10 | 2021-03-23 | Alnylam Pharmaceuticals, Inc. | GNAQ targeted dsRNA compositions and methods for inhibiting expression |
US9963700B2 (en) | 2008-12-10 | 2018-05-08 | Alnylam Pharmaceuticals, Inc. | GNAQ targeted dsRNA compositions and methods for inhibiting expression |
US20100168206A1 (en) * | 2008-12-10 | 2010-07-01 | Jared Gollob | GNAQ Targeted dsRNA Compositions And Methods For Inhibiting Expression |
US20100166661A1 (en) * | 2008-12-11 | 2010-07-01 | Bojian Zheng | siRNA COMPOSITIONS AND METHODS FOR POTENTLY INHIBITING VIRAL INFECTION |
US8664188B2 (en) * | 2008-12-11 | 2014-03-04 | Xiangxue Group (Hong Kong) Company Limited | siRNA compositions and methods for potently inhibiting viral infection |
US20110245325A1 (en) * | 2008-12-12 | 2011-10-06 | Kureha Corporation | Pharmaceutical composition for treatment of cancer and asthma |
US8389711B2 (en) * | 2008-12-12 | 2013-03-05 | Kureha Corporation | Pharmaceutical composition for treatment of cancer and asthma |
US9493774B2 (en) | 2009-01-05 | 2016-11-15 | Rxi Pharmaceuticals Corporation | Inhibition of PCSK9 through RNAi |
US10167471B2 (en) | 2009-01-05 | 2019-01-01 | Rxi Pharmaceuticals Corporation | Inhibition of PCSK9 through RNAI |
US9023820B2 (en) | 2009-01-26 | 2015-05-05 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing apolipoprotein C-III expression |
US9428751B2 (en) | 2009-01-26 | 2016-08-30 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing apolipoprotein C-III expression |
US20100197773A1 (en) * | 2009-02-03 | 2010-08-05 | Birgit Bramlage | Compositions and methods for inhibiting expression of ptp1b genes |
US11667915B2 (en) | 2009-02-04 | 2023-06-06 | Phio Pharmaceuticals Corp. | RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
US9745574B2 (en) | 2009-02-04 | 2017-08-29 | Rxi Pharmaceuticals Corporation | RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
US10479992B2 (en) | 2009-02-04 | 2019-11-19 | Phio Pharmaceuticals Corp. | RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
US9993567B2 (en) | 2009-03-23 | 2018-06-12 | Quark Pharmaceuticals, Inc. | Composition of anti-ENDO180 antibodies and methods of use for the treatment of cancer and fibrotic diseases |
US10653619B2 (en) | 2009-03-23 | 2020-05-19 | Medtronic, Inc. | Drug depots for treatment of pain and inflammation |
US8444983B2 (en) | 2009-03-23 | 2013-05-21 | Quark Pharmaceuticals, Inc. | Composition of anti-ENDO180 antibodies and methods of use for the treatment of cancer and fibrotic diseases |
US8815586B2 (en) | 2009-04-24 | 2014-08-26 | The Board Of Regents Of The University Of Texas System | Modulation of gene expression using oligomers that target gene regions downstream of 3′ untranslated regions |
US20100273863A1 (en) * | 2009-04-24 | 2010-10-28 | Board Of Regents, The University Of Texas System | Modulation of Gene Expression Using Oligomers That Target Gene Regions Downstream of 3' Untranslated Regions |
US8822426B2 (en) | 2009-05-05 | 2014-09-02 | Beeologics Inc. | Prevention and treatment of nosema disease in bees |
US8933049B2 (en) * | 2009-05-05 | 2015-01-13 | Medical Diagnostic Laboratories, Llc | Repressor on IFN-λ promoter and siRNA against ZEB1 and BLIMP-1 to increase IFN-λ gene activity |
US9932579B2 (en) | 2009-05-05 | 2018-04-03 | Beeologics Inc | Prevention and treatment of Nosema disease in bees |
US20140057960A1 (en) * | 2009-05-05 | 2014-02-27 | Medical Diagnostic Laboratories, Llc | Novel repressor on ifn-lambda promoter and sirna against zeb1 and blimp-1 to increase ifn-lambda gene activity |
US20110020300A1 (en) * | 2009-05-15 | 2011-01-27 | Genentech, Inc. | Compositions and methods for inhibiting expression of glucocorticoid receptor (gcr) genes |
US9957505B2 (en) | 2009-06-01 | 2018-05-01 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotides for multivalent RNA interference, compositions and methods of use thereof |
US9200276B2 (en) | 2009-06-01 | 2015-12-01 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotides for multivalent RNA interference, compositions and methods of use thereof |
US20110015252A1 (en) * | 2009-06-15 | 2011-01-20 | Kevin Fitzgerald | Lipid formulated dsrna targeting the pcsk9 gene |
US10053689B2 (en) | 2009-06-15 | 2018-08-21 | Arbutus Biopharma Corporation | Methods for increasing efficacy of lipid formulated siRNA |
US8598139B2 (en) | 2009-06-15 | 2013-12-03 | Alnylam Pharmaceuticals, Inc. | Lipid formulated dsRNA targeting the PCSK9 gene |
US9051567B2 (en) | 2009-06-15 | 2015-06-09 | Tekmira Pharmaceuticals Corporation | Methods for increasing efficacy of lipid formulated siRNA |
US8273869B2 (en) | 2009-06-15 | 2012-09-25 | Alnylam Pharmaceuticals, Inc. | Lipid formulated dsRNA targeting the PCSK9 gene |
US8569256B2 (en) | 2009-07-01 | 2013-10-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
US9018187B2 (en) | 2009-07-01 | 2015-04-28 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
US11786598B2 (en) | 2009-07-01 | 2023-10-17 | Arbutus Biopharma Corporation | Lipid formulations for delivery of therapeutic agents |
US9878042B2 (en) | 2009-07-01 | 2018-01-30 | Protiva Biotherapeutics, Inc. | Lipid formulations for delivery of therapeutic agents to solid tumors |
US8283333B2 (en) | 2009-07-01 | 2012-10-09 | Protiva Biotherapeutics, Inc. | Lipid formulations for nucleic acid delivery |
US11446383B2 (en) | 2009-07-01 | 2022-09-20 | Arbutus Biopharma Corporation | Lipid formulations for delivery of therapeutic agents |
US9816091B2 (en) | 2009-07-13 | 2017-11-14 | Somagenics, Inc. | Chemical modification of short small hairpin RNAs for inhibition of gene expression |
US10870850B2 (en) | 2009-07-13 | 2020-12-22 | Somagenics, Inc. | Chemical modification of short small hairpin RNAs for inhibition of gene expression |
US8871730B2 (en) | 2009-07-13 | 2014-10-28 | Somagenics Inc. | Chemical modification of short small hairpin RNAs for inhibition of gene expression |
US20110201667A1 (en) * | 2009-07-20 | 2011-08-18 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing ebola virus gene expression |
US8716464B2 (en) | 2009-07-20 | 2014-05-06 | Thomas W. Geisbert | Compositions and methods for silencing Ebola virus gene expression |
US9187748B2 (en) | 2009-07-20 | 2015-11-17 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing ebola virus gene expression |
US9029338B2 (en) | 2009-08-14 | 2015-05-12 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus |
US8859516B2 (en) | 2009-09-15 | 2014-10-14 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes |
WO2011035065A1 (en) | 2009-09-17 | 2011-03-24 | Nektar Therapeutics | Monoconjugated chitosans as delivery agents for small interfering nucleic acids |
US8916693B2 (en) | 2009-09-17 | 2014-12-23 | Nektar Therapeutics | Monoconjugated chitosans as delivery agents for small interfering nucleic acids |
US9187746B2 (en) | 2009-09-22 | 2015-11-17 | Alnylam Pharmaceuticals, Inc. | Dual targeting siRNA agents |
US9222086B2 (en) * | 2009-09-23 | 2015-12-29 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing genes expressed in cancer |
US20130065939A1 (en) * | 2009-09-23 | 2013-03-14 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing genes expressed in cancer |
US8962584B2 (en) | 2009-10-14 | 2015-02-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Compositions for controlling Varroa mites in bees |
US10801028B2 (en) | 2009-10-14 | 2020-10-13 | Beeologics Inc. | Compositions for controlling Varroa mites in bees |
US9662348B2 (en) | 2009-10-14 | 2017-05-30 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Compositions for controlling Varroa mites in bees |
US9101643B2 (en) | 2009-11-03 | 2015-08-11 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR) |
US20110110483A1 (en) * | 2009-11-06 | 2011-05-12 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for migrating fuel assemblies in a nuclear fission reactor |
US20110166199A1 (en) * | 2010-01-07 | 2011-07-07 | National Cheng Kung University | RNAi COMPOUND TARGETED TO THROMBOSPONDIN-1 AND APPLICATIONS THEREOF |
US8377902B2 (en) * | 2010-01-07 | 2013-02-19 | National Cheng Kung University | RNAi compound targeted to thrombospondin-1 and applications thereof |
US8722641B2 (en) | 2010-01-29 | 2014-05-13 | St. Jude Children's Research Hospital | Oligonucleotides which inhibit p53 induction in response to cellular stress |
US9540647B2 (en) | 2010-03-19 | 2017-01-10 | University Of South Alabama | Methods and compositions for the treatment of cancer |
US9186370B2 (en) * | 2010-03-19 | 2015-11-17 | University Of South Alabama | Methods and compositions for the treatment of cancer |
US20130224311A1 (en) * | 2010-03-19 | 2013-08-29 | University Of South Alabama | Methods and compositions for the treatment of cancer |
US9340786B2 (en) | 2010-03-24 | 2016-05-17 | Rxi Pharmaceuticals Corporation | RNA interference in dermal and fibrotic indications |
US9963702B2 (en) | 2010-03-24 | 2018-05-08 | Rxi Pharmaceuticals Corporation | RNA interference in dermal and fibrotic indications |
US10913948B2 (en) | 2010-03-24 | 2021-02-09 | Phio Pharmaceuticals Corp. | RNA interference in dermal and fibrotic indications |
US11118178B2 (en) | 2010-03-24 | 2021-09-14 | Phio Pharmaceuticals Corp. | Reduced size self-delivering RNAI compounds |
US10662430B2 (en) | 2010-03-24 | 2020-05-26 | Phio Pharmaceuticals Corp. | RNA interference in ocular indications |
US9080171B2 (en) | 2010-03-24 | 2015-07-14 | RXi Parmaceuticals Corporation | Reduced size self-delivering RNAi compounds |
US10240149B2 (en) | 2010-03-24 | 2019-03-26 | Phio Pharmaceuticals Corp. | Reduced size self-delivering RNAi compounds |
US9095504B2 (en) | 2010-03-24 | 2015-08-04 | Rxi Pharmaceuticals Corporation | RNA interference in ocular indications |
US10184124B2 (en) | 2010-03-24 | 2019-01-22 | Phio Pharmaceuticals Corp. | RNA interference in ocular indications |
US11584933B2 (en) | 2010-03-24 | 2023-02-21 | Phio Pharmaceuticals Corp. | RNA interference in ocular indications |
US8455455B1 (en) | 2010-03-31 | 2013-06-04 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing genes involved in hemorrhagic fever |
US9095561B2 (en) * | 2010-05-12 | 2015-08-04 | University Of South Carolina | Methods for affecting homology-directed DNA double stranded break repair |
US20140010893A1 (en) * | 2010-05-12 | 2014-01-09 | University Of South Carolina | Methods for Affecting Homology-Directed DNA Double Stranded Break Repair |
US9006417B2 (en) | 2010-06-30 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
US9518272B2 (en) | 2010-06-30 | 2016-12-13 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
US11718852B2 (en) | 2010-06-30 | 2023-08-08 | Arbutus Biopharma Corporation | Non-liposomal systems for nucleic acid delivery |
US9404127B2 (en) | 2010-06-30 | 2016-08-02 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
US9642872B2 (en) | 2010-09-30 | 2017-05-09 | University Of Zurich | Treatment of B-cell lymphoma with microRNA |
US20140315973A1 (en) * | 2010-10-07 | 2014-10-23 | Agency For Science, Technology And Research | Parp-1 inhibitors |
US9970005B2 (en) | 2010-10-29 | 2018-05-15 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
US9260471B2 (en) | 2010-10-29 | 2016-02-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
US11193126B2 (en) | 2010-10-29 | 2021-12-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
US11932854B2 (en) | 2010-10-29 | 2024-03-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
US9173894B2 (en) | 2011-02-02 | 2015-11-03 | Excaliard Pharamaceuticals, Inc. | Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (CTGF) |
US9611478B2 (en) | 2011-02-03 | 2017-04-04 | Mirna Therapeutics, Inc. | Synthetic mimics of miR-124 |
US9233121B2 (en) * | 2011-03-11 | 2016-01-12 | Board Of Regents Of The University Of Nebraska | Compositions and methods for the treatment of cancer |
US20140057962A1 (en) * | 2011-03-11 | 2014-02-27 | Surinder K. Batra | Compositions and Methods for the Treatment of Cancer |
US11306314B2 (en) | 2011-06-21 | 2022-04-19 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof |
US10273478B2 (en) | 2011-06-21 | 2019-04-30 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of expression of protein C (PROC) genes |
US11118181B2 (en) | 2011-06-21 | 2021-09-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of expression of protein C (PROC) genes |
US10557139B2 (en) | 2011-06-21 | 2020-02-11 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof |
US9322018B2 (en) * | 2011-06-21 | 2016-04-26 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof |
US9315813B2 (en) | 2011-06-21 | 2016-04-19 | Alnylam Pharmaceuticals, Inc | Compositions and methods for inhibition of expression of apolipoprotein C-III (APOC3) genes |
US20140179768A1 (en) * | 2011-06-21 | 2014-06-26 | Alnylam Pharmaceuticals, Inc. | ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
US11866709B2 (en) | 2011-06-21 | 2024-01-09 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof |
US11332743B2 (en) | 2011-06-21 | 2022-05-17 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof |
US11130953B2 (en) | 2011-06-21 | 2021-09-28 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof |
US10337010B2 (en) | 2011-06-21 | 2019-07-02 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof |
US11306316B2 (en) | 2011-06-21 | 2022-04-19 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof |
US9068184B2 (en) | 2011-06-21 | 2015-06-30 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of expression of protein C (PROC) genes |
US10934545B2 (en) | 2011-06-21 | 2021-03-02 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof |
US11306315B2 (en) | 2011-06-21 | 2022-04-19 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof |
US11525138B2 (en) | 2011-06-21 | 2022-12-13 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof |
US10550390B2 (en) | 2011-06-21 | 2020-02-04 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof |
US9725718B2 (en) | 2011-06-21 | 2017-08-08 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of expression of protein C (PROC) genes |
US9228188B2 (en) | 2011-06-21 | 2016-01-05 | Alnylam Pharmaceuticals, Inc. | Compositions and method for inhibiting hepcidin antimicrobial peptide (HAMP) or HAMP-related gene expression |
US9771591B2 (en) | 2011-06-21 | 2017-09-26 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof |
US11834662B2 (en) | 2011-06-21 | 2023-12-05 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof |
US11840692B2 (en) | 2011-06-21 | 2023-12-12 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof |
US9970006B2 (en) | 2011-06-21 | 2018-05-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of expression of apolipoprotein C-III (APOC3) genes |
DE102011118024A1 (de) | 2011-08-01 | 2013-02-07 | Technische Universität Dresden | Inhibitor der Expression der Pro-Caspase 1 |
US9644241B2 (en) | 2011-09-13 | 2017-05-09 | Interpace Diagnostics, Llc | Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease |
US10655184B2 (en) | 2011-09-13 | 2020-05-19 | Interpace Diagnostics, Llc | Methods and compositions involving miR-135b for distinguishing pancreatic cancer from benign pancreatic disease |
US10570391B2 (en) | 2011-11-18 | 2020-02-25 | Alnylam Pharmaceuticals, Inc. | RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases |
US9399775B2 (en) | 2011-11-18 | 2016-07-26 | Alnylam Pharmaceuticals, Inc. | RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases |
US9464291B2 (en) * | 2012-01-06 | 2016-10-11 | University Of South Alabama | Methods and compositions for the treatment of cancer |
US20140364485A1 (en) * | 2012-01-06 | 2014-12-11 | University Of South Alabama | Methods and compositions for the treatment of cancer |
US10214745B2 (en) | 2012-03-15 | 2019-02-26 | The Scripps Research Institute | Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF |
US9808479B2 (en) | 2012-09-05 | 2017-11-07 | Sylentis Sau | SiRNA and their use in methods and compositions for the treatment and / or prevention of eye conditions |
US10011832B2 (en) | 2012-09-05 | 2018-07-03 | Sylentis Sau | SiRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
US20150202223A1 (en) * | 2012-10-02 | 2015-07-23 | The General Hospital Corporation | Methods relating to dna-sensing pathway related conditions |
US9814741B2 (en) * | 2012-10-02 | 2017-11-14 | The General Hospital Corporation | Methods relating to DNA-sensing pathway related conditions |
US11542493B2 (en) | 2012-11-27 | 2023-01-03 | The Children's Medical Center Corporation | Targeting BCL11A distal regulatory elements for fetal hemoglobin reinduction |
US20160215285A1 (en) * | 2012-12-30 | 2016-07-28 | The Regents Of The University Of California | Methods of modulating compliance of the trabecular meshwork |
US9920320B2 (en) * | 2012-12-30 | 2018-03-20 | The Regents Of The University Of California | Methods of modulating compliance of the trabecular meshwork |
US20160032402A1 (en) * | 2013-03-15 | 2016-02-04 | Novartis Ag | Biomarkers associated with brm inhibition |
US9850543B2 (en) * | 2013-03-15 | 2017-12-26 | Novartis Ag | Biomarkers associated with BRM inhibition |
US20160024504A1 (en) * | 2013-03-15 | 2016-01-28 | Constellation Pharmaceuticals, Inc. | Treating th2-mediated diseases by inhibition of bromodomains |
US11377667B2 (en) | 2013-07-19 | 2022-07-05 | Monsanto Technology Llc | Compositions and methods for controlling Leptinotarsa |
US10597676B2 (en) | 2013-07-19 | 2020-03-24 | Monsanto Technology Llc | Compositions and methods for controlling Leptinotarsa |
US11840686B2 (en) | 2013-08-28 | 2023-12-12 | Ionis Pharmaceuticals, Inc. | Modulation of prekallikrein (PKK) expression |
US11053500B2 (en) * | 2013-08-28 | 2021-07-06 | lonis Pharmaceuticals, Inc. | Modulation of prekallikrein (PKK) expression |
US10934550B2 (en) | 2013-12-02 | 2021-03-02 | Phio Pharmaceuticals Corp. | Immunotherapy of cancer |
US10011837B2 (en) | 2014-03-04 | 2018-07-03 | Sylentis Sau | SiRNAs and their use in methods and compositions for the treatment and/or prevention of eye conditions |
US10604758B2 (en) | 2014-03-25 | 2020-03-31 | Arcturus Therapeutics, Inc. | Therapeutic oligomers for treating amyloidosis |
US9982259B2 (en) | 2014-03-25 | 2018-05-29 | Arcturus Therapeutics, Inc. | Transthyretin allele selective UNA oligomers for gene silencing |
US10683500B2 (en) | 2014-03-25 | 2020-06-16 | Arcturus Therapeutics, Inc. | UNA oligomers having reduced off-target effects in gene silencing |
US9856475B2 (en) | 2014-03-25 | 2018-01-02 | Arcturus Therapeutics, Inc. | Formulations for treating amyloidosis |
US11091770B2 (en) | 2014-04-01 | 2021-08-17 | Monsanto Technology Llc | Compositions and methods for controlling insect pests |
US11124794B2 (en) | 2014-04-25 | 2021-09-21 | The Children's Medical Center Corporation | Compositions and methods to treating hemoglobinopathies |
US10287588B2 (en) | 2014-04-25 | 2019-05-14 | The Childrens's Medical Center Corporation | Compositions and methods to treating hemoglobinopathies |
US10662429B2 (en) | 2014-04-25 | 2020-05-26 | The Children's Medical Center Corporation | Compositions and methods to treating hemoglobinopathies |
US11739329B2 (en) | 2014-04-25 | 2023-08-29 | The Children's Medical Center Corporation | Compositions and methods to treating hemoglobinopathies |
US11279934B2 (en) | 2014-04-28 | 2022-03-22 | Phio Pharmaceuticals Corp. | Methods for treating cancer using nucleic acids targeting MDM2 or MYCN |
US11613752B2 (en) | 2014-05-01 | 2023-03-28 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating PKK expression |
US11124792B2 (en) | 2014-07-29 | 2021-09-21 | Monsanto Technology Llc | Compositions and methods for controlling insect pests |
US10378012B2 (en) | 2014-07-29 | 2019-08-13 | Monsanto Technology Llc | Compositions and methods for controlling insect pests |
US11079379B2 (en) | 2014-08-29 | 2021-08-03 | Alnylam Pharmaceuticals, Inc. | Methods of treating transthyretin (TTR) mediated amyloidosis |
US10060921B2 (en) | 2014-08-29 | 2018-08-28 | Alnylam Pharmaceuticals, Inc. | Methods of treating transthyretin (TTR) mediated amyloidosis |
US11926828B2 (en) | 2014-09-05 | 2024-03-12 | Phio Pharmaceuticals Corp. | Methods for treating aging and skin disorders using nucleic acids targeting TYR or MMP1 |
US10900039B2 (en) | 2014-09-05 | 2021-01-26 | Phio Pharmaceuticals Corp. | Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1 |
US11446380B2 (en) | 2014-10-10 | 2022-09-20 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
US10478500B2 (en) | 2014-10-10 | 2019-11-19 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression |
US10513703B2 (en) | 2014-11-10 | 2019-12-24 | Alnylam Pharmaceuticals, Inc. | Hepatitis B virus (HBV) iRNA compositions and methods of use thereof |
US11060091B2 (en) | 2014-11-10 | 2021-07-13 | Alnylam Pharmaceuticals, Inc. | Hepatitis B virus (HBV) iRNA compositions and methods of use thereof |
US11142766B2 (en) | 2014-11-17 | 2021-10-12 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof |
US11408001B1 (en) | 2014-11-17 | 2022-08-09 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof |
US10968449B2 (en) | 2015-01-22 | 2021-04-06 | Monsanto Technology Llc | Compositions and methods for controlling Leptinotarsa |
US10519447B2 (en) | 2015-04-01 | 2019-12-31 | Arcturus Therapeutics, Inc. | Therapeutic UNA oligomers and uses thereof |
US10570393B2 (en) | 2015-04-13 | 2020-02-25 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof |
US11198872B2 (en) | 2015-04-13 | 2021-12-14 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof |
US11572543B2 (en) | 2015-05-08 | 2023-02-07 | The Children's Medical Center. Corporation | Targeting BCL11A enhancer functional regions for fetal hemoglobin reinduction |
US20180195064A1 (en) * | 2015-06-30 | 2018-07-12 | Tadamitsu Kishimoto | Novel therapeutic agent for a lung disease and/or method for screening for the same |
US10550387B2 (en) * | 2015-06-30 | 2020-02-04 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic agent for a lung disease and/or method for screening for the same |
US11279931B2 (en) | 2015-06-30 | 2022-03-22 | Tadamitsu Kishimoto | Therapeutic agent for a lung disease and/or method for screening for the same |
US11001845B2 (en) | 2015-07-06 | 2021-05-11 | Phio Pharmaceuticals Corp. | Nucleic acid molecules targeting superoxide dismutase 1 (SOD1) |
US10808247B2 (en) | 2015-07-06 | 2020-10-20 | Phio Pharmaceuticals Corp. | Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach |
US11312962B2 (en) | 2015-07-10 | 2022-04-26 | Ionis Pharmaceuticals, Inc. | Modulators of diacyglycerol acyltransferase 2 (DGAT2) |
US10421964B2 (en) | 2015-07-23 | 2019-09-24 | Arcturus Therapeutics, Inc. | UNA oligomers and compositions for treating amyloidosis |
US10208307B2 (en) | 2015-07-31 | 2019-02-19 | Alnylam Pharmaceuticals, Inc. | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases |
US10683501B2 (en) | 2015-07-31 | 2020-06-16 | Alnylam Pharmaceuticals, Inc. | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases |
US11286486B2 (en) | 2015-07-31 | 2022-03-29 | Alnylam Pharmaceuticals, Inc. | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases |
US10731157B2 (en) | 2015-08-24 | 2020-08-04 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotide nanoparticles for the modulation of gene expression and uses thereof |
WO2017050848A1 (en) * | 2015-09-21 | 2017-03-30 | Oommen Oommen P | Nucleic acid molecules with enhanced activity |
US11021707B2 (en) | 2015-10-19 | 2021-06-01 | Phio Pharmaceuticals Corp. | Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA |
US10246709B2 (en) | 2016-03-07 | 2019-04-02 | Arrowhead Pharmaceuticals, Inc. | Targeting ligands for therapeutic compounds |
US11174481B2 (en) | 2016-09-02 | 2021-11-16 | Arrowhead Pharmaceuticals, Inc. | Targeting ligands |
US10294474B2 (en) | 2016-09-02 | 2019-05-21 | Arrowhead Pharmaceuticals, Inc. | Targeting ligands |
US11723912B2 (en) | 2016-12-08 | 2023-08-15 | University Of Utah Research Foundation | Staufen1 agents and associated methods |
US11261441B2 (en) | 2017-03-29 | 2022-03-01 | Bluebird Bio, Inc. | Vectors and compositions for treating hemoglobinopathies |
US11324820B2 (en) | 2017-04-18 | 2022-05-10 | Alnylam Pharmaceuticals, Inc. | Methods for the treatment of subjects having a hepatitis b virus (HBV) infection |
US11788087B2 (en) | 2017-05-25 | 2023-10-17 | The Children's Medical Center Corporation | BCL11A guide delivery |
US10590416B2 (en) | 2017-07-06 | 2020-03-17 | Arrowhead Pharmaceuticals, Inc. | RNAi agents for inhibiting expression of alpha-ENaC and methods of use |
US11214802B2 (en) | 2017-07-06 | 2022-01-04 | Arrowhead Pharmaceuticals, Inc. | RNAi agents for inhibiting expression of alpha-ENaC and methods of use |
US11261447B2 (en) | 2017-07-13 | 2022-03-01 | Alnylam Pharmaceuticals, Inc. | Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
US11214801B2 (en) | 2017-09-11 | 2022-01-04 | Arrowhead Pharmaceuticals, Inc. | RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3) |
US10597657B2 (en) | 2017-09-11 | 2020-03-24 | Arrowhead Pharmaceuticals, Inc. | RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3) |
US11806360B2 (en) | 2017-09-19 | 2023-11-07 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for treating transthyretin (TTR) mediated amyloidosis |
US11739328B2 (en) | 2017-12-01 | 2023-08-29 | The Texas A&M University System | Angleman syndrome antisense treatment |
US11198869B2 (en) * | 2017-12-01 | 2021-12-14 | The Texas A&M University System | Angelman syndrome antisense treatment |
US11685920B2 (en) | 2017-12-01 | 2023-06-27 | The Texas A&M University System | Angelman syndrome antisense treatment |
US20210238590A1 (en) * | 2018-06-14 | 2021-08-05 | University Of Utah Research Foundation | Staufen1 regulating agents and associated methods |
US11946046B2 (en) * | 2018-06-14 | 2024-04-02 | University Of Utah Research Foundation | Staufen1 regulating agents and associated methods |
US11492623B2 (en) | 2018-08-13 | 2022-11-08 | Alnylam Pharmaceuticals, Inc. | Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof |
US11591544B2 (en) | 2020-11-25 | 2023-02-28 | Akagera Medicines, Inc. | Ionizable cationic lipids |
US11613751B2 (en) | 2021-03-04 | 2023-03-28 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof |
US11959081B2 (en) | 2021-08-03 | 2024-04-16 | Alnylam Pharmaceuticals, Inc. | Transthyretin (TTR) iRNA compositions and methods of use thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200299693A1 (en) | Rna interference mediating small rna molecules | |
EP2351852B1 (en) | RNA interference mediating small RNA molecules |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: EUROPAISCHES LABORATORIUM FUR MOLEKULARBIOLOGIE (E Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TUSCHL, THOMAS;WILM, MATTHIAS;LUHRMANN, REINHARD;REEL/FRAME:015060/0724;SIGNING DATES FROM 20040110 TO 20040226 Owner name: MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSC Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TUSCHL, THOMAS;WILM, MATTHIAS;LUHRMANN, REINHARD;REEL/FRAME:015060/0724;SIGNING DATES FROM 20040110 TO 20040226 |
|
AS | Assignment |
Owner name: MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ELBASHIR, SAYDA;LENDECKEL, WINFRIED;REEL/FRAME:022240/0958;SIGNING DATES FROM 20081020 TO 20081106 |
|
AS | Assignment |
Owner name: MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:EUROPAEISCHES LABORATORIUM FUER MOLEKULARBIOLOGIE (EMBL);REEL/FRAME:023486/0572 Effective date: 20091103 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, MASSACHUSET Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V.;REEL/FRAME:026583/0614 Effective date: 20110314 Owner name: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH, MASSA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V.;REEL/FRAME:026583/0614 Effective date: 20110314 Owner name: UNIVERSITY OF MASSACHUSETTS, MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V.;REEL/FRAME:026583/0614 Effective date: 20110314 |
|
AS | Assignment |
Owner name: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH, MASSA Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE OMISSION OF ASSIGNEE, MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V., PREVIOUSLY RECORDED ON REEL 026583 FRAME 0614. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNOR:MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V.;REEL/FRAME:026622/0057 Effective date: 20110314 Owner name: MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSC Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE OMISSION OF ASSIGNEE, MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V., PREVIOUSLY RECORDED ON REEL 026583 FRAME 0614. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNOR:MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V.;REEL/FRAME:026622/0057 Effective date: 20110314 Owner name: UNIVERSITY OF MASSACHUSETTS, MASSACHUSETTS Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE OMISSION OF ASSIGNEE, MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V., PREVIOUSLY RECORDED ON REEL 026583 FRAME 0614. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNOR:MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V.;REEL/FRAME:026622/0057 Effective date: 20110314 Owner name: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, MASSACHUSET Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE OMISSION OF ASSIGNEE, MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V., PREVIOUSLY RECORDED ON REEL 026583 FRAME 0614. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNOR:MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V.;REEL/FRAME:026622/0057 Effective date: 20110314 |